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CONTINUING MEDICAL EDUCATION (CME) 
This activity (“Association for Molecular Pathology 2011 Annual Meeting”) has been planned and implemented 
in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical 
Education (ACCME) through the joint sponsorship of the Federation of American Societies for Experimental 
Biology (FASEB), the American Society for Investigative Pathology (ASIP) and the Association for Molecular 
Pathology (AMP). FASEB is accredited by the ACCME to provide continuing medical education for physicians. 
 
FASEB designates this “live” educational activity (“AMP 2011 Annual Meeting”) for a maximum of 25 AMA PRA 
Category 1 Credit(s)™.  Physicians should only claim credit commensurate with the extent of their participation 
in the activity.   
 
CME application forms are available online (www.amp.org) beginning November 17, 2011 and must be 
submitted no later than March 1, 2012.  Should you have questions, contact the ASIP/AMP Administrative Office 
(301-634-7939; email amp@asip.org) or the FASEB Office of Scientific Meetings and Conferences (301-634-
7010; email fasebcme@faseb.org), 9650 Rockville Pike, Bethesda, MD 20814.  
   
Meeting Objective/Target Audience 
The objective of the “AMP 2011 Annual Meeting” is to increase basic and applied pathology knowledge, 
focusing on the molecular diagnosis and prognosis of disease as well as targeted molecular therapies.  The 
meeting will provide a forum for the exchange of new research by scientists and investigators and is designed to 
support participants’ lifelong learning towards a goal of promoting patient safety and improving patient care. The 
AMP 2011 Annual Meeting is designed to meet the participants’ educational needs in the physician competency 
area of Medical Knowledge, as defined by the Accreditation Council for Graduate Medical Education (ACGME) 
and the American Board of Medical Specialties (ABMS). At the completion of this activity, participants should be 
able to: 1)  discuss the research underway and/or current diagnostic approaches to molecular hematopathology 
(including clonality, translocations, and point mutations), the molecular testing of tumors in anatomic pathology, 
molecular techniques that aid in resolving diagnostic dilemmas in infectious diseases, and molecular genetic 
testing of inherited diseases; 2) demonstrate a gained level of knowledge of the methods and techniques being 
used by researchers and practitioners; and 3) utilize information and data that lead to improvements in human 
health.  The AMP 2011 Annual Meeting is especially targeted to clinical practitioners, research scientists, 
medical education professionals, and students, residents, and postdoctoral fellows with an interest in gaining a 
basic and/or advanced understanding of diagnostic, prognostic, and therapeutic approaches in the areas of 
hematopathology (leukemias, lymphomas, lymphoproliferative disorders), solid tumors and soft tissue tumors, 
infectious diseases (viral, bacterial, fungal, parasitic), and inherited diseases.    
 
Disclosure of Financial Relationships and Resolution of Conflicts of Interest 
The Federation requires that audiences at FASEB-sponsored educational programs be informed of the 
organizers’ and presenters’ (speaker, faculty, author, or contributor) academic and professional affiliations, and 
the existence of any relevant financial relationship a presenter has with any proprietary entity producing health 
care goods or services consumed by, or used on patients, with the exemption of non-profit or government 
organizations and non-health care related companies.  The intent of this disclosure is not to prevent a speaker 
from making a presentation.  This policy allows the listener/attendee to be fully knowledgeable in evaluating the 
information being presented. All CME activities are evaluated by the participants for the presence of any 
commercial bias and this input is used for subsequent CME planning decisions.  The primary purpose of this 
activity is educational and the comments, opinions, and/or recommendations expressed by the faculty or 
authors are their own and not those of the Federation, ASIP, or AMP.       
 
Disclosure includes any relationship that may bias one's presentation or which, if known, could give the 
perception of bias.  These situations may include, but are not limited to: 1) stock options or bond holdings in a 
for-profit corporation or self-directed pension plan; 2) research grants; 3) employment (full or part-time); 4) 
ownership or partnership; 5) consulting fees or other remuneration; 6) non-remunerative positions of influence 
such as officer, board member, trustee, or public spokesperson; 7) receipt of royalties; 8) speaker's bureau; 9) 
other.  For full-time employees of industry or government, the affiliation listed in the Program will constitute full 
disclosure.   
 
Several of the organizers of this educational activity disclosed a relevant financial relationship that, in the 
context of their presentation could be perceived by some as a real or apparent conflict of interest. The 
disclosures have been reviewed and conflicts of interest resolved or managed.  If an organizer is not listed, then 
he/she had no relationship to disclose. 
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 Research Grants – Abbott, Qiagen 
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Consulting – Genentech 
  
Abstract Author Disclosures 
Only the abstracts listed below are included as CME content of the AMP 2011 Annual Meeting and will be 
defended in oral presentations.  The other abstracts submitted to the AMP 2011 Annual Meeting that are 
published in The Journal of Molecular Diagnostics are not included as a CME activity. 
 GENETICS: G42, G51, G60, G64 
 HEMATOPATHOLOGY: H02, H04, H18, H20 
 INFECTIOUS DISEASES: ID11, ID45, ID50, ID65 
 SOLID TUMORS: ST11, ST14, ST24, ST56 
The following presenters and/or the coauthors of orally presented abstracts have indicated a relationship that, in 
the context of their presentation, could be perceived by some as a real or apparent conflict of interest.  The 
disclosures have been reviewed and conflicts of interest resolved or managed.  If an author is not listed, then 
he/she did not disclose a relevant financial relationship. 
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GENETICS 
 
G01. An Uncommon Prothrombin Gene Variant in an African-American Woman 
with a Stroke 
S.G. Spitzer, J. Plunkitt, l. Donarrumo 
SUNY at Stony Brook, Stony Brook, NY. 
Introduction: Mutations in coagulation Factor II (Prothrombin) and Factor V are the 
most prevalent hereditary risk factors for thrombophilia. Prothrombin mutation 20210 
was first described in 1996; it consists of a G to A mutation that leads to increased 
prothrombin levels in blood. The mutation is found in up to 2% of the Caucasian 
population but is rare in people of African or Asian descent. Carriers and homozygous 
individuals are at increased risk of developing deep vein thrombosis as well as obstetric 
and fetal complications. In this study we describe the identification of an uncommon 
prothrombin variant in a patient who presented with a stroke. Methods: A 47-year-old 
black female from Jamaica with a history of hyperlipidemia and syncope was admitted 
to the stroke service with right sided hemiplegia (leg weaker than arm) and expressive 
aphasia. The MRI revealed a left frontoparietal infarct. The TEE showed evidence of a 
patent foramen ovale. Genomic DNA was extracted from peripheral blood and analyzed 
by real-time PCR for Factor V Leiden and prothrombin mutations. Results: The 
prothrombin 20210 assay showed an abnormal melting curve that was not consistent 
with wild-type or the 20210 G>A mutation. The melting curve showed two peaks, one at 
59°C (wild-type allele) and an unknown peak at 53°C (the 20210 G>A mutation gives a 
peak at 49°C). To further characterize this unusual finding this region of the 
prothrombin gene was sequenced. The patient’s DNA was amplified with primers PT5’ 
and PT3” (PT5’: 5’-TCTAGAAACAGTTGCCTGGC-3’ and PT3’: 5’-ATAGCACTGGGA-
GCATTGAAGC-3’). The amplification product was then purified and sequenced by the 
Sanger method using fluorescent labeled dideoxynucleotide triphosphates (ddNTPs) as 
DNA chain terminators. The sequence showed the presence of a C to T transition at 
position 20209; the normal G was present at position 20210. The Factor V Leiden 
mutation was not present. Conclusions: This patient is heterozygous for a 20209 C>T 
mutation. This rare mutation has been previously described in a small number of Middle 
Eastern and African-American patients in whom it was associated with recurrent 
spontaneous abortions, intrauterine growth retardation or neonatal demise. In this 
patient the 20209 C>T mutation was associated with stroke rather than obstetrical 
complications. This case also illustrates how real-time PCR coupled with melting point 
analysis can detect new or unusual variants that may be missed by other molecular 
techniques. 
 
G02. Laboratory Validation of the Abbott Cystic Fibrosis Genotyping Assay on 
the Applied Biosystems 3500 xL Instrument 
H.N. Todd1, J.B. Morgan1, J.W. Longshore2 
1Carolinas Medical Center, Charlotte, NC; 2Carolinas Pathology Group, Charlotte, NC. 
Introduction: Cystic fibrosis (CF) is one of the most common inherited disorders. It is a 
complex multisystem disorder but the majority of disease morbidity and mortality is 
associated with pulmonary manifestations. Mutations within the CFTR gene have been 
shown to be responsible for this autosomal recessive disease. The Abbott Cystic 
Fibrosis Genotyping Assay is a robust assay that is FDA cleared for IVD use on the 
Applied Biosystems 3100 instrument. It detects 32 mutations as part of a core panel 
and additional polymorphisms in a separate panel. The Applied Biosystems 3500 xL is 
the newest generation capillary electrophoresis instrument and offers significant 
performance advantages over the 3100 instrument. Methods: A panel of samples 
containing all 23 ACMG recommended mutations was obtained from Coriell along with 
10 samples of known CFTR intron 8 poly-T genotype, 27 laboratory confirmed CFTR 
negative samples, as well as the SeraCare Accurun 632 CF control. The samples were 
amplified and the OLA performed according to the IVD protocol in an Applied 
Biosystems 9700 thermocycler. Following amplification and OLA, the samples were 
subjected to capillary electrophoresis and analysis on an Applied Biosystems 3100 and 
an Applied Biosystems 3500 xL with both utilizing POP-6 polymer. The amplification, 
OLA, capillary electrophoresis, and analysis of all study samples were performed 
multiple times on multiple days to thoroughly evaluate the performance of the 3500 xL 
instrument for the CF assay. Results: In all cases, the identical CFTR and intron 8 
poly-T genotype was obtained by both the 3100 and 3500 xL instruments. However, the 
3500 xL offered several operator convenience and assay performance advantages 
versus the 3100. The pre-formulated instrument consumables such as the polymer 
pouch, cathode and anode buffer containers, and capillary array provided an ease of 
use advantage and the integrated RFID tags on these products allowed improved 
instrument QA and QC. Additionally, the 3500 xL offered increased sample throughput 
due to decreased electrophoresis time and increased sample capacity. All of these 
instrument and software improvements offer significant advantages when running the 
Abbott CF Genotyping Assay on the 3500 xL. Conclusions: The Abbott CF Genotyping 
Assay produces identical genotyping results on the Applied Biosystems 3500 
instrument when compared to the 3100. Given its robust and reliable performance 
during this validation study and the significant advantages of the 3500 xL, it can be 
validated as a viable instrument for the Abbott CF Genotyping Assay in the clinical 
laboratory. 
 
G03. Comparison of the Performance of Micofludics with Capillary 
Electrophoresis as a Platform for PCR Analysis for FMR1 Premutations 
G.A. Toruner, D. Streck, R. Kurvathi, J. Dermody 
UMDNJ-New Jersey Medical School, Newark, NJ. 
Introduction: Usage of capillary electrophoresis for the evaluation of PCR products to 
assess the expansions of the CGG triplet repeats in the 5’UTR of the FMR1 gene is 
becoming a standard approach for Fragile X testing. Direct amplification of the CGG 
repeat region with flanking primers for allele sizing and triplet repeat primed PCR (TRP-
PCR) for the detection of expansions as “stutter bands” are among the most common 
PCR applications. In both these assays fluorescently labeled primers are utilized and 
the generated amplicons are visualized and detected by capillary electrophoresis. Our 
objective was to evaluate the performance of a commercially available microfluidics 
platform and compare it to capillary electrophoresis. Methods: Archived genomic DNA 
specimens (n=47), previously tested for FMR1 expansions were analyzed. A 
commercially available FMR1 test kit (Abbott Diagnostics) was utilized. Our testing 
strategy involved using “primer 1” for allele sizing initially. If the results could not be 
ascertained with “primer 1”, the TRP-PCR experiments were done using “primer 2”. 
Electrophoresis of PCR products was performed on the 3130XL Genetic Analyzer 
(Applied Biosystems) and 2100 Bioanalyzer (Agilent Technologies). Results: Forty-
seven DNA samples were tested using “Primer 1”. 32 samples had normal alleles, 4 
samples had premutations (80-144 repeats) and 11 female samples showed single 
bands after capillary electrophoresis. The analysis of the PCR products on microfluids 
revealed identical results. The eleven samples with single peaks were also analyzed by 
TRP-PCR using “Primer 2”, FMR1 expansions were detected in three cases. 
Conclusions: Long run time (~4hrs) and the high cost of fluorescent primers are the 
issues with capillary electrophoresis for assessment of FMR1 expansions. The 
advantage of a microfluidics based platform is shorter run time (30 minutes) and 
possibility of using non-florescent primers. Our experiments established the proof of 
principle that the microfluidics based electrophoresis can be utilized for FMR1 testing. 
 
G04. Long-Range PCR for Clinical Mutation Detection of SFTPA1 and SFTPA2 
Genes 
C. Horton1, M. Mitui1, C. Garcia2, J. Park1 
1Children's Medical Center Dallas, Dallas, TX; 2University of Texas Southwestern 
Medical Center, Dallas, TX. 
Introduction: Germ line mutations in Surfactant Protein A (SP-A) are correlated with 
severe pulmonary disease. SP-A exists as two isoforms, SPA-1 (SFTPA1) and SPA-2 
(SFTPA2); these surfactants serve two main roles in the lungs: alveolar gas exchange 
and innate immune defense. Both genes are located on the q arm of chromosome 10 
and have >98% and >90% sequence identity in their coding and non-coding regions, 
respectively. The high identity of the two genes makes traditional PCR design and DNA 
sequencing exceptionally challenging. We have developed a genetic DNA sequencing 
test based on long-range PCR for the clinical detection of mutations in SFTPA1 and 
SFTPA2. Methods: Primer pairs were designed to specifically amplify approximately 10 
kb of genomic sequence for both SFTPA1 and SFTPA2. PCR amplification using 
Takara 'One Shot LA PCR' was performed for each gene on genomic DNA extracted 
from whole blood. The two PCR products were purified using Qiagen's 'QIAquick PCR 
Purification microcentrifuge' kit. Each PCR product underwent restriction enzyme 
digestion with EcoRV to confirm the specific identity of SFTPA1 or SFTPA2. The PCR 
products were sequenced using internal primers with Applied Biosystems (AB) BigDye 
Terminator 3.1 and purified using AB BigDye Xterminator kit. Capillary electrophoresis 
of the sequenced fragments was performed on an AB 3130xl to generate 
chromatograms. The chromatograms were analyzed and interpreted using AB 
Sequence Analysis, FinchTV (Geospiza), Mutation Surveyor (Softgenetics), and Alamut 
(Interactive Biosoftware). Results: Gel electrophoresis demonstrated the distinct 
banding patterns that are specific for SFTPA1 and SFTPA2 PCR products digested by 
EcoRV. Bi-directional DNA sequence was obtained for all coding sequence with quality 
scores in Mutation Surveyor greater than 20.The chromatograms showed gene-specific 
alleles at areas of non-homology for all four exons in the two genes. Samples with 
previously reported mutations were accurately called by the mutation software. 
Conclusions: Although long-range PCR is not typically used for clinical sequencing 
and mutation detection, it is useful for genes such as SFTPA1 and SFTPA2, which 
have high similarity and limited unique sequences for priming. In the research setting, 
investigators of these genes have been limited to priming sites that also contain single-
nucleotide polymorphisms of unknown significance. Using long-range PCR, we are able 
to avoid priming sites that contain single-nucleotide polymorphisms and specifically 
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amplify SFTPA1 and SFTPA2 in individual reactions. As additional clinically significant 
genes are discovered that have isoforms possessing high sequence identity, long-range 
PCR may have a more prominent role in clinical DNA sequencing tests.  
 
G05. Homocysteine and MTHFR Gene Polymorphism in Alzheimer's Disease 
and Other Dementia 
W. Lee1, S. Kang2, Y. Jeon2, S. Cho1, M. Kim2 
1Kyung Hee University School of Medicine, Seoul, Republic of Korea; 2Kangdong 
University Hospital, Seoul. 
Introduction: The elderly population rise due to increased life expectancy has also 
resulted in an increased prevalence of dementia. Alzheimer’s disease (AD) is 
characterized by progressive cognitive decline and is the most common type of late-life 
dementia. However, the pathogenesis of AD has not been fully understood. Genetics 
and vascular components such as atherosclerosis play a role in the onset of the 
disease. This study aimed to analyze relationships between MTHFR gene 
polymorphism and homocysteine, lipid profiles, folate, and vitamin B12 in dementia 
including Alzheimer’s disease and minor cognitive impairment. Methods: A total of 151 
patients with complaints of memory decline were included in this study. Patients were 
divided into four groups, AD (N=26), vascular dementia (N=7), minor cognitive 
impairment (N=27) and normal cognitive function (control group, N=91) according to 
MMSE scores and clinical criteria by NINCDSADRDA. MTHFR gene polymorphisms 
were determined using Seeplex MTHFR C677T/A1298C kit (Seegene, Seoul, Korea). 
Homocysteine levels were tested using Hitachi 7600 (Hitachi High-technology 
corporation, Tokyo, Japan). Folate and vitamin B12 levels were determined using Advia 
Centaur (Simens Healthcare Diagnostic, NY, USA). We also determined e4 allele of 
apolipoprotein E gene (APOE). Results: Homocysteine, folate, and vitamin B12 were 
not significantly different among the four groups. However, homocysteine levels were 
significantly increased in AD (13.87 ȝEq/L) compared to the control group (7.66 
ȝEq/L)P=0.007). Our data showed no significant difference in frequencies of MTHFR 
677 and 1298 genotypes among the four groups. Divided into six groups according to 
haplotypes of MTHFR 677 and 1298, homocysteine levels did not significantly differ 
among these groups. However, homocysteine levels were significantly increased in 
677TT compared to 677CC (P=0.015). Apolipoprotein E genotyping: e2e3 (8.7%), e2e4 
(1.4%), e3e3 (65.2%), e3e4 (24.6%). The frequencies of the APOE genotypes did not 
differ significantly among the four groups (P = 0.350). APOE e4 allelic frequencies were 
43.8% in the AD group and 23.5% in the control group. APOE e4 carriers had 
significantly decreased HDL-C and apoA1 levels as compared to APOE e4 non-carriers 
(P < 0.001 and P = 0.001, respectively). Conclusions: Homocysteine levels were 
significantly increased in AD and in MTHFR 677TT genotype. Longitudinal studies 
including a larger patient cohort are needed to confirm these results and evaluate 
vitamin therapy for AD or minor cognitive impairment. 
 
G06. Assessment of a Novel Point-of-Care Assay to Detect the CYP2C19*2 
Single Nucleotide Polymorphism 
M.J. Kluk, J.L. Mega, W. Hochholzer, C. Ruff, D. Berg, L. Grip, M.S. Sabatine,  
J.A. Longtine 
Brigham and Women's Hospital, Boston, MA. 
Introduction: Data suggest that the CYP2C19*2 variant is an important determinant of 
a patient’s pharmacologic and clinical response to clopidogrel, and this information has 
been incorporated into the updated FDA label. Accordingly, molecular laboratories may 
be requested with increasing frequency to rapidly assess for this variant to aid clinicians 
in selection and/or dosing of antiplatelet therapy. As part of the ELEVATE-TIMI 56 
clinical trial, we compared a novel point-of-care assay for CYP2C19*2 to a sequencing-
based assay. Methods: A Research Use Only (RUO) prototype of the Nanosphere 
Verigene 2C19/CBS Nucleic Acid Assay (which assesses *2-*10, *13 and *17) and a 
Pyrosequencing assay (laboratory-developed) were used to assess CYP2C19*2 status 
in peripheral blood genomic DNA from 333 ELEVATE-TIMI 56 patients; samples were 
individually tested by the Nanosphere assay using whole blood and were batch-tested 
by Pyrosequencing after DNA isolation and PCR. We compared the concordance rate, 
turnaround times (TAT), hands-on times (HT) and other features. Results: Genotype 
results confirmed by both methods were: wild type (at *2 locus) 245/333 (74%); 
heterozygous *2 allele 80/333 (24%); homozygous *2 allele 6/333 (1.8%). The 
concordance rate between the two methods was >99% (331/333). The two cases with 
initially discrepant results (heterozygotes by Verigene, wild type by Pyrosequencing) 
were repeated and determined to be wild type by both methods. TAT for Verigene was 
~3.5 hours with 15 minutes HT per individual sample. Pyrosequencing (including DNA 
isolation and PCR) had a TAT of ~5 hours with a HT of 90-120 minutes per batch. 
Verigene was relatively simple to operate and assessed 10 additional CYP2C19 SNPs 
whereas Pyrosequencing was designed to only assess CYP2C19*2. The 
Pyrosequencing platform, due to the 96-well plate format, had a greater capacity to 
simultaneously run larger batches of specimens. Conclusions: Both the RUO 
prototype of the Nanosphere Verigene 2C19/CBS Nucleic Acid Assay and laboratory-
developed Pyrosequencing were robust, accurate platforms for assessment of 
CYP2C19*2. Pyrosequencing was technically more complex and had a slower 
turnaround time, but appears well suited for laboratories with high daily testing volumes 
that choose to batch-test specimens and assess fewer SNPs. The Verigene assay with 
its simple operation and multiplexing capability appears well suited for either point-of-
care operation or for laboratories with moderate daily testing volumes that require faster 
turn around and prefer to test specimens individually. 
 
G07. Rapid Targeted Prenatal Detection of Sex Chromosomal Aneuploidies 
Using Quantitative Fluorescence Polymerase Chain Reaction in Singapore 
D. Lu1, G. Leow1, S.S. Ho1, L. Chiu1, E.S. Koay1, S. Baig2, S.S. Chong1, L. Gole1,  
J. Chan1, M. Choolani2 
1National University Health System, Singapore, Singapore; 2National University of 
Singapore, Singapore. 
Introduction: Conventional cytogenetic analysis for prenatal diagnosis requires 7-14 
days before results are released. This long waiting time can cause parental anxiety. 
Common fetal chromosomal aneuploidies can be detected by rapid targeted tests such 
as interphase fluorescence in situ hybridization (FISH), multiplex ligation-dependent 
probe amplification (MLPA) and quantitative fluorescent PCR (QF-PCR). We have 
developed QF-PCR as a clinical test to detect fetal autosomal aneuploidies. To detect 
sex chromosome aneuploidies, we now explore additional microsatellite markers 
located on chromosomes X and Y to be included into our established QF-PCR test. 
Methods: A total of eight markers [polymorphic (DXS6785, DXS6789, DXS6803, 
DXS6809, XHPRT, X22); non-polymorphic (AMXY); chromosome Y-specific (SRY)] 
were analyzed. Assay validation was performed with 24 archived DNA samples with 
known sex chromosome abnormalities determined by cytogenetic analysis 
[45,XO(n=7), 47,XXX(n=2), 47,XXY(n=8), 47,XYY(n=1), mos45,XO/46,XY(n=2), 
mos45,XO/46,XX(n=1), mos45,XO/46,X,r(X)(p22.3q28)(n=1), 46,X,psu 
idic(X)(p11.1)(n=1), 46,X,i(X)(q10)(n=1)]. In our blinded study, DNA was isolated from 2 
ml of amniotic fluid collected from mothers undergoing routine amniocentesis at 18-22 
gestational weeks (n=100). Results: In our validation study, 45,XO, 
mos45,XO/46,X,r(X)(p22.3q28) and mos45,XO/46,XY samples showed single allele in 
each X-chromosome marker, with the presence of Y-chromosome-specific alleles 
(SRY, AMY) in mos45,XO/46,XY samples. mos45,XO/46,XX showed two alleles in all 
X-chromosome markers and was unable to detect monosomy X. Both 46,X,psu 
idic(X)(p11.1) and 46,X,i(X)(q10) samples showed the presence of an additional X-
chromosome. XXY and XYY samples were detected with double allele dosage of X- or 
Y-chromosome markers with the addition of single allele dosage of Y- or X- 
chromosome markers respectively. In our blinded study, all samples (n=100) showed 
normal male and female chromosomes (XY,n=47; XX,n=53) as confirmed by their 
respective karyotypes (100 percent specificity, lower 95 percent CI, 95.4). 
Conclusions: QF-PCR can detect monosomy X and mosaic monosomy X/XY at 23.8-
50 percent mosaicism, and unable to detect mosaic monosomy X/XX. The presence of 
an additional dosage of Xq markers does not necessary indicate trisomy X, as shown in 
psu idic(X)(p11.2) and i(Xq) samples with Xq duplication. Additional Xp markers are 
required. Our present panel of markers can detect XXY, XYY, normal XX and XY with 
100 percent specificity. Karyotyping is recommended in the presence of abnormal 
results. Although QF-PCR is unable to detect abnormalities in chromosomal structure 
such as ring chromosome and balance translocation, sex chromosome aneuploidies 
can be detected. Results can be released within 48 hours of sample collection, 
alleviating parental anxiety and improving clinical management of affected pregnancies. 
 
G08. Sanger Sequencing Assay to Detect 2C19 Allele Variants Associated with 
Plavix Metabolism 
E. Aquino, J.J. Krolewski, J.Y. Chan, P.M. Ward 
University of California, Irvine Medical Center, Orange, CA. 
Introduction: Plavix is given to patients with cardiovascular disease in order to reduce 
the risk of heart attack, unstable angina, stroke, and cardiovascular death. The drug is 
metabolized to its active form primarily by the CYP450 isoenzyme 2C19. The CYP450 
super-family of genes displays varying degrees of intra-family homology; specifically 
2C19 has high homology with 2C9, which generates inherent challenges for complex 
detection assays. Here we have designed a Sanger sequencing based assay to detect 
those 2C19 alleles with clinical associations. Methods: PCR and sequencing primers 
were developed and used to amplify 2C19 gene 5’ UTR and exons 1, 3, 4, 5 and 8. 
Sanger sequencing assays were performed on DNA from the Coriell repository and 
CAP proficiency surveys using BigDye Terminator Mix version 3.1 (ABI). Sequence 
analysis was done on a 3130 genetic analyzer using sequencing software version 5.3.1 
(ABI). 2C9 sequence-exclusions were confirmed by interrogating 2C19 non-
homologous regions. Results: 2C19 sequences were generated for each of the target 
exons and 5’ UTR. These sequences were compared to NCBI reference data to detect 
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*2 681G>A, *3 636G>A, *4 1A>G, *8 358T>C, *9 431G>A *10 680C>T, *13 128C>T 
and *17 -806C>T alleles. All genotypes generated by our Sanger sequencing assay 
were 100% concordant with those known genotypes used in the analyses. 
Conclusions: Stringent primer design allowed CYP2C19 alleles to be amplified in the 
absence of contaminating 2C9 sequences. This allows more accurate elucidation of 
CYP2C19 genotypes and predicts a more accurate metabolizer phenotype. 
 
G09. Novel FLCN c.1490_1491delTG Mutation in a Patient with Spontaneous 
Pneumothorax 
G. Park1, S. Lee2 
1Chosun University College of Medicine, Gwangju, Republic of Korea; 2Chosun 
University College of Medicine, Gwangju. 
Introduction: The cause of primary spontaneous pneumothorax (PSP) is obvious. 
Recently, the FLCN mutation was suggested to be a causal factor in PSP. Herein, we 
report a novel FLCN mutation in a patient with PSP. Methods: A 43-year-old Korean 
female patient with chief complaint of repetitive PSP had numerous emphysematous 
bullae and multiple large cysts based upon high resolution computer tomography. 
Genomic DNA and total RNA were isolated from venous blood, and cDNA was 
synthesized. All coding exons and flanking intronic regions of FLCN gene were 
amplified by PCR and directly sequenced. Also, we amplified and sequenced the entire 
coding region of FLCN mRNA. For determining the amount of FLCN transcripts of the 
patient compared with normal persons (n=20), we performed the relative quantitative 
real-time ddCt analysis compared with ABL transcripts. All relative quantitative real-time 
RT-PCR were executed in triplicate. Results: The FLCN c.1490_1491delTG 
(p.Val497Glyfs*22) mutation in exon 13 was found in the genomic DNA and mRNA 
levels. Quantitative real-time RT-PCR revealed a similar amount (2''Ct = 0.99) of FLCN 
transcripts from the PSP patient compared with normal persons. This mutation can 
escape nonsense-decay system, because premature termination codon generated by 
c.1490_1491delTG mutation is located less than 50-55 bp downstream of the last exon 
13 to exon 14 junction. Conclusions: We identified a novel FLCN c.1490_1491delTG 
mutation in a patient with PSP. 
 
G11. Validation of INFINITI Microarray System for Pharmacogenetic Testing of 
CYP2D6 for Tamoxifen Therapy 
G. Murugesan, K.M. McDonnell, S. Ganapathy, R.R. Tubbs, T.M. Daly 
Cleveland Clinic, Cleveland, OH. 
Introduction: Tamoxifen is an estrogen receptor (ER) antagonist that blocks estrogen 
binding to ER leading to the inhibition of ER+ cancer cells. The pro-drug tamoxifen is 
converted into active metabolite endoxifen by Cytochrome P450 (CYP) enzymes, 
primarily by CYP2D6. Formation of active metabolite is associated with the variants of 
CYP2D6 gene. Loss of function mutation in CYP2D6 can impair the metabolism of 
tamoxifen. Consequently, ER+ breast cancer patients with the loss of function variants 
in CYP2D6 may not benefit from tamoxifen therapy. Identifying these patients by 
genotyping CYP2D6 gene variants will be useful to tailor individualized breast cancer 
therapy. Methods: Genomic DNA isolated from 47 split-specimens that were previously 
genotyped for CYP2D6 and 16 Coriell DNAs of known genotypes were analytically 
validated by genotyping with a FDA cleared commercial platform INFINITI from 
AutoGenomics. The INFINITI employs an array-based assay (CYP2D6I) encompassing 
15 variants. The assay involves a multiplex PCR amplification of genomic DNA followed 
by allele-specific primer extension using fluorescently labeled dCTP and hybridization 
on to a micro-array coated with capturing oligonucleotides specific for the primer-
extended products. A built-in confocal microscope is enabled to capture fluorescent 
signal from the pre-determined hybridization spots corresponding to specific alleles and 
genotypes deciphered from the signal ratio. For analytical validation, we have 
determined accuracy, method comparison, intra- and inter-assay precision, sensitivity 
and specificity of the CYP2D6I assay. Results: Accuracy of the CYP2D6I assay, 
determined by comparing the consistency in genotyping calls between known and 
observed results, was in total agreement for fourteen alleles common to both methods 
for split specimens and the known variants of Coriell DNAs. Three specimens 
genotyped in six replicates within the same run and in duplicates over five days yielded 
reproducible results without any discrepancy. Sensitivity of the assay determined with 
three specimens in duplicates demonstrated that accurate genotype calls could be 
generated with DNA amount ranging from ~5 ng to 150 ng per reaction compared to the 
recommended level of 75 ng DNA per reaction. The assay was specific as there was no 
false positive or false negative, the template-free control remained negative and the 
hybridization and background controls met the assay criteria. Conclusions: CYP2D6 
assay using the INFINITI platform has been analytically validated with satisfactory 
results. Performance for accuracy, precision, sensitivity and specificity has shown that 
CYP2D6 assay is reliable. Although this assay can genotype fifteen variants, clinical 
utility of many of the ethnocentric variants are yet to be established.  
G12. Detection and Characterization of Fragile X Expansion Mutations Using 
PCR-based Assays 
E.H. Palacios1, L. Zhou2, D. Behlendorf1, E. Berry-Kravis2, N. Marlowe1 
1Celera Corporation, Alameda, CA; 2Rush University Medical Center, Chicago, IL. 
Introduction: Fragile X diagnostic testing involves determining the size of the CGG 
repeat in the FMR1 promoter and the level of promoter methylation. PCR amplification 
of the FMR1 CGG repeat in combination with Southern Blot (SB), despite being 
laborious and time-consuming, is commonly used for this purpose. In this research 
study we evaluated whether three laboratory-developed (LD) PCR-based protocols 
could reliably identify, size, and determine promoter methylation status of expanded 
FMR1 alleles. Methods: Ninety-one clinically derived DNA samples (previously 
analyzed and blinded by RUMC) containing FMR1 full mutations, premutations, and 
mosaic mutations were tested by the LD FMR1 screening and sizing protocols. A 
subset (n=20) was assessed for methylation at the FMR1 promoter using quantitative 
real-time PCR. Briefly, genomic DNA samples were bisulfite converted using a 
commercial kit. Novel oligonucleotides to ActinB (ACTB) enabled us to control for the 
amount of input DNA that was successfully bisulfite converted and pipetted. Novel 
oligonucleotides to the FMR1 promoter region spanning several CpGs, were used to 
amplify DNA that was methylated and had been bisulfite converted. Our results were 
compared to results from in-house combined PCR-Southern blot methodology obtained 
at RUMC. Results: Fifty-two samples were identified as expanded by the screening 
protocol and the remaining 39 were determined to contain normal FMR1 alleles. We 
found 100% concordance in identifying premutation, full mutation and mosaic samples. 
Among the samples tested, 18 had expansions only within the premutation range (55-
200 repeats), 19 had expansions only within the full mutation range (>200 repeats, with 
17 having large expansions of >1000 repeats), and 15 had distinct expansions both 
within the premutation and full mutation range (pre-/full mutation mosaics). Among 20 
samples tested using the novel FMR1 methylation assay, we detected 0% methylation 
in three normal males (m), 42% to 52% in four normal females (f), 6% to 57% in three 
premutation samples (m+f), 33% to 99% in seven mosaic samples (m+f) and 85-100% 
in three full mutation males. Eighteen of 20 results were in good agreement with the 
Southern blot data. Two samples were quantitatively different (87% vs 100% SB and 
72% vs 40% SB), possibly reflecting different CpG targets tested by the two methods. 
Conclusions: These lab-developed protocols are rapid and reliable methods for the 
detection and characterization of expanded FX alleles. PCR-based assays are 
desirable for laboratories conducting FX clinical testing as they quickly identify the 
presence of expansion mutations; determine allele size, and quantify the level of FMR1 
promoter methylation. 
 
G13. HLA-B*5801, a Strong Pharmacogenetic Marker for Severe Cutaneous 
Adverse Drug Reaction Caused by Allopurinol in Thai Population 
W. Tassaneeyakul1, S. Tiamkao1, N. Prabmeechai1, T. Kongpan1, P. Chumworathayi1, 
U. Khunarkornsiri2, P. Konyoung2, S. Vannaprasaht1, A. Sangviroon3 
1Khon Kaen University, Khon Kaen, Thailand; 2Udonthani Hospital, Udonthani; 3Police 
General Hospital, Bangkok. 
Introduction: Allopurinol is the most common drug used for lowering uric acid and for 
treatments of hyperuricemia and gouty arthritis. This drug has been reported as a 
common culprit drug for severe cutaneous adverse drug reactions (SCADR) including 
Stevens–Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN) and 
Hypersensitivity syndrome (HSS) in several countries. Although a strong association 
between allopurinol-induced SCADR and HLA-B*5801 has been reported in Han 
Chinese, only a moderate association was observed in other populations. The present 
study aimed to investigate the association between allopurinol-induced SCADR and 
HLA-B*5801 in a Thai population. Methods: Forty-one allopurinol-induced SCADR and 
81 allopurinol-tolerant patients were recruited in the study. Genomic DNA was extracted 
from peripheral blood. The presence of HLA-B*5801 allele in these patients was 
determined using a PG5801 DNA detection kit. Results: The HLA-B*5801 allele was 
detected in all of the allopurinol-induced SCADR patients (41/41, 100%) but only 10 out 
of 81 allopurinol-tolerant patients (12.40%). The risk of allopurinol-induced SCADR was 
markedly higher in patients with HLA-B*5801 when compared with those that did not 
carry this allele. The sensitivity and specificity of the HLA-B*5801 allele for prediction of 
allopurinol-induced SCADR were 100% and 87.65%, respectively. Conclusions: The 
HLA-B*5801 is a good pharmacogenetic marker for screening of Thai patients who are 
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G14. Association of Chromosome 9p21 Polymorphism with Coronary Artery 
Disease in Western Indians  
B. Das1, A. Bhanushali1, A. Contractor2, V.T. Shah3 
1Super Religare Laboratories Ltd, Mumbai, India; 2Asian Heart Institute, Mumbai; 
3V.T.Shah Clinic and Diagnostics Center, Mumbai. 
Introduction: Indians have a high propensity to develop Coronary Artery Disease 
(CAD) and it has been estimated that 60% of the world’s cardiac population will be in 
India by the year 2020. In this context it is very important to evaluate the new markers 
especially genetic variants in the Indian population, which is a heterogenous group, in 
addition to the traditional risk factors. Genome-wide studies have implicated the 58kb 
region of chromosome 9p21 to be associated with CAD. Several SNPs were implicated 
in this region (viz rs1333049, rs10757278, rs10757274, rs2383206, rs1004638 
rs10116277, rs1333040, rs2383207, rs1994016 etc). In the current study we have 
evaluated the association of SNP rs10757278 A/G at the 9p21 locus with CAD, 
especially in Western Indians (Indo-European population). Methods: Genotyping for 
rs10757278 A/G was done by direct sequencing in 215 cases with confirmed CAD and 
150 controls. To determine association of the variant rs10757278 with CAD, both 
univariate and multivariate analysis were performed. For the calculation of the 
Framingham Risk Score (FRS) with the 9p21 information a value of 1, 0, and -1 was 
given for the genotype GG, AG, AA, above that determined by the traditional FRS score 
and the number of individuals getting reclassified determined. Results: Statistically 
significant differences were seen in the smoking status (P<0.01), presence of family 
history (P<0.0001), diabetes (P<0.0001) as well as hypertension (P<0.0001) in cases 
vs controls. The reported minor allele frequency (0.53 in controls) for this SNP in our 
population is almost the same as in other ethnic groups except African Americans. A 
higher frequency of the rs10757278 G allele was seen in cases as compared to the 
controls (0.64 vs 0.53), and associates with increased risk for CAD (OR 1.832 per G 
allele 95% 1.035-3.242, P 0.042) in the univariate analysis. In the stepwise backward 
logistic regression model LDL levels (P<0.0001) and 9p21 rs10757278 variant 
(P=0.035) were associated with the risk of CAD. No association with prevalent 
myocardial infarction as the event versus CAD, was seen in a univariate analysis. 
Addition of the 9p21 allele to Framingham risk score FRS, resulted in a shift of 17% of 
individuals from the low risk category to the intermediate-low (>5% to <10% 10-year 
risk) and 7% from intermediate-low to intermediate-high (>10% to <20% 10-year risk) 
categories. Conclusions: In conclusion the 9p21 locus is significantly associated with 
the risk of CAD in the select Indian population.  
 
G15. De Novo Marker Chromosome Unraveled to be Chromosome 18 in a Girl 
with Mental and Motor Retardation 
Z. Yilmaz, Y.K. Terzi, I. Erol, O. Ozer, F. Sahin 
Baskent University Faculty of Medicine, Ankara, Turkey. 
Introduction: Conventional cytogenetic analysis is not sensitive enough to detect 
submicroscopic chromosomal rearrangements that lead to copy-number gains or losses 
that might be responsible for clinical phenotypes. Recently a new array based 
technology called array Comparative Genomic Hybridization (aCGH) has been used to 
detect submicroscopic chromosomal abnormalities that cannot be detected by 
conventional cytogenetic analysis. Using this technology allows us to detect 
submicroscopic genomic changes in children with idiopathic intellectual disabilities, 
mental retardation, autism, developmental delay and multiple congenital anomalies. 
Methods: In the present study, we analyzed a 6-year-old girl with mental and motor 
retardation. The parents requested genetic testing for their child and they also wanted 
to learn prenatal diagnosis opportunities for future pregnancies. Conventional 
cytogenetic analysis was performed and the karyotype was reported as 47,XX,+mar 
while the parents’ karyotypes were 46,XX and 46,XY. For more detailed analysis, 
Roche NimbleGen Human CGH 3x720K Whole-Genome Tiling v3.0 Array was used. 
For the analysis of raw data web based Genoglyphix program (Signature Genomics) 
was used. Results: Five chromosomal regions were marked by the program 
automatically after analysis. Two of them were copy losses and three were copy gains. 
However, only one region was found to be clinically significant. This region was located 
at 18p11.32-18p11.21, and 1124 probes marked this region as a copy gain. This region 
comprises 72 genes and 43 of them are OMIM genes. Also copy gain in this region was 
found to be related to Holoprosencephaly 4 syndrome. The result was confirmed by 
fluorescent in situ hybridization (FISH) of metaphase spreads of the patient with whole 
chromosome probe 18, which hybridized with normal chromosomes 18 and the marker 
chromosome. Conclusions: Genome-wide array analysis gives us an ability to analyze 
submicroscopic chromosomal rearrangements and uncovered complex karyotypes that 
cannot be discerned by using conventional cytogenetic analysis. In the current case, 
after determining the marker chromosome, we were able to inform the parents about 
prenatal diagnostic procedures for future pregnancies. 
 
G16. Large Deletions Resulting in Cystic Fibrosis in Three Patients and 
Discussion of the Methods Used 
T.B. Balci1, Z. Yilmaz1, F.M. Hantash2, C.M. Strom2, T. Cok1, F. Sahin1 
1Baskent University Faculty of Medicine, Ankara, Turkey; 2Quest Diagnostics Nichols 
Institute, San Juan Capistrano, CA. 
Introduction: Cystic fibrosis (CF) is one of the most common autosomal recessive 
diseases for which mutations in the Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR) gene are responsible. Mutations in the CFTR gene include missense, 
nonsense, frameshift, splicing, and also small and large deletions and insertions. 
However, the frequency of the large genomic rearrangements such as large deletions 
or insertions are rare (2.57%). Methods: Here we present three patients who have 
large deletions in the CFTR gene with different diagnostic approaches. Genomic DNA 
was extracted from peripheral blood lymphocytes. CFTR gene mutations were analyzed 
by using reverse hybridization assay and a single multiplex semi-quantitative PCR 
(SMSQ-PCR) methods. Results: Case 1 is an 11-year-old girl who has a family history. 
Reverse hybridization assay revealed that the proband carried a homozygous R334W 
mutation. The father was heterozygous for R334W and the mother revealed normal 
genotype. Chromosome analyses were performed to exclude any chromosomal 
rearrangement involving the CFTR region. QF-PCR was performed and showed the 
different parental origins of chromosome 7 in the first child. Additionally, SMSQ-PCR 
was used to amplify the promoter and 27 exons of the CFTR gene. A deletion of exons 
4 through 10 of the CFTR gene was found in a heterozygous state in the mother and in 
the proband, which explained the genotype and phenotype of the proband. There was 
no deletion or duplication detected in father’s DNA. Case 2 is an 1-year-old girl, who 
was referred for CFTR mutation screening. As a result of the reverse hybridization 
assay, wild-type probes of intron 4 and 5, exon 4, 7, 9, 10 were not amplified and we 
thought that the patient had a large deletion including these regions. For confirmation of 
this result, reverse hybridization assay was also performed for the parents and results 
revealed normal genotype. Case 3 is a 1.5-year-old girl who had hyponatremia, 
metabolic alkalosis, persistent vomiting and malnutrition. It was found that the patient 
had a homozygous deletion in intron 12 by reverse hybridization. Parents did not accept 
mutation screening and other molecular studies for the confirmation of our results. 
Conclusions: Reverse hybridization assay is a useful and rapid method to analyze 
common mutations responsible for CF. However, in some rare cases such as having 
genomic rearrangements, results should be confirmed by another method like multiplex 
semi-quantitative PCR. Defining the molecular pathology is important for diagnosis and 
genetic counseling for future pregnancies. 
 
G17. Molecular Genetic Testing for Fragile X Syndrome: Laboratory 
Performance on the College of American Pathologists Proficiency Surveys (2001-
2009) 
K.E. Weck1, B. Zehnbauer2, M. Datto3, I. Schrijver4 
1University of North Carolina , Chapel Hill, NC; 2Centers for Disease Control and 
Prevention, Atlanta, GA; 3Duke University Medical Center, Durham, NC; 4Stanford 
University School of Medicine, Stanford, CA. 
Introduction: Molecular genetic testing for fragile X syndrome encompasses detection 
of the size of the CGG trinucleotide repeat region in the 5’ untranslated region of the 
FMR1 gene and of methylation associated with full mutations. The College of American 
Pathologists (CAP) offers biannual proficiency testing for molecular analysis of fragile X 
syndrome. The purpose of this study was to analyze laboratory performance on the 
CAP fragile X proficiency surveys from 2001 to 2009. Methods: Individual laboratory 
responses were analyzed for accuracy of genotype determination (normal, gray zone, 
premutation or full mutation) and size analysis of the FMR1 trinucleotide repeat region. 
The sensitivity and specificity of testing for fragile X were calculated. The mean, 
median, and standard deviation of reported repeat sizes were calculated using Excel. 
Performance for repeat sizing was evaluated based on variance from the median 
values. Results: Overall, laboratories demonstrated an analytical sensitivity of 99% and 
95.5% for detection of full mutations in males and females, respectively, a sensitivity of 
98% for detection of premutations, and a specificity of 99.9%. Measurement of the size 
of the CGG repeat region demonstrated good interlaboratory concordance overall. An 
increase in the range of reported sizes was observed with increasing repeat number. 
For the majority of surveys, more than 90% of responding labs measured within two 
repeats of the median for normal alleles with 20-33 CGG repeats and within five repeats 
of the median for alleles with 42 repeats. For premutation samples with 90 repeats, an 
average of 86% of laboratories measured within ten repeats of the median result. For 
full mutation alleles, an average of 88% of laboratories reported results within two 
standard deviations from the median result. Performance for measuring repeat size in 
the premutation range improved over time, with a tighter distribution of sizes reported 
and a smaller percentage of labs reporting outlier results, coincident with an increased 
percentage of laboratories using capillary electrophoresis rather than gel-based PCR 
for fragment sizing. Conclusions: Molecular genetic testing for fragile X syndrome 
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demonstrated excellent sensitivity and specificity by laboratories participating in the 
CAP surveys. Allele sizing demonstrated good performance overall and has improved 
over the time frame analyzed for premutation alleles, where size analysis is important to 
determine risk of expansion to a full mutation in carrier females. Participation in 
proficiency testing is useful for laboratories to assess individual performance and to 
determine when they should recalibrate their assays.  
 
G18. Performance of STR Genotyping in Samples Referred for Molar 
Pregnancy Testing  
L.V. Furtado1, C.N. Paxton2, M. Jama2, A.R. Wilson2, E. Lyon1,3, E. Jarboe1,  
H.M. Thaker1,4 , K. Geiersbach1,3 
1University of Utah Health Science Center, Salt Lake City, UT; 2ARUP Laboratories, 
Salt Lake City, UT; 3ARUP Institute for Clinical and Experimental Pathology, Salt Lake 
City, UT; 4Primary Children’s Medical Center, Salt Lake City, UT. 
Introduction: Molecular genotyping using PCR amplification of short tandem repeats 
(STRs) is an established method for accurately diagnosing and classifying complete 
and partial hydatidiform moles using DNA extracted from fresh or formalin-fixed, 
paraffin-embedded (FFPE) samples from products of conception (POCs). STR analysis 
can potentially identify other genomic imbalances, such as trisomy, which can also be 
implicated in early pregnancy losses and can morphologically mimic molar pregnancy 
on histologic examination. We reviewed all cases referred for hydatidiform mole testing 
by microsatellite genotyping in our institution to determine the technical performance of 
the STR assay and to investigate cases of potential trisomy. Methods: Genotyping was 
performed on 95 samples using a commercial multiplex PCR-based assay (Identifiler, 
Applied Biosystems), capillary electrophoresis (ABI 3100), and genotyping software 
(GeneMapper, Applied Biosystems). Biallelic peak area ratios were calculated by 
dividing the peak area of the longer allele (B) by the peak area of the shorter allele (A). 
Reference intervals for biallelic loci were established using maternal tissue (expected to 
be 1:1) and partial hydatidiform moles (expected to be 1:2 or 2:1), and these reference 
ranges were used to investigate possible trisomies in nonmolar pregnancies. A 
separate panel of STR primers for chromosomes 16, 18 and 21 was used to investigate 
nonmolar cases exhibiting possible trisomy, and these cases were also reviewed 
independently by two pathologists with expertise in placental pathology who were 
blinded to genotyping results. Results: Of the 95 samples tested, 41 were classified as 
molar pregnancies (24 complete and 17 partial moles). Among 53 nonmolar specimens, 
11 had allelic ratios suggestive of trisomies (9 trisomy 16; 1 trisomy 18; 1 trisomy 21). 
One of the 95 samples could not be analyzed due to lack of amplifiable maternal DNA. 
Mini-STR primers confirmed trisomic allelic pattern in all of the cases with residual 
sample available for testing. Pathologic features were suggestive of molar pregnancy in 
all 11 cases with confirmed or suspected trisomy. One of the nonmolar specimens 
showed mosaicism for biparental and androgenetic cell lines, and this case was 
histologically classified as placental mesenchymal dysplasia on retrospective review. 
Conclusions: Trisomy can morphologically simulate pathologic features observed in 
hydatidiform moles. Microsatellite genotyping is valuable in the diagnosis of molar 
pregnancy and detect aneuploidy, which can be confirmed using additional STR 
markers on the suspected abnormal chromosome.  
 
G19. Affymetrix 2.7Mb High Resolution Genome-Wide SNP Array in Clinical 
Practice 
E. Cho, E. Lee 
Greencross Reference Laboratory, Yongin, Kuwait. 
Introduction: Pathogenic copy number variants (CNVs) are found in 5% to 15% of 
individuals with intellectual disability using different array platforms. It is expected that 
the arrays with higher resolution genome coverage detect CNVs more accurately and 
allow identification of smaller CNVs. Methods: We applied Affymetrix Cytogenetics 
Whole Genome 2.7M array to assess CNV detection in 20 cases (various microdeletion 
syndromes and cases with marker chromosome), which contain pathogenic CNVs 
previously detected. Also we applied array in 40 cases with intellectual disability or 
multiple congenital anomalies. Results: As a diagnostic test, detection rate of 
pathogenic CNV was 17.5% (7 in 40). Detected pathogenic CNVs included 0.9-Mb 
microdeletion at 2q22.3 (ZEB gene deletion: Mowat-Wilson syndrome) and 1.1-Mb 
microdeletion at 4q21.21q21.22 (novel microdeletion syndrome published in J. Med. 
Genet, 2010 47:377-84). One case showed two significant genomic imbalances that 
might originate from unbalanced translocations. One case showed 40-Mb long 
continuous stretches of homozygosity at 11q. Two cases had a small telomeric 
imbalance. However, confirmatory test with telomere MLPA could not detect any 
abnormalities. Conclusions: We validated Affymetrix microarray for the previously 
known microdeletion syndromes and concluded microarray analysis significantly 
improves the diagnostic yield and the quality of the diagnostic laboratory workflow. 
However, careful interpretation and confirmatory tests were needed in the case of small 
telomeric imbalances.  
G20. Clinical Evaluation of Two Commercially Available PCR-Based Methods 
for the Detection of FMR1 Mutation  
J. Juusola, P. Anderson, F. Sabato, D.S. Wilkinson, A. Pandya, A. Ferreira-Gonzalez 
Virginia Commonwealth University, Richmond, VA. 
Introduction: The current workflow for diagnostic laboratories performing fragile X 
testing is time consuming and labor intensive. Additionally, current methods are limited 
in the range of repeat sizes and degree of mosaicism that can be detected. Recently-
developed PCR-based assays simplify workflow, amplify full mutation alleles, and 
improve sensitivity for detecting low-level mosaicism. Methods: We evaluated the 
performance characteristics and workflow of two commercially available methods for 
determining FMR1 mutation status using 36 known Coriell DNA samples and NIST 
standards and 40 previously tested anonymized patient samples. We tested 22 normal, 
10 intermediate, 27 premutation, and 17 full mutation samples. We also tested each 
method’s ability to detect mosaicism (ranges: 90% to 1% for males; 50% to 1% for 
females). One method was an RUO kit from Asuragen (AmplideX FMR1 PCR 
reagents). Only the CGG primers were tested. The second method used a set of ASRs 
from Abbott Molecular, and consisted of Primer Set 1 (for gender determination and 
repeat sizing) and Primer Set 2 (for screening of expanded alleles). Each assay was 
evaluated for accuracy, precision, correlation with previous results, and workflow. 
Results: Both methods performed equally well in accuracy (+/1 repeat) compared to 
NIST standards and Coriell samples. Precision studies showed similar results for both 
systems (+/-0.04 to 0.12 repeats SD from mean). Both methods correlated with 
expected results for the selected Coriell samples from a previous consensus study, and 
showed 100% concordance with the genotype of previously analyzed patient samples. 
The Asuragen method was able to detect full mutation mosaicism down to 5% and 
premutation mosaicism to 1%. The Abbott Primer Set 2 was able to detect both full 
mutation and premutation mosaicism down to 25%. Neither method reveals methylation 
status. The most significant difference between the two methods is the workflow. The 
Asuragen method includes PCR followed by a single injection and analysis with 
capillary electrophoresis. The Abbott method includes two PCR reactions. The PCR 
product from Primer Set 2 (screening) can be analyzed directly by capillary 
electrophoresis, while the PCR product for Primer Set 1 (sizing) is first checked by 
agarose gel electrophoresis, enabling visualization of full mutation products as smears, 
followed by post-PCR clean-up and two injections on capillary electrophoresis (one for 
short and one for long fragments). Conclusions: The two PCR-based methods that we 
evaluated for the determination of FMR1 mutation status are concordant with expected 
results in their final diagnoses and significantly differ only in their workflow.  
 
G21. Clinical and Molecular Characterization of a Korean Patient with 9q22.3 
Microdeletion Detected by Array Comparative Genomic Hybridization 
C. Jung1, E. Shin1, K. Lee1, S. Kim2 
1Neodin Medical Institute, Seoul, Republic of Korea; 2Busan St. Mary’s Medical Center, 
Busan. 
Introduction: Chromosomal disorders are often suspected in patients who display 
developmental delay, mental retardation, or dysmorphic features. However, the 
presence of submicroscopic genomic deletions or duplications cannot be detected by 
conventional chromosomal analysis. Array comparative genomic hybridization (CGH) is 
a newly developed molecular cytogenetic technique that enables the identification of 
copy number alterations in the human genome. Here we report a 9p22.3 microdeletion 
by array CGH in a child with dysmorphic features. The 9q22.3 microdeletion is recently 
proposed syndrome characterized with overgrowth, psychomotor delay, and distinct 
facial features including trigonocephaly, epicanthic folds, small mouth with thin upper 
lip, low set ears with ear lobule uplift. Methods: G-banded chromosome analysis was 
performed in the patient. Array CGH using human 135K whole-genome arrays (Roche 
NimbleGen, Germany) was also performed, and the results were analyzed using 
Genoglyphix software (Signature genomics, USA) and the online genome databases. 
The clinical and molecular findings were considered the implications through review of 
literatures published about 9q22.3 microdeletion. Results: Chromosome study showed 
that the patient had 46,XX,t(9;10)(q22.3;q11.2). And array CGH revealed a 4.7 Mb 
interstitial deletion involving 9q22.31-q22.33 region. She had similar findings with 
9q22.3 microdeletion including overgrowth, facial dysmorphism, and hypotonia. A 
female infant was delivered at 36 weeks of gestational age by vaginal delivery. At birth, 
she was large for the gestational age and showed macrocephaly with a birth weight of 
2920g (>95%), length 51cm (>95%), and head circumference 36cm (>95%). 
Dysmorphic features included frontal bossing, small mouth with thin upper lip, low set 
ears with ear lobule uplift and short neck. Brain MRI and cardiac echocardiography 
showed mild ventriculomegaly and patent ductus arteriosus. The neonatal period was 
complicated by respiratory difficulties due to respiratory distress syndrome, feeding 
difficulties and hypotonia. Besides the deleted portion in the patient contains PTCH1 
gene responsible for nevoid basal cell carcinoma syndrome (NBCCS, Gorlin syndrome, 
OMIM #109400) and thus the patient should be observed carefully. Conclusions: In 
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the present study, we identified a 9q22.3 microdeletion in a child with overgrowth and 
dysmorphic features. To the best of our knowledge, this is the first case of 9p22.3 
microdeletion in Korea. The result from our study demonstrates that array CGH is a 
useful method for detection of subtle genomic imbalance and prediction of clinical 
outcome. Further analyses such as FISH are needed to validate this study and a long-
term follow-up of the patient would contribute to extend our understanding about 9q22.3 
microdeletion. 
 
G22. Clinical Application of Warfarin Pharmacogenetics (PGx): the Experience 
of the Philadelphia Veterans Affairs Medical Center (PVAMC)  
R. Ochs1, L.J. Chandler1,2, E. Pollak1,2, P. Jacobs2, J.L. Sepulveda1,2 
1University of Pennsylvania, Philadelphia, PA; 2Philadelphia VAMC, Philadelphia, PA. 
Introduction: Warfarin is a major cause of adverse drug reactions and morbidity. 
Single nucleotide polymorphisms (SNPs) in the CYP2C9 and VKORC1 genes affect 
warfarin metabolism and anti-coagulation response, and have been associated with 
dosing requirements and outcomes of warfarin therapy. Clinical use of warfarin PGx 
correlated with decreased hospitalization rates in a recent prospective study. While 
ongoing large-scale randomized studies may ultimately determine the cost-
effectiveness of routine warfarin PGx, several clinical groups are using PGx to help 
guide therapy or explain atypical therapeutic responses. We report the experience of 
the PVAMC, where warfarin PGx has been available for clinical use since June, 2008. 
Methods: PGx was requested in 49 patients with difficulties in establishing a stable 
warfarin dose. Patients were followed by PharmD providers in the Anticoagulation Clinic 
and included 48 males, 26 Caucasian, and 23 (47%) African-American patients. DNA 
was extracted from EDTA-anticoagulated blood using EasyMag (Biomerieux) and 
analyzed by microarray using the CYP2C9-VKORC1 assay and the Autogenomics 
Infiniti analyzer. Clinically relevant SNPs measured include CYP2C9 *2-6, *11, and 
VKORC1 3673. Patients had 4-51 visits for potential dose adjustments. The last 
prescribed warfarin dose was compared to the PGx-predicted dose according to the 
http://www.warfarindosing.org algorithm. An interpretative note including PGx-guided 
dose recommendations was created by a pathologist on the patient's electronic medical 
record. Linear regression and analyses of variance with Holm-Sidak correction were 
used for statistical testing. Results: CYP2C9 variants were identified in 15 (31%) 
patients: homozygous *2 (1), and heterozygous *2 (4), *3 (5), *5 (1), *6 (2), and *11 (2). 
VKORC1 genotype distribution at the 3673 site was as follows: A/A (4), G/A (16), and 
G/G (29). African-Americans comprised 72% of the patients with the G/G genotype, 
while Caucasians accounted for 88% of G/A and 75% of A/A. There was a good 
correlation between PGx-predicted dose and last prescribed dose (R2=0.60). Patients 
with 3673 G/G, a variant associated with warfarin resistance, and wild-type CYP2C9, 
had higher final dose requirements (p<0.001), larger increases from initial dose 
(p=0.005), and wider ranges of dose adjustments (p=0.029), as compared to other 
genotypes. Conclusions: These data suggest that PGx-guided warfarin dosing 
recommendations may be useful even in a well-managed anticoagulation clinic 
environment with close patient follow-up, particularly when a large proportion of African-
American patients results in high prevalence of warfarin resistant genotypes. Effective 
communication between the laboratory and the anticoagulation providers is essential for 
proper interpretation of warfarin PGx results. 
 
G23. High Prevalence of Simultaneous Factor V Leiden, Prothrombin G20210A 
and MTHFR C677T Mutations in Lebanese Patients Referred for Thrombophilia 
Workup  
H. Halas, R. Hoteit, R.A. Mahfouz 
American University of Beirut Medical Center, Beirut. 
Introduction: Molecular diagnostics has markedly improved the diagnosis and work-up 
of different clinical conditions including hypercoagulable state or thrombophilia where 
different genes are involved. In this report, which is the largest report in the medical 
literature and the first in Lebanon, we describe the prevalence of simultaneous 
mutations in the three major thrombophilia genes, Factor V, Factor II, and 
Methylenetetrahydrofolate reductase. Methods: Study Samples and DNA Extraction: 
we analyzed 2248 cases referred for thrombophilia workup at the American University 
of Beirut Medical Center. The patients, based on the specialty of the referring 
physicians, were mainly referred for work-up of recurrent abortions, deep vein 
thrombosis (DVT), stroke, pulmonary embolism (PE) and catheter thrombosis between 
January 2003 and February 2011. Their DNA was originally extracted using the PEL-
FREEZ extraction kit (PEL-FREEZ, DYNAL, USA) and stored at -80°C for later use. 
PCR and Reverse Hybridization: To test for the various genotypic profiles of the Factor 
V, Prothrombin, and Methylenetetrahydrofolate genes, the FV-PTH-MTHFR StripAssay 
(ViennaLab, Austria) was used and the manufacturer’s protocol was followed as 
recommended. This assay screens for the G1691A, G20210A, and C677T mutations of 
the Factor V, Prothrombin, and MTHFR genes, respectively, whereby in vitro, the 
different gene sequences are simultaneously amplified and biotin-labeled in a single 
amplification reaction. Results: Out of the 2248 referred patients, 25 (1.11%) had 
Factor V, Factor II, and MTHFR gene mutations simultaneously. As deduced from the 
referral diagnosis stated by the physician, 13 patients out of the 25 had DVT, 5 had 
recurrent abortions, 4 had stroke, 2 patients experienced catheter thrombosis, and 1 
patient had both DVT and PE. Conclusions: With this presumably high prevalence rate 
of triple mutations, the Lebanese community again shows a more peculiar and specific 
finding for this special population and may label the Lebanese people as “more prone” 
for thrombotic disorders. We highly advocate for clinical studies to be performed at a 
larger scale in Lebanon (as well as other countries) for better correlation with the 
genetic findings based on this and other national and international studies.  
 
G24. Combined Sanger- and Pyrosequencing in the Molecular Evaluation of 
Dysfibrinogenemia 
A. Roy1,2, O. Bilen1,2, E. George1, L. Millecker2, D. Lopez-Terrada1,2, L. Venkateswaran2, 
R. Hurwitz2, J. Teruya1 
1Baylor College of Medicine, Houston, TX; 2Texas Children's Hospital, Houston, TX. 
Introduction: Fibrinogen, a plasma glycoprotein synthesized by the liver, is an 
essential component of the blood clot. The mature protein is composed of three 
subunits, encoded by one of three homologous genes on Chromosome 4q: fibrinogen 
alpha (FGA), fibrinogen beta (FGB) and fibrinogen gamma (FGG). More than 40 
mutations in FGA, FGB and FGG have been reported in autosomal dominant 
dysfibrinogenemia, a disorder defined by normal levels of functionally abnormal plasma 
fibrinogen. Patients with dysfibrinogenemia may remain clinically asymptomatic or 
present with bleeding and/or thrombosis. Dysfibrinogenemia is screened in the 
laboratory through a combination of prolonged thrombin time and reptilase time and 
decreased fibrinogen activity/antigen ratio. However, these tests do not distinguish 
between acquired and inherited forms of fibrinogen dysfunction and neither predict the 
recurrence risk nor assist in the decision to institute therapy. We hypothesize that 
genetic analyses of fibrinogen genes can be useful in diagnostic confirmation and in 
predicting the clinical presentation of inherited dysfibrinogenemia. Methods: Seven 
subjects were consented on an IRB-approved protocol at Texas Children's Hospital 
based on either abnormal screening tests, or history of unexplained bleeding and/or 
thrombosis. Five members of a multigenerational family, including four with abnormal 
screening tests and one unaffected member, and two additional probands were 
recruited. Controls were unaffected family members or unrelated individuals without 
laboratory abnormalities. PCR and direct Sanger sequencing was performed in 
duplicate on genomic DNA extracted from peripheral blood using primers amplifying all 
6 coding exons of FGA. Separate PCR and pyrosequencing primers, designed to 
amplify and confirm hot-spot mutations in exon 2 of FGA were evaluated using 
PyroMark PSQ-Gold SQA reagents on the PSQ-96MA pyrosequencer (Qiagen Inc., 
CA) Results: Mutations were identified in FGA in all six cases with either positive 
history or laboratory evidence of dysfibrinogenemia. Whereas the unaffected relative 
was wild type, all four affected members of the single family were heterozygous for the 
c.104G>A (R35H) mutation that affects thrombin-mediated fibrinopeptide A release. 
These patients may have an increased risk of spontaneous abortions and postpartum 
bleeding. The remaining two patients were heterozygous for known deleterious 
mutations c.103C>T (R35C) and c.112A>G (R38G). Each mutation was confirmed in a 
separate pyrosequencing assay. The molecular analyses showed perfect correlation 
with the laboratory abnormalities. Conclusions: Molecular analyses of suspected 
dysfibrinogenemic patients using a combination of traditional sequencing and 
pyrosequencing can be a useful adjunct tool in providing diagnostic confirmation, and 
general risk assessment for selected well-characterized mutations. 
 
G26. Hereditary Amyloidosis: More than Just Transthyretin 
M. Shiller, K. Schowalter, J. Theis, C. Klein, A. Dogan, W.E. Highsmith 
Mayo Clinic, Rochester, MN. 
Introduction: Mutations in transthyretin (TTR) account for 95% to 98% of hereditary 
amyloidosis. Transthyretin synthesis occurs in the liver, and phenotypic manifestations 
are peripheral polyneuropathy and/or cardiomyopathy, with or without eye or brain 
involvement. Therapeutic management varies based on the origin of the amyloid 
protein, with liver transplantation implemented in individuals with TTR amyloidosis. 
However, at least 2% to 5% of hereditary amyloidosis is due to aberrantly folded protein 
products of other genes. Some of these other genes also have potential founder effects, 
genotype-phenotype correlations, and specific therapies. In order to capture the 
remaining genetic etiologies for hereditary amyloidosis, we developed gene sequencing 
assays to confirm suspected mutations in additional genes, some of which were 
detected by tissue laser-capture tandem mass spectrometry (LC MS/MS) in patients 
with this presumed clinical diagnosis. Methods: Sequencing assays using universal 
primer sequence tags were developed for whole blood specimens for the following 
genes: ApoA1, ApoA2, Fibrinogen Alpha (FGA), GelsolinA (GsnA), and Lysozyme 
(Lys). To design the primers, each gene was analyzed in Alamut® v1.5, and the coding 
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sequence was obtained from the UCSC genome browser website. Potential SNPs were 
obtained using the Oligo Typer Analyzer program (Mayo Clinic, Rochester). Each 
primer was analyzed for melting temperature, potential hairpins, and other features. The 
assays were validated on 22 samples as follows: ApoA1 (9); FGA (7); GsnA (5); Lys 
(1). Samples were obtained from our LC MS/MS lab (3), Mayo Clinic research 
laboratories (5), and outside research laboratories (14) for both intra- and interassay 
precision and accuracy. Results: We identified pathogenic changes in three cases of 
non-TTR familial amyloidosis detected by LC MS/MS. Mutations were confirmed in the 
19 cases with known variants. The repeat rate due to signal intensity or base call quality 
issues was less than 5% for four of five genes. ApoA2 required a second set of primers 
that decreased the repeat rate to 11% for raw signal, and 3% for quality. Conclusions: 
In each case, the sequencing primers designed for each respective gene successfully 
identified known pathogenic mutations. Clinically, identification of the genotype for 
amyloidosis is important to properly direct the management of the patient and for 
genetic counseling for the family. These tests will provide valuable information for cases 
in which less common familial amyloidoses are identified, either clinically, or by 
advanced laboratory methods such as LC MS/MS.  
 
G27. Effective Detection of Germline Copy Number Variations of Cancer 
Predisposition Genes Using a Whole Genome Array with Exon Coverage of 
Disease Genes 
W. Bi, S. Cheung, A. Patel 
Baylor College of Medicine, Houston, TX. 
Introduction: Constitutive (germline) genetic variations have been associated with 
increased risk of cancer with or without congenital defects. Some of the detected 
variations are copy number variations (CNVs). Methods: We have been using 
customized oligonucleotide-based arrays for the detection of CNVs associated with 
genetic diseases by chromosomal microarray analysis (CMA). Our clinical array allows 
the interrogation of not only the entire genome but also exon coverage of more than 
1700 disease or candidate genes including over three dozen genes relevant to cancer 
family syndromes. Results: Out of >25,000 patients referred to for CMA testing, we 
identified 59 patients with germline copy number losses of cancer predisposition genes. 
The involvement of cancer risk genes are unexpected in most cases except for some 
cases referred for neurofibromatosis, WAGR, and retinoblastoma. A small deletion 
containing only part of a single gene were identified in six patients including three 
patients having a deletion within the PMS2 gene of ~1 kb, ~4 kb, and ~10 kb in size, 
and the other three patients having a ~8 kb deletion of the exon 3 to 5 of PTEN, a ~12 
kb deletion of the exon 3 of SDHB, and a ~41 kb deletion of the exon 41 to 58 of NF1, 
respectively. One patient has a ~ 4 kb deletion including the exon 5 to 10 of MSH6 and 
the 3’ untranslated region of an adjacent gene. The remaining patients have a deletion 
of >0.9 Mb in size containing multiple genes. The copy number losses in three cases 
are part of a complex rearrangement. Of the 20 unrelated patients with parental 
information, the deletions in ~85% (17/20) patients are de novo and the remaining 
~15% (3/20) rearrangements are maternally inherited. These inherited rearrangements 
include the two small deletion involving SDHB or MSH6 and a recurrent 0.9 Mb deletion 
involving TMEM127 in 2q11.2 identified in two siblings. Conclusions: Our data 
demonstrated that array CGH using a high density whole genome array are effective in 
detection of large copy number changes spanning the entire cancer predisposition gene 
that may be undetectable by DNA sequencing. In addition, exon-by-exon coverage of 
disease genes allows small variations involving only part of a single gene to be 
detected. Because most of these CNVs are accidental findings in patients referred for 
developmental defects, cancer genetic counseling and parental studies are needed for 
cancer surveillance and recurrent risk estimation.   
 
G28. A 106 Mutation Cystic Fibrosis Laboratory Developed Testing Using the 
Sequenom MassARRAY®: Performance in the First 18,000 Tests 
M. Shiller, W.E. Highsmith, L.T. Holtegaard 
Mayo Clinic, Rochester, MN. 
Introduction: In 2001, the ACOG and ACMG recommended population-based carrier 
screening for cystic fibrosis (CF) using a panel of 23 mutations. Since that time, some 
have argued that expanded panels with additional mutations would be useful in non-
Northern European populations. We co-developed a CF screening test with Sequenom, 
Inc. that targets 106 mutations. Analytical verification of the assay has been presented 
(JMD 2010, 12:611-619). Methods: The Mass Array CF screening test was validated 
according to CLIA guidelines. Since validation, the Molecular Genetics Laboratory has 
tested 18,559 clinical samples. The workflow consists of 8 multiplex PCR reactions, 
removal of dNTPs and primers with AMPure resin (Beckman-Coulter), 8 multiplex single 
base extension (SBE) reactions, desalting with an ion exchange resin, spotting the 
extended SBE products on a MassARRAY® chip, and analysis by MALDI-TOF mass 
spectrometry. 48 samples and controls are run per batch in 384 well plates. All steps 
are automated, and the test requires 9 hours to complete. Results: Of the clinical 
samples tested, 586 were for a possible or known diagnosis of CF, pancreatitis, or male 
infertility; the remainder had indications for testing of routine carrier screening, a family 
history of CF, a partner that was a known CF carrier, or no indication given. Of the total 
number of samples tested, 821 (4.4%) had at least one mutation. Of the 124 mutations 
detected in the diagnostic cases, 114 (91.9%) were ACMG panel mutations, 78 of 
which were dF508. Of the 695 mutations identified in samples tested for carrier status, 
627 (90.2%) were ACMG panel mutations (443 dF508) and 68 (9.8%) were non-panel. 
Two mutations were identified in one individual with a referral for carrier screening. The 
genotype for this individual was dF508/R117H-7T. Two mutations were detected in 3 
individuals with no indications for testing provided. In two cases, the 2nd mutations 
were known to be associated with mild disease, 3849+10kbC>T and D1152H. One 
individual was homozygous for 3849+10kbC>T. We have detected 46 different 
mutations, including 21 of the 23 mutation ACMG panel (711+1G>T and R334W have 
not yet been detected). We have identified 2 mutations that are not on any other 
currently available panel. Conclusions: Of all detected mutations, nearly10%, were 
non-ACMG panel mutations, indicating that a significant fraction of the population can 
benefit from screening with an expanded panel.  
 
G29. Comparison of Extracted DNA vs. Non-Extracted Sample (Direct) for the 
Detection of Factor V Leiden, Factor LI, And MTHFR Single Nucleotide 
Polymorphisms from Whole Blood and Buccal Swabs 
E. Eleazar, M.J. Young, S. Dempsey, M. Aye, M. Tabb, M. Exner 
Focus Diagnostics, Cypress, CA. 
Introduction: Molecular methods traditionally entail extraction of nucleic acids prior to 
performing amplification and detection steps. We have developed reagents that enable 
direct sample-to-answer detection of nucleic acids from various specimen types without 
performing any nucleic acid isolation or purification steps. We used reagents to detect 
factor V Leiden, factor II, and methylenetetrahydrofolate reductase (MTHFR) single 
nucleotide polymorphisms (SNPs) from whole blood and buccal swab samples, and 
compared methods using nucleic acid extraction to the direct detection methodology. 
Methods: Whole blood (previously tested by a reference method) and buccal swab 
samples were evaluated. Whole blood was collected using EDTA, sodium citrate, or 
sodium heparin as an anticoagulant. Real-time PCR assays were performed to 
compare extracted DNA vs. extraction-free (direct) amplification of these samples. The 
master mix utilized for direct testing was optimized to provide robust amplification 
directly from specimens, even in the presence of potential inhibitory substances. 
Results: Genotypes obtained for both alleles were in 100% agreement with those 
obtained by the reference method. In addition, complete concordance was obtained 
between extracted samples and those that were amplified directly without extraction. 
Direct detection was achieved with both whole blood (in all anti-coagulants; EDTA, 
sodium citrate, and sodium heparin) and buccal swab samples, and none of the 
samples showed inhibition. Testing time (from sample to result) was less than 40 
minutes for both sample types. Conclusions: The ability to directly amplify and detect 
nucleic acids without previous extraction and purification processes demonstrates the 
robust nature of the amplification chemistry. In addition, accurate direct detection and 
discrimination of various SNPs was achieved from both sample types. 
 
G30. CNV and Incomplete Linkage Disequilibrium Interference with the HCP5 
Genotyping Assay for Abacavir Hypersensitivity 
R. Melis1, E. Lyon1,2, G.A. McMillin1,2, P.R. Slev1,2, J.J. Swensen1,2 
1ARUP Institute for Clinical and Experimental Pathology, Salt Lake , UT; 2University of 
Utah School of Medicine, Salt Lake City, UT. 
Introduction: Abacavir sulfate (Ziagen®) is an effective antiretroviral drug used to 
manage HIV infection, but 5% to 8% of patients develop abacavir hypersensitivity 
reaction (ABC-HSR). ABC-HSR is a life threatening condition that is ethnic-dependent 
and associated with the human leukocyte antigen HLA-B*5701 allele. Current 
guidelines for antiretroviral treatment recommend screening for HLA-B*5701 prior to 
initiating abacavir therapy. However, HLA typing or sequencing remains prohibitively 
expensive for routine screening. In Caucasians a SNP (rs2395029) in the major 
Histocompatibility Complex P5 (HCP5) gene, is reported to be in linkage disequilibrium 
(LD) (r2=1) with the HLA-B*5701 allele. Genotyping for HCP5 has been increasingly 
adopted as a simple, inexpensive method to screen for ABC-HSR. In this study we 
evaluated the genotype concordance between the HCP5 SNP and HLA-B*5701 allele in 
a large sample set. Methods: 1,889 DNA samples were genotyped for the HCP5 
polymorphisms by real-time hybridization probe assay and for the HLA-B*5701 allele by 
PCR with sequence specific primers (PCR SSP). Results: Overall, a good correlation 
between the two genotyping methods was found with analytical sensitivity (0.99%) and 
specificity (0.99%). Interestingly, the HCP5 SNP could not be amplified in two samples, 
both negative for HLA-B*5701. Further investigations with a custom comparative 
genomic hybridization (CGH) array demonstrated that both samples were homozygous 
for large deletions including the HCP5 gene. The Database of Genomic Variants shows 
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that this region encompassing the HCP5 gene is the site of a recurrent copy number 
variation (CNV), and that does not extend to the HLA-B locus. In addition, nine samples 
with discordant genotyping results between the two methodologies were identified. 
These included: eight samples HLA-B*5701 negative/HCP5 positive, and one sample 
HLA-B*5701 positive/HCP5 negative. Conclusions: HCP5 genotyping results showed 
a good correlation with HLA-B*5701 typing by PCR SSP. However we have detected 
two samples with homozygous deletions of the HCP5 gene and found the locus is the 
site of a CNV that does not include the HLA-B locus. The fact HCP5 occurs within a 
region of CNV and the possibility that linkage disequilibrium between the HLA-B*5701 
and HCP5 SNP may vary between ethnicities is a concern. The possibility of incomplete 
disequilibrium and CNV should considered, particularly when HCP5 genotyping is 
performed in patients who are not of European ancestry. 
 
G31. Frequency of 3' Deletions in PMS2 
C.P. Vaughn1, C.L. Baker1, J.J. Swensen1,2, W.S. Samowitz1,2 
1ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; 2University 
of Utah Health Sciences Center, Salt Lake City, UT. 
Introduction: Lynch syndrome is characterized by mutations in one of four mismatch 
repair genes, MLH1, MSH2, MSH6, or PMS2. While the detection of mutations in PMS2 
is greatly complicated by numerous pseudogenes, long-range PCR can be employed to 
specifically amplify the gene and detect sequence changes. For detection of large 
deletions, multiplex ligation-dependent probe amplification (MLPA) has been employed 
for exons 1 – 11. We have recently described an MLPA-based method that avoids 
PMS2CL, a pseudogene with extensive homology to the 3' end of PMS2, and now 
permits detection of deletions for this region of the gene (exons 12 – 15) as well. 
However, the frequency of 3' deletions of PMS2 has not yet been determined. 
Methods: Sixty-three samples for which immunohistochemical staining suggested a 
PMS2 mutation, but for which no mutation was identified using previously available 
methods, were evaluated for 3' deletions in PMS2 using our new method. This method 
utilizes MLPA probes for PMS2 and PMS2CL with the selection of appropriate 
reference samples and sequencing the gene and pseudogene in this region. Results: 
Evaluation of this cohort of samples identified six samples with deletions in the 3' region 
of the gene, including three previously reported samples with deletions in intron 12 – 
exon 15, exons 13 – 15, and exons 14 – 15. Of the additional three samples with 
deletions, one sample harbored an exon 13 deletion and two samples harbored exon 
14 deletions. Overall, 6/63 (9.5%) samples in which PMS2 mutations had not been 
identified by existing methodologies harbored deletions in the 3' region of PMS2. 
Conclusions: These results indicate that ~10% of samples suspected of harboring a 
PMS2 mutation based on immunohistochemical staining, for which mutations have not 
yet been identified, may benefit from testing using the new methodology.  
 
G32. Rapid Single-Tube Genotyping of 23 CFTR Mutations Using High 
Resolution Melt Analysis (HRMA) 
L. Xu, J.A. Yancy, C. Armstrong, L. Jiang, R. Howell 
Canon US Life Sciences, Rockville, MD. 
Introduction: Mutations in the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene are responsible for cystic fibrosis and CFTR-related disorders. Both can 
affect multiple systems/organs in the body, including the lungs, pancreas, intestines, 
and liver.  In the non-Hispanic white population CF disease incidence is estimated at 1 
in 2500. Though the incidence is less in other ethnic populations, ACOG has 
recommended carrier and prenatal screening as part of routine practice because it has 
become increasingly difficult to assign a single ethnicity to affected individuals. 
Molecular diagnostics are routinely used for carrier screening and for diagnosis 
confirmation of other positive/borderline CF newborn screening tests. Commercially 
available tests can take up to 8 hours to perform and require several tube transfers. We 
have developed a rapid single-step detection method to screen for the 23 CFTR 
mutations recommended by ACOG using HRMA. Small amplicon assays were 
designed to genotype 18 of the 23 loci of interest. The remaining 5 mutations (A455E, 
ǻI507/ ǻF508, G551D/R553X) employ unlabeled probes following amplification for 
genotyping. In addition to genotyping disease-associated mutations this method can 
identify benign variants known to interfere with the identification of ǻF508 or ǻF507 
mutations. Methods: PCR reactions were amplified on the Roche LightCycler®480 
system in the presence of LCGreen®Plus dye. Eighteen targets used routine 
amplification conditions and 5 targets were amplified using asymmetric PCR and had 
an additional probe that was blocked from participating in amplification. HRMA was 
performed at a rate of 0.6°/sec on all amplicons or amplicon/probe mixes immediately 
following PCR in the same tube in the same instrument. HRMA data was downloaded 
to in-house developed software or MeltWizard (courtesy of Carl Wittwer) for pattern 
analysis. Thirty-two genomic DNAs acquired from the Coriell Institute and one from 
patient DNA were tested for each target. Thirteen synthetic plasmid DNA constructs 
specifically designed for the targeted regions were also tested. Expected amplicon size 
was confirmed using the Agilent Bioanalyzer instrument. Genotypes were called based 
on pattern analysis. Results: All 33 genomic DNAs and 13 synthetic DNAs showed the 
expected genotype with HRMA. Challenge with synthetic DNAs that represent benign 
mutants demonstrated patterns that could be distinguished from the clinically relevant 
ǻF508 or ǻI507 mutations. Conclusions: We have demonstrated a rapid sensitive 
method for detection of CF mutations. In addition, this method can easily distinguish 
clinically relevant ǻF508 or ǻI507 variants from benign variants F508C, I506V, and 
I507V. 
 
G33. Germline Mutations in MLH1 and MSH2 in Korean Hereditary Non-
Polyposis Colorectal Cancer (HNPCC) Patients 
S. Kim1, S. Kim1, J. Kim1, C. Yu1, H. Chung2, S. Chun1, W. Lee1, W. Min1 
1 University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of 
Korea; 2Cheil General Hospital and Woman's Healthcare Center, Seoul. 
Introduction: Hereditary non-polyposis colorectal cancer (HNPCC), the most common 
hereditary colon cancer syndrome, is an autosomal dominant disorder with defects in 
mismatch repair (MMR) system. Identification of MMR gene mutations can have direct 
clinical implications in management and counseling of HNPCC families. We tested 27 
suspected HNPCC Korean patients for germline mutations in two MMR genes, MLH1 
and MSH2. Methods: Suspected HNPCC patients were enrolled according to the 
clinical manifestation and Amsterdam criteria II in Asan medical center. Tumors were 
tested for MLH1 and MSH2 immunohistochemical staining (IHC) and microsatellite 
instability (MSI), a hallmark of HNPCC. Germline MMR gene mutations (MLH1 and 
MSH2) were tested with PCR direct sequencing method covering all the coding regions. 
The remaining mutation-negative cases were analyzed using multiple ligation 
dependent probe amplification (MLPA). Clinical data were obtained by chart audit. 
Results: Among 27 suspected HNPCC patients, four patients have MLH1 gene 
mutations: c.1758dupC, c.1721T>C, c.666T>G and c.2101C>A. Eight patients have 
MSH2 mutations: c.2361dupT, c.1024delinsAA, c.1147C>T, c.2068C>T, 
c.2633_2634delAG, c.-225G>C, c.2006G>A and c.1168C>T. Three mutations 
(c.2361dupT, c.1024delinsAA, c.2068C>T) in the MSH2 gene have not been reported 
elsewhere. There was no patient whose MLPA results were positive for MLH1 or MSH2. 
Conclusions: In this study, 4 patients (14.8%) had MLH1 gene mutations and 8 
patients (29.6%) had MSH2 mutations. We identified three novel mutations in MSH2 
gene. Identification of MLH1 and MSH2 mutations is important for predictive diagnosis 
and clinical management of HNPCC patients. We described the incidence and 
distribution of MMR gene in Korean HNPCC patients. Also, our results could broaden 
the spectrum of MLH1 and MSH2 mutations by identifying three novel mutations. 
Further investigation including systematic familial studies with larger cohorts of patients 
should be conducted.  
 
G34. Investigation of Exon-Focused Array CGH as a Diagnostic Tool for Copy 
Number Mutations in Mendelian Disorder 
C. Ki1, J. Kim2, Y. Kim2, S. Lee1, J. Kim1 
1Samsung Medical Center, Seoul, Republic of Korea; 2Samsung Changwon Hospital, 
Changwon City. 
Introduction: Copy number changes including deletion and duplication mutations in 
human genome have been known as important cause of Mendelian disorders. Recently 
major advancement in detection of copy number change has been achieved by 
development of microarray technique. The aim of this study is to explore the possibility 
of exon-focused microarray CGH as diagnostic tools of Mendelian disorders by gene 
copy number change. Methods: Diagnostic usefulness of exon-focused microarray 
CGH was investigated about 87 Mendelian disorders using the NimbleGen Human 
CGH 3*720K Whole-Genome Exon-Focused Array (Nimblegen, Roche, USA). Copy 
number change was measured about 7 healthy controls and 14 cases that showed 
copy number change by MLPA methods, and Probe signal stability was measured by 
coefficient variance (CV)% of probe signal ratio about each genes. In addition, we 
compare the probe composition of MLPA and exon-focused array CGH about 4 disease 
categories that include Charcot Marie-Tooth/Hereditary Neuropathy with liability to 
Pressure Palsies Disease, Von Hippel Lindau Syndrome, Spinal Muscular Atropy and 
Duchene Muscular Dystrophy. Results: Among 87 genes, 75 showed CV less than 
10% and 49 genes had 1 more probes in all exon. Genes with pseudogenes including 
SMN, SMN2, CYP21A2, PMS2, and PRSS1 showed high CV% and also gene dosage 
showed difference with expected results. In case of genetic disease that showed 
mutation pattern with whole gene deletion or duplications, exon focused array CGH 
detected the accurate gene dosage. In case of copy number mutation with exonic level, 
copy number changes of two more exons were detected by exon focused array CGH. 
However, copy number change in single exon was detected by modification of analysis 
program algorism. Conclusions: Exon-focused array CGH method was considered as 
useful diagnostic tools for the detection of Mendelian disorder by gene dosage mutation 
because in had much more probe numbers than MLPA and stable fluorescence signal 
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ratio about each probes. But it could not measure the accurate gene dosage in the 
presence of pseudogenes.  
 
G35. Fragile X Carrier Screening and Allele Distribution of the FMR1 Gene in 
Korean Women 
H. Choung, Y. Kim 
Samkwang Medical Laboratories, Seoul, Republic of Korea. 
Introduction: Fragile X syndrome (FXS), the most common form of familial mental 
retardation, is caused by the expansion of CGG sequences in the 5’ untranslated region 
of the FMR1 gene on the X chromosome. Previous studies have suggested that 
prevalence of FXS in Korean population was lower than that observed in Caucasians. 
In addition, no premutation alleles were found in a previous screening among the 
general Korean women. The aim of this study was to investigate the prevalence of 
carriers of premutation-size alleles and the distribution of the FMR1 alleles in Korean 
women. Methods: The study subjects were Korean women without mental retardation 
from January 2007 to April 2011. We analyzed a total of 20,023 normal female subjects 
and attempted to estimate the frequency of the FMR1 allele. Their CGG repeats were 
determined by using PCR and fragment analysis. Results: Among a total of 40,046 
alleles, 39,952 alleles (99.77%) were within the normal range. The number of normal 
CGG repeats ranged from 8 to 44, with a modal number of 28 (39.06%), a second peak 
at 29 (25.69%). 11 subjects were shown to have a premutation allele (55-73 repeats). 
Intermediate allele was defined as 45–54 repeats, and a total of 83 alleles were found 
within this range (0.21%). Conclusions: This is the first large study focusing on the 
prevalence of FXS and the FMR1 allele distribution by analyzing the normal, 
intermediate and premutation alleles in the Korean female population. In this study, the 
prevalence of carriers of premutation-size alleles in Korean women can be estimated to 
be 1 in about 2,000. 
 
G36. FLCN Mutations in Korean Patients with Primary Spontaneous 
Pneumothorax 
G. Park, R. Hong 
Chosun University College of Medicine, Gwangju, Republic of Korea. 
Introduction: FLCN gene is introduced to a causative gene of primary spontaneous 
pneumothorax (PSP). We investigated FLCN mutations in Korean patients with PSP. 
Methods: The 48 patients with PSP were enrolled in this study. DNA was extracted 
from formalin-fixed paraffin embedding lung tissue. We amplified and sequenced each 
exon and the adjacent intron from exon 4 to exon 14 using previously reported primers. 
Results: Four mutations that were c.712G>A in exon 7, c.880G>A in exon 9, 
c.1223A>G, and c.468_470delTTC in exon 11 were revealed. The 23 genetic variations 
with one nucleotide change were identified in exons and introns. Conclusions: Unlike 
previous Caucasian studies, nonsense mutation and frameshift mutation in genomic 
DNA level is relatively low incidence in Korean patients with PSP.  
 
G37. Novel Alternative Splicing of FLCN Gene 
G. Park1, S. Lee1, W. Park2 
1Chosun University College of Medicine, Gwangju, Republic of Korea; 2Chosun 
University Graduate School, Gwangju. 
Introduction: FLCN gene is related with primary spontaneous pneumothorax (PSP) 
and several tumors. We identified a novel alternative splicing of FLCN gene and 
investigated its clinical significances. Methods: The PSP patients (n=10) and normal 
persons (n=20) were enrolled in the study. Genomic DNA and total RNA were extracted 
from venous blood sample, and cDNA was synthesized. We amplified and sequenced 
each exon and the adjacent intron in genomic DNA level. The entire coding region in 
mRNA was amplified, sequenced and was cloned. We sequenced the entire cloning 
cDNA region from 20 colonies per each sample. Long PCR and direct sequencing from 
exon 2 to exon 5 were performed in genomic DNA. For identifying proportion of mRNA 
with alternative splicing, we performed a colony PCR from 96 colonies per each sample 
using primers for amplification of deletional region, and we also performed a real-time 
ddCt analysis using alternative splicing-specific primers and alternative splicing-
nonspecific primers. Results: In mRNA level, FLCN c.-113_-25del89 in exon 3 was 
identified. However, this variation and any nucleotide changes in junction region of exon 
2 to exon 4 according to the reference sequence (NM_144606) were not observed in 
genomic DNA level. In colony cDNA sequencing, mRNA with exon 3 deletion had the 
heterzygotic evidences identified in exon region of genomic DNA level. In colony PCR 
and real-time ddCt analysis, proportion of mRNA with total deletion of exon 3 induced 
by alternative splicing was about 30%. Above findings were similar between the PSP 
patients and normal persons. Conclusions: Novel alternative splicing of FLCN gene 
may be a normal variant in blood cells.  
 
G38. Identification of a Small 15q13.3 Deletion in Several Patients: Further 
Evidence Implicating CHRNA7 in the 15q13.3 Deletion Phenotype 
N. Hoppman-Chaney, K.E. Wain, J.C. Hodge 
Mayo Clinic, Rochester, MN. 
Introduction: The 15q13.3 microdeletion syndrome is a recently described disorder 
characterized by highly variable presentations, which may include intellectual disability, 
cardiac malformations, seizures, autism, and psychiatric conditions such as 
schizophrenia or bipolar disorder. This deletion is inherited in approximately 75% of 
cases and has been found in mildly affected and normal parents, suggesting incomplete 
penetrance. The common deletion size is approximately 2 Mb and contains several 
genes; however the gene(s) responsible for the resulting clinical features have not been 
clearly defined. Recently, a few patients were described with a smaller, approximately 
680 kb deletion including only the CHRNA7 gene and, in some cases, a portion of the 
OTUD7A gene. These patients demonstrated a wide range of neurodevelopmental 
symptoms similar to those observed with the larger 15q13.3 microdeletion including 
mental retardation, developmental delay, and seizures. Methods: Array comparative 
genomic hybridization (array CGH) testing, using either an Agilent 44k or 180k 
oligonucleotide array, was used to identify clinically relevant gains or losses. Data was 
compiled from a database of patient samples tested in the Mayo Clinic Cytogenetics 
Laboratory from 2008-2011. Of these cases where a deletion of CHRNA7 was 
detected, results were confirmed by fluorescent in situ hybridization (FISH) using the 
BAC probe RP11-106H13. Results: We identified an approximately 600 kb deletion 
including only the CHRNA7 gene in 5 affected individuals. One of these patients was 
referred for a pervasive developmental disorder, while another (at age 5 weeks) had 
failure to thrive. The remaining three patients are family members (a brother and sister 
and their paternal first cousin) who are described as having cognitive deficits and/or 
developmental delays, and one child also has behavioral issues. The father of the 
siblings and the mother of their first cousin are siblings themselves and therefore are 
likely carriers; both have psychiatric problems. Confirmation testing for CHRNA7 
deletion in these individuals is pending. Conclusions: The 5 patients in our study, like 
those described previously in the literature, have a significant amount of phenotypic 
overlap when compared to patients with the larger 15q13.3 microdeletion. Therefore, 
these results provide further evidence implicating CHRNA7 as the gene responsible for 
the neurodevelopmental phenotype spectrum resulting from 15q13.3 microdeletion. 
 
G39. Comparative Study of xTag 60 Cystic Fibrosis Test v2 with CF InPlex® 
Panel Utilizing Archived and Freshly Extracted DNA  
S.A. Marconi1, C.L. Bissaillon1, J.T. Tamsin1, K.A. Lebel1, G.J. Tsongalis2, F. Moore1 
1Baystate Health, Springfield, MA; 2Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: The xTAG Cystic Fibrosis 60 kit v2 (Luminex, Austin, TX) simultaneously 
detects and identifies a panel of 60 mutations and variants in the Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR) gene in human blood specimens. This 
panel includes the mutations and variants currently recommended by the American 
College of Medical Genetics and American College of Obstetricians and Gynecologists 
(ACMG/ACOG.) The xTAG Cystic Fibrosis 60 kit v2 is a qualitative genotyping test that 
provides information intended to be used for carrier testing in adults of reproductive 
age, as an aid in newborn screening, and in confirmatory diagnostic testing in newborns 
and children. Methods: Genomic DNA was extracted from 79 whole blood samples 
using the Qiagen EZ1 XL or manual DNA extraction. Recently extracted DNA samples, 
archived DNA stored at -80°C, and rehydrated DNA samples stored in GenTegra DNA 
tubes (IntegrenX, Pleasanton, CA) were used in conjunction with the xTAG Cystic 
Fibrosis 60 kit v2 on the Luminex 200 system. All DNA samples were diluted to a 
concentration of 20ng/Pl with nuclease free water. The xTAG CF60 kit v2 protocol was 
followed using Cycling Condition 1 for PCR and Allele Specific Primer Extension 
(ASPE) steps. Coriell cell lines were used as positive controls. All samples had been 
previously tested with the Hologic CF InPlex Invader assay (Hologic, Bedford, MA). 
Results: Of the 79 samples, 29 were normal, 48 were heterozygous, and 2 were 
homozygous mutant. Results showed that the xTAG CF 60 kit v2 produced accurate, 
reproducible results from -80°C archived DNA, rehydrated DNA and recently extracted 
DNA with no significant decrease in signal detection. There was also no overall 
increase in background signal. All controls gave the expected results and all results 
were concordant with those obtained from previous testing using the InPlex® CF 
Molecular Test. Conclusions: The xTAG Cystic Fibrosis 60 kit v2 with Cycling 
Condition 1 was able to detect up to 60 mutations with accuracy and precision from 
frozen archived, rehydrated archived, and recently extracted genomic DNA.  Due to the 
expanded detection capability of the xTAG Cystic Fibrosis 60 kit v2, we were also able 
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G40. A 106 Mutation Cystic Fibrosis Laboratory Developed Test Using the 
Sequenom MassARRAY®: Analytical Validation 
L.(. Holtegaard1, J. Stoerker2,3, J. Winters1, L. Couteau1, W.E. Highsmith1 
1Mayo Clinic, Rochester, MN; 2Sequenom, Ann Arbor, MI; 3AscendantMDx,  
Ann Arbor, MI. 
Introduction: In 2001, the ACOG and ACMG recommended population based carrier 
screening for cystic fibrosis (CF) using a panel of 23 mutations. Since that time, some 
have argued that expanded panels with additional mutations would be useful in non-
Northern European populations. We co-developed a CF screening test with Sequenom, 
Inc. that targets 106 mutations. Analytical verification of the assay has been presented 
(JMD 2010;12:611-9). Methods: The version of the test that was validated at Mayo 
Clinic differed from that described in 2 of the 106 mutations, the PCR clean-up, and the 
QC/resulting software. The test was validated according to CLIA guidelines. The 
accuracy was determined by running 664 samples (4% carriers) in parallel with the 
70+6 Tag-It analyte-specific reagent set from Luminex, Inc.; a 43 sample, 27 mutation 
“challenge panel” that contained 7 potentially interfering variants; and a set of synthetic 
controls that contain 104 of the 106 mutations. Precision was assessed with 96 
samples, 8 examples each of 11 mutations and wild type (WT), run daily for 3 days. 
Analytical sensitivity was assessed both by dilution a dF508 sample into WT and by 
testing the assay response with decreasing amounts of input DNA. Analytical specificity 
was determined by electrophoresis of all PCR products and by examination of the large 
number of WT samples run in the Accuracy study. Results: There were no 
discordances with the challenge panel or synthetic control panel. In the parallel analysis 
study, one sample had 3 mutations with a false positive Exon2,3del. In the 12x8x3 
precision study, there were 3 discordant samples: 2 were due to transcription errors in 
the original result and one was due to a rare polymorphism at the SBE primer site. We 
were able to detect 10% dF508 alleles in a WT background. One mutation assay, 712-
1G>T, required 10 ng of input DNA. All the other assays were robust to 2 ng of input 
DNA. All the PCR products gave single bands on PAGE, and no WT samples from the 
Luminex assay gave positive results. Conclusions: Accuracy, precision and analytical 
sensitivity and specificity were excellent. One false positive was noted, and current 
practice is to verify any Exon2,3del positives with MLPA. Of the 106 mutations targeted 
by the test, not all were included in the validation due to the rarity of the samples. Thus, 
our practice is to sequence verify the first two examples of any mutation not tested 
during validation. 
 
G41. Effectiveness of an Expanded Mutation Panel Versus the ACMG 
Recommended Panel in Detecting CFTR Mutations in Pancreatitis Patients 
J. Juusola, A. Ferreira-Gonzalez 
Virginia Commonwealth University, Richmond, VA. 
Introduction: As more non-geneticists are ordering genetic testing, the molecular 
diagnostic laboratory often plays a critical role in guiding the clinician to the most 
informative and cost-effective testing for their patients. Without this guidance, the 
clinician may order the largest mutation panel available just to cast a wide net (“more 
must be better”), without understanding the actual benefit (or lack thereof) of such 
testing. As an example, samples from the pancreatitis clinic at our institution have been 
sent out for CFTR mutation testing using a 97 mutation panel available at a commercial 
laboratory. We offer an FDA-cleared 32 mutation panel in-house. Both panels include 
the 23 most common mutations recommended by ACMG for cystic fibrosis mutation 
screening. Methods: To determine the efficacy of ordering the larger mutation panel for 
pancreatitis patients, we first performed a literature review to determine which 
mutations are typically seen in the CFTR gene in patients with idiopathic chronic 
pancreatitis. We then compiled the results from testing performed on patients between 
January 2009 and April 2011 to determine what mutations were identified by the send-
out testing and whether those mutations would have been identified by our in-house 32 
mutation panel. Results: The literature review revealed that most mutations that are 
identified in patients with pancreatitis are either present in the 23 mutation ACMG panel 
or in neither the 32 mutation panel nor the 97 mutation expanded panel. The analysis of 
our send-out testing revealed that between January 2009 and April 2011, a total of 81 
samples were sent for CFTR mutation testing, of which, 71 samples (88%) were 
negative for the 97 mutations tested. Of the 10 positive samples (12%), 8 were 
heterozygous for a common mutation (4 samples with delta F508 and 1 sample each 
for G542X, N1303K, 3120+1G>A, R553X) and 2 samples were compound 
heterozygous (R117H/R560T, deltaF508/L206W). Twelve total mutations were detected 
in the samples that were sent out for testing, including 5 delta F508 mutations in both 
heterozygous and compound heterozygous samples. Of the 8 different mutations 
detected, only the L206W mutation is not included in our in-house 32 mutation panel. 
All of the other mutations detected are included in our panel. Conclusions: The 
analysis showed that there is little additional benefit from ordering an expanded CFTR 
mutation panel for pancreatitis patients. As a result, we are able to recommend initial 
testing with the 32 mutation panel, followed by sequencing if indicated. 
G42. A Multi-Gene Assay Coupled with Bioinformatics: An Interdisciplinary 
Approach to Pharmacogenetics Testing 
G. Garrison, J. Scull, D. Selph, B. Winfrey, C. Vnencak-Jones 
Vanderbilt University Medical Center, Nashville, TN. 
Introduction: The rationale for the “Pharmacogenomic Resources for Enhanced 
Decisions in Care and Treatment” (PREDICT) initiative at our institution is to provide 
real-time genotype analysis and decision support to facilitate individualized drug 
therapy. Implementation of this initiative involved adoption of a mid-throughput multi-
gene assay in the clinical laboratory. An interdisciplinary team approach was required 
and a bioinformatics infrastructure was essential for quality control (QC) reports and 
delivering patient results to healthcare providers in a timely, comprehensive, and secure 
manner. Methods: 2000 DNA samples primarily from patients in the catheterization lab 
were referred for testing using the VeraCode ADME (Absorption, Distribution, 
Metabolism, Excretion) Core Panel Kit (Illumina) and the BeadXpress plate reader 
(Illumina). The kit interrogates 185 loci across 34 genes. Cell line control DNA with 
known genotypes was used as positive controls on each 32 specimen plate. Results: 
Genotype results on 34 genes were generated, reviewed and securely stored. 
Currently, only CYP2C19 variants are reported with associated decision support for 
Clopidogrel dosage. Sophisticated bioinformatics generate comprehensive QC reports 
to monitor for sample reproducibility, variant allele frequencies and locus performance. 
Reproducibility for Paragon and Coriell control DNA cell lines at 185 loci was 99.58% 
and 98.34%, respectively. A monthly QC plate was initiated to monitor the 
reproducibility of patient results by performing random repeat testing of patient 
specimens from the preceding month and checking for concordant results at all 185 
loci. Thus far, 64 samples have been retested, with 98.67% concordance across all loci 
and 100% concordance for CYP2C19 variants. Observed CYP2C19 allele frequencies 
are similar to that previously reported from the Database of Single Nucleotide 
Polymorphisms (dbSNP). 15/185 loci are consistently “poor performers” failing to 
provide results in >95% of patient samples analyzed on each plate. Conclusions: 
Implementation of clinical testing for pharmacogenetic variants utilizing this assay 
requires stringent review of the results. The establishment and monitoring of multiple 
QC indicators is essential and helps to ensure the accuracy of the results reported by 
this test. The established bioinformatics infrastructure coupled with the genotype data 
generated from the ADME kit enables genetically informed medicine and allows 
expansion of the decision support process for drug dosing of other known allelic 
variants for genes included in this kit. 
 
G43. Development of a Multi-Locus Coronary Heart Disease (CHD) Genotyping 
Assay and Assessment of Accuracy and Robustness 
D. Lew1, N. Bui1, C. Marchis1, H. Harrison1, B. Davis1, A. Cairo1, J.J. Sninsky1,  
J.J. Devlin1, J. Shabbeer2, J. Amos Wilson2, J. Catanese1 
1Celera, Alameda, CA; 2Berkeley HeartLab, Alameda, CA. 
Introduction: Current cardiovascular risk assessment algorithms fail to predict many 
cardiovascular events. The polygenic nature of cardiovascular disease and modest risk 
estimates of the SNPs associated with CHD make the case for aggregating genetic 
information into a risk score to provide a more compelling case for individualized patient 
management. We have developed a multiplex assay that examines 20 genetic 
polymorphisms that have been found to be associated with coronary heart disease in 
multiple well-powered studies. Many of the 20 SNPs are in genes that may be involved 
in the pathogenesis of CHD including cholesterol homeostatis, platelet function, 
thrombosis, cell cycle progression, cell migration, protein secretion, and inflammation. 
Several SNPs are in genes or chromosomal regions that have functions yet to be 
determined. Here we demonstrate the performance characteristics of this multiplex 
assay on remnant, de-identified clinical samples. Methods: DNA was extracted on an 
automated platform from 1 mL samples of de-identified blood from 500 individuals 
collected as part of routine clinical testing by Berkeley HeartLab (Alameda CA). After 
quantitation and normalization, the DNA samples were multiplex PCR amplified. An 
Oligonucleotide Ligation Assay incorporating custom sequence-tagged Luminex® 
beads and biotin/Streptavidin Phycoerythrin detection was used for the automated 
simultaneous determination of all 20 genotypes by generic research software that 
compares the ratio of fluorescent signals between the two alleles for each SNP. 
Results: The 500 DNA specimens were genotyped with the CHD multiplex assay at 
various DNA concentrations. Genotype call rates remained above 99% with as little as 
0.3 ng input genomic DNA. Genotype call concordance remained at 99.99% over the 
range of 0.3 to 3.0 ng input genomic DNA. All 500 samples were also genotyped at 3.0 
ng input DNA using another validated technology, allele-specific, real-time PCR. Call 
concordance was 99.93%, between the two technologies. Conclusions: We evaluated 
a multi-locus genetic assay that simultaneously detects 20 SNPs that have been found 
to be reproducibly associated with CHD. The study demonstrated a >99% call rate and 
genotype concordance when compared with allele-specific, real-time PCR genotyping. 
The assay requires as little as 0.3 ng DNA, an elapsed time of 7 hrs, hands on time of 
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85 min, and is readily amenable to high throughput automation. This CHD assay will 
facilitate the collection of allele frequency and genetic association data from additional 
studies of different risk and ethnic groups.  
 
G44. A Fragile X Screening Program Utilizing the Amplidex FMR1 and mPCR-
CE Assays by Asuragen 
K.A. Lebel1, A.M. Tyropolis1, F. Moore1, S.M. Pflueger1, G.J. Tsongalis2 
1Baystate Health, Springfield, MA; 2Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: Fragile X Syndrome is the most common form of inherited intellectual 
impairment and a known genetic cause of autism. Risk assessment and clinical 
diagnosis of the disease is defined by the number of CGG repeats and methylation 
status of the FMR1 gene located at Xq27.3. Normal repeat sizes range from 15-44, 
grey zone from 45-55, premutation from 56-199, and full mutation greater than 200 
CGG repeats. The risk of CGG repeat expansion occurs from the mother passing a 
premutation or full mutation gene to her offspring. Fragile X carrier screening has been 
increasing within the past few years. Here we discuss the importance of prenatal carrier 
screening. Methods: A total of 323 peripheral blood specimens submitted for prenatal 
screening were extracted utilizing the EZ1 Advanced XL (Qiagen, Valencia, CA) and 
tested utilizing the Amplidex FMR1 assay (Asuragen, Austin, TX).  Results were 
reported in CGG repeat size after capillary electrophoresis. Specimens with a pre- or 
full mutation were tested for methylation status utilizing the mPCR FMR1 assay 
(Asuragen, TX). Results: At our institution, a total of 323 specimens for fragile X testing 
were submitted with an indication of prenatal carrier screening (with or without history of 
developmental delay) during a 9 month period. 319 were reported normal to grey zone 
range with no risk for expansion to full mutation in the fetus. Two specimens were 
reported in the premutation range with risk to full mutation. Both patients reported family 
history of learning disabilities. Methylation status revealed partial methylation of the 
FMR1 gene in both cases. One specimen was reported as a full mutation with risk of 
carrying an affected fetus. Methylation status was analyzed as partially methylated in 
this sample. This patient reported no family history of developmental delay or learning 
disability. Conclusions: Although our small study revealed a risk detection rate of 1%, 
the detection of an undiagnosed full mutation carrier increased the awareness of the 
incidence of this disease in the general population. The utilization of the Amplidex 
FMR1 PCR assay makes carrier screening easy and affordable to serve the prenatal 
population. Further analysis of pre and full mutations utilizing the methylation PCR 
assay delivers a full diagnosis to the clinician and patient, providing information needed 
to make difficult decisions in pregnancy outcome.  
 
G45. Carrier Screening for Fragile X Through a Polymerase Chain Reaction-
Based Method  
S. Baccam1, J. Dylewska2, J.H. Yu2, E. Pergament1, S. Bai1 
1Northwestern Reproductive Genetics Inc., Chicago, IL; 2Abbott Molecular Inc.,  
Des Plaines, IL. 
Introduction: Fragile X is the most common known cause of male related mental 
retardation. The disease causing gene, FMR1, is located on Xq27.3. A dynamic 
expansion of CGG repeats in the promoter region silences its expression in the affected 
individuals. Southern Blot analysis is the most common technique used to determine 
the expansion status of the CGG repeats in the FMR1 gene. However, performing 
Southern Blot analysis is a relatively labor-intensive, time-consuming clinical technique. 
These limitations drive clinical laboratories to seek alternative techniques to replace the 
conventional Southern Blot in testing Fragile X. Here we present a PCR based high 
throughput method to determine the CGG repeat size in female patients planning 
pregnancy or in early pregnancy. Methods: The CGG repeat region is amplified using 
Abbott’s FMR1 PCR primers (set 1 and set 2), then sized through capillary 
electrophoresis. The individuals with CGG repeats range from normal to premutation 
can be accurately sized with primer set 1. The primer set 1 limits its power on the large 
allele due to the insufficient amplification of CGG repeats more than 230. Therefore, an 
individual with family history or presenting a large band on the agarose gel 
electrophoresis will be screened with primer set 2, which mainly detects the full 
mutation allele with higher sensitivity. Results: In our study, 2235 patients were 
screened using primer set 1 from 2009 through 2011. Among all the patients, 55 
intermediate carriers (2.44%) and 10 premutation carriers (0.45%) were detected, 
respectively. In addition, a validation study was conducted with individuals that were 
normal, intermediate carriers, permutation carriers and full mutation carriers that were 
examined by using primer set 2. All the samples were read with the correct CGG repeat 
size information. This achieved the aim to test the accuracy and sensitivity of the primer 
set 2. Conclusions: In conclusion, we demonstrate a powerful PCR based screening 
method used for identifying the presence of intermediate mutation, premutation and full 
mutation in the FMR1 gene.  
 
G46. Molecular Follow-up of Newborn Biotinidase Screening in California 
Reveals Multiple Novel Mutations 
N. Dharajiya1, T. Cowan1, J. Zehnder1, N. Kazerouni2, F. Lorey2, I. Schrijver1 
1Stanford University, Palo Alto, CA; 2California Department of Public Health,  
Richmond, CA. 
Introduction: Biotinidase deficiency is an autosomal recessive condition characterized 
by neurocutaneous symptoms including seizures, hypotonia, skin rash, alopecia, and 
developmental delay. Biotin supplementation initiated early in life prevents these 
sequelae. Therefore, newborn screening is offered in all states and many countries 
worldwide to identify potential patients and prevent clinical manifestations. Molecular 
analysis has enabled identification of mutations in the biotinidase (BTD) gene following 
enzyme analysis in serum, including the D444H mutation associated with partial 
biotinidase deficiency. Confirmatory molecular diagnosis is particularly useful in cases 
where sample mishandling may have lead to artifactually decreased biotinidase activity. 
Methods: Eighteen patients identified by newborn screening were enzymatically 
confirmed with profound (11) or partial (7) biotinidase deficiency. De-identified dried 
blood spots were received from the California Genetic Disease Screening Program for 
molecular analysis. BTD sequencing was performed using ABI Genetic Analyzer 3130. 
The assay targeted all four exons extending more than 20 bases into flanking introns 
and approximately 140 bases of 5’UTR. Results: BTD sequencing revealed two 
mutations in 10/11 newborns with profound deficiency. Seven of the 11 patients with 
profound deficiency had one novel mutation in conjunction with one severe known 
mutation, suggesting that the novel mutations are pathogenic. The known severe 
mutations identified include c.98_104del7insTCC, V62M, R157H, A171T, L176N, 
Y454C, Q456H and T532M. One patient with profound deficiency carried a novel 
missense mutation predicted to be pathogenic, a second mutation was not detected by 
our assay. Six of the seven patients with partial deficiency had one severe mutation 
together with the D444H (variant) allele, consistent with their enzymatic diagnosis. The 
seventh patient was homozygous for Y454C, a mutation previously reported in cis with 
R79C and in trans with R157H in a single patient; the enzymatic effects of Y454C 
homozygosity are unknown. Overall, we discovered eight novel mutations in our total of 
18 samples (22% of alleles). Parent studies are required to determine the cis-trans 
relationships. Conclusions: The BTD sequencing assay identified two mutations in 
17/18 samples with either partial or profound enzyme deficiency. The relatively large 
number of novel mutations detected in this cohort might reflect the ethnically diverse 
population in California. Sequence analysis is an excellent confirmatory test and can 
help differentiate between partial and profound biotinidase deficiency by the nature of 
mutations identified. Molecular follow up of enzymatic biotinidase assay is also likely to 
be beneficial for counseling purposes. 
 
G47. Performance Characteristics of the eSensor® 2C19 Assay for the 
CYP2C19 Genotyping 
M. Sabato, L. Evans, E. Tully, M. Voelkner, D. Wilkinson, A. Ferreira-Gonzalez 
Virginia Commonwealth University Health System, Richmond, VA. 
Introduction: Recent studies have confirmed the importance of CYP2C19 genotypes 
to outcomes in clopidogrel treated patients. The studies indicated that CYP2C19*2 and 
other CYP2C19 loss-of-function alleles play an important role in clopidogrel non-
responsiveness and adverse clinical outcomes. Whereas, the CYP2C19*17 has been 
associated with ultrarapid enzymatic activity and increased medication metabolism. The 
US Food and Drug Administration has added a box warning to the clopidogrel label 
suggesting that adjusting the dose or using alternative antiplatelet agents should be 
potentially implemented for high-risk individuals identified based on the CYP2C19 
genotype. The eSensor® 2C19 test for research use only (GenMark CYP2C19 assay) 
(GenMark Diagnostics Inc, CA) identifies 12 nucleotide variants, including the ones 
relevant to clopidogrel. Here, we describe the performance characteristics of the 
GenMark CYP2C19 assay. Methods: A reproducibility study was performed by two 
operators using the same kit lot. Eleven DNA control samples previously genotyped by 
the AmpliChip assay as *1, *2 and *3 were tested on 3 runs performed on three days. In 
a method comparison study, 63 DNA samples were genotyped using the GenMark 
CYP2C19 assay and results compared to the expected genotype. These samples 
included 50 anonymized DNA patient samples previously extracted by the Qiagen EZ1 
DNA Blood kit and genotyped by the Roche AmpliChip; 8 Coriell DNA samples 
characterized by the Roche Amplichip, AutoGenomics INFINITI, Laboratory Developed 
Test (LDT) RFLP, TaqMan LDT and Luminex; 3 ParagonDx controls and 2 proficiency 
testing samples. Eight anonymized DNA patient samples previously extracted by the 
Roche MagNA Pure LC DNA Isolation Kit were genotyped by the GenMark CYP2C19 
assay to evaluate the ability of different extraction methods to produce results. Results: 
Results from the reproducibility study were 100% correct when compared with the 
expected results. In a method comparison study, 100% concordance with the expected 
genotypes was obtained for 62 samples. One sample gave an invalid test result for two 
consecutive runs. When results for all the samples were compared to the AmpliChip 
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platform, 24/62 samples previously genotyped as *1 gave a *17 allele. This discrepancy 
is due to the fact that the AmpliChip assay does not interrogate for *17 allele. Genotype 
calls were obtained using DNA from both extraction methods. Conclusions: The 
GenMark CYP2C19 assay provided good quality performance for the CYP2C19 
mutation panel that influence the metabolism of clopidogrel. 
 
G48. AGG Genotyping Reclassifies Expansion Risk for Equivalently Sized 
Intermediate and Premutation Fragile X Alleles: Outcomes of a Multicenter Study 
of 469 Mother-Child Transmissions 
A.G. Hadd1, S. Sah1, E.G. Allen2, A. Glicksman3, S. Sherman2, E. Berry-Kravis4,  
F. Tassone5, C. Yrigollen5, A. Cronister6, M. Jodah7, N. Ersalesi3, T. Brown3, R. Shroff1, 
G.J. Latham1, S.L. Nolin3 
1Asuragen, Inc., Austin, TX; 2Emory University School of Medicine, Atlanta, GA; 
3Institute for Basic Research in Developmental Disabilities, Staten Island, NY; 4Rush 
University Medical Center, Chicago, IL; 5University of California Davis, Davis, CA; 
6Genzyme, Inc., Cambridge, MA; 7Genzyme Genetics, Cambridge, MA. 
Introduction: Increased screening of pregnant women for their fragile X status has led 
to the identification of more intermediate and small premutation alleles whose stability is 
poorly understood. Earlier studies have suggested that the presence of AGGs 
interspersed within the repeat and the length of uninterrupted CGGs at the 3’ end of the 
repeat may influence repeat expansion. Until now, the ability to determine AGG status 
in female samples has been technically prohibitive due to two X chromosomes. Thus, 
genetic counseling has been limited to interpretations of risk based solely on the 
number of CGG repeats. A combination of PCR methods has allowed us to examine 
the effect of AGG substructure on CGG repeat instability. Methods: Genomic DNA 
samples corresponding to 469 mother-child transmissions were obtained from 4 
institutions following IRB approval. The number and allele location of interspersed AGG 
were established using the AmplideX™ FMR1 CGG repeat primed PCR (RUO) and two 
novel research PCRs. Results: The number of AGG interruptions and the length of 
continuous CGG repeats fundamentally shifted the risk profile for CGG expansion. 
Between 50-54 repeats, the risk of expansion based on CGG repeats alone was 26%. 
However, in alleles of this size, the expansion risk was 100% without AGG, 28% with 1 
AGG and only 11% with 2 AGG. Moreover, the magnitude of repeat expansion was 
larger for equivalently sized alleles that lacked AGG. The shortest unstable length was 
25 uninterrupted CGGs (in a 45 CGG allele) and the smallest number of uninterrupted 
CGG repeats that expanded to a full mutation in a single transmission was 51 (of 61 
total repeats). For females, the pure CGGs at the 3’ end of the repeat region was the 
best predictor of the change in repeat length (p<.0001,R2=0.21) and explained twice 
the variance compared with total repeat length alone. Conclusions: This highly 
powered, large-scale AGG genotyping study provides the most definitive data to date 
on AGG interruptions. Either the number of AGGs or the 3’ pure CGG repeat length 
more accurately estimates the risk for instability compared to the current standard of 
repeat size alone. AGG genotyping will thus allow risk estimates to be revised for 
repeat instability in newly identified intermediate and small premutation alleles. 
 
G49. A Multiplexed Genotyping Test for CYP2C19 Using VeraCode Beads on 
the BeadXpress System 
M. Chelliserry, R.E. Lenta, J.C. San, W.M. Goldstein, E.S. Winn-Deen, E.J. Peters 
Illumina, Inc, San Diego, CA. 
Introduction: Understanding the role of inter-individual genetic variability in drug 
response or disposition is a key step toward personalized medicine. The CYP450 2C19 
enzyme, which is encoded by the CYP2C19 gene, plays a role in the metabolism of 
many drugs currently in clinical use. An individual’s CYP2C19 gene may contain 
genetic polymorphisms that affect the functional activity of the resulting CYP2C19 
enzyme in that individual. This inter-individual variation in enzyme activity and resulting 
drug exposure can affect therapeutic response of drugs metabolized by CYP2C19. 
Methods: Here we describe the development of a new multiplexed assay, 
theVeraCode CYP2C19 Genotyping Test, for the detection and genotyping of 
CYP2C19 alleles on the BeadXpress® reader. The test is designed to detect the 
CYP2C19 *2, *3, *4, *5, *6, *7, *8, and *17 alleles, and is intended to identify a subject’s 
CYP2C19 genotype using genomic DNA extracted from whole blood. The assay 
technology involves multiplex PCR followed by target specific extension (TSE) of the 
two alleles at the single nucleotide polymorphism (SNP) of interest. This process also 
incorporates a modified nucleotide that allows site specific labeling after hybridization of 
the amplified product to the VeraCode® beads. Results: The VeraCode CYP2C19 
Genotyping Test allows up to 96 samples to be genotyped within a 4-hour shift with less 
than 30 minutes of hands-on time from extracted DNA to genotype data. The assay had 
a call rate of >99% when tested on over 250 unrelated blood samples. Additional data 
generated with the Caucasian, Asian, and Yoruban HapMap samples (N=286) indicated 
excellent reproducibility (>99%) and accuracy (>99%) when compared to results 
obtained with alternative genotyping methods and bi-directional sequencing. For rare 
alleles that are present in the US population at a frequency of < 0.1%, synthetic, 
plasmid-based DNA samples were used to verify assay performance. Conclusions: 
The VeraCode CYP2C19 Genotyping Test allows the genotyping of CYP2C19 alleles in 
a simple, high throughput workflow with a short hands-on and total run time. This test is 
for Research Use Only.   
 
G50. A Multiplexed Genotyping Test for CYP2C9/VKORC1 Using VeraCode 
Beads on the BeadXpress System 
M. Chelliserry, R.E. Lenta, J.C. San, W.M. Goldstein, E.S. Winn-Deen, E.J. Peters 
Illumina, Inc, San Diego, CA. 
Introduction: Warfarin is an important anticoagulant that has large inter-individual 
variation in response and resulting maintenance dose requirements. A portion of this 
inter-individual variation in drug response is due to polymorphisms in the CYP2C9 and 
VKORC1 genes, whose gene products play a role in warfarin’s pharmacokinetics and 
pharmacodynamics. Assessing a subject’s CYP2C9/VKORC1 genotype prior to 
initiating warfarin therapy may reduce the incidence of adverse events associated with 
warfarin therapy. Methods: Here we describe the development of a new multiplexed 
assay, the VeraCode CYP2C9/VKORC1 Genotyping Test, for the detection and 
genotyping of CYP2C9 (*2 and *3) and VKORC1 (-1639G>A) variants on the 
BeadXpress® reader. The test is intended to identify a subject’s CYP2C9/VKORC1 
genotype using genomic DNA extracted from whole blood. The assay technology 
involves multiplex PCR followed by target specific extension (TSE) of the two alleles at 
the single nucleotide polymorphism (SNP) of interest. This process also incorporates a 
modified nucleotide that allows site specific labeling after hybridization of the amplified 
product to the VeraCode® beads. Results: The VeraCode CYP2C9/VKORC1 
Genotyping Test allows up to 96 samples to be genotyped within a 4-hour shift with less 
than 30 minutes of hands-on time from extracted DNA to genotype data. The assay had 
a call rate of >99% when tested on over 250 unrelated blood samples. Additional data 
generated with the Caucasian, Asian, and Yoruban HapMap samples (N=286) indicated 
excellent reproducibility (>99%) and accuracy (>99%) when compared to results 
obtained with alternative genotyping methods and bi-directional sequencing. 
Conclusions: The VeraCode CYP2C9/VKORC1 Genotyping Test allows the 
genotyping of CYP2C9 and VKORC1 genes in a simple, high throughput workflow with 
a short hands-on and total run time.  
This test is for Research Use Only.   
 
G51. Importance of Complete Genomic Analysis Using Conventional G-Banded 
Chromosome Analysis and SNP Microarray Analysis in Cases with Known 
Chromosome Abnormalities 
T.A. Smolarek, S.L. Zimmerman 
Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 
Introduction: Historically, G-banded chromosome analysis has been the gold standard 
for initial analysis of individuals with a complex clinical phenotype. Previous studies 
have clearly documented the utility of microarray analysis in the genomic study of 
these, suggesting that this may be more useful as a first-line test for these individuals. 
Array studies also are useful in further characterizing the genomic content of known 
chromosomal abnormalities. We compared results from cases with a known 
chromosome abnormality to the results obtained from microarray analysis to determine 
what percentage of chromosome abnormalities would be missed if an array-first 
approach were used. Methods: The Illumina Infinium assay was performed on 
approximately 3191 DNA samples using either the 370K, 610K or Omni1-Quad 
BeadChip Platform. B-allele frequency and Log2R ratio were analyzed using the 
Illumina GenomeStudio analysis software with DNA copy number changes prioritized 
using cnvPartition software. The majority of these cases had either a normal 
chromosome analysis result or had no previous chromosome analysis performed. 
However, 95 of the 3191 cases (3%) previously were known to have a visible 
chromosome abnormality by standard GTG-banding prior to array studies, which 
included suspected balanced rearrangements, known unbalanced rearrangements, 
mosaicism and aneuploidy. Results: Of the 3191 cases, 95 had a known chromosome 
abnormality, while 75 (78.9%) showed a clear benefit using SNP array analysis that 
more clearly characterized the abnormality present or showed no additional complexity 
to the previously known imbalance. However, 11 cases (11.6%) showed no evidence of 
a genomic imbalance suggesting that the rearrangement was truly balanced, and nine 
of the cases (9.5%) had a genomic imbalance that was an additional finding other than 
the suspected chromosomal abnormality or was in addition to the known aneuploidy 
suggesting a more complex genome is present than was anticipated. Conclusions: 
SNP microarray analysis is clearly a valuable tool in the analysis of cases with a 
complex clinical phenotype. However, if an array-first approach is utilized, there is still a 
clear benefit of performing standard G-banded chromosome analysis in these cases.  
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G52. Beyond Southern Blot Analysis: Fragile X Syndrome Case Studies and 
Analysis of New Sample Types Using FMR1 Methylation PCR 
R. Cao1, S. Filipovic-Sadic1, A.G. Hadd1, F.J. Ramos2, R. Willemsen3, E. Berry-Kravis4, 
G.J. Latham1 
1Asuragen, Inc., Austin, TX; 2University of Zaragoza Medical School, Zaragoza, Spain; 
3Erasmus MC, Rotterdam; 4Rush University Medical Center, Chicago, IL. 
Introduction: Fragile X syndrome (FXS) is associated with the expansion of a CGG 
trinucleotide repeat in the 5'-untranslated region of the FMR1 gene with consequent 
hypermethylation of CpG islands and gene silencing. While advances in FMR1 PCR 
have led to the routine detection of full mutation alleles >200 CGG, molecular diagnosis 
of FXS still relies on Southern blot (SB) analysis to determine methylation status. 
However, SB analysis is extremely laborious, low throughput, and requires large 
quantities of genomic DNA. The quality of data can be ambiguous to interpret and novel 
sample types, such as hair follicle DNA that may be better correlated with clinical 
phenotype, are excluded. This study applies novel PCR technologies, including an 
optimized methylation PCR (mPCR-CE), to a series of fragile X case studies and 
including sample types of different cellular/germ layer origin. Methods: Genomic DNA 
from whole blood, hair follicle, and/or mouthwash samples were obtained from 
collaborators at Rush University Medical Center or the University of Zaragoza Medical 
School. DNA samples were processed using AmplideX™ CGG Repeat Primed (RP) 
PCR (RUO), and/or mPCR-CE research reagents. The results were compared with 
both SB analysis and cognitive and other clinical assessments performed by the clinical 
collaborators. Results: Cases representing both stable and unstable transmissions 
from parent to child, and the full range of methylation status in fully expanded FMR1 
alleles were evaluated. All mPCR-CE results from were highly correlated to phenotype 
and SB analysis. In addition, CGG RP PCR and mPCR-CE were performed to assess 
mesodermal (blood) and ectodermal (hair follicle and mouth cells) specimens from 
individuals within a family with two fragile X children. Repeat mosaicism and 
methylation status were dependent on the sample type with hair and mouth DNA 
showing greater correlation with low IQ than the whole blood samples. Conclusions: 
The evaluation of a novel PCR-only workflow across several fragile X case studies 
provided a comprehensive genetic profile including quantification of repeat size and 
methylation status in both mesodermal and ectodermal sample types. The research 
methods revealed both typical and atypical genotypes that were highly correlated to 
patient phenotypes. These results underscore the utility of PCR for routine CGG sizing 
and methylation assessment without SB analysis and may improve the understanding 
of fragile X genotype/phenotype correlations. In the future, this research may impact 
selection of patients most likely to respond to new treatments for FXS.  
 
G53. Identification of New Mutations in the KCNJ2 Gene in Patients with 
Andersen-Tawil Syndrome 
H. Wang, B.A. Westerfield, L.S. Pena, A. Do, G.A. Rodriguez, W. Zou, D.J. Penny,  
Y. Fan 
Department of Pediatrics, Baylor College of Medicine, Houston, TX. 
Introduction: Andersen-Tawil syndrome (ATS) is a rare autosomal dominant genetic 
disorder characterized by a triad of episodic flaccid muscle weakness, ventricular 
arrhythmias and prolonged QT interval, and anomalies such as low-set ears, ocular 
hypertelorism, small mandible, fifth-digit clinodactyly, syndactyly, short stature, and 
scoliosis. The clinical manifestations of ATS vary greatly among patients. KCNJ2, 
encoding the inward rectifier potassium channel 2 protein (Kir2.1), is the only gene 
known to be associated with ATS. The KCNJ2 gene is located at 17q23, and its open 
reading frame is not interrupted by introns. The deduced protein sequence comprises 
427 amino acids with two putative membrane-spanning regions connected by a pore-
forming domain, and cytoplasmic N- and C-terminal domains. To date, more than 40 
KCNJ2 mutations have been reported to be responsible for ATS. Methods: We 
conducted KCNJ2 mutation analysis in a cohort of 129 cases with suspected ATS 
referred to our center for genetic testing. Peripheral blood-derived genomic DNA was 
used to amplify the coding exon of the KCNJ2 gene by PCR. The PCR products were 
purified and analyzed by bidirectional sequencing. Bioinformatics methods were 
employed to predict the functional consequence of the variants identified. Results: 
Mutational analysis showed that a total of 16 mutations in the KCNJ2 gene were found 
in 34 patients. All of the mutations are missense mutations including 4 novel mutations 
not described previously, c.211G>T (D71Y), c.389C>T (T130M), c.578T>C (L193P) and 
c.653G>C (R218P), to our knowledge. To classify the four missense variants, 
computational analyses by SIFT and PolyPhen-2 revealed that three of the four 
missense variants (D71Y, L193P and R218P) might affect protein function of KCNJ2. 
Each of mutations T75M, T130M, G144S, T192I and R218Q was found in 2 patients, 
and R67W, R82W and G144A in 3, and R218W in 8. These reoccurring mutations may 
represent mutation hot-spots of KCNJ2 in patients with ATS. Conclusions: Our study 
further expanded the mutational spectrum of the KCNJ2 gene in patients with ATS. The 
data will be useful for the diagnosis and management of ATS patients. Functional 
studies of the four missense mutations identified are ongoing. 
 
G54. Analytical Performance Characteristics of the Invader® MTHFR A1298C 
Test 
C. Mielke, P. Peterson, A. Choudoir, C. Moehlenkamp, J. Koelbl, K. Williamson,  
A. Lukowiak, S. Day 
Hologic Molecular Diagnostics, Madison, WI 
Introduction: The Invader® 5, 10-Methylenetetrahydrofolate Reductase (MTHFR) 
A1298C test is designed to use Invader Plus chemistry, a combination of PCR target 
amplification and Invader® signal amplification to detect and genotype a single point 
mutation (A to C at position 1298) of the human MTHFR gene in isolated genomic DNA 
obtained from whole blood.  Studies were undertaken to determine the analytical 
accuracy compared to bi-direction sequencing, upper and lower limits of detection, 
interfering substances effects, and lot-to-lot reproducibility. Methods: Accuracy was 
determined by testing extracted DNA from 348 blood samples using the Invader 
MTHFR A1298C test and bi-directional sequencing and percent agreement determined. 
Upper and lower limits of detection were determined by testing 40 replicates of genomic 
DNA samples (wild-type and heterozygous genotypes) at concentrations of both 5 
ng/µL and 80 ng/µL and at 10-fold extremes (e.g. 0.5 ng/µL and 800 ng/µL), prior to 
1:20 dilution for the Invader® reaction, and the Invader® results compared to bi-
directional sequencing. Heparin (1500 U/dL human whole blood), bilirubin (10mg/dL 
human whole blood), cholesterol (300mg/dL human whole blood), potassium EDTA (1.8 
mg/mL human whole blood), hemoglobin (up to 0.2% in whole blood), and ethanol-
based wash buffer (5% in DNA sample) were tested as potential interfering substances. 
Samples were also analyzed using the Invader® MTHFR A1298C test with three 
different lots of the reagents and observed agreement between all three lots and bi-
directional DNA sequencing determined. Results: Observed agreement between 
Invader® MTHFR A1298C and bi-directional DNA sequencing was 99.71% (347/348 
with 1/348 being an equivocal call), for upper and lower limits of detection determination 
at 5-80ng/µL concentrations agreement was 100% (80/80), and for samples tested at 
10-fold extremes agreement was 67.5% (54/80) at 0.5 ng/µL (below the normal range 
of the assay) and 100% (80/80) at 800 ng/µL concentrations. All substances examined 
for potential interference had no impact on Invader® MTHFR A1298C performance. 
Observed agreement between three lots of the Invader® MTHFR A1298C test and bi-
directional DNA sequencing was 100% (48/48). Across all genotypes tested, across all 
three (3) lots, the overall agreement with bi-directional sequencing was 100%. 
Conclusions: The Invader® MTHFR A1298C test is a sensitive, reproducible and 
highly accurate method for detecting and genotyping a single point mutation (A to C at 
position 1298) of the human MTHFR gene in isolated genomic DNA obtained from 
whole blood. 
 
G55. A Familial Chromosome 2p Duplication in a Chimeric Infant with 
Nephrotic Syndrome  
S.K. Mongia, N. Chorny, A.K. Mongia, C. Yudis, A. Nicastri, F. Lacbawan 
SUNY Downstate Medical Center, Brooklyn, NY. 
Introduction: We describe here the clinical manifestations and chromosomal defects in 
a 4-month old infant who presented with nephrotic syndrome. The patient was born to 
non-consanguineous Hispanic parents with a non-significant maternal and pregnancy 
history but repeated pregnancy losses in maternal aunt. The infant has ambiguous 
genitalia with left cryptorchidism and left Ebstein anomaly with persistent proteinuria 
and slightly elevated serum AFP levels. Except for cryptorchidism and pulmonic 
stenosis, other characteristic features of the disorders of the RAS-MAPK pathway, 
Noonan (NS), Cardio-facio-cutaneous (CFC) or Costello Syndrome, were not present. 
We demonstrate an integrated laboratory work up and analysis that may help explain 
clinical findings in complicated cases such as ours. Methods: G-banded chromosomal 
study was performed in the patient’s peripheral blood followed by array Comparative 
Genomic Hybridization (aCGH) with 1 Mb Hu BAC array. The same aCGH was done in 
the mother’s sample. The patient underwent renal biopsy and right orchiectomy. 
Histologic, electron microscopic, and immunohistochemical examination with antibody 
to WT1 of the renal biopsy as well as histomorphologic examination of the excised 
testis were done. Results: Cytogenetic analysis showed 46,XY/46,XX and aCGH 
revealed a 110 kb (hg19: 39,227,561-39,337,844) duplication of chromosome 2p22.1 
region in the infant. The same duplication was noted on aCGH of the mother. The 
duplicated region spans the SOS1 gene on chromosome 2p21. The renal biopsy 
revealed diffuse global moderate mesangial hypercellularity with swollen proximal 
tubules. Immunohistochemistry with WT1 antibody revealed strong positive staining in 
podocyte nuclei. There was diffuse and complete effacement of the foot processes on 
electron microscopy. Histologic examination of the testis revealed ovotestis with chronic 
inflammation and fibrosis. Conclusions: We report a unique case of familial 2p22.1 
duplication chimeric infant with ovotestis, Ebstein anomaly and nephrotic syndrome, 
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lacking typical features of NS-CFC-CS spectrum. From the scheme of laboratory 
examinations already performed and if mutation analyses of NPHS1 and NPHS2, the 
most frequent causes of congenital nephrotic syndrome, proved to be negative, it is 
conceivable that the maternal origin of SOS1 duplication is a pathologic copy number 
variant. Though SOS1 missense mutations are second most common cause of NS and 
encode products that enhance RAS and ERK activation, inherited duplication of SOS1 
gene has not been reported to date. Besides the cytogenetic abnormality in our case, a 
defect in the RAS-MAPK pathway may possibly explain the phenotype in this case. 
 
G56. Ongoing Experience Using a Prognostic Test for Prediction of Severe 
Curve Progression in Adolescent Idiopathic Scoliosis Patients 
L. Nelson, D. Cook, K. Ward 
Axial Biotech, Inc., Salt Lake City, UT. 
Introduction: Adolescent Idiopathic Scoliosis (AIS) is a curvature of the spine greater 
than 10 degrees (Cobb angle) with no known cause. It affects 2% to 4% of the pediatric 
population. The majority of patients will not progress, but there is no reliable way to 
predict the expected clinical course. We have developed a DNA-based prognostic test 
(AIS-PT) to predict risk of progression to a severe curve. The test is designed to use at 
diagnosis of AIS. The AIS-PT identifies mild scoliosis patients at low risk of progressing 
to a severe curve (NPV > 99%). We report our experience over the first two and a half 
years of testing. Methods: The AIS-PT uses a DNA panel of 53 markers and current 
Cobb angle to assign a risk of progression score (1-200). Risk scores correlate with the 
patient’s risk of progressing to a severe curve (>40° curve in an individual still growing). 
Saliva samples are collected, DNA extracted and genotypes determined using Taqman 
chemistry. The risk of progression score is calculated using a logistic regression 
algorithm. A physician survey regarding incorporation of the test into their practices has 
also been conducted. Results: Samples from 3181 patients have been submitted. 2791 
patients were within indications for testing and were reported. The mean age of patients 
tested was 11.9 years for females and 12.6 years in males (p < 0.177). The mean Cobb 
angle is 18.7 degrees, 24% of girls tested were postmenarcheal and the most common 
initial Cobb value was 25 degrees. In the 1535 patients presenting with Cobb angles 
less than 20 degrees, 65.0% were identified as low risk and 0.5% were identified as 
high risk. In the 737 patients with Cobb angles less than 15 degrees, 82% were 
identified as low risk and no patients were identified as high risk. A total of 74 
physicians responded to the survey. Conclusions: Initial use of AIS-PT testing has 
been directed toward older and higher acuity patients than most school screening 
series would predict as the expected populations. This is mostly likely because 
physicians using the test are seeing higher acuity patients. In patients most comparable 
to those expected from school screening populations (Cobb angle 10-15 degrees), the 
test performed similarly to validation populations where 75% of patients were identified 
as low risk. There were more out of indications samples submitted (12.3%) than 
expected indicating the need for additional education. Surgeons report that the test 
helps in making management decisions. 
 
G57. A Multi-Center Reproducibility Study of the Invader® MTHFR C677T and 
Invader® MTHFR A1298C Tests 
M. Curtis1, T. Monroe2, Y. Besse2, S. Krygier2, J. Ledford3, N. Quigley3, D. Anderson3, 
C. Moehlenkamp1, K. Williamson1, S. Day1 
1Hologic Molecular Diagnostics, Madison, WI; 2Spectrum Health, Grand Rapids, MI; 
3Molecular Pathology Laboratory Network, Inc., Maryville, TN. 
Introduction: The Invader® 5, 10-Methylenetetrahydrofolate Reductase (MTHFR) 
C677T and Invader® MTHFR A1298C tests using Invader Plus chemistry, a 
combination of target amplification by PCR and Invader® signal amplification sequence 
detection by Invader® chemistry are designed to detect the MTHFR C677T and 
A1298C mutations on DNA isolated from human whole blood. A multi-center study was 
undertaken to determine the reproducibility of these assays. Methods: Testing took 
place at 3 sites with 6 operators (2 per site). The study was conducted in two main 
phases, proficiency phase (Phase 1) and an Invader® test performance phase (Phase 
2). The proficiency phase ensured that each site and operator had the required 
expertise so that meaningful molecular test reproducibility measures could be 
calculated from the data generated from performance phase. Upon successful 
completion of Phase 1, Phase 2 testing took place, with samples for each of the two 
tests consisting of 9 human whole blood samples and 6 genotype-specific Invader 
controls, extracted using site-specific standard laboratory methods to obtain 5-80 ng/Pl 
genomic DNA per sample. Samples included 3 representatives of each genotype, WT, 
HET and MUT and were extracted by each operator on each of 5 non-consecutive 
days. Extracted DNAs were tested in duplicate and genotype-specific controls were 
tested in singlicate. Reproducibility was assessed 1) within operator (within day); 2) 
between day (within operator); 3) between operators (within site); and 4) between sites. 
One-sided 95% confidence lower limits were calculated by the Wilson score method for 
each proportion of valid results as compared to independent bi-directional sequencing 
(SeqWright, Houston, TX). Results: There was 100% reproducibility for all 4 test 
conditions for both the MTHFR C677T and MTHFR A1298C tests. One-sided 95% 
confidence lower limits ranged from 99.0% (within operator/within day), to 99.5% for 
between day (within operator) and between operators (within site) for both tests. 
Conclusions: At three separate sites with six operators, all aspects examined 
demonstrated 100% reproducibility results for the Invader® MTHFR C677T test and the 
Invader® MTHFR A1298C test. The Invader® MTHFR C677T and Invader® A1298C 
tests demonstrated the reproducibility required for routinely detecting the MTHFR 
C677T and A1298C mutations in clinical blood samples. 
 
G58. Is Self-Reported Race Sufficient in Molecular Genetics Clinical Testing 
Interpretations 
L. Nelson, R. Chettier, K. Ward 
Axial Biotech, Inc., Salt Lake City, UT. 
Introduction: The frequency of genetic variants can differ between races/ethnicities. 
These differences can alter interpretations of test results and change evaluation of risk. 
Typically, patients self report race/ethnicity. This information is used to interpret results 
where race/ethnicity risk differences are known. Another approach is to assume any 
race differences are small and not alter interpretations based on race. This tactic avoids 
the controversy and uncertainty of including race as an important factor of medicine. 
We have developed a DNA-based prognostic test to predict risk of progression to a 
severe curve in patients with Adolescent Idiopathic Scoliosis (AIS-PT). The test was 
originally validated in self-reported Caucasians and so we have limited the indicated 
use to that group, relying on self-reported race. In this study we sought to determine 
whether self-reported race was adequate to determine whether a patient was indicated 
for the test. Methods: The AIS-PT uses a DNA panel of 53 markers and current Cobb 
angle to assign a risk of progression score (1-200). Risk scores correlate with the 
patient’s risk of progressing to a severe curve. Of the 53 markers, 19 show genetic 
differentiation between Caucasian, Asian and Black sub populations. Genotypes using 
these markers from 3816 self-reported Caucasian samples along with Hapmap 3 
reference samples CEU (Caucasian), YRI (African) and CHB (Asian) were used to 
complete principle component analysis (PCA) to estimate the accuracy of self reported 
Caucasian ancestry. Samples submitted as Hispanic were added to the PCA analysis 
to look for the degree of Caucasian admixture in self-reported Hispanics. Results: In 
the PCA analysis the self-reporting status of Caucasians is highly accurate. 97.9% of 
self identified Caucasians fell within three SDs of the Caucasian cluster. 79 patients, 
however, fell outside this quadrant. 37 “Caucasian” samples should have been 
interpreted as Asian samples and 42 “Caucasian” samples should have been 
interpreted as African samples. When looking at self reported Hispanics the majority of 
the samples show significant admixture with Caucasians and should have received an 
interpretation. Conclusions: The data in our study shows self-reported race is usually 
accurate for Caucasians, however, a small percentage of patients should have received 
different interpretations. The majority of Hispanics could have been tested due to 
significant Caucasian admixture. In the future we plan to screen ethnicity using these 19 
markers and for those falling outside the Caucasian cluster complete additional 
ancestry informative marker analysis so the most accurate interpretation can be given. 
 
G59. Mutational Analysis of the SOD1, FUS, TARDBP, ANG, OPTN, PON1, 
PON2, and PON3 Genes in Korean Patients with Amyotrophic Lateral Sclerosis 
(ALS) 
M. Kwon1, J. Kim2, C. Ki2 
1Kangbuk Samsung Hospital, Seoul, Republic of Korea; 2Samsung Medical Center, 
Seoul. 
Introduction: Amyotrophic lateral sclerosis (ALS) is one of the most common adult-
onset neurodegenerative diseases. Mutations in the SOD1 are the most frequent 
genetic defects known to underlie ALS and to account for 20% of familial ALS (FALS) 
and 2% to 4% of apparently sporadic ALS (SALS). Recently, the cause of ALS has 
been attributed to mutations in several genes. However, there has been no report on 
the molecular genetic analysis for major ALS genes involving a large series in Korea. 
The aim of this study was to determine the mutation frequencies and spectrums of each 
major ALS gene in Korean ALS. Methods: Two hundred fifty-eight patients were 
included in the study; 9 FALS index cases and 249 SALS patients. We applied PCR 
and direct sequencing of all coding exons and flanking intronic sequences of the SOD1, 
FUS, TARDBP, ANG, OPTN, PON1, PON2, and PON3 genes in all the patients. The 
sequences of the patients were compared with reference sequences to detect any 
sequence variations. Results: The overall frequency (FALS and SALS) of major ALS 
gene mutations was 8.1% (21/258); 88.9% (8/9) of FALS and 5.2% (13/249) of SALS. 
In FALS, 6 SOD1 mutations were observed in seven patients and only one FUS 
mutation was found. In SALS, 3 SOD1, 4 FUS and each two PON1, PON2, and PON3 
mutations were found. Fourteen mutations were not previous reported. No mutation 
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was found in ANG, TARDBP, or OPTN.    Conclusions: We determined the mutational 
spectrums of the major ALS genes in Korean ALS patients, which not only considerably 
higher frequency of SOD1 mutations causing FALS, but also further highlight the 
importance of FUS and PONs. The frequency of SOD1 gene mutations in Korean FALS 
(77.8%, 7/9) is much higher than those reported in the other ethnic groups but only one 
SALS case had SOD1 gene mutation. Therefore, screening of SOD1 gene is highly 
recommended in Korean FALS but other genes should be further studied in order to 
reveal the genetic background of Korean SALS. 
 
G60. A Comprehensive Review of Genetics Sendout Testing 
B. Vennapusa, J.A. Kant 
University of Pittsburgh Medical Center, Pittsburgh, PA. 
Introduction: We have experienced, as perhaps others have, a steady increase in 
sendout testing requests for genetic diseases, notwithstanding active utilization review 
engagement with clinicians across the spectrum of clinical specialties over more than a 
decade. The fruits of the Human Genome Project and ongoing gene annotation efforts 
have contributed to this, yet our impression is the ‘yield’ on much of this testing is low. 
We wanted to confirm or refute that impression and assemble data for laboratorians 
and clinicians to evaluate circumstances in which sendout testing is most useful. 
Methods: Our plan is to review 5 consecutive years of experience 2006 – 2010. We 
have completed the review for 2009 of sendout genetic tests extracted from our 
laboratory’s internal database. Permission was obtained from the UPMC Hospital QA 
Committee. Information extracted (or looked up) included test result, patient age, 
gender, and ordering physician. Data on current pricing of these tests was also 
gathered. Results: Test requests ranged from 1 to 14 for a given sample with a mean 
of ~2/sample. Some patients had tests on more than one sample. One clinician ordered 
33% of all sendout tests. Of 2,576 discrete genetic sendout test results, 2,457 (95.4%) 
were for patients in whom there was no history of a known familial mutation. Of these, 
301 (12.3%) gave ‘positive’ results that feel into ACMG category 1 and 2 variants. 
Variants of uncertain significance (VUS) were seen in (49) (2%) of tests. Of no surprise, 
60 (50.4%) of 119 tests for known familial variants were positive. Gender was 
represented relatively equally (1,354 male vs. 1,223 female). Samples from children 0-
10 and 11-20 years of age comprised 56% and 22%, respectively, of sendout tests 
requested; tests on patients older than 50 were 6% of total requests. A preponderance 
(68%) of tests were requested by medical geneticists (47%) and neurologists (21%), 
particularly in pediatrics. Total list price cost to the institution was $3,074,494, although 
discounts are available in some instances. Conclusions: This snapshot of data from 
one year’s genetic sendout testing indicates a relatively low positive rate for results, 
particularly when one considers testing is ‘confirmatory’ for a number of patients who 
meet clinical criteria for a specific disease diagnosis. We are currently completing 
analysis for the other 4 years and plan to compile 'testing profiles' for discussion with 
specific specialty groups of physicians to identify criteria that enhance the use of 
genetic sendout testing in patient management. 
 
G61. Analytical Performance Characteristics of the Invader® MTHFR C677T 
Test 
C. Mielke, P. Peterson, A. Choudoir, C. Moehlenkamp, J. Koelbl, K. Williamson,  
A. Lukowiak, S. Day 
Hologic Molecular Diagnostics, Madison, WI. 
Introduction: The Invader® 5, 10-Methylenetetrahydrofolate Reductase (MTHFR) 
C677T test is designed to use Invader Plus chemistry, a combination of PCR target 
amplification and Invader® signal amplification to detect and genotype a single point 
mutation (C to T at position 677) of the human MTHFR gene in isolated genomic DNA 
obtained from whole blood. Studies were undertaken to determine the analytical 
accuracy compared to bi-direction sequencing, upper and lower limits of detection, 
interfering substances effects, and lot-to-lot reproducibility. Methods: Accuracy was 
determined by testing extracted DNA from 361 blood samples using the Invader 
MTHFR C677T test and bi-directional sequencing and percent agreement determined. 
Upper and lower limits of detection were determined by testing 40 replicates of genomic 
DNA samples (wild-type and heterozygous genotypes) at concentrations of both 5 
ng/µL and 80 ng/µL and at 10-fold extremes (e.g. 0.5 ng/µL and 800 ng/µL), prior to 
1:20 dilution for the Invader® reaction, and the Invader® results compared to bi-
directional sequencing. Heparin (1500 U/dL human whole blood), bilirubin (10mg/dL 
human whole blood), cholesterol (300mg/dL human whole blood), potassium EDTA (1.8 
mg/mL human whole blood), hemoglobin (up to 0.2% in whole blood), and ethanol-
based wash buffer (5% in DNA sample) were tested as potential interfering substances. 
Samples were also analyzed using the Invader® MTHFR C677T test with three different 
lots of the reagents and observed agreement between all three lots and bi-directional 
DNA sequencing determined. Results: Observed agreement between Invader® 
MTHFR C677T and bi-directional DNA sequencing was 99.0% (359/361 with 2/361 
being equivocal calls), for upper and lower limits of detection determination at 5-
80ng/µL concentrations agreement was 100% (80/80), and for samples tested at 10-
fold extremes agreement was 100% (80/80) at 0.5 ng/µL and at 800 ng/µL 
concentrations. All substances examined for potential interference had no impact on 
Invader® MTHFR C677T performance. Observed agreement between three lots of the 
Invader® MTHFR C677T test and bi-directional DNA sequencing was 100% (48/48). 
Across all genotypes tested, across all three (3) lots, the overall agreement with bi-
directional sequencing was 100%. Conclusions: The Invader® MTHFR C677T test is a 
sensitive, reproducible and highly accurate method for detecting and genotyping a 
single point mutation (C to T at position 677) of the human MTHFR gene in isolated 
genomic DNA obtained from whole blood. 
 
G62. Validation of a Laboratory-Developed Method Using Affymetrix® SNP 6.0 
Arrays for High-Resolution SNP Analysis 
B. Boyadzhyan, A. Lvovich, M.A. Lee, M. Telatar 
Quest Diagnostics Nichols Institute, Valencia, Valencia, CA. 
Introduction: SNP arrays can provide accurate genotyping data and kilobase-
resolution detection of copy number variants (CNVs). We developed and validated a 
method using Affymetrix® SNP 6.0 chips for high-resolution SNP and CNV analysis. 
Methods: Genomic DNA was extracted from residual samples originally tested for 
various indications (36 blood samples tested by PCR for trisomy 13/18/21, X-Y 
aneuploidy, T-cell gene rearrangement, alpha-thalassemia, or MTHFR and HFE 
genotype; 10 amniotic fluid samples tested by PCR and GTG chromosome analysis for 
trisomy 13/18/21). DNA was digested with NspI and StyI, ligated to adaptors, and PCR-
amplified. PCR product was purified using magnetic beads, fragmented, end–labeled, 
and hybridized to the chips, followed by staining and scanning. Data were analyzed 
using Affymetrix® GTC software. Obtained data were used to define data quality values 
and QC matrix. Results: All blood sample results were concordant with the original test, 
showing method accuracy. The mean call rate for clinical blood samples from >60 runs 
was 98.7%; contrast QC=2; and MAPD (median absolute pairwise difference)=0.28. 
The method demonstrated good reproducibility in inter- and intra-run studies: mean call 
rate >99%; contrast QC>2; and MAPD<0.29. One amniotic fluid sample failed PCR and 
was not tested on the chip; the remaining 9 generated results on SNP 6.0 chips 
concordant with the original tests, including correct gender calls. Analysis of additional 
samples is required to establish contrast QC and MAPD values for amniotic fluid. 
Conclusions: This method using SNP 6.0 chips showed high reproducibility and 
accuracy and can be performed within 3 days post-extraction. 
 
G63. A Multi-Center Reproducibility Study of the Invader® FACTOR II 
(Prothrombin/G20210A) and Invader® Factor V (G1691A) Tests 
A. Lukowiak1, N. Quigley2, J. Ledford2, D. Anderson2, S. Beqaj3, J. Soper4, D. Jordan4, 
J. Koelbl1, K. Williamson1, M. Curtis1, S. Day1 
1Hologic Molecular Diagnostics, Madison, WI; 2Molecular Pathology Laboratory 
Network, Inc., Maryville, TN; 3DCL Medical Laboratory, Indianapolis, IN; 4DCL 
Laboratory, Indianapolis, IN. 
Introduction: The Invader® Factor II (Prothrombin/G20210A) and Invader® Factor V 
(G1691A) tests using Invader Plus chemistry, a combination of target amplification by 
PCR and Invader® signal amplification sequence detection by Invader® chemistry are 
designed to detect the Factor II (prothrombin/G20210A) and Factor V Leiden (G1691A) 
mutations on DNA isolated from human whole blood. A multi-center study was 
undertaken to determine the reproducibility of these assays. Methods: Testing took 
place at 3 sites with 6 operators (2 per site). The study was conducted in two main 
phases, proficiency phase (Phase 1) and an Invader® test performance phase (Phase 
2). The purpose of the proficiency phase was to ensure that each site and operator had 
the required expertise in the fundamental methodologies so that meaningful molecular 
test reproducibility measures could be calculated from the data generated from the 
Invader® test performance phase. Upon successful completion of Phase 1, Phase 2 
testing took place, with samples for each of the two tests consisting of 15 leukocyte-
depleted human whole blood samples spiked with genotype-specific human cell lines 
were extracted using site-specific standard laboratory methods to obtain 5-80 ng/Pl 
genomic DNA per sample. Samples included 3 representatives of each genotype, WT, 
HET and MUT and were extracted by each operator on each of 5 non-consecutive 
days. Extracted DNAs were tested in duplicate and genotype-specific controls were 
tested in singlicate. Reproducibility was assessed 1) within operator (within day); 2) 
between day (within operator); 3) between operators (within site); and 4) between sites. 
One-sided 95% confidence lower limits were calculated by the Wilson score method for 
each proportion of valid results as compared to independent bi-directional sequencing 
(SeqWright, Houston, TX). Results: There was 100% reproducibility for all 4 test 
conditions for both the Factor II and Factor V tests. One-sided 95% confidence lower 
limits ranged from 99.0% (within operator/within day) for both the Factor II 
(prothrombin/G20210A) and Factor V (G1691A) mutations, to 99.6% for between day 
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within operator) and between operators (within site) for both tests. Conclusions: At 
three separate sites with six operators, all aspects examined demonstrated 100% 
reproducibility results for the Invader® Factor II test and the Invader® Factor V test. 
The Invader® Factor II (Prothrombin/G20210A) and Invader® Factor V (G1691A) tests 
demonstrated the reproducibility required for routinely detecting the Factor II 
(Prothrombin/G20210A) and Factor V (G1691A) mutations. 
 
G64. Next Generation Sequencing in Clinical Diagnostic Laboratories: 
Implementation of Quantitative and Qualitative Controls in Dual Genome Analysis  
W. Zhang, H. Cui, L. Wong 
Medical Genetics Laboratories, Baylor College of Medicine, Houston, TX. 
Introduction: Advances in genomic technology have made sequencing of the entire 
human genome possible. The next generation sequencing (NGS) technology has been 
widely used in research laboratories. However its application to molecular diagnosis in 
clinical laboratories is still in its infancy due to the lack of guidelines from CAP or CLIA. 
The ability to sequence a group of target genes by NGS is particularly useful for 
molecular diagnosis of genetically heterogeneous clinical syndromes. Mitochondrial 
disorders are a group of complex diseases that can be caused by mutations in both 
nuclear and mitochondrial genomes. Current molecular diagnosis requires multiple 
different and complementary methods, including sequencing, qPCR, Southern blot or 
array CGH, for the detection and quantification of mutations. To develop a one-step 
comprehensive NGS for molecular diagnosis of mitochondrial disorders in a clinical 
setting with the implementation of proper quantitative and qualitative controls. 
Methods: A target gene selection followed by high throughput "deep" coverage NGS 
approach was validated with the indexed qualitative and quantitative controls analyzed 
along with each sample for quality assurance. Results: We demonstrated an average 
coverage of >500X for targeted nuclear genes and >5000X for each of the 16,569 
bases of the mitochondrial genome. Nucleotide changes are correctly called with 
quantitative information. The limit of detection of a heteroplasmic change is calculated 
to be about 1.5%. Small and large insertion/deletions were correctly detected with clear 
breakpoints and percentage of heteroplasmy. Conclusions: This target gene 
enrichment deep sequencing approach provides a one-step comprehensive molecular 
analysis for patients with suspicion of mitochondrial diseases in a timely, accurate, and 
cost-effective manner suitable for clinical application. It allows simultaneous analysis of 
a set of nuclear genes targeted to mitochondria and the whole mitochondrial genome 
for point mutations and deletions with quantitative information. The inclusion of control 
samples assure the highest quality performance required in a clinical laboratory.  
 
G65. Amyloid Precursor Protein (APP) Gene Study in Korean Alzheimer’s 
Disease Patients  
W. Lee1, M. Kim2, S. Kang2, Y. Jeon2, S. Cho1 
1Kyung Hee University School of Medicine, Seoul, Republic of Korea; 2Kang Dong 
Kyung Hee University Hospital, Seoul. 
Introduction: Alzheimer’s disease (AD) is characterized by progressive cognitive 
decline. While the cause of AD has not been fully understood, genetics plays a role in 
the onset of the disease. Until now 4 genes are well known to be involved in AD; 
amyloid precursor protein (APP)  gene, presenilin 1 (PSEN1) gene, presenilin 2 
(PSEN2) gene, and e4 allele of apolipoprotein E (APOE)  gene, which seems to be the 
most significant susceptible gene for sporadic and familial AD. In this study, we planned 
to screen APP mutations in codon 717 in Korean sporadic AD (SAD), minor cognitive 
impairment (MCI) and individuals with the normal cognitive function through PCR-
RFLP. Simultaneously, sequencing analysis from codon 713 to codon 717 of exon 17 in 
APP genes was performed in SAD and MCI patients to investigate the presence of 
other point mutations. Methods: A total of 165 patients with complaints of the memory 
decline were included in this study performed at our hospital. In the outpatient clinic, 
patients underwent neurologic evaluations and a mini-mental state examination 
(MMSE). Thirty-two patients were diagnosed to probable SAD according to the National 
Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s disease 
and Related Disorder Association (NINCDSADRDA) criteria. Institutional Review Board 
approval and patient informed consent were obtained for this study. Total patients were 
divided into 3 groups according to the clinical diagnosis; SAD (n =32), minor cognitive 
impairment (MCI) (n =30) and normal cognitive function group (n =103). The exon 17 of 
APP gene was amplified using described specific primer; BclI (SIGMA, Saint Louis, 
USA) digests of these PCR products Results: A total of 165 patients with complaints of 
the memory decline were included in this study performed at our hospital. In the 
outpatient clinic, patients underwent neurologic evaluations and a mini-mental state 
examination (MMSE). Thirty-two patients were diagnosed to probable SAD according to 
the National Institute of Neurological and Communicative Disorders and Stroke-
Alzheimer’s disease and Related Disorder Association (NINCDSADRDA) criteria. 
Institutional Review Board approval and patient informed consent were obtained for this 
study. Total patients were divided into 3 groups according to the clinical diagnosis; SAD 
(n =32), minor cognitive impairment (MCI) (n =30) and normal cognitive function group 
(n =103). Conclusions: The results of this study indicate that the presence of point 




H01. Improved FISH Detection of Chromosomal Abnormalities Using CD138 
Magnetic Microbeads Sorted Plasma Cells in Multiple Myeloma  
D. Li, C. Casas, M.A. Brinn, J. Peng, M. Veguilla, A. Prada, Y. Fan 
University of Miami, Miller School of Medicine, Miami, FL. 
Introduction: Multiple myeloma (MM) is a plasma cell neoplasm. Karyotype and 
fluorescence in situ hybridization (FISH) provide valuable prognostic information. 
However, low percentage and slow growth of plasma cells in bone marrow samples 
have been the main obstacles in obtaining results reflecting the true lesions. Modified 
FISH protocols such as simultaneous FISH and immunohistochemistry staining for 
immunoglobulin light chain, and FISH following Giemsa staining for plasma cell 
capturing have been used for MM. We are validating a method of targeted FISH by 
plasma cell sorting and our preliminary results have showed a dramatic improvement in 
abnormality detection. Methods: Plasma cells were enriched by CD 138 magnetic 
microbeads for targeted FISH. A >90% of purity of plasma cells was reached as 
confirmed by May-Giemsa-Grünwald staining. For each bone marrow sample, FISH 
was performed on both sorted plasma cells and unsorted bone marrow cells for 
comparison. DNA probes for 5q31 (EGR1, D5S721-D5S23), 7q31 (D7S486, CEP7) and 
14q32 (IGH) were used for validation. Results: Studies have been done on 14 cases 
and a comparison of the results has demonstrated a dramatic increase of abnormality 
detection when sorted plasma cells were used for targeted FISH. Chromosomal 
abnormalities were detected in 12 of the 14 cases (85.7%). In 2 cases (14%), regular 
FISH showed negative results with all the 3 probes while targeted FISH detected 
abnormalities in up to >86% of cells. Targeted FISH also revealed a much higher 
percentage of abnormal cells than the regular FISH did in the abnormal cases. For 
example, when FISH on unsorted samples detected additional copy of chromosome 5 
in 7%, 8%, 12.5%, 20%, 25.5%, 48.5%, and 72.5% of cells, respectively, in 7 cases, 
targeted FISH detected this abnormality in 14%, 70.5%, 84.5%, 31%, 82%, 98%, and 
100% of cells respectively. Similar results were also observed with the probes for 
chromosome 7 and 14q32. Interestingly, we observed abnormalities involving either 
chromosome 5 or 7 or both in up to 93.5% of cells without IGH rearrangement in 6 
cases (6/14, 43%). Conclusions: We are in the process of validating targeted FISH by 
CD138 plasma cell sorting for routine clinical use. Our initial results have shown that 
this method can significantly improve abnormality detection for MM patients. IGH 
rearrangement has been considered as the primary event of MM. Our observation of 
chromosome abnormalities without IGH rearrangement in 6 of 14 cases suggests 
presence of complex genomic mechanisms of MM development and progression.  
 
H02. Analysis of Clonal T-Cell Receptor Gene Rearrangements Utilizing Next 
Generation Sequencing 
T.C. Greiner 
University of Nebraska Medical Center, Omaha, NE. 
Introduction: Over the past 20 years various methods for detection of gene 
rearrangements have been described with capillary electrophoresis now being the 
predominant method. Recently, the utilization of next-generation sequencing of PCR 
amplified products has been described in order to delineate the polyclonal repertoire of 
immunoglobulin and T-cell receptor gene rearrangements in genetic disorders, bone 
marrow reconstitution, and other clinical settings. The goal of the report is to 
demonstrate how next–generation sequencing could be used to detect clonal T-cell 
populations. Methods: Four cell lines (CEM, HSB2 JURKAT and MOLT4) derived from 
lymphoblastic leukemia and five patient samples were utilized for amplification with 
primers to the individual T-cell receptor gamma (TRG) genes and the families of T-cell 
receptor beta (TRB) genes. Peripheral blood was used as a polyclonal control. The 
sequencing was performed on an Illumina GIIA system by Adaptive TCR Technologies 
utilizing proprietary methods.  The T-cell lines were chosen to illustrate a combination of 
known gene rearrangement sequences representing the different families of TRG 
variable and joining genes. Sanger sequencing of the TRG gene rearrangements was 
also performed in the four cell lines. Results: The number of sequences analyzed 
ranged from 250,000 to 6,000,000 sequences. TRG gene rearrangements including V2, 
V8, V9, and V10 were identified from the cell lines, but not the expected V11.  The 
results of the patient samples demonstrate in two-dimensional and three-dimensional 
histograms the predominance of one T-cell receptor gene rearrangement over several 
others in the mixtures with polyclonal T cells. The 3D histogram analysis of peripheral 
blood demonstrates that some gene rearrangement families are more commonly used; 
similar to that seen in the normal distribution with capillary electrophoresis.  Individual 
polyclonal sequences each comprised less than 0.1% of the total sequences in the 
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patient samples. Errors can be detected in sequences that each only comprises less 
than 0.01% of the total sequences. Conclusions: This work demonstrates the proof of 
concept for the use of next generation sequencing in order to identify clonal T-cell 
receptor gene rearrangements.  
 
H03. Distinct Molecular Characteristics of FLT3 Mutations Involving Multiple 
Internal Tandem Duplications  
A.N. Bartley, R. Luthra, H. Yao, Z. Zuo, J. Medeiros, K.P. Patel 
The University of Texas MD Anderson Cancer Center, Houston, TX. 
Introduction: Internal tandem duplications (ITDs) of the juxtamembrane domain of the 
FMS-like tyrosine kinase 3 (FLT3) gene are associated with poor outcome in patients 
with acute myeloid leukemia (AML). Previous smaller studies have suggested possible 
prognostic significance of size and allelic burden of FLT3-ITD. A subgroup of FLT3-ITD 
mutations involves greater than 1 ITD, i.e. multiple ITDs (mITDs). The frequency of 
mITD and comparison with single ITD (sITD) has not been investigated. Here, we 
characterize a large number of patients with single and mITD mutations with a specific 
focus on size, allelic ratio and mutational profile. Methods: We reviewed the results of 
FLT3 mutation testing in 10,351 bone marrow or peripheral blood specimens of patients 
with myeloid neoplasms (mostly AML). Exons 14 and 15 and the intervening intron of 
FLT3 were amplified from DNA using fluorescent-based PCR with subsequent capillary 
electrophoresis to distinguish wild from mutant genotypes. The results of concurrent or 
subsequent molecular studies for mutations of NPM1, RAS, CEBPA, and KIT were 
included when available. Statistical analysis was performed using the Student’s t-test 
and Fisher’s exact test. Results: 571 (6%) samples showed a FLT3-ITD mutation. Of 
these, 362 (63%) showed 1 ITD and 209 (37%) showed >1 ITD with 121 (21%) cases 
showing 2 ITDs and 88 (15%) cases showing 3 ITDs. The size of the largest ITD in 
cases with mITDs was significantly longer (mean: 80, median: 66, range: 21-342) than 
cases with a sITD (mean: 54, median: 45, range: 3-240), p<0.005. Cases with mITDs 
showed higher percent allelic burden i.e. mutant/total (mean: 41, median: 44, range: 2-
98) compared with cases with sITD (mean: 24, median: 17, range: 0.4-89), p<0.005. 
mITDs were less frequently associated with NRAS mutations (6/113, 5%) than sITD 
(22/122, 18%), p<0.005. There was no significant difference in the frequency of NPM1, 
KRAS, CEBPA and KIT mutations between the two groups. Conclusions: mITDs 
account for 37% of all FLT3-ITD mutations. mITD cases have longer ITD lengths, 
significantly higher allelic burden, and are less frequently associated with NRAS 
mutations. These results suggest that within FLT3-ITD mutations, mITDs represent a 
specific subgroup. With the availability of therapeutic FLT3 and MAPK/RAS inhibitors, 
these results may have important clinical implications. 
 
H04. Targeted Next Generation Sequencing of Clinically Significant Gene 
Mutations and Translocations in Leukemia 
E. Duncavage1, H. Abel1, P. Szankasi2, T.W. Kelley3, J.D. Pfeifer1 
1Washington University, St Louis, MO; 2ARUP Laboratories, Salt Lake City, UT; 
3University of Utah, Salt Lake City, UT. 
Introduction: Leukemias are currently subclassified based on the presence of 
recurrent cytogenetic abnormalities and gene mutations. These molecular findings are 
the basis for risk-adapted therapy; however, such data are generally obtained by 
disparate, labor-intensive, and often low-resolution methods in the clinical laboratory. 
Using targeted next generation sequencing (NGS) we demonstrate that prognostically 
significant translocations and gene mutations, including SNPs and insertions/deletions 
(indels) can be identified simultaneously in multiplexed sequence data. Methods: We 
designed a capture panel consisting of 20 genes involved in leukemia prognosis 
including those involved as translocations and gene mutations. Capture probes were 
designed to 2X tile across both introns and exons of genes, and totaled ~1.0Mb in size. 
Genomic DNA was then isolated from five well-studied cell lines including OCI-AML3, 
MV4-11, K562, kasumi-1, and NB4, as well the non-enriched bone marrow of one 
patient with newly-diagnosed AML. Cell line DNA was sequenced in multiplex on an 
Illumina HiSeq with 2x101bp paired-end reads, while the patient sample was 
sequenced on a GAIIx with 2x60bp reads. Sequence data were then aligned to build 37 
of the human genome using both bwa and Novoalign.  SNPs were called with the GATK 
Unified Genotyper and common mutations filtered against dbSNP. Small and medium-
sized indels were detected using Pindel, while translocations were identified using a 
combination of Breakdancer and Slope. All translocations were subsequently verified by 
PCR and Sanger sequencing. Results: Using our approach, we were able to identify all 
published mutations occurring in the five sequenced cell lines, including the 30bp FLT3 
IDT in MV4-11, NPM1 insertion in OCI-AML3, and KIT D822K mutation in kasumi-1. 
Furthermore, we pinpointed DNA-level translocations in 3 of 3 cell lines with 
translocations covered by our capture panel.  Similarly, we correctly identified the 
t(9;11) translocation in the patient-derived sample in addition to all commonly tested 
gene mutations. Conclusions: Using an analysis pipeline consisting of freely available 
software, we correctly identified all published gene mutations, including larger 
insertions, occurring in five cell lines, and simultaneously identified DNA-level 
translocations in 3 of 3 cases covered by the capture panel. We applied these same 
methods to patient-derived DNA with similar success. We found that by coupling paired 
and single end read analysis we were able to identify DNA-level translocations without 
false positive results by capturing only one translocation partner. We conclude that 
targeted NGS is a methodology well-suited to the detection of a full spectrum of 
clinically relevant mutations in hematologic malignancies.   
 
H05. Identification of MYC-IGH@ Translocation in Burkitt’s Lymphoma by 
DNA-based Looped Ligation Assay (LOLA) 
S. Harada, E. Silzle, M. Lemas, R.F. Ambinder, C.D. Gocke 
Johns Hopkins Medical Institutions, Baltimore, MD. 
Introduction: Burkitt’s lymphoma (BL) harbors a hallmark translocation of MYC on 
chromosome 8q24 juxtaposed to one of the immunoglobulin heavy or light chain genes. 
Translocation breakpoints of MYC are scattered over 340 kb upstream of and within 
MYC, and the IGH@ breakpoints in the switch Į, Ȗ, µ regions and the joining (JH) 
regions cover ~300 kb. Detection of this translocation at the DNA level is complicated. 
We have recently developed a ligation-based assay (LOLA) for long range haplotype 
mapping and detection of translocations. In this study, we employed LOLA to detect 
MYC-IGH@ translocations in the DNA of BL cell lines. Methods: LOLA identifies 
linkage between widely separated genetic loci. Thirty oligonucleotide sets were 
prepared to cover a 200 kb span upstream of MYC (6 locations) and the switch (Į, Ȗ 
and µ) and JH regions and 50 kb upstream of JH region of IGH@ (5 locations). DNA 
was isolated from BL cell lines (Raji, Akata, Rael, Daudi, and AG876). DNA (500 ng) 
and oligos were mixed and the ligation reaction was carried out at 60°C for 1 hr. PCR 
was then performed with primers complimentary to M13 tails on the outermost 
oligonucleotides. The diagnostic products were identified using capillary electrophoresis 
(ABI 3130) and GeneMapper software (ABI). Results: The LOLA produced a specific 
diagnostic peak in all samples tested. Different cell lines were discriminated by different 
combinations of oligos. Raji had breakpoints at exon 1 of MYC and the Ȗ switch region 
of IGH whereas Akata and Rael had breakpoints at exon 1 and the µ switch region. The 
breakpoints for Daudi were 125 kb upstream of MYC and into the JH region. The 
AG876 breakpoints were located 150 kb upstream of MYC and at the µ switch region. 
Interestingly, the pattern of LOLA peaks in Raji and Akata indicates the presence of 
both derivative t(8;14) chromosomes. All findings matched either sequence data at the 
break points (Daudi, AG876) or mapping data (Raji, Akata) reported in the literature. 
This is the first report on the breakpoint for Rael. Conclusions: The LOLA assay is a 
powerful method for DNA-based detection of translocations where the locations of the 
breakpoints are not well known, such as in BL. It also can map translocations to a 
desired resolution and demonstrates the presence of derivative chromosomes. This 
strategy could be applied to identifying unknown breakpoints at the DNA level. 
 
H06. Molecular and Cytogenetic Abnormalities in Acute Myeloid Leukemia - A 
Review and Description of Cases Studied at the Cytogenetics and Molecular 
Pathology Laboratory of a Brazilian Hospital 
R. Sitnik, E.D. Velloso, R.A. Santana, C.H. Motta, J.B. Furtado, N.S. Bacal,  
P.A. Silveira, C.B. Moyses, J.R. Rebello Pinho 
Hospital Albert Einstein, São Paulo, Brazil. 
Introduction: Cytogenetic abnormalities already well studied and new molecular 
markers are the basis for classification, prognosis and treatment in acute myeloid 
leukemia (AML). Particularly in AML with normal karyotype, NPM1 and FLT3 mutations 
are often associated with good and poor prognosis, respectively. In this study we have 
validated molecular tests for detection of NPM1 and FLT3 mutations and verified their 
frequency in AML patients sent to our laboratory. Methods: After approval of the 
institution ethical committee, a study was conducted from 03/2009 to 10/2010 in which 
30 samples from AML patients were screened for FLT3 and NPM1 mutations. Blood 
samples were collected for PCR, cytogenetic (25 patients) and immunophenotyping 
studies. After DNA extraction, NPM1 mutations and FLT3-ITD were detected through 
PCR reactions with a labeled primer and capillary electrophoresis analysis. FLT3-TKD 
mutation was detected through regular PCR and sequencing. Immunophenotyping 
studies were performed on a flow cytometer (EpicsXL, MCL) and G banding karyotypes 
were described according to ISCN 2009. AML stratification was performed according to 
Döhner et al, 2010. Results: Studying 30 samples from AML patients, we observed 
33.3% frequency of NPM1 mutation and an equal number for FLT3-ITD, which 
amounted to 50% and 40% in cases with normal karyotype. Eight percent of cases with 
normal karyotype and genotype NPM1+/FLT3- are included in the group of good 
prognosis AML. In 6 patients both mutations were found and we did not find FLT3-TKD 
mutation in our population. We did not observe the typical phenotype of AML with 
normal karyotype and mutated NPM1 (HLA-DR and CD34 negative) in this series. 
Conclusions: In this small cohort, the frequency for FLT3 and NPM1 mutations was 
similar to the described by other groups. We did not detect any FLT3-TKD mutation, 
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which have shown a low prevalence in other Brazilian studies, when compared to 
American and European casuistic. Regarding immuphenotyping, we could not verify 
some literature data, such as a lower frequency of CD56 expression on FLT3+ patients 
or lack of CD34 and HLA-DR expression on NPM1+ patients. Finally, the study of FLT3 
and NPM1 mutations in this cohort changed the prognostic classification in 8% of 
patients, from intermediate to low risk AML. Therefore, it is necessary to include 
molecular markers on the diagnostic workup of AML patients, in order to improve the 
classification, since this will impact directly on therapeutic decisions. 
 
H07. Development of a Single Tube TCRG Assay 
R. Ringler, J. Shaw, J.E. Miller 
Invivoscribe, San Diego, CA. 
Introduction: The human T cell receptor gamma (TCRG) gene locus has long been the 
target of PCR-based clonality testing, as rearrangement of these genes generate a 
clonal test result in greater than 90% of all people with T-ALL, and TCRG is a marker 
for a number of other lymphoproliferative disorders. However, analysis of TCRG test 
data has proved challenging, as false-positives can result from misinterpretation of 
minor peaks. Here we present data generated with an improved TCRG assay that 
detects the vast majority of TCRG rearrangements using a single, multiplex master mix. 
Master mix primers target all TCRG gamma variable regions and joining regions 
involved in gene rearrangements associated with lymphoid malignancies. The assay 
also generates a more comprehensive data set from patient samples, as some T-cell 
lymphoproliferative disorders involve V and J regions that would not be identified with a 
single VȖ(1-8) and JȖ1/2 primer set. Since all of the J region primers are labeled with 
the same fluorochrome the test also generates a more robust and easily interpretable 
Gaussian distribution. Methods: Amplification of similar-sized amplicons from all of the 
TCRG gene rearrangements should allow for identification of a quantitative threshold 
for a positive result and help to avoid false positive results. Twelve cell lines known to 
have clonal T-cell rearrangements were diluted into a tonsil DNA at a 5% level and 
were tested in parallel using the TCRG Gene Clonality Assay (BIOMED2 Tubes A and 
B) and the T Cell Receptor Gamma Gene Rearrangement 2.0 Assay (TCRG-6FAM, 
single tube). Amplification products were run on an ABI 3130xl capillary electrophoresis 
instrument. Results: Six of the cell lines tested with the TCRG-6FAM master mix 
generated two clonal products; testing the same six cell lines with the two BIOMED2 
master mixes generated only one clonal product. Products generated with the new 
TCRG-6FAM master mix also exhibited a significantly higher fluorescent signal. Data 
indicate that this increased signal facilitates interpretation of ambiguous peaks. In 
addition, clonal products generated with the new TCRG master mix fall within the 
comparatively tighter, single contiguous size range of 159 base pairs to 207 base pairs, 
whereas the products generated using the two BIOMED2 master mixes fall into four 
different size ranges from 156 base pairs to 240 base pairs. Conclusions: Initial results 
show that this assay detects a wider range or rearrangements and provides a more 
clearly defined clonal peak within the polyclonal background. 
 
H08. A Quantitative, Pyrosequencing-Based Assay to Detect MPL Mutations 
J.A. Schumacher1, S. Kim1, P. Szankasi1, J. Prchal2, T.W. Kelley2 
1ARUP Laboratories, Salt Lake CIty, UT; 2University of Utah, Salt Lake City, UT. 
Introduction: Mutations in exon 10 of the myeloproliferative leukemia virus oncogene 
(MPL) are present in approximately 5% of patients with primary myelofibrosis (PMF) 
and 1% of patients with essential thrombocythemia (ET). MPL encodes a 
transmembrane receptor protein tyrosine kinase that acts as a receptor for 
thrombopoietin (TPO). The most common MPL mutations are the W515K and W515L 
mutations, which lead to augmented or constitutive activation of the JAK/STAT 
signaling pathway to TPO and contribute to the neoplastic phenotype. MPL-mutated 
patients typically demonstrate no evidence of JAK2 mutations. Thus, MPL mutation 
testing represents an important component of the workup of patients suspected of 
having a myeloproliferative neoplasm. Here we describe a fast and easy quantitative 
pyrosequencing-based assay designed to detect MPL W515K and W515L mutations. 
Methods: Wild-type, W515K, and W515L plasmids were synthesized using standard 
amplification and site-directed mutagenesis reactions. One W515K, three W515L 
mutant patient specimens, and twenty JAK2-mutated specimens were subjected to 
granulocyte enrichment followed by PCR amplification of MPL in duplicate. Amplicons 
were subjected to Pyrosequencing on the Pyromark Q24 instrument using a nucleotide 
dispensation order designed to detect and quantitate MPL codon 515. Sensitivity and 
reproducibility experiments were carried out using diluted plasmid DNA. Results: The 
wild-type, W515K, and W515L plasmid specimens were amplified successfully and 
quantitative pyrosequencing indicated purity of >98%. One W515K and three W515L 
patient specimens yielded results similar to those from another reference laboratory, 
within 2%. Twenty JAK2-mutated specimens were determined to be wild type for MPL 
using our assay. Plasmid dilution experiments demonstrated sensitivity to 5% mutant in 
a background of wild type, and reproducibility experiments demonstrated that the 5% 
sensitivity was 100% reproducible. Conclusions: We have developed and validated a 
quantitative pyrosequencing-based assay designed to detect MPL mutations in PMF 
and ET. Our assay is robust, specific, sensitive, and reproducible and provides an 
important diagnostic aid for those patients who test negative for JAK2 mutations.   
 
H09. Genetic Polymorphisms and the Treatment Outcome in Standard-Risk 
Pediatric Acute Lymphoblastic Leukemia 
Q. Wei1, M.A. Lovell1, T. Garrington2, S. Tong2 
1Children's Hospital Colorado, Aurora, CO; 2University of Colorado Anschutz Medical 
Campus, Aurora, CO. 
Introduction: Acute lymphoblastic leukemia (ALL) is the most common childhood 
cancer and accounting for 25% of all pediatric cancers in children. Only 50 years ago, 
the disease was uniformly fatal with an Overall Survival (OS) rate < 5%. Modern-day, 
multi-drug chemotherapy is associated with an overall survival rate over 80%. 
Standard-risk ALL comprises the majority of ALL with an overall survival approaching 
90%. Despite this success, children who relapse from this disease accounts for the 
majority of pediatric cancer-related deaths. Treatment protocols have incorporated 
somatic but not host genetic features in the treatment regimens. The current study 
examined 12 genetic polymorphisms affecting the pharmacodynamics and 
pharmacokinetics of antileukemic drugs in an attempt to identify biologic markers 
related to the risk of disease relapse. Methods: Genomic DNA were extracted from the 
diagnostic bone marrow or peripheral blood specimens from 125 pediatric standard-risk 
ALL patients. Genetic polymorphism detection was carried out with either with 
TaqMan® genotyping techniques or conventional gel electrophoresis. Statistical 
analyses were performed with SAS/STAT software (SAS Institute Inc., NC) at the 
Colorado Biostatistics Consortium. Results: The GSTM1 null genotype was associated 
with a decreased risk of disease relapse (HR = 0.394, 95% CI = 0.127 - 1.224, P = 
0.107). A combination analysis of the GSTM1 and GSTT1 genotypes revealed a 
stronger association between both the GSTM1 and GSTT1 normal genotype and an 
increased risk of leukemia relapse (HR = 2.73, 95% CI = 0.9 – 7.9, P = 0.063), 
compared with patients having either the GSTM1 or GSTT1 null genotype. A “drug 
exposure” model was used in this study. The risk of relapse in individual with a low or 
intermediate “drug exposure” genotype increased 2.4-fold (HR = 2.39, 95% CI = 0.8 – 
6.9, P = 0.107) compared to the high “drug exposure” genotype. No significant 
associations with relapse were observed for the CYP1A1, CYP2B6, CYP3A4, CYP3A5, 
MTHFR C667T, MTHFR A1298G, or TYMS polymorphisms. Conclusions: The 
findings from this single institution study suggest that polymorphisms within genes of 
the GST superfamily may influence the treatment outcome in standard-risk ALL. They 
also point to the need for prospective, large multi-institutional studies to validate these 
findings prior to clinical implementation. 
 
H10. Lyophilized Cell Controls for BCR-ABL Quantitative RT-PCR 
Y. Huang1, T. Hsu1, D. Sher1, J.E. Miller1, L. Fletcher2, S. Branford2, J. Shaw1 
1Invivoscribe, San Diego, CA; 2Institute of Medical and Veterinary Scince, Adelaide, 
Australia. 
Introduction: Accurate detection and measurement of BCR-ABL transcripts by qRT-
PCR is important for clinical management of patients with BCR-ABL positive CML and 
ALL. We report the development of controls for the common fusion transcripts, which 
can be used as full assay quality controls and validation Methods: These BCR-ABL 
controls are three panels of lyophilized cells that identify the b3a2, b2a2, and e1a2 
BCR-ABL transcripts.  Each panel consists of negative, 10-1 and 10-3 lyophilized cells. 
The negative cells are HL-60 cells that do not express any BCR-ABL transcripts. The 
10-1 and 10-3 cells are BCR-ABL expressing cells diluted in HL-60 cells at 1:10 and 
1:1000, respectively. Prior to lyophilization, cells were suspended in 2X PBS and filled 
into 3mL glass vials at approximate 1.0×106 cells per vial. The freeze-dried products are 
capped in a desiccated nitrogen atmosphere. For each transcript, 3 batches of 
lyophilized cells were produced. The inter-batch variations were assessed for RNA 
yields using RNeasy Mini Kit. An in-house developed one-step qRT-PCR method was 
used to test these panels. The b3a2 panel was further evaluated using a laboratory 
developed assay for copy number of b3a2 and the endogenous gene BCR. Results: 
The average RNA yields per vial were 5.93±1.38 µg, 4.33±0.51 µg, and 4.77±1.21 µg, 
respectively, for b3a2, b2a2, and e1a2. Based on the one-step qRT-PCR method, the 
mean b3a2 Ct values and %CV were 21.95 (4.34%CV) for the 10-1 control and 29.03 
(2.75%CV) for the 10-3 control. The mean b2a2 Ct values and %CV were 25.99 
(3.53%CV) for the 10-1 control and 33.27 (1.89%CV) for the 10-3 control. The mean 
e1a2 Ct values and %CV were 29.30 (2.60%CV) for the 10-1 control and 36.67 
(2.17%CV) for the 10-3 control. The ǻCt between the 10-1 and 10-3 controls were 
7.08±0.37, 7.28±0.45, and 7.37±0.43 for b3a2, b2a2, and e1a2, respectively. Using a 
two-step qRT-PCR, the mean b3a2 copy number from 6 extractions was 2.72×105 and 
3.02×103 for the 10-1  and 10-3 controls, respectively; the mean BCR copy number was 
2.38×105, 4.07×105 and 3.18×105 for the negative, 10-1 , 10-3 controls, respectively; the 
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mean%b3a2/BCR was 74.88% and 1.04% for 10-1  and 10-3, respectively; after applying 
the laboratory-specific IS conversion factor of 1.25, the mean%b3a2/BCR-IS was 
93.6% and 1.30%. Conclusions: We have developed cell controls that can be used to 
monitor assay performance, including sample processing, for the BCR-ABL qRT-PCR 
assay.  
 
H11. Testing for WT1 Mutations in Acute Myeloid Leukemia 
P. Szankasi1, D.W. Bahler1,2, T.W. Kelley1,2 
1ARUP Laboratories, Salt Lake City, UT; 2University of Utah, Salt Lake City, UT. 
Introduction: Cytogenetically normal acute myeloid leukemia (CN-AML) is a 
heterogeneous AML subgroup with intermediate-risk prognosis. Testing for mutations in 
several genes, including NPM1, CEBPA, FLT3, DNMT3A, and WT1, allows for further 
risk stratification of CN-AML patients. In addition, combinations of these gene mutations 
can lead to complex prognostic phenotypes. Here we describe our findings with a test 
for mutations in WT1 that may be associated with a poor prognosis. Methods: Genomic 
DNA was isolated from residual whole blood and bone marrow specimens that 
underwent flow cytometric leukemia/lymphoma panel testing at ARUP Laboratories. 
WT1 exons 3, 7, 8, and 9 were PCR amplified and sequenced. Results were correlated 
with flow cytometry phenotype and NPM1 and CEBPA mutation status. No cytogenetic 
information was available. Results: Out of 88 total AML cases we identified 4 with a 
WT1 exon 7 mutation. No mutations were found in exons 3, 8, and 9. In addition, 24 
cases harbored the WT1 exon 7 SNP rs16754, homozygous in 4 cases, which has 
been associated with a more favorable prognosis, especially in the NPM1/FLT3 high-
risk subgroup of CN-AML. Two cases harbored both the SNP and an exon 7 mutation. 
Two out of 4 cases with a WT1 mutation also harbored favorable prognosis CEBPA 
double mutations and all WT1 mutant cases were CD7 positive. Conclusions: We 
describe a test for identification of WT1 mutations in AML. As previously reported, 
mutations were most frequently observed in the zinc finger region of the protein. The 
association of both poor (WT1) and favorable (CEBPA) prognostic markers confirms 
that accurate prognosis in CN-AML requires testing for multiple gene mutations. 
 
H12. Sequencing the PKLR Gene after Enzymatic Detection of Red Cell 
Pyruvate Kinase (PK-R) Activity 
L.A. Frederick, K.C. Swanson, D.S. Viswanatha, J.D. Hoyer, J.L. Oliveira 
Mayo Clinic, Rochester, MN. 
Introduction: Red cell pyruvate kinase (PK-R) deficiency is an autosomal recessive 
disease and a frequent cause of hereditary non-spherocytic hemolytic anemia. 
Mutations in the PKLR gene are associated with decreased PK-R enzyme activity and 
red cell hemolysis, putatively involving erythrocyte ATP depletion. Currently used 
enzymatic clinical assays for PK-R activity include a substantial inconclusive range, 
affecting diagnostic accuracy. Asymptomatic constitutional heterozygotes and some 
normal individuals have mildly decreased enzyme activity levels, whereas occasional 
symptomatic patients can show paradoxically normal to elevated PK-R activity, possibly 
due to reticulocyte or leukocyte interferences. Analysis of PKLR gene mutations may 
therefore be of value to unambiguously classify these patients. Methods: DNA was 
extracted from post-diagnostic patient blood samples analyzed for PK-R activity in the 
Mayo Clinic Metabolic Hematology laboratory. The PKLR gene was amplified using six 
primer sets and amplification products were directly sequenced using Sanger method 
(ABI 3130xl Genetic Analyzer) and analyzed for mutations using Sequencher software. 
Samples without mutations or with heterozygous mutation status were also screened by 
PCR for large deletions of exons 4 through 10 and exons 11 and 12. Results: Eighteen 
samples were evaluated for PK-R activity and sequenced for the PKLR gene. Two 
samples had decreased PK-R activities (<2.7 U/g Hb), one sample had an elevated 
activity of 20.1 U/g Hb, four were inconclusive (2.7 – 6.6 U/g Hb) and eleven samples 
had normal PK-R activity (6.7- 14.3 U/g Hb). Complex heterozygous mutations were 
found in both samples with PK-R activity <2.7. There was a single heterozygous 
mutation in one sample that had a low-normal value of 6.8 U/g Hb, and no other 
mutations or deletions were found in the remaining samples. Conclusions: Our 
sequencing-based strategy successfully identifies PKLR gene mutations in enzyme 
deficient patients. PKLR sequencing of samples with inconclusive or normal enzymatic 
results aids in the diagnosis of PK-R deficiency and can be of particular value when 
anomalous enzyme studies occur in clinically symptomatic patients. Although the gene 
mutation frequency is relatively high (0.6% to 6% in the general population) and 
asymptomatic heterozygous carriers frequently manifest mildly reduced enzymatic 
activity, our study demonstrates that many samples with mildly reduced enzymatic 
levels are not associated with mutations in the PKLR gene. In the setting of non-
spherocytic hemolytic anemia, PKLR sequencing data is useful to distinguish those with 
clinically significant pyruvate kinase deficiency as the pyruvate kinase enzyme activity 
level can be decreased by unrelated causes. 
 
 
H13. Molecular Analysis of CEBPA Gene Mutation in Cytogenetic Normal 
Acute Myeloid Leukemia (NK-AML) from Indian Population 
B. Das, F. Ahmad, S. Rajput 
Super Religare Laboratories Ltd, Mumbai, Maharastra, India. 
Introduction: The CEBPA is a transcription factor strongly implicated in myelopoiesis 
through control of proliferation and differentiation of myeloid progenitors. Mutation of 
CEBPA has been reported in ~10% to 15% of normal karyotype AML, and has been 
associated with good outcome. In the current study, we investigated the CEBPA 
mutations in AML patients with normal cytogenetics, and set out to explore its 
prevalence, distribution pattern and correlation with other molecular markers. Methods: 
Thirty-six AML subjects were investigated for CEBPA mutation by fluorescence-based 
multiplex PCR fragment analysis. All the data were analyzed using gene mapper 
software. The status of other molecular markers (FLT3, NPM1, WT1 and KIT) was 
available as per our previous work. Results: Fragment analysis showed 7 CEBPA 
mutations in 4 (11.1%) of 36 AML patients. Mutations were detected throughout the 
entire coding region of CEBPA gene flanking the hot-spot regions of the TAD1, TAD2 
(N-terminal) and BR, LZ domain (C-terminal) of the CEBPA protein. Three of the 7 
CEBPA mutations were located in the N-terminal part of the protein, while remaining 4 
of the 7 mutations were located in the C-terminal encoding the bZip domain of CEBPA 
protein. Among the four positive cases; 2 patients (#14 and #29) had mutations at N 
and C terminal regions. Of these, case #14 showed an insertion of +4bp, +5bp affecting 
the TAD1 and TAD2, and an insertion of +3bp probably affecting BR/LZ domain. The 
second case (#29) showed an insertion of +9bp and +3bp affecting TAD1 and BR/LZ 
domains respectively. The remaining 2 of 4 positive cases showed mutations only in C 
terminal region (#28 and #36). Notably, both of these cases revealed an insertion of 
+6bp each, most likely affecting the BR domain of the CEBPA protein. Assessment of 
CEBPA mutation and other molecular markers viz., FLT3, NPM1, and WT1, may permit 
normal karyotype AML to split into clinically distinct subgroups. Indeed we observed 
one case (#14) that had additional FLT3 mutation. Another case (#29) showed 
simultaneous mutations in CEBPA and WT1 gene, while interestingly none of the 
CEBPA mutant cases showed any association with NPM1 and KIT mutation. 
Conclusions: The prevalence of CEBPA mutations observed in the current study is 
comparable to worldwide incidence (10% to 15%). Available literature suggests CEBPA 
mutation to be associated with good clinical outcome (in absence of FLT3 mutation); 
hence its inclusion in diagnostic evaluations of AML may allow assignment of patients 
to better-defined risk categories. 
 
H14. Promoter Methylation of CDKN2A, MGMT, and CDH1 in Multiple Myeloma 
H. So1, A. Oh1, J. Lee1, J. Kim1, Y. Choi2, Y. Chang1 
1Korea Cancer Center Hospital, Nowon-gu, Seoul, Republic of Korea; 2University of 
Science and Technology, Daejeon, Korea. 
Introduction: Aberrant DNA methylation is involved in the initiation and progression of 
carcinogenesis and includes hypermethylation of CpG islands of tumor suppressor 
gene promoters. Cyclin-dependent kinase 2A (CDKN2A), O6-methylguanine DNA 
methyltransferase (MGMT), and E-cadherin (CDH1) are known to be hypermethylated 
in various neoplasms. We investigated the methylation status of these genes using 
pyrosequencing in multiple myeloma (MM). Methods: Three cell lines, ARH77, 
RPMI8226, and MC/CAR, and bone marrow aspirates from 10 patients with MM were 
analyzed by pyrosequencing. The methylation index (MtI) of each gene promoter was 
calculated as the average value of methylated cytosine [(mC)/(mC+C)]. 
Hypermethylation was defined as MtIs of CDKN2A >0.047, MGMT >0.053, and CDH1 
>0.081. Results: CpG island hypermethylation of promoters of CDKN2A, MGMT, and 
CDH1 were found in all the MM cell lines. Mean MtI of CDKN2A, MGMT, and CDH1 in 
cell lineswere 0.937, 0.250, and 0.576, respectively. Hypermethylation of CDKN2A, 
MGMT, and CDH1 were detected in 80% (8/10), 56% (5/9), and 89% (8/9) of the MM 
patients, respectively. Mean MtIs of CDKN2A, MGMT, and CDH1 in the MM patients 
were 0.108, 0.093, and 0.243, respectively, which were significantly higher than control 
group (P<0.05). Conclusions: Our results suggest that hypermethylations of tumor 
suppressor genes (CDKN2A, MGMT, and CDH1) are frequent events in MM, which 
may play an important role in the progression of carcinogenesis. Pyrosequencing is 
useful for detection of methylation and it offers quantitative data and high throughput.  
 
H15. MicroRNA Profiles in Chronic Lymphocytic Leukemia  
P. Kaur1, H.B. Steinmetz1, C.L. Lefferts1, A.V. Danilov2, G.J. Tsongalis2,3 
1Dartmouth Hitchcock Medical Center, Lebanon, NH; 2Dartmouth-Hitchcock Medical 
Center and Norris Cotton Cancer Center, Lebanon, NH; 3Dartmouth Medical School, 
Hanover, NH. 
Introduction: miRNAs have been shown to modulate hematopoietic lineage 
differentiation and play important gene-regulatory roles. Several miRNAs are known to 
be either up- or down-regulated in chronic lymphocytic leukemia (CLL). In this study we 
evaluated an eight miRNA profile in patients with CLL. Methods: miRNA was isolated 
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from B-cell enriched (RosetteSep Human B Cell Enrichment Cocktail, StemCell 
Technologies, Vancouver, BC, Canada) peripheral blood from 60 individual CLL 
samples that was passed thru a ficoll Hypaque gradient. The patients’ ages ranged 
from 47 to 92 years and 25 of these were treated previously while 35 were untreated. 
Total RNA was extracted using the mirVana™ miRNA Isolation KIT (Ambion). 
Expression of miR15a, miR16-1, miR29a, miR181a, miR155, miR21, miR223, miR29c 
and U47 (an endogenous control) in each sample was determined using TaqMan® 
MicroRNA Assays (Applied Biosytems). In addition, expression of these miRNAs was 
determined in B cells from normal samples. The 'CT of the normal (CTnormal - 
CTendogenous control) and CLL samples (CTCLL sample - CTendogneous control) 
were calculated, and relative comparison of normal and CLL samples was made using 
the ''CTmethod ('CTCLL sample - 'CTnormal). Results: In this study, we found 
that there was no change in expression patterns for miRNAs 181a and 155 between the 
treated and untreated groups. miR15a and miR16-1 expression was similar to baseline 
controls in the treated population but down-regulated in 28% of the untreated samples. 
miR29a was down-regulated in both patient populations. miR21 and miR29c were up-
regulated in all of the treated CLL patients but down-regulated in 20% and 17%, 
respectively, of the untreated samples. While miR223 was down-regulated in both 
patient populations, there was a 6 log decrease in the untreated samples versus the 
treated samples. All values were normalized to the U47 control miRNA and a significant 
result was considered as a change greater than 1 log. Conclusions: Our results show 
that miRNA expression levels in CLL patients differ significantly between treated and 
untreated patients, as well as from that of normal patients. These results suggest that 
one role for miRNA profiling may be in determining the prognosis and potential 
outcomes in treated CLL patients. Further studies are needed to confirm these findings.  
 
H16. Multi-Site Evaluation of a Multiplex Assay for the Rapid Detection of 
Leukemia-Associated Fusion Transcripts 
C.D. Gocke1, H. Newell2, W. Laosinchai-Wolf3, C. Higgs1, J. Karp1, M. Griffiths2,  
J. Mason2, E. Labourier3 
1Johns Hopkins University School of Medicine, Baltimore, MD; 2West Midlands 
Regional Genetics Laboratory, Birmingham, UK; 3Asuragen Inc., Austin, TX. 
Introduction: Selection of optimal treatment approaches for leukemia patients entails 
accurate risk-based classification and analysis of multiple recurring chromosomal 
abnormalities. At the molecular level, analysis of the corresponding fusion transcripts 
confirms the initial diagnosis, provides additional prognostic information, and pinpoints 
targets suitable for subsequent disease monitoring. Rapid molecular methods are 
required to complement standard cytogenetic techniques and speed-up the workup of 
leukemia patients. The objective of this study was to evaluate the performance of a 
multiplex molecular assay for the simultaneous detection of 12 leukemia fusion 
transcripts and to compare to standard cytogenetic methods. Methods: The Signature® 
LTx RUO (Research Use Only) was evaluated at 3 sites using archived total RNA 
isolated from whole blood or bone marrow. Total RNA (100-400 ng) was reverse 
transcribed into cDNA and amplified by multiplex PCR using target-specific, biotin-
modified primers. GAPDH transcripts were co-amplified in each sample and 
concurrently analyzed to serve as endogenous internal controls. The PCR products 
were then sorted on a liquid bead array containing oligonucleotide probes specific for 
each marker and detected using the Luminex® 100 or 200 Systems. Results: A total of 
198 residual RNA samples were successfully tested at 3 sites. Specific detection of 
BCR-ABL1 e13a2, e14a2, or e1a2, TCF3-PBX1, ETV6-RUNX1, MLL-AF4 e9e5 or 
e10e4, PML-RARA bcr1 or bcr3, CBFB-MYH11 type A or D, and RUNX1-RUNX1T1 
was confirmed in 105 positive samples. There was >98% agreement with historical 
karyotype and/or FISH data. The assay helped resolve complex cytogenetic cases and 
positively identified the expected fusion transcript in RNA samples from patients with 
low blast count or at relapse. Additional analytical experiments with cell line RNAs and 
synthetic transcripts confirmed assay specificity, established a preliminary sensitivity of 
at least 1%, and showed that the panel content can be increased to include additional 
rare variants and other fusion transcripts. Conclusions: The assay is compatible with 
representative RNA samples extracted from various lymphoid and myeloid 
malignancies, including AML, CML, ALL, MDS and MPN. The assay has the advantage 
of typing individual fusion transcripts that can facilitate follow-up analyses and disease 
monitoring. It can also streamline laboratory operations with results generated in less 
than 5 hours and a multiplex format compatible with panel expansion. Overall, the 
assay is a sensitive and specific molecular research tool attuned to the clinical 
laboratory workflow and complements standard cytogenetic methods. 
 
H17. KIT Mutation Is Rare in Acute Myeloid Leukemias, Almost Always 
Involves Exon 17, and Occurs Predominantly in AML with t(8;21)(q22;q22) 
Z. Zuo, W.O. Greaves, R. Luthra, R. Sargent, S.S. Chen, J. Galbincea, L. Medeiros,  
C. Yin 
University of Texas MD Anderson Cancer Center, Houston, TX. 
Introduction: Activating KIT mutations play a role in leukemogenesis and are most 
frequently reported in core binding factor acute myeloid leukemias (AML). We review 
our experience with KIT mutation frequency in a large cohort of AML patients, and 
correlate KIT mutational status with prognosis. Methods: We searched our database 
for AML cases that were assessed for KIT mutations from 2002-2010. Mutational 
analysis of KIT exons 8 and 17 was performed by PCR and sequencing. Clinical and 
laboratory data were obtained from the medical records. Results: 16 of 1150 (1.4%) 
AML cases had KIT mutation including 10 women and 6 men with a median age of 44 
years (range, 19-65). KIT-mutated cases were classified using the WHO scheme as: 
AML with t(8;21)(q22;q22) (n=11), AML with inv(16)(p13.1q22)/t(16;16)(p13.1;q22) 
(n=2), AML without maturation (n=2), and AML with myelodysplasia-related changes 
(n=1). All patients had thrombocytopenia, 14 had anemia, 6 had leukocytosis, and 6 
had leukopenia. The median blast count in bone marrow was 74% (range, 24% to 
96%). Flow cytometric analysis showed CD19 and CD56 expression in 7 and 10 cases 
of AML with t(8;21)(q22;q22), respectively. Four patients had t(8;21)(q22;q22) as a sole 
aberration; others had more than one abnormality including +4 in 3 and +8 in 2 patients. 
KIT mutations were identified in exon 17 in 14 patients (87%, 13 codon 816, 1 codon 
822) and exon 8 in 2 (1 codon 413, 1 codon 421). The mutation L421I has not been 
reported previously. NRAS mutation was detected in 2 patients; none had FLT3 
mutation. All patients received chemotherapy, and 3 underwent bone marrow 
transplantation. With a median follow-up of 10.5 months (range, 3-53), 8 patients died 
of disease, 6 remained in clinical remission, and 2 had persistent AML. Compared with 
patients with KIT-negative AML with t(8;21)(q22;q22) seen during the same interval 
(n=29), KIT-mutated patients were more frequently women, and had a higher bone 
marrow blast count and shorter overall survival (p<0.05). Conclusions: KIT mutations 
in AML are rare, and occur almost exclusively in core binding factor AMLs, particularly 
AML with t(8;21). KIT mutations almost always involve exon 17, and are associated with 
shorter overall survival. Our data suggest that routine screening of all AML patients for 
KIT mutation is not necessary, nor is routine analysis of exon 8 indicated. KIT mutation 
analysis can be focused on exon 17 and be performed in patients with core binding 
factor AML, particularly patients with AML with t(8;21).  
 
H18. DNMT3A Mutations in Acute Myeloid Leukemia and Myelodysplastic 
Syndrome  
T.N. Mitchell1, J. Yao2, C. Hedvat 1, K. Nafa1 
1Memorial Sloan-Kettering Cancer Center, New York, NY; 2SUNY Downstate Medical 
Center, New York, NY. 
Introduction: Somatic mutations in the DNA methyl transferase 3A gene (DNMT3A, 
2p23) were discovered in 20 to 22% of de novo AML and recently in MDS and MPN. 
The most common DNMT3A mutation in exon 23 at codon R882 was found in more 
than 60% of AML cases in the initial report. Most of these mutations were located in one 
the three functional domains of DNMT3A protein: methyltransferase (MTase, 634-907 
aa) encoded by exons 16 through 23, proline-tryptophan-proline (PWWP, 289-362 aa) 
and Zinc finger (ZNF, 528-605 aa) encoded by exons 8-9 and exons 14-15, 
respectively. Mutations in DNMT3A provide new insights into pathogenesis of myeloid 
malignancies and could lead to new therapeutic possibilities. In addition, DNMT3A 
mutations were associated with poor outcome. Methods: We studied a series of 71 
AML (both de novo and secondary) and 31 MDS cases for mutations in exons 14, 15, 
17, 18, 19, and 23 of DNMT3A in a. PCR amplification of the 6 exons was performed in 
5 separate reactions (exons 18 and 19 were amplified together). PCR products were 
purified and sequenced by the Sanger method in forward direction. All positive cases 
were re-amplified and bidirectionally sequenced. Results: We identified DNMT3A 
mutations in 11 AML cases (11/71=15.5%) and 2 MDS cases (2/31= 6.5%). A total of 
15 DNMT3A mutations were found in the 13 cases (9 males and 4 females). Two AML 
cases had two mutations each (p.598X/p.V657M; p.R882H/p.V690G). Eight mutations 
were located in exon 23 at codon 882 (6 R882H, 2 R882C), 3 in exon 15, 3 in exon 17 
and one in exon 19. Six mutations were not reported previously: one frameshift 
mutation in exon 15 p.E561fs650X that adds 90 amino acids before a stop codon, one 
in frame deletion in exon 17 p.E667_I770delEDSI, and two missense mutations: 
p.R596Q, p.V657M, p.V690G, and p.F734L. No mutations were found in exons 14 and 
18. Conclusions: Our results confirm the presence of DNMT3A mutations in a 
significant number of AML cases and in a lower frequency in MDS. Testing for DNMT3A 
mutations in AML and MDS patients may be of prognostic value and could be used as a 
marker to detect minimal residual disease. 
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H19. Protein-Tyrosine Phosphatase, Nonreceptor-Type 6 (SHP1) Expression 
Loss as an Alternate Drug Resistance Mechanism in Chronic Myelogenous 
Leukemia 
A. Liu, K. Maloney, J. McCall, L. Buckingham 
Rush University Medical Center, Chicago, IL. 
Introduction: Chronic myelogenous leukemia (CML) patients can be refractory to 
imatinib mesylate therapy targeting the BCR-ABL kinase. Resistance in the absence of 
detectable abl kinase mutations suggests the presence of alternative mechanisms of 
resistance. The protein-tyrosine phosphatase, nonreceptor-type 6 (PTPN6, SHP1) 
down-regulates (dephosphorylates) signal transduction factors required for cell 
proliferation. The purpose of this study is to investigate the role of SHP1 in CML 
patients with and without detectable abl kinase mutations. We hypothesize that 
decreased expression of SHP1 is an alternative mediator of imatinib resistance. 
Methods: Sensitivity to imatinib was defined as a three log decrease in BCRabl/abl 
transcript levels in12 months or less. Transcript numbers were quantified using qPCR 
standard curves made with synthetic oligomers. The ratio of SHP1 transcripts/abl 
transcripts (SHP1/abl) was measured in RNA from 53 imatinib-sensitive and 47 
imatinib-resistant patients with CML and ten normal controls. Results: Average 
SHP1/abl was similar in normal cells and CML (p=0.747). The average SHP1/abl ratio 
was lower in imatinib-resistant CML cases (18.6), than in imatinib-sensitive cases (29.2; 
p=0.172). SHP1 transcript levels equal to or less than abl transcript levels (SHP1/abl 
<1.00) were significantly associated with resistance to imatinib (Chi-Square p=0.020). 
Taking account of abl kinase mutations, T315I, M351T, E255V and E255K, the average 
SHP1/abl ratio was highest in five sensitive cases found to have mutations, 42.7 vs 
27.7 in sensitive cases (n=48) without abl kinase mutations. Lower levels of SHP1 were 
observed in seven resistant cases with mutations (22.2). The average SHP1/abl ratio 
was lowest in imatinib-resistant cases without detectable abl kinase mutations (18.0; 
n=40). Conclusions: The results are consistent with SHP1 loss contributing to imatinib 
resistance in CML. Negative regulation of signal transduction factors, including src 
kinases, by SHP1 phosphatase would suggest a mechanism for the activity of src 
kinase inhibitors such as dasatinib or dual agents such as bafetinib. These agents may 
counteract loss of SHP1 activity in imatinib-resistant cases of CML or ALL, especially 
those without detectable abl kinase mutations.  
 
H20. Array Cytogenomics as a Diagnostic Aid for Acute Myeloid Leukemia: A 
Comparison of Four Different Platforms 
J.P. Segal1, V. Aikawa1, R. Daber2, J.J. Morrissette1 
1University of Pennsylvania, Philadelphia, PA; 2Children's Hospital of Philadelphia, 
Philadelphia, PA. 
Introduction: Array-based cytogenomic platforms have become mainstream diagnostic 
tools for constitutional chromosomal abnormalities not detectable by traditional 
cytogenetics. However, the chromosomal complexities seen in human cancer have 
delayed the implementation of this technology for personalized tumor analysis. As a first 
step towards validating array-based cytogenomics for cancer specimens, we selected 
eight cases of acute myeloid leukemia (AML) with defined cytogenetics and assayed 
them using four competing array platforms from Illumina, Affymetrix, Nimblegen-Roche 
and Agilent. Here we present the results of our comparative analysis, which 
demonstrate the relative strengths and weaknesses of the technologies. Methods: 
Eight cases of AML representing a spectrum of cytogenetic findings were selected for 
molecular analysis following routine cytogenetic analysis of bone marrow aspirates. 
DNA was isolated pre-culture (Puregene, Gentra) and submitted for array analysis at 
each company’s laboratory. DNA was then processed on the four array platforms, and 
the resulting data was returned for our review. Data analysis, including aberrant calls, 
was also provided by several of the participating companies to allow for comparison of 
our analysis pipeline with the company’s analysis software. Results: Three of the 
platforms tested included both copy number and genotyping probes (Illumina, 
Affymetrix and Agilent), while the Nimblegen platform analyzed copy number only. 
Cytogenetically visible abnormalities present in a high percentage of cells were 
generally detectable by all platforms. Detection of abnormalities present at low levels 
was more complicated, with each platform having different detection limits. Inclusion of 
SNP probes allowed for increased sensitivity to low level events, and was crucial for 
detecting copy neutral loss of heterozygosity not detectable by cytogenetics. Probe 
density for both copy number and genotyping probes was also found to be important for 
accurately determining the size of affected regions. Sensitivity to detecting the 
percentage of cells affected by each abnormality also proved to be important in 
determining the clonal diversity of the tumor. Conclusions: Analysis of our samples on 
all four platforms allowed us to assess the strengths and weaknesses of each of the 
underlining technologies. Given the types of aberrations found in malignancies and 
issues related to clonality, key aspects required for successful incorporation of arrays 
into cancer cytogenetics include: the power to detect copy neutral LOH and aberrations 
present in a low percentage of cells, and the ability to accurately quantify the 
percentage of cells affected by each abnormality. Each platform analyzed has 
overlapping abilities, with no single platform performing best in all areas.  
 
H21. TP53 DNA-Binding Motif Mutation Is Found in High-Risk, Untreated 
Chronic Lymphocytic Leukemia Patients with Chromosome 17p Deletion 
S.A. Schichman1,3, A. Stone1, M. Winters1, W. Carter1, L. Frederick2, C.S. Zent2,  
D.S. Viswanatha2 
1Central Arkansas Veterans Healthcare System, Little Rock, AR; 2Mayo Clinic, 
Rochester, MN; 3University of Arkansas for Medical Sciences, Little Rock, AR. 
Introduction: Interstitial deletion of chromosome 17p (17p-) detected by fluorescence 
in situ hybridization (FISH) and p53 mutations are unfavorable prognostic markers in 
chronic lymphocytic leukemia (CLL) and are associated with significantly poorer 
response to chemoimmunotherapy and decreased overall survival. We applied SNP-
based whole genome copy number variation (CNV) analysis to characterize CLL 
patients with 17p-. DNA sequencing was used to identify mutations in the TP53 gene. 
Methods: We performed CNV analysis and TP53 sequencing on 6 patients with early-
intermediate stage, untreated CLL who had high risk for disease progression based on 
molecular and immunophenotypic markers. All six patients had 17p- and 13q- detected 
by FISH. CLL cells and normal cells were separated from patient peripheral blood by 
immunomagnetic beads. CNV analysis was performed on purified genomic DNA from 
CLL and normal cells for each patient to distinguish acquired copy number changes in 
malignant cells from polymorphic CNVs in the human genome. The Illumina human 
660w-quad beadchip, a SNP-based microarray, was used for CNV analysis. Data was 
analyzed by CNV partition and PennCNV software. TP53 mutation analysis was 
performed by dideoxy sequencing of PCR products amplified from TP53 exons 4-9. 
Results: CNV analysis detected 17p- in 6 out of 6 patients with 17p- by FISH. One 
sample had 17p- in 20% of nuclei by FISH, which is near the current detection level of 
SNP-based copy number analysis (estimated at 15% to 20%). Four patients had 
hemizygous deletions covering the entire p arm of chromosome 17. Two patients had 
hemizygous interstitial deletions of 17p that spanned 17 Mb and 580 Kb respectively. 
All 17p deletions included the region of TP53. Additionally, patients with 17p- had 
numerous acquired copy number aberrations (CNAs) in the CLL genome located on 
chromosomes 1, 2, 3, 4, 9, 10, 13, 15, 18, and 20. These CNAs included hemizygous 
deletions, homozygous deletions, duplications, and uniparental disomy. Four of the six 
17p- patients had TP53 mutations located in the p53 DNA-binding motifs (DBMs), 
specifically between amino acids 109 and 286. Conclusions: SNP-based CNV 
analysis enables detailed characterization of complex copy number aberrations in the 
CLL genome, including large and small interstitial deletions of chromosome 17p. The 
majority of our CLL patients with 17p- also have TP53 mutations involving the DBMs, 
which have been associated with especially poor prognosis. Analysis of TP53 mutation 
status complements SNP-based CNV evaluation. TP53 screening is essential in CLL 
patients requiring treatment for progressive disease. 
 
H22. Detection of Minor Clones with Internal Tandem Duplication Mutations of 
FLT3 Gene in Acute Myelogenous Leukemia Using Delta-PCR 
K. Beierl1, L. Tseng2, R. Beierl1, S. Mosier1, A. Stafford1, C.D. Gocke1, J.R. Eshleman1, 
M. Lin1 
1Johns Hopkins University School of Medicine, Baltimore, MD; 2National Taiwan 
University Hospital, Taipei, Taiwan. 
Introduction: Internal tandem duplication (ITD) mutations of the FLT3 gene have been 
associated with poor prognosis in acute myelogenous leukemia (AML). Detection of 
minor clones or minimal residual leukemia clones with ITD mutations may be essential. 
In clinical diagnostic laboratories, ITD mutations are usually detected using PCR 
followed by capillary electrophoresis with an analytic sensitivity of 5% to 10% blasts. 
Since the potential amplicon size varies greatly and multiple mutations may be present, 
PCR detection of ITD mutations using capillary electrophoresis may be challenging, 
particularly when the peak height is low. Methods: In our previous study, we developed 
a triple-primer strategy, delta-PCR, to ensure PCR specificity and to improve sensitivity. 
The primer design is analogous to semi-nested PCR, but all three primers are used 
simultaneously in a single-step reaction. The internal primer functions as a confirmatory 
“probe”, since it was designed at a defined distance (the delta) from the external primer. 
A pair of amplicons differing in size by the delta indicates an ITD mutation. In the 
current study, delta-PCR was used to detect ITD mutations with a sensitivity of 0.1% 
leukemic cells. 109 cases with newly diagnosed or relapsed AML were analyzed, 
including serial samples from 3 cases. Results: Delta-PCR was able to detect single or 
multiple ITD mutations with an allele burden (peak height ratio of mutant allele to wild-
type allele) of the dominant clone ranging from 0.2% to more than 100% among all 31 
cases with previously documented ITD mutations, a 0.01% allele burden among 1/75 
cases with previously reported ITD-negative results, and a 0.1% allele burden in 1 of 3 
cases with previously reported ITD-negative results in the initial diagnostic specimens 
and ITD-positive results at the same size in follow-up specimens. These data indicate 
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that minor leukemic clones (allele burden of less than 1%) may become prominent 
clones later in the course of the disease. Conclusions: In summary, delta-PCR detects 
ITD mutations with improved sensitivity and may be useful for detection of minimal 
residual leukemia. Detection of minor clones with ITD mutation at the time of diagnosis 
may be clinically significant since they may become predominant in relapsed or 
refractory leukemias.  
 
H23. Evaluation of Acute Myeloid Leukemia Specimens by Array CGH Reveals 
New Abnormalities across Prognostic Groups 
R.A. Schultz1, T.C. Brown2, M. Andreeff3, R. Wang3, L.J. Campbell4, M. Wall4,  
J. Schoumans5, J. Han6, U. Surti7, K.A. Kolquist8, K. Ouahchi8, E. Crawford9,  
S. Stewart9, M. Fang10, W. Hsu11, R.R. Tubbs12, J.R. Cook12, J. Fink13, A. Furrow1,  
L.G. Shaffer1, B.C. Ballif1 
1Signature Genomic Laboratories, PerkinElmer Inc., Spokane, WA; 2CSI Laboratories, 
Alpharetta, GA; 3MD Anderson Cancer Center, Houston, TX; 4St. Vincent's Hospital 
Melbourne, Fitzroy, VIC, Australia; 5Centre Hospitalier Universitaire Vaudois, Lausanne, 
Switzerland; 6Dong-A University College of Medicine, Busan, Korea; 7Magee-Womens 
Hospital of UPMC, Pittsburgh, PA; 8Pathology Associates Medical Laboratories, 
Spokane, WA; 9Genetics Associates Inc., Nashville, TN; 10Fred Hutchinson Cancer 
Research Center, Seattle, WA; 11Rush University Medical Center, Chicago, IL; 
12Cleveland Clinic Foundation, Cleveland, OH; 13Hennepin County Medical Center, 
Minneapolis, MN. 
Introduction: The clinical heterogeneity of acute myeloid leukemia (AML) is well 
appreciated and cytogenetics play a key a role in predicting survival, with risk defined 
as good [e.g., t(8;21), inv(16), t(15;17)], intermediate [e.g., normal karyotypes, +8, 
t(3;5), t(9;11)] and poor [e.g., complex, 5q-, 7q-, other 11q23, inv(3)]. Although patients 
can be assigned to prognostic risk groups based on the cytogenetic findings, further 
refinement of these groups based on additional genetic findings should prove helpful for 
tailoring prognostic and treatment decisions. Microarray analysis (aCGH) of other 
hematological disorders has proven a powerful means to characterize disease, and the 
technology is gaining popularity both as a discovery tool and a diagnostic test, offering 
a higher resolution analysis compared to traditional cytogenetic approaches. We have 
utilized aCGH to analyze two series of cases with AML, reflecting a diversity of prior 
cytogenetic findings. Methods: We have developed the Signature OncoChip™ oligo-
based microarray platform with genome-wide backbone coverage (1 probe/35 Kb) and 
higher density coverage for >1800 cancer features (1 probe/0.2-7.0 Kb) to detect copy 
number alterations (CNAs) for a diversity of hematologic disorders. aCGH was 
performed on two sets of AML specimens including a series of 63 AML cases (#1), all 
with known abnormal karyotypes representing those categories mentioned above, and 
a second series of 10 cases (#2) principally with normal karyotypes or novel balanced 
translocations, and generally poor outcome. Results: Analysis of a series #1 detected 
all prior cytogenetically recognized copy gains and losses in 57/63 (>90%) cases 
analyzed. Low level mosaicism (LLM) (5% to 20%) accounted for all abnormalities not 
detected. Results defined karyotypically complex cases and also identified non-
recurrent CNAs across prognostic groups [e.g., deletions of 1q21.1 (GPR89B), 5q25.1 
(RANBP17), 12p13.2 (ETV6), 13q14.2 (RB1), 16q21 (CDH8)]. For series #2, of 5 
karyotypically normal cases, aCGH revealed multiple abnormalities in two of these 
cases (40%) [+8 with deletions 3p14.1 (FOXP1, MITF), 9q21.2->q33.2, 17q11 
(homozygous NF1); and -7, +8, +11, +15]. For cases with novel balanced 
translocations, aCGH revealed additional novel alterations (80%) [e.g., deletions of 
11p13 (WT1, LMO2 and CAPRIN1), 17q21 (WNT3), and 15q14->q21.1 (B2M, 
TP53BP1, and RASGRP1) and partial tandem duplication of MLL]. Conclusions: 
aCGH analysis of AML cases identified all abnormalities previously detected by 
cytogenetics (excluding LLM). Additional alterations were identified across prognostic 
groups consistent with the higher resolution of the technology. Interestingly, cases with 
normal karyotypes or novel balanced translocations and generally poor outcome 
revealed the highest number of new findings.  
 
H24. Detection of RAS Mutations in Multiple Myeloma Using Sequenom 
MassArray Platform 
A. Oultache, L. Borsu, A. Marchetti, N. Mensah, H. Landau, C. Hedvat 
Memorial Sloan Kettering Cancer Center, New York, NY. 
Introduction: Multiple myeloma (MM) is an incurable hematologic malignancy with a 
three to four year median survival. Activating mutations in the RAS oncogene (NRAS, 
KRAS) are present in 30 to 40% of cases and are thought to represent an early event in 
the disease progression. Whole genome sequencing and other studies have shown that 
RAS family genes are the most frequently mutated genes in this disease. We 
investigated the use of mass spectrometry for the detection of specific RAS mutations 
in MM. Methods: Genomic DNA was extracted from BM aspirates from 19 patients with 
confirmed MM. We used Sequenom Mass Spectrometry Genotyping for specific 
mutations in codon 12, 13, 61 and 146 of KRAS and NRAS. The performance of this 
platform has been validated in our laboratory and the results are deemed accurate. The 
specific mutations are detected by amplification of the corresponding exons by PCR, 
followed by single base extension at the site of the point mutation. The extension 
product is detected by Tandem-Mass spectrometry on the Sequenom MassArray 
Spectrometer. Results: Seven cases (37%) were positive for RAS oncogene 
mutations. Four cases showed KRAS mutations: one codon 12 (G12D), two codon 61 
(Q61L, Q61H) and one codon 146 (A146V) mutation. Three cases harbored NRAS 
mutations: one codon 13 (G13R) and two codon 61 (Q61R) mutations. Conclusions: 
Using Sequenom MassArray technology, we found RAS oncogene mutations in 37% of 
MM samples, similar to the frequency reported in the literature. This platform affords 
precise, rapid and reliable detection of specific RAS mutations and further studies 
investigating the significance of RAS mutations in combination with other genetic 
lesions in MM are planned. In addition to standard genomic analysis, individual 
sequencing studies have the potential to create a personalized approach to the 
diagnosis and treatment of MM. 
 
H25. NPM1 Mutation Occurs in a Subset of Ph+ AML Suggesting that this 
Entity Is Distinct from CML in Myeloid Blast Phase 
S. Konoplev, C. Yin, S.M. Kornblau, H.M. Kantarjian, M. Konopleva, M. Andreeff, G. Lu, 
Z. Zuo, R. Luthra, L.J.. Medeiros, C.E. Bueso-Ramos 
UT MD Anderson Cancer Center, Houston, TX. 
Introduction: The existence of de novo acute myeloid leukemia (AML) associated with 
t(9;22)(q34;q11.2)/BCR-ABL1, also known as Philadelphia chromosome-positive (Ph+) 
AML, is controversial. Investigators who doubt the existence of Ph+ AML suggest that 
criteria for distinguishing Ph+ AML from chronic myelogenous leukemia (CML) initially 
manifesting in a myeloid blast phase (BP) are not convincing. Other means of 
distinguishing Ph+ AML from CML-BP would be helpful. Methods: We searched the 
files of our hospital for AML cases associated with t(9;22)(q34;q11.2)/BCR-ABL1 
between January 1998 and January 2009. Patients with a history of chronic or 
accelerated CML, a CML-like picture after therapy, splenomegaly, or basophilia were 
excluded. We also identified a group of 12 patients with CML in myeloid BP with a 
documented antecedent CP during the same study period for comparison. BCR-ABL1 
fusion transcripts were assessed by real-time qRT-PCR. Mutational analyses of the 
NPM1 (n=7) and FLT3 (n=4) genes were performed using PCR/capillary 
electrophoresis. Results: We identified 7 patients with de novo Ph+ AML. There were 4 
men and 3 women, 22-76 years of age (median, 66 years). Conventional cytogenetics 
showed t(9;22)(q34;q11.2) in all patients; qRT-PCR proved BCR-ABL1 in all 6 cases 
assessed. Two of 7 (29%) patients had NPM1 mutation; both were alive in molecular 
remission 20 and 57 months after diagnosis, respectively. FLT3 was wild type in 4 
cases tested, including both patients with NPM1 mutation. None of 12 patients who had 
CML-BP had NPM1 mutation. Conclusions: The detection of NPM1 mutations in Ph+ 
AML supports the existence of Ph+ AML as an entity distinct from CML in myeloid BP. 
Although the study group is small, the frequency of NPM1 mutation in Ph+ AML is 
similar to AML cases in general. It is also of interest that both patients with NPM1 
mutation responded well to therapy with molecular remission. 
 
H26. A Photodiode Array for KIR Genotyping  
B. Han1, J. Kim2, H. Park1,5, O. Kwon3, K. Hwang3, Y. Kim4, E. Oh4 
1YeBT.Co. Ltd., Seoul, Republic of Korea; 2Seoul National University College of 
Medicine, Seoul; 3CELLTEK Co., LTD., Seoul; 4School of Medicine, The Catholic 
University of Korea, Seoul; 5School of Dentistry and Dental Research Institute, Seoul 
National University, Seoul. 
Introduction: In this study, we designed a technique for killer cell immunoglobulin-like 
receptor (KIR) genotyping by photodiode array (PDA). Genes encoding KIRs are 
variable among individuals. The detection methods for KIR genotyping have been 
developed using various technologies. Methods: The PCR-amplified biotinylated 
exon4, 5, and 9 were hybridized to the immobilized probe DNA on the photodiode 
surface, and the chip was incubated in an anti-biotin antibody-conjugate gold 
nanoparticle solution. The silver enhancement by the gold nanoparticles bound to the 
biotin of the target KIR genes precipitates silver metal particles at the chip surfaces, 
which block light irradiated from above. The resulting drop in output voltage depends on 
the amount of target DNA present in the sample solution, which allows the specific 
detection and the quantitative analysis of the complementary target DNA. Results: The 
PDA chip showed high relative signal ratios of KIR probe DNA hybridized to 
complementary target DNA, indicating an excellent capability in discriminating the 
presence and absence of the 16 KIR genes. Conclusions: This chip assay allows for 
efficient genotyping of the KIR locus. 
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H27. Clinical Evaluation of a Quantitative RQ-PCR Assay for NPM1 Mutant 
Expression in Acute Myeloid Leukemia (AML) Using the Ipsogen NPM1 
MutaQuant RUO Kit 
M. Grinkemeyer1, M.H. Voelkner1, P.E. Morris1, C.D. Gocke2, M.F. Sabato1,  
D.S. Wilkinson1, D. Williams1, A. Ferreira-Gonzalez1 
1Virginia Commonwealth University, Richmond, VA; 2Johns Hopkins University School 
of Medicine, Baltimore, MD. 
Introduction: Mutant Nucleophosmin (NPM1 mutant) mRNA may be a significant 
marker for classification, prognosis, and treatment decisions for AML patients. In 
addition, quantitative monitoring of NPM1 mutant messenger RNA activity may assist 
providers to assess minimal residual disease (MRD) and molecular disease relapse 
well in advance of hematologic disease relapse, possibly extending the survival of these 
patients. Here we evaluated the performance characteristics of a commercially 
available assay, Ipsogen NPM1-A MutaQuant RQ-PCR for the quantitation of mutant 
NPM1 in AML patients. Methods: Precision and linearity studies were carried out using 
the NPM1 mutation positive OCI-AML3 cell line (German Collection of Microorganisms 
and Cell Cultures DSMZ, Germany) diluted in the CCRF (American Type Culture 
Collection, VA) cell line. Linearity was assessed by evaluating five dilutions (OCI-AML3 
cells diluted in CCRF cells) in duplicate in 3 separate experiments on 3 separate days 
and an additional two duplicate dilutions on 2 additional days. Precision was assessed 
by evaluating a high and a low dilution tested in duplicate on 5 separate days. Clinical 
correlation studies were carried out using 30 peripheral blood and bone marrow 
samples that had been qualitatively tested for NPM1 mutations at outside laboratories. 
Three normal peripheral blood samples were also evaluated. All results were 
normalized using ABL gene expression (i.e. NPM1 copy number divided by ABL copy 
number multiplied by 100 and reported as %NCN; i.e. NCN = normalized copy number). 
Results: The relationship between the log%Normalized Copy Number vs. Ct was linear 
with an R2 value > 0.99 and efficiency greater than 90% (slope = -3.50) with a tested 
lower limit of quantitation of 10 OCI-AML3 cells/999,990 CCRF cells. For precision, the 
high and low dilutions were repeated in duplicate on 5 separate days yielding the 
following: 10 OCI-AML3 cells/999,990 CCRF cells — mean = 0.091%NCN, SD = 0.039, 
CV = 43.65 and 100,000 OCI-AML3 cells/900,000 CCRF cells — mean = 
197.936%NCN, SD = 52.222, CV = 26.38. A 100 percent correlation between positivity 
and negativity was obtained for all clinical samples tested at outside laboratories. The 3 
normal samples also tested as negative. Conclusions: The Ipsogen NPM1 MutaQuant 
RUO kit is a good method for quantitation of mutated NPM1 mRNA expression in 
patients with known NPM1 mutation positive AML.  
 
H28. Performance Variability of BCR-ABL Monitoring Tests: Impact of PCR 
Platform Standardization on Health Care Systems  
P.L. Reddy1, M.M. Moradian2, M.M. Quigley3, C.D. Watt4, P. Choppa5, N.T. Potter6, 
W.W. Wong7, S.A. Campbell7, S. Wang8, A.A. Mignault8, F. Yang8, P. Stiegler9,  
D.F. Ossa10, B.M. Manning10, H.A. Hoefling10, A.M. Stein10, M. Wetzler11 
1University of Chicago Medical Center, Chicago, IL; 2Kaiser Permanente Southern 
California, Los Angeles, CA; 3Scripps Green Hospital, La Jolla, CA; 4Hospital of the 
University of Pennsylvania, Philadelphia, PA; 5Clarient/GE, Aliso Viejo, CA; 6Molecular 
Pathology Laboratory Network, Inc., Maryville, TN; 7Cepheid, Sunnyvale, CA; 8Novartis, 
Cambridge, MA; 9Duke Clinical Research Institute, Durham, NC; 10Novartis Pharma AG, 
Basel, Switzerland; 11Roswell Park Cancer Institute, Buffalo, NY. 
Introduction: This study examines inter- and intra-lab variability (and clinical 
consequence) among BCR-ABL monitoring tests. Three labs with the GeneXpert® Dx 
System (GX) using the Cepheid BCR-ABL Monitor Assay with an international scale 
(IS) conversion factor and 3 labs with lab-developed tests (LDTs) were compared in a 
system modeling CML patients (pts). Methods: K562 cell-spiked blood corresponding 
to BCR-ABL(IS) ratios ranging from ~10% to ~0.01% was tested. Scenarios included: 1) 
health care system (HCS) relying on 3 GX labs; 2) HCS relying on 3 LDT labs (without 
IS standardization). Results: Test of means showed no statistical difference between 
GX sites, whereas all LDTs differed significantly. The ratio of median measurements for 
each spike level (highest divided by lowest site) was less than 2 for the GX sites for all 
levels (<1.6 for spike levels >0.1% BCR-ABL(IS)) whereas LDT ratios ranged from 22 at 
a spike level of 0.13%, to ~10 for all other levels. The variability in the LDT-based HCS 
was considerably higher than that in the GX-based HCS. The LDT labs consistently 
reported either higher or lower values than the GX sites, indicating that inter-lab 
variability among LDTs could improve with IS standardization. Objective criteria for 
attainment of major molecular response (MMR) were applied against 100 virtual patient 
transcript profiles (VTPs) modeled after actual BCR-ABL pts observed in the IRIS 
clinical trial using the underlying data. Inter-lab pairwise discordance in MMR scoring 
ranged between 4% to 7% of VTPs within the GX HCS, 20% to 57% of VTPs within the 
LDT HCS, and 8% to 49% of VTPs between labs in the 2 different HCSs. Within the GX 
HCS, scoring per NCCN criterion (3-log reduction) vs IS criterion (0.1%(IS)) resulted 
in discordant interpretation of MMR among 2% to 13% of VTPs (intra-lab variability and 
MMR determination details for all sites will be presented). Using budget impact 
modeling, the economic benefits of a standardized platform were examined. For 100 pts 
monitored by guidelines, an estimated cost savings of $43,000 could be achieved over 
1 year. Conclusions: Because inter-lab variation and differences in defining MMR 
could result in different interpretations for management of CML pts, these data 
underscore the need for PCR standardization. Automated platform standardization and 
adoption of the IS can improve BCR-ABL inter-lab variation. Because the standardized 
manufacturing and QC schema reduce the scope for test validation, test duplication, or 
QC panels, the standardized platform represents a potential cost-saving alternative.  
 
H29. Cell Compartment Discrepancies in Hematopoietic Stem Cell 
Transplantation Chimerism Analysis 
K. Rivera-Roman, F.J. Bolanos-Meade, E.J. Fuchs, L. Luznik, C.D. Gocke, S. Harada 
Johns Hopkins University School of Medicine, Baltimore, MD. 
Introduction: After treatment with an allogeneic hematopoietic stem cell transplant 
(HSCT), chimerism analysis is critical in ascertaining graft success, disease recurrence, 
and treatment complications such as graft versus host disease (GVHD). The utility of 
chimerism analysis in subsets of blood cells is not well studied. Methods: We studied 
chimerism analysis results retrospectively in 76 patients who had undergone HSCT for 
malignancy. Chimerism was determined by PCR amplification of short tandem repeats 
in bone marrow (BM) and unfractionated (UF) and/or CD3+ sorted cells from peripheral 
blood (PB). A significant discrepancy between UF and CD3+ compartments was 
defined as >10% difference in chimerism. Results: Fifty-two patients achieved 
complete donor engraftment by day 30 post HSCT. Twenty-four patients showed mixed 
chimerism and, among these, 14 showed significant discrepancies. In 10 patients (6 
lymphoma, 4 leukemia), CD3+ cells of patient origin were present at a higher 
percentage than in UF cells, while 4 patients presented with a higher percentage of UF 
cells of patient origin. The latter 4 patients (all leukemia) showed poor clinical response 
(3 relapsed, 1 had graft failure). Consecutive analysis at 1-2 month intervals showed 
that patients with >50% CD3+ patient cells (3 patients total) in their PB by 6 months 
after transplantation had either graft rejection (1) or disease relapse (2). Those who 
presented with <50% CD3+ patient cells (6) eventually converted to complete donor 
chimerism. Discrepancies were transient (defined as <3 months) in 4 patients while 4 
others demonstrated persistence of the discrepancy for >6 months. For those patients 
with paired BM, the patient chimerism in the BM more closely matched the UF than the 
CD3+ fraction. No correlation was found between rate of GVHD and/or graft failure and 
presence or level of discrepancy of mixed chimerism. Conclusions: We conclude that 
cell compartment discrepancy is a fairly common phenomenon in allogeneic HSCT 
patients. In about half of patients it is transient while others have longer lived cell 
compartment discrepancy. Analysis of bone marrow chimerism does not substitute for 
analysis of either cell compartment, as it fails to reliably predict their chimerism. 
Regardless of discrepancy, high levels of CD3+ patient cells in the peripheral blood 
appear to correlate with poor clinical outcome. In cases with discrepancy, a low level of 
CD3+ patient cells but higher UF patient cells correlates with relapse, although this 
group also contains a higher proportion of leukemia patients than the other group. 
 
H30. High Resolution Melting Analysis as an Upfront Cost Effective Screening 
Method for Detection of KIT Exon 17 Mutations in Acute Myeloid Leukemia in the 
Clinical Laboratory 
B.A. Barkoh, D. Do, S. Hai, C. Yin, S. Chen, R. Sargent, L. Mederios, R. Luthra,  
K. Patel 
The University of Texas M.D. Anderson Cancer Center, Houston, TX. 
Introduction: Gain of function mutations in Exon 17 of KIT occur at a low frequency in 
acute myeloid leukemia (AML) and are associated with poor prognosis. A review of 
clinical test database at our diagnostics laboratory showed that mutations in exon 17 of 
KIT were detected in only 70 of 2975 (2.4%) specimens by Sanger sequencing. To 
reduce the effort and costs associated with the sequencing of such low frequency 
mutations, we developed and validated a high resolution melting analysis (HRMA) 
screening method to detect variants in exon 17 of KIT. Methods: A total of 127 
peripheral blood or bone marrow aspirates from patients with AML previously tested by 
Sanger sequencing for KIT exon17 mutations were included in this validation study. The 
study cases were selectively enriched for KIT mutations (N=52; codon 813(N=4), codon 
816 (N=36), codon 822 (N=4) and codon 798(N=8)). HRMA was performed using 50 ng 
of DNA on the LightCycler® 480 (Roche, Indianapolis, IN). HRMA-PCR products were 
sequenced in all cases. The assay sensitivity was determined by using serial dilution of 
positive cell line (Kasumi) DNA into a negative cell line (HL60) DNA. Results: Variant 
calls were made by HRMA in 62/127 cases that included all 52 cases previously shown 
to have mutations by Sanger sequencing. Sanger sequencing of the post HRMA 
product also confirmed mutations in these 52 samples. The remaining 10 HRMA 
variants were wild type by Sanger sequencing (false positive rate: 7.9%). Notably, there 
were no false negative calls by HRMA. HRMA accurately genotyped 92.1% of the 
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cases. The sensitivity of the HRMA assay was 10% in our serial dilution studies. Post-
validation application of HRMA in routine diagnostics workflow detected variants in 
32/303 (10.6%) of AML samples, resulting in 89.4% reduction in Sanger sequencing 
volume. Conclusions: HRMA is a reliable screening tool that provides an efficient 
alternative to Sanger sequencing for low frequency mutations resulting in time, cost and 
labor savings and improving turnaround time for majority of cases.  
 
H31. GUSB or BCR, but not ABL, Is the Best Internal Control Gene for BCR-
ABL1 Quantification 
K. Nie, P. Lu, Y. Wang 
Weill Cornell Medical College, New York, NY. 
Introduction: The control gene for BCR-ABL1 quantification serves as the internal 
caliber to control for RNA loss from the step of cell preparation to PCR. It also controls 
for pre-analytical RNA degradation. As the control for both RNA quantity and quality, 
the control gene is the single most important determinant for accurate BCR-ABL1 
quantitative assessment. Several years ago, the International BCR-ABL RQ-PCR 
Standardization Group recommended that ABL, BCR or GUSB be used as the control 
gene for BCR-ABL1 quantification (Blood, 108, 28-37, 2006). However, our analysis of 
the recent CAP surveys (presented before the International BCR-ABL RQ-PCR 
Standardization Group in December 2009) showed, with data collected from more than 
100 participating labs, that ABL-controlled BCR-ABL1 levels provide significantly 
different quantitative values from those that are expected for the survey samples. In 
comparison, BCR- or GUSB-controlled BCR-ABL1 levels were accurate. This 
observation remains true for several recent CAP surveys. We have been interested in 
the identification of the best control gene. Previously, we showed that GUSB and G6PD 
are the best control genes by comparing 14 candidates (including ABL and GUSB, but 
not BCR) using the six most relevant criteria (J Mol Diagn 2006, 8:231-239, 2006 and J 
Mol Diagn 2006, 8:385-389). Owing to the more frequent occurrence of G6PD 
mutations in the hereditary disorder of G6PD deficiency, GUSB was recommended as 
the most suitable control gene. Methods: In the current study, using serial dilutions of 
cell lines (K562 into HL60) and primary cells (CML into normal total white cells), we 
determine the dynamic range of BCR-ABL1/ABL1, BCR-ABL1/GUSB and BCR-
ABL1/BCR. Results: We show that ABL-controlled BCR-ABL1 quantification exhibits a 
much narrower linear range than BCR- or GUSB-controlled BCR-ABL1 quantification. 
Conclusions: By comparing and contrasting the three recommended control genes, 
our results further demonstrate that GUSB or BCR, but not ABL, is the best internal 
control gene for BCR-ABL1 quantification. The limitations of using ABL as the control 
gene, in compliance with the recommendations by the International BCR-ABL RQ-PCR 
Standardization Group, will be shown and discussed.  
 
H32. High Resolution Whole Genome Scanning for Acquired Copy Number and 
Copy Neutral Alterations in Cytogenetically Normal Multiple Myeloma 
V. Hucthagowder1, M. Fiala1, J. Paasch1, M. Tomasson1, R. Vij1, S. Kulkarni1,2 
1Washington University School of Medicine, St Louis, MO; 2Siteman Cancer Center, St 
Louis, MO. 
Introduction: Multiple myeloma (MM) is the second most common hematological 
malignancy, characterized by uncontrolled accumulation of clonal plasma cells. Clinical 
and cytogenetic features have been the major prognostic markers for the overall 
management of this incurable disease. Cytogenetically, the prognostication has been 
significantly hampered to an extent by the small number of monoclonal plasma cells 
and the low proliferative activity in the bone marrow. Although FISH analysis has been 
a valuable tool in clinical diagnostics, the fast emerging genome-wide chromosomal 
microarray analysis (CMA) has provided an improved understanding of MM 
pathogenesis. Methods: Our goal was to identify the global genomic aberrations using 
high resolution SNP array in 20 cytogenetically normal MM patients. To aid 
identification of the true somatic mutations in tumor genome we used patient’s matched 
normal genome derived from skin biopsies. This approach is very important to 
determine which copy number alterations are inherited versus acquired. DNA was 
isolated both from CD138 positively selected plasma cells and skin. Affymetrix SNP 6.0 
microarray was used to deduce copy number and copy neutral alterations. The data 
was analyzed using Nexus copy number analysis software. All the samples passed the 
SNP QC and the call rate were >94%. Results: The genomic aberrations in the 
abnormal patients well correlated with the reported cytogenetic analysis. Interestingly, 
all the cytogenetically normal patients showed abnormality throughout the genome in 
our cohort. Genomic abnormalities were present in all the chromosomes with over 25% 
gains in 1q, 3, 5, 7, 9, 11, 15, 18, 19, 21 and deletions in 1p, 6q, 8, 12p, 13, 14, 16q and 
22. In particular, deletion of chromosome 1p, 6q, and 8p and amplification of 
chromosome 11 were significantly different between these groups. We also observed 
LOH on chromosome 1, 9, 11, 16 and 19 in the cytogenetically normal group. Overall 
our results emphasize the growing importance of the CMA in identifying the 
cytogenetically unidentified genomic aberrations. In conclusion, we identified novel 
genomic abnormalities in nearly all the cytogenetically normal patients and our data 
correlates well with the known pattern of genomic aberrations in MM pathogenesis. 
Conclusions: The contextual relevance of these mutations will be better understood 
with analyses of additional clinically and demographically stratified cytogenetically 
normal MM patients. Whole genome scanning for copy number alterations will help in 
precisely prognosticating MM, in risk based stratification of treatment and perhaps 
survival.  
 
H33. Re-evaluation of Molecular Diagnostic Tests for T-Cell Receptor Clonality 
in Taiwanese Populations 
W. Huang1, Y. Chen2, C. Ho2 
1National Cheng Kung University, Tainan, Taiwan; 2National Cheng Kung University 
Hospital, Tainan, Taiwan. 
Introduction: Monoclonal expansion of T-cell receptor (TCR) genes is an important 
marker for T-cell malignancy. The genetic features shown by TCR gene 
rearrangements offer useful markers to distinguish lymphoid hyperplasia from 
malignancy from TCL, especially for cases with atypical histopathological features. 
Therefore, the molecular diagnosis of TCR gene clonality has been used in TCL 
diagnosis for years. We used BIOMED-2 protocols to detect the clonality of these genes 
in TCL in southern Taiwan. Heteroduplex analysis was used after PCR reactions. TCR 
clonality rate was 76% (19 in 25 cases) for TCL, which was lower than previously 
reported in western populations (95%). We hypothesized that the TCR genes present 
sequence polymorphisms between Taiwanese and western populations and some 
BIOMED-2 primers might not be suitable for Taiwanese cases. Methods: We 
performed 5’-RACE cDNA amplification approach, followed with ligation-mediated PCR, 
and amplified cDNAs of the various TCRȕ genes in healthy Taiwanese individuals. The 
cDNA products of these TCRȕ genes were sequenced. Results: We found that some 
variable (V) and joining (J) genes presented sequence variations between our subjects 
and western populations, based on the sequence comparison of the TCRȕ genes in our 
subjects and the ones in the databank of the International ImMunoGeneTics Information 
System® (IMGT, Geneva, Switzerland). We are now initiating a next-generation 
sequencing approach to gain all of the TCR gene sequences in Taiwanese populations. 
Conclusions: The sequencing results will be used to develop a new and improved set 
of specific PCR primers for TCR clonality in Taiwan, probably also in other Asian 
countries. 
 
H34. SNP Copy Number Array Is a Practical Alternative to Cytogenetics in the 
Detection of Common and Cryptic Mutations in Patients with Leukemia and 
Lymphoma 
S.R. Stowell, D.F. Saxe, D.V. Spencer, C.E. Hill, S. Li, A.B. Carter, M.R. Rossi,  
K.P. Mann 
Emory University, Atlanta, GA. 
Introduction: While morphological analysis of neoplastic cells provides significant 
insight into disease, understanding the molecular changes associated with neoplastic 
transformation provides critical prognostic information and guides appropriate 
treatment. Cytogenetic approaches such as G-band and FISH analysis detect genetic 
abnormalities that commonly occur in hematolymphoid malignancy, but they have 
limited resolution. In order to provide comprehensive molecular characterization of copy 
number abnormalities in hematological malignancies, we validated the use of Illumina 
HumanOmni1Quad SNP copy number arrays (SNParray) to determine cryptic and 
gross genetic alterations, including copy neutral loss of heterozygosity, in routine 
clinical specimens. Methods: 45 blood and bone marrow specimens received by the 
Oncology Cytogenetics Laboratory at Emory University for routine FISH and G-band 
analyses were identified. Excess samples were stored at 4°C and submitted to the 
CLIA-certified Cancer Genomics Shared Resource at Emory’s Winship Cancer Institute. 
DNA was extracted and quality was assessed using a NanoDrop spectrophotometer. 
Whole genome copy number analysis was performed using the SNParray that contains 
more than 1.1 million probes and has a mean probe spacing of 2.4 kb. Data analysis 
was performed using the Illumina KaryoStudio software and aligned to NCBI human 
build 36.3 (hg18). Microarray results were compared to G-band and FISH results. 
Results: SNP copy number analysis of the 45 samples was concordant with deletions 
and duplications identified by FISH and/or G-banding. This included a broad range of 
abnormalities seen in ALL, AML, multiple myeloma and follicular lymphoma. In addition, 
the SNP array identified a cryptic IKZF1 mutation not previously detected in a patient 
with relapsed ALL. Further analysis demonstrated several other samples with clinically 
relevant copy number abnormalities undetectable by routine G-band or FISH analysis. 
Conclusions: With the assistance of a CLIA certified genomics core, we have 
implemented a clinical diagnostic workflow for molecular pathology and oncology 
cytogenetics services at Emory University. While the clinical utility of SNP copy number 
arrays for cancer diagnostics continues to be explored, we are now able to provide a 
broad-range clinical and translational resources to complement routine cytogenetic and 
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molecular genetic analysis. Although clinical reporting of SNP copy number data is 
currently restricted to known and/or actionable abnormalities, collection of these clinical 
genomic datasets will provide an invaluable resource for future diagnostic, prognostic 
and therapeutic correlates. 
 
H35. Detection of MPL Mutations by a Novel Allele-Specific PCR-Based 
Strategy 
B.L. Betz, H.C. Weigelin, K.S. Elenitoba-Johnson 
University of Michigan, Ann Arbor, MI. 
Introduction: MPL  gene mutations occur in primary myelofibrosis (PMF) and essential 
thrombocythemia (ET) at a frequency of approximately 10% and 3%, respectively. 
Testing for MPL mutations can aid in the diagnosis of these myeloproliferative 
neoplasms and is recommended in patients with suspected PMF or ET who lack the 
JAK2 V617F mutation. In this setting, the presence of an MPL mutation establishes a 
clonal myeloproliferation and meets a major diagnostic criterion in the most recent 
revision of the WHO classification of ET and PMF. Several methods have been 
developed to detect MPL mutations, with both Sanger sequencing and high resolution 
melting (HRM) being commonly utilized. Our aim was to develop and implement a 
robust and sensitive MPL mutation test that could be easily deployed in our laboratory. 
Methods: A novel allele-specific PCR assay capable of detecting four MPL mutations 
(W515L, W515K, W515A, S505N) was developed and optimized. The assay utilizes a 
two-tube multiplexed PCR format with detection by capillary electrophoresis. Genomic 
DNA from 15 reference specimens (5 positive, 10 negative) was tested and results 
compared to those obtained by Sanger sequencing. Results from 111 consecutive 
specimens referred to our laboratory for testing were also reviewed. Results: The 
multiplexed allele-specific assay reliably detected each of the MPL mutations down to 
2.5% mutant allele. The 5 mutation positive reference specimens were readily detected 
by both the allele-specific assay and Sanger sequencing. Mutation levels in the 
reference specimens ranged from ~50% to 95%. Of the 111 specimens received for 
MPL testing, 104 tested negative and 7 positive (all W515L). Two of the W515L 
mutations were present at less than 10% mutant allele and were not easily detected by 
Sanger sequencing. Results from all allele-specific PCR tests were easily interpreted. 
Conclusions: Allele-specific PCR represents a viable platform for MPL mutation 
testing. Our assay provides a simple, efficient, and sensitive method that is capable of 
detecting the vast majority (>95%) of MPL mutations associated with ET and PMF. 
Sanger sequencing may have insufficient sensitivity to detect cases with low-level MPL 
mutations. 
 
H36. Acute Myeloid Leukemias with Isolated Del(6p): A Rare Entity with a 
Common Deleted Region Confined to 6p23~P24 and Infrequent Mutations of 
FLT3, RAS, KIT and NPM1 
R. Kanagal-Shamanna, K.H. Young, S. Chen, R. Muddasani, L.J. Medeiros, G. Lu 
The University of Texas M.D. Anderson Cancer Center, Houston, TX. 
Introduction: Recurrent chromosomal abnormalities in acute myeloid leukemia provide 
valuable pathogenetic and prognostic information. Isolated abnormalities of 
chromosome 6p in acute myeloid leukemia are rare. Until now, only 3 cases of de novo 
AML with isolated del(6p) have been reported. The frequency of genetic mutations in 
NPM1, FLT3, RAS and KIT in this group is not known. We report the clinicopathologic 
and molecular genetic features of 6 additional cases of AML with del(6p) as the sole 
abnormality. Methods: All cases of acute leukemia with isolated del(6p) between 1997 
and 2011 in the cytogenetic database at our institution were retrieved. Bone marrow 
aspiration and biopsy specimen slides were reviewed. Clinical information was obtained 
from the medical records. Genomic DNA from bone marrow aspirate samples was 
amplified by PCR followed by mutational screening for NPM1 (Capillary 
electrophoresis), FLT3, KIT (direct Sanger sequencing), and RAS (pyrosequencing). 
Results: Six cases of acute leukemia with isolated del(6p) were identified, all of which 
showed myeloid immunophenotype. These included 5 women and 1 man with a median 
age of 58 years (range, 39~68 years). The initial blood counts demonstrated a median 
white blood cell count was 4.35 K/UL (range, 1.2~6.8), median hemoglobin was 9.9 
G/DL (range, 9.8~11.4), and median MCV was 82 FL (range, 79~100). The median 
platelet count was 111 K/UL (range, 26~293). The median bone marrow blast count 
was 43% (range, 25~60%). Morphologically, dysplasia was most commonly seen in the 
granulocytic lineage in the form of Pseudo-pelger Huet neutrophils. The cases were 
classified as AML with myelodysplasia related changes (n=3), AML with maturation 
(n=2) and therapy related AML (n=1) using the WHO classification. The common 
deleted region all cases was small and confined to 6p23~p24. Mutation studies on 4 
cases with available DNA revealed no mutations of FLT3 (n=3), RAS (n=4) or KIT 
(n=3). NPM1 mutation was seen in 1 out of 4 cases tested. All but 1 patient died with a 
median survival of 10 months (7~18 months). The patient with NPM1 mutation is alive 
at 34 months follow-up. Conclusions: AML with isolated del(6p) is characterized by a 
distinct female predominance in older adults and frequent granulocytic dysplasia. The 
common deleted region (6p23~p24) in all cases may harbor a potential tumor 
suppressor gene. None of the cases demonstrated any mutations in FLT3, RAS or KIT. 
Mutation in NPM1 gene was present in the patient who was alive at last follow-up.  
 
H37. Pros and Cons of Cancer Microarray Testing: Experience from Validation 
on Hematological Malignancies 
M. Fang1, S. McElhone2, S. O'Hara-Larrivee2, C. Friedman2, G. Randhawa2, M. Chiu2, 
K. Kroeger2 
1Fred Hutchinson Cancer Research Center, Seattle, WA; 2Seattle Cancer Care 
Alliance, Seattle, WA. 
Introduction: Microarray testing has become the standard of care in the diagnosis of 
constitutional chromosome abnormalities in patients with congenital abnormalities and 
developmental disorders. Various microarray platforms have contributed greatly to the 
understanding of global somatic genetic imbalance associated with cancer by many 
research studies. Application of clinical testing with the microarray technology has 
gained popularity. The establishment of optimal practice standards and guidelines 
requires the experience from multiple testing centers. Methods: We have validated 71 
specimens from 66 patients with hematological malignancies, including 43 myeloid 
disorders and 18 lymphoid disorders, using four different commercial array platforms. 
Among these, 15 samples were tested on at least two different types of arrays. Data 
analysis was performed both with the manufacturer’s software and with the Nexus 
software examining copy number aberrations (CNA) as well as loss of heterozygosity 
(LOH). Results: Compared with known cytogenetic abnormalities, microarray testing 
was able to detect additional CNA in 57% of all specimens and copy neutral LOH in 
21% of specimens tested with SNP-arrays, highlighting the advantage of significantly 
improved resolution of this technology in general and the unique strength of the SNP-
arrays. As expected, balanced translocations, low-level mosaicism, and clonal evolution 
could not be detected (14%). One sample with a balanced translocation, however, 
demonstrated deletions of breakpoint regions on both chromosomes involved. All 
platforms were similar in performance although one missed a small deletion. In acute 
lymphocytic lymphoma, the most frequent aberration was 9p deletion encompassing the 
p16 gene locus (38%), followed by deletions of 1p, 6q, 9q and 17p. All but 17p deletion 
appeared to be associated with patients who have deceased in our cohort. For 
myelodysplasia and acute myeloid leukemia, the most frequent CNAs were the typical 
5q-, 7q-, 13q-, 20q- and trisomy 8 (30% to 40%). Deletion 7q was clearly more 
prevalent among deceased patients while 20q- was only detected in patients who 
survived longer. Conclusions: Despite the recognized limitations, microarray testing for 
cancer improves detection sensitivity in general and allows identification and better 
characterization of novel prognostic markers. 
 
H38. A Novel Nanofluidics-Based Approach for Simultaneous and Quantitative 
Detection of Multiple Recurrent Translocations in Hematologic Malignancies 
W.O. Greaves, K.P. Patel, N. Reddy, S. Rodriguez, S. Hai, B. Mishra, B.A. Barkoh,  
S.S. Chen, L.J. Medeiros, R. Luthra 
The University of Texas M.D. Anderson Cancer Center, Houston, TX. 
Introduction: Chromosomal translocations that result in chimeric transcripts are useful 
as molecular markers for a variety of hematologic malignancies. Current molecular 
approaches to interrogate these markers include quantitative (qPCR) assessment of 
each translocation individually or qualitative assessment of a predefined set of 
translocations as in Signature® LTx (LTx) Panel (Asuragen, Austin, TX). These 
approaches require 1-2 Pg of RNA/sample. Alternatively, FISH can be used, but this 
approach also is limited by the evaluation of one translocation at a time and is both 
labor-intensive and costly. To overcome these limitations, we developed a novel 
nanofluidics-based approach for simultaneous and quantitative detection of multiple 
translocations using nanograms of RNA in nanoliter reaction volumes. Methods: We 
utilized Integrated Fluidic Circuit (IFC) arrays (Fluidigm®, San Francisco, CA) and 
Taqman probe-based qPCR to simultaneously detect 10 leukemia-associated fusion 
transcripts: b2a2/b3a2 and e1a2 forms of BCR/ABL1 [t(9;22)(q34;q11.2], 
RUNX1/RUNX1T1 [t(8;21)(q22;q22)], E2A/PBX1 [t(1;19)(q23;p13.3)], ETV6/RUNX1 
[t(12;21)(p13;q22)], PML/RARĮ long and short forms [t(15;17)(q22;q12)], CBFȕ A and D 
variants [inv(16)(p13.1q22)], and MLL/AF4 [t(4;11)]. ABL was assessed as an internal 
control. A total of 112 peripheral blood or bone marrow aspirate specimens (AML 67, 
ALL 35, CML 7, other: 3), previously tested by qualitative LTx panel were analyzed by 
the nanofluidic 48X48 IFC array format that allows analysis of 48 samples and 48 
targets/ sample. A total of 60 ng of RNA was used for each sample. Each of the targets 
was analyzed in triplicate. Plasmids containing known amounts of fusion sequences 
were utilized to generate standard curves for quantification. Results were also 
compared with available karyotype and FISH results. Results: IFC arrays correctly 
detected fusion transcripts with high specificity. Data output was easy to interpret and 
results were highly reproducible. FISH and IFC arrays were in concordance in all but 
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two cases, where IFC arrays, but not FISH, detected a translocation. Overall 
concordance between nanofluidics and LTx screen was 99.7% across all 
translocations. Unlike the qualitative screen, IFC arrays do not require a second qPCR 
assay for quantification. Conclusions: Simultaneous and quantitative detection of 
multiple recurrent translocations using nanofluidics arrays provide an efficient and cost-
effective tool for rapid screening and classification of newly diagnosed leukemias and, 
for quantitative monitoring. Since each transcript is analyzed in individual wells, 
additional targets can be easily added to the panel without altering existing assays. 




ID01. Evaluation of the BD MAX GBS Assay to Detect Group B Streptococcus 
in LIM Broth Enriched Antepartum Vaginal-Rectal Swab Specimens 
J. Schwartz, J. Makin, B. Robinson-Dunn, B.L. Boyanton 
Beaumont Hospitals, Royal Oak, MI. 
Introduction: Group B Streptococcus (GBS) remains the leading cause of neonatal 
morbidity and mortality in the United States. Traditionally, the Centers for Disease 
Control and Prevention (CDC) have recommended antepartum culture-based screening 
at 35 to 37 weeks gestation to detect GBS colonization. Revised CDC guidelines now 
support the use of molecular-based methods for antepartum screening. In August 2010, 
the BD MAX GBS assay (Becton Dickinson) was approved by the FDA for detection of 
GBS from LIM broth enriched antepartum vaginal-rectal swabs. This assay is performed 
on the BD MAX system - a fully automated, bench-top instrument integrating sample 
preparation, nucleic acid extraction, real-time PCR-based amplification, and detection of 
the cfb gene of GBS. The goal of this study was to determine the test performance 
characteristics, approximate cost per test, and work-flow efficiency of the BD MAX GBS 
assay and CDC-recommended culture methods. Methods: Vaginal-rectal swabs, 
collected from women (n=200) at 35 to 37 weeks gestation, were plated to modified 
Granada agar (MGA: Northeast Laboratories), then inoculated into LIM broth (Becton 
Dickinson). Following 24 hr incubation MGA was observed for GBS (orange colonies); if 
negative, LIM broth was plated to sheep blood agar (Becton Dickinson) for detection of 
GBS (hemolytic and non-hemolytic) over the next 48 hr and confirmed by conventional 
methods (catalase and CAMP). For the BD MAX GBS assay, 15 µL of LIM broth at 24 
hr incubation was tested according to the manufacturer’s instructions. Results: Of the 
200 swab specimens tested, 42 and 154 were positive and negative, respectively, by 
both real-time PCR and culture. Four specimens yielded discrepant results and were 
tested by an alternate real-time PCR method (GeneOhm Strep B, Becton Dickinson). 
Following discrepant analysis, the BD MAX GBS and culture-based tests yielded 
identical sensitivity and specificity (97.7% and 100%). Throughput on the BD MAX GBS 
assay was about 3 hours for 24 specimens. The approximate cost and hands-on-time 
per test was: BD MAX GBS ($27, 1.5 min); culture ($4.29, 3.3 min). Conclusions: The 
BD MAX GBS assay performed equivalent to our culture-based method and 
concomitantly reduced the amount of required hands-on-time by 50%. The BD MAX 
GBS assay is an efficient, stream-lined alternative approach for antepartum GBS 
screening with significant advantages over traditional culture-based methods. 
 
ID02. Evaluation of the Nanosphere Verigene® RV+ for the Detection of 
Influenza A with Subtyping, Influenza B, and Respiratory Syncytial Virus with 
Subtyping from Nasopharyngeal Swabs 
C.J. Barger, D.T. Merrick, N. Ojha 
VA Eastern Colorado Health Care System, Denver, CO. 
Introduction: Multiplexed real-time RT-PCR is a popular method for rapid detection of 
respiratory viruses from clinical specimens because of high diagnostic accuracy and 
improved turnaround-time. Nonetheless, real-time RT-PCR is labor intensive, requires 
batch testing, and requires specialized personnel and equipment. Verigene® 
Respiratory Virus Plus Nucleic Acid Test (RV+) is a recently FDA-Cleared RT-PCR 
assay with microarray based detection for a fully automated process from nucleic acid 
extraction to result generation in <2.5 hours. We aimed to compare the performance of 
the Verigene® RV+ with several real-time RT-PCR assays for detecting Influenza A 
with subtyping, Influenza B, and respiratory syncytial virus (RSV) with subtyping. 
Methods: Nasopharyngeal and throat swabs were collected from consecutive patients 
as part of routine clinical care from years 2008 to 2010. These samples were originally 
evaluated for Influenza A with subtyping, Influenza B, RSV with subtyping by Prodesse 
ProFlu+/ProFlu-ST (Waukesha, WI), Luminex xTAG RVP (Austin, TX), and CDC test kit 
(Atlanta, GA). The unused portion of these samples was archived. We utilized archived 
samples to evaluate Influenza A with subtyping, Influenza B, and RSV with subtyping 
using Verigene® RV+ (Nanosphere, Inc., Northbrook, IL). All assays were performed 
according to the manufacturer’s recommendations. Results: We compared the assays 
on a combined total 95 respiratory specimens: 77 nasopharyngeal swabs, 9 throat 
swabs and 9 viral cultures. The sensitivities of the Verigene® RV+ were as follows: 
97.4% (38/39) for Influenza A detection only with 91.6% (11/12) for H3 subtyping, 100% 
(11/11) for H1 subtyping, and 87.5% (14/16) for 2009H1N1 subtyping; 100% (11/11) for 
Influenza B detection; and 100% (20/20) for RSV detection only with 100% (5/5) for A 
subtyping and 100% (4/4)for B subtyping. The specificity of the Verigene RV+ was 
100% (25/25 negative samples). Conclusions: Our results suggest that Verigene® 
RV+ performs well for detection of Influenza A with subtyping, Influenza B, and RSV 
with subtyping in a veteran population. From our experience, the Verigene® RV+ assay 
is desirable for a laboratory seeking a test of “moderate complexity” that can be 
performed by the general laboratory staff with minimal hands-on required. 
 
ID03. Evaluation of CervistaTM HPV 16/18 Genotyping Assay: A Single 
Institute’s Experience 
P. Mai, Y. Bai 
University of Texas Health Science Center, Houston, TX. 
Introduction: Infection with high-risk (HR) subtypes of human papillomavirus (HPV) is 
associated with cervical cancer and precancerous cervical lesions. HPV types 16 and 
18 are recognized as both highly oncogenic and persistent. The HPV 16/18 genotyping 
is recommended by the American Society for Colposcopy and Cervical Pathology 
(ASCCP). Our lab is the first in Houston, TX to use the FDA-approved CervistaTM HPV 
16/18 assay for clinical diagnosis. We have analyzed the assay data. The correlation 
between the molecular and cytological results is also reviewed. Methods: The cervical 
specimens were obtained from the Outreach OB clinics in Houston area and were 
collected in PreservCyt® Solution. The GenfindTM DNA Extraction Kit was used for 
sample preparation. A Cervista HR HPV screening assay was initially performed to 
determine the presence of HR HPV. The CervistaTM HPV 16/18 genotyping was 
followed using the ASCCP guideline. The corresponding cytological findings were 
obtained from the medical records. Results: 255 HR HPV positive samples were tested 
for HPV 16/18 from September 2010 to April 2011. 63/255 were positive for HPV 16 
(§25%). 9/255 were positive for HPV 18 (3.5%). 1/255 was positive for both HPV 16 
and 18 (§0.4%). 182 other samples were tested negative for both HPV 16 and 18 
(71%).  Among the HPV 16 positives, there were 11 ASCUS, 2 ASC-H, 10 LSIL, 2 
HSIL, and the rest 38 cases were normal on cytology. Among the HPV 18 positives, 
there were 2 ASCUS, 4 LSIL, 1 HSIL, and 3 of normal cytology. The specimen positive 
for both HPV16 and 18 was found to be LSIL. The prevalence of HPV16 among women 
with ASCUS in our patient population is §17.5% (11/63), which is comparable with the 
manufacture report. However, the prevalence of HPV 18 with ASCUS cytology is 20% 
(2/10) in our patients, which is significant higher than reported by the manufacture. 60% 
(38/63) and 33% (3/9) of our patients were positive for HPV 16 and HPV 18, but with 
normal cytology, respectively, indicating a high oncogenic potential associated with a 
HPV infection in our patient population. Conclusions: The CervistaTM HPV 16/18 
genotyping assay has been reviewed after 8-month clinical application in our molecular 
laboratory. The molecular and cytological correlation has been analyzed. The 
prevalence of HPV 16 and 18 with ASCUS cytology is estimated for our patient 
population. The information is essential for the quality assessment. 
 
ID04. The Internal Control in the Cervista HPV HR Assay Identifies Clinical 
Specimens with Insufficient Cellularity  
A. Willis, K.E. Youens, G.A. Hosler, P.J. Washington, K. Murphy 
Propath, Dallas, TX. 
Introduction: Detection of high-risk HPV in cervical cytology specimens is widely 
accepted as an important part of cervical cancer screening. As a screening test, HPV 
detection assays must have a very high sensitivity, as false-negative results fail to 
identify women who may be at increased risk of developing cervical cancer. The 
internal control in the Cervista HPV HR assay is intended to distinguish truly negative 
results from false negative results caused by inadequate specimen cellularity. Here we 
review our data from specimens that were unsatisfactory for cytologic evaluation in 
order to determine whether the internal control truly identifies specimens with 
insufficient cellularity for testing. Methods: We reviewed our database for specimens 
that were unsatisfactory for cytologic evaluation and underwent HPV testing. We 
identified 181 specimens tested using the Cervista HPV HR assay (Hologic Inc.), and 
172 specimens tested using the hybrid capture 2 assay (hc2, Qiagen). For each cohort, 
we reviewed the cause of the unsatisfactory cytology and the results of HPV testing. 
Results: In our Cervista cohort, 94 (51.9%) specimens were unsatisfactory for cytologic 
evaluation due to low cellularity. Of these, 51 (54.3%) gave an insufficient signal from 
the internal control, and 43 (45.7%) reported a result (40 negative, 3 positive). The 
remaining 87 specimens (48.1%) were unsatisfactory for cytologic evaluation for 
reasons other than cellularity (interfering substance, excessive lubricant, etc.). Of these, 
14 (16.1%) gave an insufficient signal from the internal control, and 73 (83.9%) reported 
a result (66 negative, 7 positive). All specimens with an insufficient internal control 
signal would have been reported as negative in the absence of the internal control. In 
our hc2 cohort, 82 (47.7%) specimens were unsatisfactory for cytologic evaluation due 
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to low cellularity; 78 (95.1%) tested negative, 4 (4.9%) positive. Ninety specimens 
(52.3%) were unsatisfactory for cytologic evaluation for reasons other than cellularity; 
77 (85.6%) tested negative, 13 (14.4%) positive. Conclusions: In specimens 
satisfactory for cytologic evaluation, our laboratory’s rate of low internal control signal in 
the Cervista HPV HR assay is approximately 1.1%. In contrast, in specimens with 
inadequate cellularity for cytologic evaluation, our rate of low internal control in this 
study was 54.3%. The hc2 assay does not have an internal control, so all specimens 
tested with hc2 reported a result. Our data indicate that the internal control in the 
Cervista HPV HR assay does identify specimens with insufficient cellularity, and likely 
reduces the risk for false negative results. 
 
ID05. SeptiFast for Diagnosis of Sepsis in Severely Ill Patients from a Brazilian 
Hospital 
R. Sitnik, A.R. Marra, R.C. Petroni, O.P. Ramos, M.D. Martino, J. Pasternak,  
O.S. Santos, C.L. Mangueira, J.R. Rebello Pinho 
Hospital Albert Einstein, São Paulo, Brazil. 
Introduction: Sepsis is a leading cause of morbidity and mortality in hospitalized 
patients worldwide. Conventional blood culture (BC) is the gold standard for pathogens 
detection, but time required to results can range from 1 to 5 days depending on the 
organism. Recently, molecular methods for diagnosis of bloodstream infections were 
developed and are being used as an adjunct to traditional methods for faster and 
accurate results. In this study we tested and validated a multiplex real-time PCR for 
simultaneous detection of 25 common pathogens (bacteria and fungi). Methods: A 
prospective study was performed in 114 cases of critically ill patients from the Intensive 
Care Unit (ICU) of a private hospital. The study was conducted from 12/2008 to 
10/2009 and was approved by the institution ethical committee. Blood samples were 
simultaneously collected for PCR and BC testing. PCR tests were performed in the 
LightCycler 2.0 System (LCS) and analyzed by the SeptiFast software (Roche 
Diagnostics). This assay amplifies the internal transcribed spacer (ITS) region between 
the 16S and 23S ribosomal DNA sequences of Gram-positive and Gram-negative 
bacteria, and the 18S and 5.8S ribosomal DNA sequence of fungi. Conventional BC 
was performed using BACTEC Plus Aerobic/F and BACTEC Plus Anaerobic/F bottles. 
All bottles were monitored by BACTEC 9240 blood culture system (BD). Results: 
Among the 114 cases, LCS was positive result in 23 (20.2%) and BC in 17 (14.9%). A 
total of 27 cases (23.7%) were positive by one of the two assays. In 12 patients, the 
same pathogen was identified. From the 15 discordant results, 4 patients were positive 
only with BC (2 S.epidermidis and 2 P. cepacea), 10 were positive only with LCS         
(5 P. aeruginosa, 1 C. tropicalis, 1 S. aureus, 1 C. glabrata, 1 K. pneumoniae and 1 E. 
cloacoe) and in one patient different pathogens were identified (K. pneumoniae by LCS 
and B. cepacea by BC). This last patient had a positive culture result for K. pneumoniae 
in tracheal aspirate. Time for BC results was 5 days for negative results and 3.5 days 
for positive results. SeptiFast results can be achieved in less than 8 hours. 
Conclusions: The present study suggests that SeptiFast is an important complement 
for sepsis diagnosis. Both tests should be performed in patients from whom this 
diagnosis is suspected. SeptiFast allows a faster diagnosis of bacterial and fungal 
infections and may reduce the ICU time as well as allow the rationalization of antibiotics 
use.  
 
ID06. The Need for Human Papillomavirus (HPV) Testing for Primary Anal 
Screening 
S. Lee, Y. Elshimali, A. Scarsella 
Consolidated Laboratory Services, Van Nuys, CA. 
Introduction: Infection with oncogenic types of HPV is a well-established risk factor for 
the development of genital carcinoma. The prevalence of anal HPV infection among 
men who have sex with men (MSM) is very high. However, currently there is no 
consensus on routine testing for anal cancer screening among MSM. This study was 
designed to evaluate HPV testing results on normal cytology samples to assess the 
value of HPV testing for primary screening. Methods: A total of 1241 ThinPrep anal 
swab samples from MSM were screened for cytology between January 2010 and April 
2011. There were 77 (6.2%) normal cytology samples selected for this study. A residual 
sample with 4-8 ml aliquots was first treated with STAR (Stool Transporting and 
Recovery) buffer then HPV DNA was isolated by using High Pure PCR template 
preparation kits (Roche). HPV DNA was identified by a semi-nested (MY11/MY09/GP6+ 
primers) PCR procedure. HPV genotypes, including 14 high-risk (HR: 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and 2 low-risk (LR: 6, 11), were detected by a 
one-step multiplex PCR with HPV genotype-specific primers. Beta-globin and 
Aminolevulinate delta-synthase 1 were amplified as internal controls for PCR. 
Approximately 200 ng DNA was used for each PCR reaction. The HPV genotypes were 
identified by the expected sizes of the amplicons on the 4% NuSieve® 3:1 plus agarose 
gel (Lonza) by electrophoresis. Results: HPV DNA was detected in 53 of 77 (68.8%) 
normal cytology samples. There were multiple types found individually, including 2 
(13.3%), 3 (17.0%), 4 (15.1%) and 3.7% for 5 and 6 types, respectively. There were 9 
specimens with unknown types (17.0%) and 16 samples with a single type (30.2%). 
The HPV genotypes identified with frequency were 16 (24.5%), 18 (13.7%), 31 (7.5%), 
33 (11.3%), 35 (9.4%), 39 (11.3%), 45 (5.6%), 51 (9.4%), 52 (16.9%), 56 (11.3%), 58 
(16.9%), 59 (13.2%), 66 (11.3%), and 68 (15.0%). There was no inhibitory effect 
observed on the PCR reaction. Conclusions: A very high percentage of HR HPV 
genotypes was detected in normal cytology samples from MSM. Our study 
demonstrated that a negative HPV test result has a better negative predictive value 
than a normal cytology result. We propose that HPV testing replace cytology testing for 
primary anal sample screening.  
 
ID07. Analysis of External Run Control QC for Quantitative CMV and EBV Viral 
Load Assays with Automated Extraction and PCR Setup 
J. Sipley1, C. Azurin1, H. Rennert2 
1New York Presbyterian Hospital, New York, NY; 2Weill Cornell Medical College, New 
York, NY. 
Introduction: The analysis of run control data for QC of quantitative molecular virology 
testing is performed to monitor assay accuracy and precision, however; current 
Laboratory Information Software (LIS) is limited in the ability to collect, analyze, and 
display run control QC data. Automation of manual sample extraction using the 
QIAcube and PCR setup using the CAS-1200 liquid handling system (QIAgility) was 
previously implemented to maintain accurate and reproducible setup for our in-house 
quantitative CMV/EBV real-time, TM ASR assays (Qiagen-Artus), relatively new tests 
for which there is little information regarding performance in a clinical setting. Methods: 
External run control data was collected over a two year period using CMV and EBV 
OptiQuant™ viral controls obtained from Acrometrix (Benicia, CA). The results for two 
levels of control (5x103 and 5x105 for CMV, 104 and 106 copies/mL for EBV) were 
entered in Excel spreadsheets (Microsoft, Redmond, WA) and log10 transformed in a 
statistical approach to generate Levey-Jennings charts based on the mean +/- 3 SD. 
Data analysis was also performed using eQuality™ software from SeraCare (Milford, 
MA). Results: Statistical analysis demonstrated differences in the reproducibility of the 
external run controls between the CMV and EBV viral load tests, even though both 
assays are run together in the same 96 well plate of an AB7900 analyzer. The CMV 
assay 5x103 control was more reproducible (5-6%CV) than the EBV assay 104 control 
(8-11%CV) using either an Auto-Ct, or a fixed, manual Ct method in an attempt to 
improve the EBV assay reproducibility. Consistent mean values obtained from the 
external run controls in both the CMV and EBV assays indicate that accuracy was 
maintained within 0.2 log10 on an annual basis. Conclusions: Differences in the 
reproducibility of external run controls at the low level of control (5x103 for CMV, 104 
copies/mL for EBV) of two commercial quantitative real-time PCR assays for CMV and 
EBV viral load were noted, where the CMV assay was more reproducible than the EBV 
assay despite automated extraction and PCR setup utilized for both assays. The 
differences observed do not seem to be associated with the run control lot, nor with the 
assay set up. 
 
ID08. Performance Validation of Roche Cobas AmpliPrep/Cobas Taqman HIV-1 
Test Version 2.0 (CAP/CTM v2.0): Comparison to CAP/CTM v1.0 and Abbott 
m2000 Real-Time HIV-1 Assay 
L. Zhou, T. Spahlinger, M.L. Harmon, B. Schnellinger, Q. Li, C. Dejelo, C. Wojewoda, 
C. Schmotzer 
University Hospitals Case Medical Center, Cleveland, OH. 
Introduction: Since we implemented Roche CAP/CTM v1.0 assay for HIV-1 viral load 
quantification in late 2008, we have encountered reports from clinicians regarding 
increased numbers of low positives or “viral blips.” With the FDA approval of Roche 
dual-target assay, CAP/CTM v2.0, we performed a comparison study of CAP/CTM v2.0 
with CAP/CTM v1.0 and Abbott m2000 real-time HIV-1 assay, with a particular focus on 
the most clinically relevant low positive specimens. Methods: Linearity, accuracy, and 
precision of CAP/CTM v2.0 were verified by analyzing five levels of Acrometrix 
Valiquant controls in triplicate on 4 separate runs. Analytic sensitivity of CAP/CTM v2.0, 
CAP/CTM v1.0 and m2000 was evaluated with EDTA plasma spiked with 25 or 100 
copies/mL control material. Clinical specificity was evaluated by testing 35 known HIV 
negative donors. Parallel testing of 76 clinical samples was performed on CAP/CTM 
v2.0 and CAP/CTM v1.0. Correlation was evaluated using Deming regression and 
calculated bias. Additionally, 25 patient samples with low positive HIV viral load (<200 
copies/ml) by CAP/CTM v1.0 were cross-tested with CAP/CTM v2.0 and m2000. Viral 
loads of subsequent visits were followed. Results: Linear range for CAP/CTM v2.0 was 
confirmed (R2 0.9993). Standard deviation of replicates was 0.05 – 0.09 log10 
copies/mL over the dynamic range. Analytic sensitivity showed 100% detection at 25 
copies/ml and clinical specificity was 100%. Comparison of viral titer results from 
CAP/CTM v2.0 and CAP/CTM v1.0 yielded slope 1.07, intercept -0.19, R2 0.96, and 
mean bias (v2.0 – v1.0) +0.04 log10 copies/mL. Subanalysis of viral titers <200 
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copies/ml showed a mean bias of -0.19 log10 copies/mL. Eighteen of 25 low-positive 
CAP/CTM v1.0 patient samples had results available by both CAP/CTM v2.0 and 
m2000. Of these, 13/18 were positive by both assays, 1 negative by CAP/CTM v2.0, 3 
negative by m2000, and 1 negative by both. Nine of the 25 patients were negative or < 
48 copies/ml by CAP/CTM v1.0 during the follow-up period (1-12 months), 7 remained 
continuous or intermittent positive, and 3 had virologic failure (> 500 copies/ml). Six 
patients had no follow up data. Conclusions: The CAP/CTM v2.0 assay is an accurate 
and reliable test for HIV-1 viral load measurement with analytic performance 
comparable to CAP/CTM v1.0. The viral titers by CAP/CTM v2.0 for the clinically 
significant low positive range (<200 copies/ml) are lower when compared to CAP/CTM 
v1.0 but higher than m2000. 
 
ID09. Multiplex Screening for Blood-Borne Viral, Bacterial, and Protozoan 
Parasites Using the OpenArray® Platform 
E. Grigorenko1, S. Patel1, C. Fisher2, W. Brasor1, K. Munnelly1, R. Duncan2 
1LifeTechnologies, Inc, Woburn, MA; 2FDA, Bethesda, MD. 
Introduction: The use of nucleic acid tests (NAT) for detection of pathogens has 
improved the safety of blood based products. However, as more emerging pathogens 
are recommended by the FDA for testing, there is an increased need for development 
of detection platforms testing multiple blood-borne pathogens including protozoan 
parasites. Methods: Our approach to this problem is the development of platform for 
detection of multiple blood-borne pathogens using a combination of two proven 
technologies: Taqman® chemistry for target identification and quantification, and 
OpenArray® for spatial multiplexing of target-specific assays. Results: The initial panel 
consisted of 56 newly designed and previously published TaqMan® assays for 
detection: 4 viral (HIV, HBC, HCV and WNV), 2 bacterial (Gram negative and Gram 
positive), and 3 protozoan parasites (Leishmania donovani, Plasmodium falciparum, 
and Trypanosoma cruzi). Each assay had been validated for specificity and detection 
efficiency for each purified DNA or RNA in the presence or absence of complex DNA 
background. The subset of validated assays (2-3 assays per individual target) was 
selected for a final panel and it was evaluated with pathogen spiked human blood and 
plasma samples. For most of the targets the limits of detection of tested organisms 
were comparable with existing real-time platforms and it was at the level of 500 
copies/mL or higher. We achieved a sensitivity of detection of 500 copies/mL or lower 
when we incorporated a pre-amplification step with gene specific primers or used digital 
PCR for testing unamplified DNA or RNA samples. The final validation of the TaqMan® 
OpenArray® real-time PCR panel consisted of testing blinded human plasma or blood 
samples in the presence or absence of spiked pathogens. The testing of blinded 
samples produced no false-positive results and correctly identified pathogens present in 
samples with a limit of detection ranging from 10 cells/mL (T. cruzi) to 100-500 
copies/mL for viral targets. Conclusions: These results indicate that the OpenArray® 
platform in combination with TaqMan® chemistry can provide a multiplex real-time PCR 
pathogen detection method and could potentially serve as the next-generation platform 
for infectious disease testing in blood. 
 
ID10. Evaluation of Luminex Analyte Specific Reagents (ASRs) in a Multiplex 
PCR Format for the Detection of Multiple Diarrheal Pathogens 
A. Rao, K. Walker, R. Fader 
Scott and White Memorial Hospital, Temple, TX. 
Introduction: Gastrointestinal diseases presenting with identical symptoms can be 
caused by multiple infectious agents, which are diagnosed by sequential culture or 
assay methods that are time consuming and can result in inappropriate therapy. A 
rapid, multiplex assay capable of detecting these pathogens in a single PCR based 
assay would be clinically useful. Methods: We evaluated Luminex ASRs in a Multiplex 
PCR Format with a 20-plex primer mix to detect E. coli ST, LT, 0157, shiga toxin 1 and 
2, Salmonella spp., Shigella spp., Yersinia enterocolitica, Norovirus, Rotavirus, 
Adenovirus, C. difficile, Campylobacter spp., Giardia, Cryptosporidium, Vibrio spp., and 
E. histolytica on the Luminex and MagPix systems after nucleic acid extraction on the 
EasyMag platform, using 300 positive frozen or fresh stool specimens and ATCC 
culture strains. Comparators were results from culture (Salmonella and Shigella), 
enzyme immunoassays [Campylobacter and Shiga-like toxin in E. coli (STEC)], DFA 
stains (Giardia and Cryptosporidium), direct microscopy (Entamoeba species) and PCR 
(C. difficile, Norovirus). Discrepant results were resolved by sequencing and alternate 
primer pairs. Results: Sensitivity and specificity after discrepancy analysis: E. coli 
100% and 99.7% (culture/EIA 93.8% and 100%), Salmonella 94.4% and 99.6% (culture 
94.4% and 99.7%), Shigella 100% and 99.3% (culture 85.7% and 100%), Vibrio 91% 
and 99.6%, C. difficile 93.9% and 98.9% (alternate PCR 91.2% and 99.2%), 
Campylobacter 100% and 99% (EIA 80% and 100%), Giardia 94.1% and 100% (DFA 
100% and 99.7%), Cryptosporidium 99 and 100%, Rotavirus 90.9% and 99.3% (EIA 
93.8% and 98.9%), Norovirus 94.4% and 98.6% (alternate PCR 81% and 95.7%). Of 12 
samples identified as E. histolytica/dispar, only one was confirmed by both the Luminex 
and sequencing assays as E. histolytica. Total run time to final results was 5 hours. 
Limit of detection ranged from 300-2000 cfu for the bacterial pathogens. Conclusions: 
The Luminex ASRs for diarrheal pathogens are capable of reliably detecting a range of 
diarrheal agents in a multiplex format. Besides improving the specificity of detection, the 
assay identified co-infections with improved work flow efficiency. 
 
ID11. Allele Frequency of an IL28B Treatment-Predictive SNP in HCV-Infected 
Patients   
D.C. Ang, F. Yang, S. McCabe, R. Press 
OHSU, Portland, OR. 
Introduction: The likelihood of attaining a sustained virologic response in patients with 
HCV depends on viral-, disease-, and host related factors. Among host-related factors, 
the rs12979860 SNP, [CC genotype (vs CT/TT genotypes)], located 3 kb upstream of 
the IL28B gene is associated with an approximately 2- to 3-fold greater rate of 
sustained virologic response (SVR) in HCV genotype 1 infected individuals treated with 
combination pegylated IFN/ribavirin therapy. The favorable CC genotype has also been 
associated with a 3-fold increase in the rate of spontaneous clearance of HCV. In a 
recent US-based study, the favorable CC genotype was observed in 37% of 
Caucasians, 29% of Hispanics, and 14% of African Americans. We have validated an 
assay for the detection of IL28B SNP (rs12979860) by an allelic discrimination method, 
and have determined the allele frequencies in our predominantly Caucasian HCV 
population. Methods: We genotyped 112 random HCV-infected patients referred to our 
lab for HCV viral load monitoring. Human DNA was amplified using primers and 
TaqMan probes targeting the IL28B rs12979860 SNP region. Genetic variants were 
identified by an allelic discrimination method using SDS software (Applied Biosystems 
ABI 7500). The assay was validated in comparison with a commercially available 
reagent kit (LightMix Kit IL28B, rs12979860) that uses melting curve analysis to 
distinguish rs12979860 genotypes. Results: Among the 112 patients tested, 101 were 
Caucasian, 4 African American, 3 Asian, 2 American Indian, and 2 had unknown 
ethnicity. In the Caucasians, the IL28B genotype frequencies showed 34 CC (34%), 59 
CT (58%), and 8 TT (8%) genotypes. The 34% CC favorable genotype (95% CI, 25% to 
43%) in Caucasians was not significantly different than the 37% CC frequency reported 
in the literature (95% CI, 34.5% to 40%)(P=0.52). There was 100% concordance in 
IL28B genotypes between our TaqMan assay and the LightMix assay in all 50 samples 
with dual data. We also performed a blinded sample exchange of 22 DNA samples 
(comprising 6CC, 12CT, and 4TT genotype) with 2 different labs, and found 100% 
genotype concordance. Additionally, 6 samples were analyzed by Pyrosequencing, 
which confirmed the expected genotype. Conclusions: The IL28B TaqMan genotyping 
assay is technically robust and accurate, and has prognostic and treatment implications 
in patients infected with HCV, particularly hepatitis C, genotype 1. 
 
ID12. Genotyping of IL28B Polymorphism rs12979860 by High Resolution 
Melting of Unlabeled Probe 
C. Chua1, K. Poon1, L. Chiu1, J.W. Tang1, E.S. Koay1,2 
1National University Health System, Singapore, Singapore; 2National University of 
Singapore, Singapore. 
Introduction: The single nucleotide polymorphism (SNP) rs12979860 maps 3 kb 
upstream of the human interleukin 28B (IL28B) gene on chromosome 19, which 
encodes the type III interferon IFN-gamma3. Genotyping of the SNP, which comprises 
a C or T dimorphism, is clinically useful in individuals infected with HCV genotype 1 
virus (HCV-1). Treatment of chronic HCV infection generally consists of a combination 
of PEG-Interferon-alpha-2a or 2b and ribavirin. Genome-wide association studies have 
demonstrated the C/C variant is associated with an improved response and 
spontaneous clearance to the drug regimen, and its identification may allow a more 
individualized therapy and an improved sustained virological response. An unlabeled 
probe-based high resolution melting (HRM) real-time PCR has been developed on the 
LightScanner 32® (LS 32) (Idaho Technology Inc., UT, USA), to serve as a rapid and 
inexpensive method to identify the rs12979860 polymorphism in patients infected with 
HCV-1. Methods: An unlabeled probe with a C3 blocker (Suprenom, Singapore) was 
designed to perfectly match the C allele of rs12979860. Real-time PCR amplification 
was performed with a ratio of 1:5:5 of forward primer, reverse primer and unlabeled 
probe in the LightScanner® Master Mix with incorporated LC Green® PLUS (Idaho 
Tech) on the LS 32, followed by a final denaturing/ re-annealing step to generate HRM 
profiles. The region of the unlabeled probe melt was manually selected and the 
fluorescence, normalized. The LS 32® software (v1.0.0.33) was used for genotype 
analysis, clustering and auto-grouping of the unknown samples. Forty archived nucleic 
acid extracts retrieved from previously processed HCV-1a and -1b infected patient 
plasma, were analyzed. The HRM results were validated using a co-developed 
sequencing-based method. Results: HRM generated unique melting profiles for all 
three (C/C, C/T, T/T) variants. Melt peaks for the unlabeled probe with a mismatched 
base (for T allele) and a perfectly matched base (for C allele) were clearly discernable 
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at 64°C and 72°C, respectively. Normalized melt curves reproducibly showed distinct 
patterns for homozygous (C/C and T/T) and heterozygous (C/T) genotypes. Of the 40 
clinical samples tested, 27 (67.5%) had C/C; 11 (27.5%), C/T; and 2 (5%), T/T 
genotypes. Conclusions: The above rapid and low-cost in-house real-time PCR assay 
was able to genotype the clinically important IL28B polymorphism in HCV-1 infected 
patients, and provides a good alternative to Sanger sequencing. The allelic frequencies 
may account for a difference in treatment response in different ethnic groups; this 
aspect will be further investigated in our local multi-ethnic population. 
 
ID13. New HIV-1 SuperLow Assay for Viral Load Monitoring 
A.M. McClernon1,2, W.S. John1, D.R. McClernon1,2 
1bioMONTR, Research Triangle Park, NC; 2McClernon LLC, Research Triangle Park, 
NC. 
Introduction: As new antiretroviral therapies (ART) such as Integrase inhibitors 
become standard of care, accurate ultra low viral load monitoring will become 
increasingly important. Equally important will be clinical monitoring of ART potency 
using assays that detect below the current FDA approved assay cutoffs. Here we 
describe a new HIV-1 SuperLow assay for detection of HIV-1 RNA at ultra low levels, 
developed using a modified protocol of a CE marked commercial kit. Methods: Viral 
subtype B RNA was extracted on bioMerieux’s EasyMAG platform and analyzed using 
a proprietary HIV-1 SuperLow Assay that utilizes components of bioMerieux’s 
commercially available (RUO) EasyQ HIV-1 v2.0. For Linearity determination, Virology 
Quality Assurance (VQA) stock material at 107 was diluted 1:10 serially 5X in normal 
HIV-1 negative human plasma to yield dilutions of 1:10, 1:100, 1:1000, 1:10,000, 
1:100,000. The Limit of Detection (LOD) was determined by analyzing dilutions of VQA 
viral standard made in HIV-1 negative human plasma. At least 27 replicates of each 
dilution were utilized. Probit analysis was performed on HIV-1 replicate dilution series 3, 
6, 12, 24, 48, 72, 96 c/mL to determine the 95% Hit Rate using Percent Detected (PD) 
values at each dilution. Excel 2007 (Microsoft) function NORMSINV(z) was used to 
translate PD to probit values. Results: Linearity determination, testing diluted samples 
from 102 - 107 c/mL, demonstrated a proportional relationship between the dilution 
factor and number of HIV-1 RNA copies reported by the assay. The LOD was 
determined by testing replicates of normal human plasma spiked with a range of HIV-1 
RNA from 3 to 96 c/mL. Probit analysis revealed that the concentration of HIV-1 RNA 
detected with 95% probability was 15 c/mL (1.18 log c/mL). Conclusions: In this data 
set analysis, a new HIV-1 SuperLow assay demonstrated good linearity and large 
dynamic range from 3 to 8.3x106 c/mL. Probit analysis from a HIV-1 dilution series of 
subtype B specimen demonstrated an impressive 95% hit rate at 15 c/mL. The HIV-1 
SuperLow assay will be a valuable tool for monitoring HIV-1 viral load in drug 
development and clinical trial programs. 
 
ID14. Genotyping of the Hepatitis C Virus on the eSensor® XT-8 System 
R. Partha, Y. Liu, A.T. Richmond, K. Rusterholz, D. Burns, J. Hawkins, J.F. Kayyem 
GenMark Diagnostics, Carlsbad, CA 
Introduction: Hepatitis C virus (HCV) is a leading cause of chronic liver disease in the 
United States. The prevalence of HCV infection has been estimated to be 1.8% in the 
general population, resulting in an estimated 2.7 million cases of chronic HCV infection 
in the United States. The genotype is helpful in defining the epidemiology of Hepatitis C. 
More importantly, knowing the genotype of HCV is helpful in making recommendations 
and counseling regarding therapy. The eSensor® HCV Genotyping Test is a new assay 
designed to genotype a panel of 8 HCV sub-types: 1a, 1b, 2ac, 2b, 3, 4, 5 and 6ab. The 
end product of the COBAS® Taqman® HCV test (Roche Molecular Diagnostics) serves 
as the template for a nested PCR followed by a direct analysis on the electrochemical 
eSensor® XT-8 detection system. Methods: This study was designed to determine the 
specificity of the eSensor® HCV Genotyping assay compared to sequencing the end 
product of the COBAS® Taqman® HCV test in the 5’ untranslated region. Uniplex 
primers were designed to amplify conserved viral target regions for Hepatitis C 
subtypes 1a, 1b, 2ac, 2b, 3, 4, 5 and 6ab that contained hybridization sites for the XT-8 
capture probes and signal probes. For eSensor® XT-8 analysis, amplified samples 
were added to hybridization buffer containing ferrocene-labeled signal probes and then 
hybridized to electrode-bound capture probes in the eSensor® XT-8 cartridge. Hepatitis 
C genotypes were detected by measurement of the current produced at each electrode 
during alternating current voltammetry. Results: The limit of detection for genotyping 
the HCV ranged from 25 IU to 6.9 E8 IU of the input template viral load. We tested 344 
samples and achieved a combined agreement of 99.4% with zero no calls. Sequencing 
of the 5’ untranslated region was the method comparator assay. The overall assay time 
from sample to result is ~1.8 hours with ~20 minutes hands-on time. Conclusions: The 
eSensor® HCV Genotyping Test successfully genotypes sub-types 1a, 1b, 2ac, 2b, 3, 
4, 5, 6ab and mixed genotypes on the eSensor® XT-8 cartridge. This eSensor® 
product is under development and is not available for sale in the United States. 
 
ID15. Evaluation of 3 Commercial Molecular Assays for the Detection of 
Clostridium difficile in Comparison with Rapid EIA and Toxigenic Culture 
L.L. Oon, K. Lim, J.H. Ho, C.C. Ngan, S. Huang, A. Tan 
Singapore General Hospital, Singapore, Singapore. 
Introduction: Clostridium difficile infection (CDI) is the most common cause of health 
care-associated diarrhea. Enzyme immunoassays (EIAs) for glutamate dehydrogenase 
(GDH) and toxin A/B are most commonly used to diagnose CDI but lack specificity and 
sensitivity respectively. This study aims to compare the performance of three 
commercial nucleic acid amplification assays against conventional rapid EIA and 
toxigenic culture. Methods: Forty-nine stool samples from patients with suspected CDI 
were used for the study. The samples were previously tested for GDH and toxins A and 
B by TechLab C. diff Quik Chek Complete® EIA method. The three molecular assays in 
the evaluation were the Cepheid Xpert, TibMolBiol LightMix and Meridian illumigene  
C. difficile assays. The first 2 assays are based on real-time PCR while the illumigene 
assay uses loop-mediated isothermal amplification (LAMP) technology. For the Xpert 
and illumigene systems, stool samples were used directly in the assays and these 
systems performed the entire procedure from DNA extraction to result analysis. For the 
TibMolBiol assay, DNA was extracted from stool samples using the BioMerieux 
NucliSens easyMAG automated extraction system. Amplification and detection were 
performed on the Lightcycler version 2.0. All stool samples that were GDH positive and 
toxin negative by EIA were sent for C. difficile toxigenic culture. Results: Using the 
combined results of toxigenic culture, GDH and toxin EIA as the reference method, 
there were 30 positive and 19 negative toxigenic C. difficile samples in the study. All 3 
molecular assays gave similar performance results. The sensitivities for the LightMix, 
Xpert and illumigene assays were 100%, 100% and 92.9% respectively, while the 
specificities for the LightMix, Xpert and illumigene assays were 100%, 94.7% and 100% 
respectively. The hands-on and turnaround time was shortest for the Xpert assay and 
longest with the LightMix assay. For the illumigene assay, 7 (15%) samples had to be 
repeated due to initial invalid results. Conclusions: Molecular assays prove to be 
sensitive, specific and rapid for the detection of toxigenic C. difficile and are an 
attractive alternative to the current methods for the diagnosis of C. difficile infection. 
 
ID16. Laboratory Evaluation of the Idaho Technology BCID FilmArray 
S. Silbert, J. Nurmberger, C. Kubasek, D. Uy, R. Widen 
Tampa General Hospital, Tampa, FL. 
Introduction: The detection of microorganisms in blood samples has been improved 
with automation of the blood culture systems, however, identification of the agents still 
requires culture based methods that can take several days. Faster identification of 
limited types of organisms is possible through FISH methods and a few organism 
targeted PCR assays. The ability to identify a large number of the most common 
pathogens would improve patient management by allowing greater ability to target 
antimicrobial therapy. The Idaho Technology FilmArray Blood Culture Identification 
(BCID) system is a multiplex PCR assay that targets 19 bacteria, 5 yeasts, and  
4 antimicrobial resistance genes. This assay is able to provide results in approximately 
1 hour from the time a positive blood culture is flagged by the instrument. Methods: 
Blood was collected into BactAlert FAN (Biomerieux) bottles per standard of care and 
incubated in the BactAlert instrument. When a bottle was flagged as positive it was 
processed for Gram stain and subculture. Next a 250 µL sample was collected by 
syringe, added to the BCID FilmArray diluent and transferred to the sample port of the 
pouch. The pouch reagents were rehydrated using the provided reagent solution. The 
pouch was scanned by the instrument and placed in the FilmArray processor. Sample 
information was entered and the assay run was started. The instrument performed the 
extraction and nested PCR on board. Results: A total of 99 positive blood cultures 
have been processed to date. The FilmArray correctly identified the pathogen in 83 
(84%). The FilmArray did not detect probable pathogens in 13 (13%) samples however 
all of these were organisms not included in the panel. The only misidentifications (3) in 
which no other agents were identified occurred with Enterobacter cloacae, 
Acinetobacter spp., and Pseudomonas spp.,  which are known to be problems with this 
first generation system due to contaminants in the pouch assembly process. Later 
generation pouches were prepared from a different supplier of plastic and addressed 
this problem. Conclusions: The BCID FilmArray was able to detect 100% of organisms 
included in the panel and 100% of the cases with antimicrobial resistance factors that 
were included in the panel within 1 hour. Once available for routine testing this system 
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ID17. Comparison of a Rapid Lysis Method to Automated DNA Extraction for 
HSV and VZV PCR Detection from Ocular and Oral/Nasal Swab Specimens  
M. Espy, L. Sloan, S. Schneider, B. Pritt 
Mayo Clinic, Rochester, MN. 
Introduction: We process dermal and genital swabs received for Herpes Simplex Virus 
(HSV) and Varicella-Zoster Virus (VZV) PCR by a rapid cell lysis method that is faster 
and provides greater sensitivity than automated DNA extraction. Swabs from ocular and 
oral/nasal sources are also received for HSV and VZV PCR. These sources are 
collected in M4 Viral Transport Media; therefore requiring DNA extraction.  The aim of 
this study was to compare the lysis method to MagNA Pure extraction for the detection 
of HSV and VZV DNA from ocular and oral/nasal swabs. Methods: Two-hundred forty-
five swab specimens (76 ocular, and 169 oral/nasal) from patients suspected of having 
either HSV or VZV infection were processed by the rapid lysis method and the MagNA 
Pure extraction method. Dual rayon swabs were inoculated with patient specimen; one 
swab was placed in 3 mL of M4 media, followed by extraction of 200 µl on the MagNA 
Pure instrument and eluted into 100 µl. The second swab was placed into a tube 
containing 600 µl of neutralization buffer (NB), followed by heating/shaking at 99° C 
and 1400 rpm for 6 minutes. Five µl of each preparation were then assayed for the 
presence of HSV and VZV DNA by real-time PCR on a LightCycler 2.0. Results: Of 
245 specimens assayed, HSV DNA was detected in 44 (18%) and 60 (24%) specimens 
processed by the MagNA Pure and the lysis technique respectively. The 16 discrepant 
samples were originally positive. The specimens processed by the cell lysis method 
were detected on average 4 cycles (Cp) sooner than the extracted specimens. No 
inhibition was detected based on the presence of an internal control. VZV DNA was 
detected in 4 of 245 specimens (1.6%) processed by both methods. The Cp values 
were roughly equivalent. Conclusions: The lysis method is faster than automated 
extraction on the MagNA Pure instrument, and provides equal or increased sensitivity 
for detection of HSV/VZV DNA by PCR from ocular and oral/nasal swabs.  
 
ID18. Mycobacterium smegmatis Was Frequently Detected in Skin Biopsies 
from Patients with Cutaneous Infectious Granuloma 
Z. Xu1, H. Li2, D. Lu1, S. Meng2, L. Ma1, Y. Tang2 
1Beijing Children's Hospital, Capital Medical University, Beijing, China; 2Vanderbilt 
University Medical Center, Nashville, TN. 
Introduction: Cutaneous infectious granuloma (CIG) is a common soft-tissue infection 
and mycobacterial infection has been considered an etiology. MycoID, a molecular 
system combining broad-range PCR amplification and suspension array identification, 
was developed to detect and differentiate 17 medically important mycobacterium 
species. We applied the MycoID system to detect and identify Mycobacterium in skin 
biopsy specimens from patients with CIG. Methods: A total of 119 skin biopsy tissue 
specimens were collected from patients (100 children and 19 adults) between 2001 and 
2010 from Beijing. Among them, 72 were collected from patients with clinically and 
histologically confirmed CIG and 47 from patients with reactive skin rash (erythema 
nodosum, n=38; erythema induratum, n=9) as controls. DNA was extracted from 
formalin-fixed, paraffin-embedded (FFPE) biopsies by using the QIAamp DNA FFPE 
Tissue Kit (Qiagen, Valencia, CA). A real-time PCR human ȕ-actin assay was used as 
the internal quality control of extracted DNA. The MycoID system was performed to 
detect all mycobacterium species with the capacity to identify 17 medically important 
species. Results: Mycobacterial DNA was detected in 30 (41.7%) of 72 CIG and 10 
(21.3%) of 47 controls (OR=2.64, P=0.021). Mycobacterial species detected in CIG 
included M. intracellulare (1), M. tuberculosis (3), M. smegmatis (13), M. szulgai (1), M. 
kansasii (1) and other species (11). In contrast, mycobacterial species detected in the 
controls included M. tuberculosis (1), M. smegmatis (2), M. kansasii (1) and other 
species (6). M. smegmatis was detected with significantly higher frequencies in CIG 
(18.1%) than in the controls (4.3%, OR=4.92, P=0.027). Conclusions: Mycobacterial 
species, especially M. smegmatis, were detected at higher frequencies in biopsies from 
patients with CIG. The MycoID may provide an alternative tool for the diagnosis of 
mycobacterial infections in FFPE skin tissues. 
 
ID19. Derivation of Virtual Morphology, E6-E7 HPV Quantification and Cell 
Cycle Analysis Using Liquid Based Pap Samples Defines the Biology of ASCUS 
Samples 
K. Shults1, B. Lack1, M. Bonneu1, M. Alexander2, B. Patterson1 
1IncellDx, Inc., Menlo Park, CA; 2iCyt Mission Cytometry, Champaign, IL. 
Introduction: Current practice using liquid based Pap samples involves manual/image 
analysis for cell morphology, addition of biomarkers to measure cell proliferation and 
extraction of nucleic acids to determine HPV status. Recently, with the release of 3Dx™ 
technology, it is possible to derive all of the above on the same cell in suspension. In a 
test of feasibility, we analyzed 25 liquid based samples on the iCyt Eclipse Analyzer 
using its electronic volume capabilities in an attempt to derive virtual morphology of the 
cell populations on a system capable of high throughput. Methods: The samples were 
stained following published procedures with a cocktail of anti-sense oligonucleotides to 
E6,E7 of HPV and DAPI at a concentration of 1 Pg/ml after the last cell wash. The DNA 
dye was allowed to stain for 30 minutes at room temperature before collection on the 
Eclipse Analyzer. Results: The inclusion of the DNA dye allows an immediate 
assessment of the submitted sample for the presence of intact cells and our analysis 
revealed two samples that would necessitate resubmission due to a complete lack of 
events containing a nucleus. Of the remaining 23 samples, combinations of the nuclear 
dye along with cellular complexity and electronic volume allowed the derivation of 
cellular debris, enucleated and nucleated ectocervical cells along with multinucleated 
forms and polymorphonuclear leukocytes. The increasing volume of the differing 
ectocervical cell populations creates a virtual N/C ratio, and as expected this population 
exhibited an increased proliferative rate matching a dysplastic cytology. In a subset of 
the samples (n=8) all defined as ASCUS with HPV+ DNA, the E6,E7 positive samples 
(n=3) contained fewer nucleated ectocervical cells with a gross increase in PMNS and a 
moderate S-phase; the negative samples ( n=5) exhibited an increase in high N/C 
ectocervical cells with an increase in S-phase within a normal PMN background. This 
data suggests an ability to define whether ASCUS samples are normal (NILM) or 
LSIL/HSIL within the clinical designation of ASCUS. Conclusions: The combination of 
the 3Dx™ technology collected on the iCyt Eclipse Analyzer revealed the ability to 
derive virtual morphology of liquid based Pap samples while obtaining the additional 
capabilities of sample acceptance along with cell cycle analysis. Following this 
successful feasibility study, additional studies are underway to determine whether the 
ASCUS cytologic diagnosis can be eliminated. 
 
ID20. Development and Validation of a Comprehensive Vaginitis Diagnostic 
Panel 
M.J. Smith, D. Olson, R.P. Schuldt, R.C. McGlennen 
Access Genetics, Eden Prairie, MN. 
Introduction: Vaginitis is caused by several often misdiagnosed infections with an 
incidence rate of 12-13 million new cases per year. The three most common types of 
vaginitis are trichomoniasis (Trichomonas vaginalis), bacterial vaginosis (Gardnerella 
vaginalis and other opportunistic anaerobic bacteria), and candidal vulvovaginitis 
(Candida spp.) and account for 90% of vaginitis cases. Typical detection methods of 
vaginitis include wet mount to visualize clue cells, Gram-stain, culture, pH testing, and 
potassium hydroxide treatment. While these tests are an indication of the presence of 
vaginitis, they often do not determine the specific pathogen responsible for the 
symptoms. Initial treatment of vaginitis is often not successful and 50% to 80% of 
patients experience recurrence of vaginitis within 1 year. We have developed a series 
of simple, high-throughput tests to better characterize the presence, virulence, and 
concentration of organisms associated with vaginitis, as well as the ability to monitor the 
level of natural flora. Methods: The vaginitis diagnostic panel is a laboratory developed 
test utilizing multiplex PCR and automated capillary electrophoresis to detect the 
presence of the three most common causes of vaginosis. Workflow management and 
data upload, presentation, and preliminary analysis were performed using TeleGene® 
software. Clinical cutoffs based on literature values were established above the limit of 
detection of each analyte. Results: T. vaginalis, G. vaginalis, eight Candida spp., and 
an internal control marker were able to be differentiated from each other using capillary 
electrophoresis. Analytic Limit of Detection was 24 copies/mL for T. vaginalis, 1.96x103 
copies/mL for G. vaginalis, and 9.8x102 copies/mL for the Candida species. Of 112 
species tested for cross-reactivity, only Bifidiobacterium spp. above 105 copies/reaction 
had cross-reactivity with the G. vaginalis primer set. Detection rates matched literature 
values of 7% for T. vaginalis, 50% for G. vaginalis, and 20% for Candida spp. 
Conclusions: The vaginitis panel is a fast, reliable, sensitive, and cost-effective way to 
determine the causative agent of vaginitis. Reflex tests to determine the Candida 
species present, determine the presence of other organisms associated with vaginitis, 
and to determine the ratio of Lactobacillus bacteria to anaerobic bacteria will be 
developed to generate additional information. This panel of tests will allow doctors to 
more accurately determine the organism responsible for vaginitis, allow for better initial 
treatment of the infection, and provide a means to measure treatment effectiveness. 
 
ID21. Evaluation of the EraGen Multicode®-RTx PCR Assay for the Quantitative 
Detection of BK Virus in Urine and Plasma Specimens 
A. Patel, N.T. Lenny, C.E. Smith, J.L. Davis 
LeBonheur Children's Hospital, Memphis, TN. 
Introduction: Primary infection by BK polyomavirus (BKV) is typically asymptomatic 
and followed by viral latency, mainly in the urogenital tract. Reactivation of the latent 
virus may occur in immunocompromised patients and is a particular threat to renal 
transplant patients. Quantitative detection of BKV DNA in both the urine and in the 
blood is becoming increasingly important as an early marker for polyomavirus-
associated nephropathy. The EraGen Multicode®-RTx PCR assay, which uses a novel 
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Multicode chemistry, provides a quantitation BKV PCR assay that is adaptable to 
multiple DNA extraction, amplification, and detection platforms. Methods: BKV DNA 
was extracted from urine (n=38) and plasma (n=18) specimens using the automated 
NucliSENS easyMAG instrument and reagents (BioMerieux). Quantitative PCR analysis 
was performed using Multicode®-RTx PCR analyte specific reagents (EraGen 
Biosciences) and the Lightcycler 2.0 (Roche) for amplification and detection. Results: 
The linearity and precision of the EraGen assay, determined by analysis of AcroMetrix 
OptiQuant BKV quantification panel members at 5 different virus titers, demonstrated a 
linear response from 500 (Log10 = 2.7) cp/mL to 5 x 106 (Log10 = 6.7) cp/mL. This 
assay was repeated at least 5 times (CV < 2.4). Linear regression analysis of the panel 
values produced a coefficient of determination of 0.996. This data indicates a high 
degree of precision and accuracy for the assay. The limit of detection (LOD), using 
Optiquant panel BKV diluted in BKV-free urine, was 200 cp/mL. 56 clinical specimens 
(38 urine and 18 plasma) were analyzed by the EraGen assay. BKV was detected in 29 
of 32 BKV positive specimens and in 3 of 24 BKV negative specimens. Based on these 
results, the sensitivity and specificity of the assay was 90.6% and 87.5%, respectively. 
Linear regression analysis, performed on results from 23 BKV positive urine specimens, 
produced a slope of 0.897 and a coefficient of determination of 0.881. These results 
indicate consistent agreement between reference and observed values throughout the 
range of viral load levels tested. Conclusions: Quantification of BKV using an 
easyMAG extractor, EraGen reagents and Lightcycler thermocycler, was rapid and 
sensitive, and performed comparably to reference assays using both urine and plasma 
clinical samples. This assay will be useful for monitoring BKV load in transplant 
recipients. 
 
ID22. Comparison of Two Pyrosequencing Platforms for Bacterial Pathogen 
Identification 
L. Millecker1, R. Luna2, C. Webb2, P.A. Revell2, J. Versalovic2 
1Texas Children's Hospital, Houston, TX; 2Baylor College of Medicine/ Texas Children's 
Hospital, Houston, TX. 
Introduction: Pyrosequencing of the variable regions of the 16S rDNA gene is a rapid 
and effective strategy for identification of bacterial pathogens. In 2003, the Texas 
Children's Hospital (TCH) Molecular Microbiology Laboratory (MML) implemented 
pyrosequencing using the PSQ 96MA (Qiagen, Inc.) platform for the purpose of 
identifying organisms that produced inconclusive results via conventional 
microbiological techniques (morphology, biochemical testing, etc.). Recently, a new 
pyrosequencing platform, the PyroMark Q24 (Qiagen, Inc.), was introduced, offering 
improvements in the user interface as well as improvements in instrument capabilities. 
Instrument characteristics and sequencing data generated by the PSQ 96MA and the 
Q24 were compared to evaluate the performance of the Q24. Methods: From January 
to December 2010, a total of 90 diverse bacterial isolates were submitted to the TCH 
MML for molecular identification by pyrosequencing. Bacterial DNA from all 90 isolates 
was extracted and amplified separately using primers previously designed to target the 
V1, V3, and V6 variable regions of the 16S rDNA gene. Following amplification, 
samples were pyrosequenced with both the PSQ 96MA and the Q24 instruments. 
Characteristics specific to pyrosequencing were compared for each platform and 
categorized into three main groups: instrumentation (number of reaction wells, detection 
cameras, nucleotide cycle dispensations, total pyrosequencing run time, and sequence 
lengths), sample preparation (reagent and sample volumes, total set-up time), and 
computer/ software requirements. Results: Additional detection cameras on the Q24 
provided the opportunity to increase the number of nucleotide cycle dispensations 
resulting in increased run times and sequence lengths when compared to the PSQ 
96MA. Additionally, while the Q24 only had the capacity to sequence 24 samples in one 
run, the sample preparation chemistry required smaller reagent and sample volumes. 
Amplicon sizes ranged from 105bp to 192bp while read lengths averaged 34 bases per 
region for the PSQ 96MA and 51 bases per region for the Q24. Also, the Q24 is 
approximately half the size of the PSQ 96MA and requires only a USB flash drive to 
transfer run specifications and data; compared to the additional computer connection 
required for PSQ 96MA management. Conclusions: Compared to the PSQ 96MA, the 
Q24 provided longer sequences with reduced reagent and sample volumes; however, 
the Q24 required a longer pyrosequencing run time and had fewer reaction wells per 
run. Overall, reagent optimization, improvements in software, and compact instrument 
size make the Q24 an attractive pyrosequencing platform for implementation in a 
molecular diagnostics laboratory. 
 
ID23. Comparison of Assay Performance Between Cell Culture and a Rapid 
Automated Molecular Test for HSV Typing of Clinical Samples 
N. Visomblin, G. Zybina, J. Carrara, A. Ruskin, P. Lee, B. Blizard, J. Ching 
GenturaDx, Hayward, CA. 
Introduction: Laboratory confirmation of presumptive Herpes Simplex Virus (HSV) 
infection historically involves manual cell culture often exceeding 24 hour time to result. 
Molecular methods have been known to increase the positivity rate by 20% to 25%. An 
automated, rapid molecular diagnostic system may improve the availability, accuracy, 
and time to result. The investigational GenturaDx IDbox™ HSV 1/2 assay is a real-time 
PCR test for rapid and qualitative detection and discrimination of Herpes Simplex Virus 
type 1 (HSV1) and 2 (HSV2) from lesion specimens in approximately 3 hours. The 
IDbox system integrates nucleic acid extraction, purification, PCR amplification, and 
detection using disposable cassettes preloaded with specific reagents to minimize 
hands-on time, risk of errors, and contamination. The first data using clinical specimens 
was obtained in 2011 comparing the IDbox HSV 1/2 assay and the Diagnostic Hybrids 
ELVIS® HSV test kit at a clinical laboratory. Methods: Seventy-nine clinical specimens 
submitted for HSV testing were evaluated at an independent clinical laboratory with the 
GenturaDx IDbox HSV 1/2 Assay and the ELVIS HSV test kit. Discordant results were 
resolved by sending aliquots of those samples to a national clinical laboratory for 
molecular testing using the Roche LightCycler® HSV 1/2 Detection Kit for discrepancy 
analysis. Results: Of the 79 clinical specimens, 56 were from the vaginal region: 22 
from the vagina and 34 from the surrounding area. The remaining 23 samples were 
from various body sites (throat, face, male specific for example). Of the 79 specimens, 
the IDbox HSV 1/2 detected 20 more positive samples than the ELVIS assay, 12 of 
which were confirmed positive by the Roche ASR molecular method. The positivity rate 
was 59% for the IDbox and 37% for the ELVIS test. Fifty of 79 (63%) specimens had 
concordant results between the IDbox HSV 1/2 and ELVIS HSV tests. After discrepancy 
analysis, the overall concordance percentage increased to 86%. For the 56 vaginal 
region specimens alone the concordance rate after discrepancy analysis was 86%. For 
the 22 vaginal specific specimens the concordance rate was 91%. Conclusions: This 
study demonstrates that the GenturaDx IDbox HSV 1/2 assay has the potential to 
provide faster and more sensitive results than cell culture tests for the diagnosis of HSV 
1 and 2 infections. 
 
ID24. Design and Performance of Adenovirus, VZV, HSV-1, and HSV-2 Quality 
Control Materials for Assessing and Monitoring the Performance of Molecular 
Assays 
J. Boonyaratanakornkit, M. Shahbazian, A. Lau, L. Sapinoso, E.R. Schönbrunner 
Life Technologies, Benicia, CA. 
Introduction: Adenovirus, VZV, HSV-1, and HSV-2 molecular diagnostics utilize 
sample types such as cerebral spinal fluid (CSF) or plasma. Molecular assays that 
monitor viral load from transplant recipients typically utilize plasma based specimens 
and require calibrators to standardize the results. Regulations and guidance documents 
recommends the use of full process controls in similar matrices as patient specimens 
for validating/verifying assays as well for external quality control. In order to assist 
laboratories in meeting testing guidelines for plasma and CSF based Adenovirus, VZV, 
HSV-1, and HSV-2 testing, a quantification panel and high and low positive control were 
developed. Methods: Accelerated stability of the product was assessed using the 
QIAGEN Artus® VZV PCR ASR and an in-house developed HSV and Adenovirus 
assay and indicated that the product is stable for 18 months at -20°C. The performance 
of the plasma panel, which contains the 1E6, 1E5, 1E4, 1E3, and 1E2 copies/mL panel 
members, was assessed on several platforms with varying extraction, detection, and 
reagents showed a limit of detection at the 1E2 copies/mL level for the assays tested. 
Results: A reproducibility study was conducted with the High and Low Controls with the 
resulting intra-run reproducibility maximum of 35% CV and an inter-run reproducibility 
maximum of 35%. 11 laboratories evaluated the linearity, reproducibility, and LOD of 
the quality control materials on various quantitative and qualitative assay platforms. 
Conclusions: The performance and stability of Adenovirus, VZV, HSV-1, and HSV-2 
quality control materials indicates that they are useful tools to assess the performance 
characteristics of molecular assays as well as for use as a daily external run control. 
 
ID25. Electronic Medical Record-Based Syndromic Surveillance and Molecular 
Testing Data to Track Influenza Activity in a Community 
K.A. Mangold1,2, K.L. Kaul1,2, L.R. Peterson1, A.A. Robicsek1 
1NorthShore University HealthSystem, Evanston, IL; 2University of Chicago Pritzker 
School of Medicine, Evanston, IL. 
Introduction: One indicator of influenza prevalence in the community is the frequency 
of symptoms such as “fever” plus “cough” reported by patients and/or recorded by their 
attending physicians in visit notes, available through “syndromic surveillance” systems. 
We compare the frequency of influenza-like illness (ILI) symptoms among patients seen 
at NorthShore University HealthSystem over a two-year span as collected by an 
electronic medical record (EMR)-based syndromic surveillance system with the results 
of molecular testing for influenza. Methods: 847,728 primary care outpatient 
encounters were analyzed for EMR evidence of ILI. %ILI is defined as the percentage 
of these visits where fever and respiratory findings were recorded. The weekly %ILI, 
total molecular influenza tests, and positive influenza results were recorded between 
February 2009 and April 2011, and a temporal analysis was performed. Correlation 
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coefficients were calculated using Microsoft Excel. Results: Generally, %ILI tracked 
well with the number of total influenza specimens, the number of positive influenza tests 
and the percentage of influenza tests that were positive (correlation coefficients 0.77, 
0.78, 0.83), with some notable exceptions: 1) A surge of both %ILI and total influenza 
testing occurred immediately after news reports of the pandemic outbreak in Mexico. 
This surge was not correlated to positive test results, and occurred days before a 
second wave of reported ILI and molecular testing including increased positive results, 
corresponding to the true spread of pandemic influenza A in the Chicago area. 2) While 
the timing of peak ILI activity and peak testing activity were closely associated in all 
studied “flu seasons”, the quantity of testing was much greater during pandemic periods 
than non-pandemic periods despite similar ILI activity in pandemic and non-pandemic 
periods, suggesting that testing intensity does not predict disease intensity. 3) Several 
smaller spikes in %ILI occurred in December 2009 and February 2010 with no 
corresponding increase in total influenza testing or positive tests, indicating an 
interpretation by the physicians that testing for influenza was unnecessary at that time 
or that this represented another viral disease in the community with similar signs and 
symptoms as influenza. Conclusions: Although generally comparable, syndromic 
surveillance differs in important ways from laboratory testing data, preventing the 
substitution of one for the other. Used together they present a good picture of influenza 
activity. When %ILI rises and confirmed influenza does not, it suggests a non-detected 
viral illness is present in the community. 
 
ID26. Evaluation of Focus Diagnostics Simplexa™ HSV 1 & 2 Direct Sample-to-
Answer Real-time PCR Assay 
J. Chen, Y. Xie, L. Jacky, M. Aye, M. Tabb, M. Exner 
Focus Diagnostics, Cypress, CA. 
Introduction: The high prevalence of herpes simplex virus (HSV) infections makes it a 
significant public health concern. Prompt detection and differentiation of HSV infections 
can assist in patient management, and is especially important in cases of HSV 
meningoencephalitis. The Simplexa™ HSV 1 & 2 Direct assay is in development as a 
sample-to-answer multi-analyte detection system performed on the 3M Integrated 
Cycler instrument. Swabs in viral transport media and CSF specimens are loaded 
directly onto a Direct Amplification Disc without extraction or other specimen 
preparation. The goal of this study was to compare the performance of the Simplexa™ 
HSV 1 & 2 Direct assay relative to culture and to real-time PCR methods that require 
extracted specimens. Methods: Limit of detection (LoD) studies were performed to 
determine the analytical sensitivity of the assay. Inhibition, interference and cross 
reactivity were evaluated using a panel of bacteria, viruses and potentially interfering 
substances. Relative sensitivity and specificity were determined by testing blind panels 
of de-identified patient specimens and comparing results with those obtained using 
culture or a real-time PCR method that necessitate prior nucleic acid extraction. 
Results: The LoD studies showed that the Simplexa Direct assay detected HSV-1 
strains at less than 40 TCID50/mL and HSV-2 strains at less than 5 TCID50/mL. No 
inhibition, interference or cross reactivity was observed. Relative sensitivity and 
specificity for swab samples were 100% (42/42) and 97.1% (102/105) for HSV-1, and 
100% (40/40) and 100% (107/107) for HSV-2 samples. Relative sensitivity and 
specificity for CSF samples were 100% (36/36) and 97.7% (94/96) for HSV-1, and 
94.6% (35/37) and 98.9% (94/95) for HSV-2 samples. Conclusions: The Simplexa™ 
HSV 1 & 2 Direct assay was capable of directly detecting and differentiating HSV-1 and 
HSV-2 from un-extracted clinical specimens with performance comparable to real-time 
PCR method that uses upfront nucleic acid extraction. The assay and instrumentation 
provide a compact system for rapid (~1 hour) detection of HSV-1 and HSV-2 directly 
from swab and CSF samples. 
 
ID27. High-Throughput Direct Detection of Clostridium difficile from Stool 
Specimens Using the Simplexa™ C. difficile Universal Direct Assay  
Y. Chen, Y. Parocua, C. Cheng, R. Hazelo, M. Dang, H. Gregson, D. Tierney, M. Tabb, 
M. Exner 
Focus Diagnostics, Cypress, CA. 
Introduction: The increasing prevalence of C. difficile-related disease has resulted in 
the need for accurate and rapid diagnostic methods. Detection of toxin-producing 
organisms in stool samples is now routinely performed using PCR methodologies. 
However, high-throughput testing options are currently unavailable. To address this 
need, we have developed the Simplexa™ C. difficile Universal Direct Assay. This assay 
can directly detect organisms in stool without nucleic acid isolation procedures, and has 
a high throughput capacity (up to 96 samples tested in <2 hours). Methods: Fresh stool 
samples (n=189) were transferred into dilution buffer and incubated at 97°C for 10 
minutes on a heating block. Samples were then applied directly to a 96 well Universal 
Disc, along with the reaction mix, and real-time PCR was carried out using the 3M™ 
Integrated Cycler. Assay performance was determined by performing analytical limit of 
detection (LoD) and reproducibility studies. Results were compared with those of 3 
other methods: 1) a method involving a complete nucleic acid extraction step; 2) 
culture; and 3) a commercially available PCR assay. The effect of potential interfering 
substances was assessed by adding relevant concentrations of these substances to 
samples prior to testing. Results: The Simplexa™ C. difficile Universal Direct assay 
was at least as sensitive as the comparator methods, while providing greater 
throughput and more rapid test results. The LoD of the assay was 0.04 CFU/reaction. 
There was no interference from any of the 20 potential interfering substances tested, 
including blood, antibiotics, and diarrhea remedies. Inter- and intra-assay reproducibility 
assays yielded CVs of <2%. Results from a single specimen could be obtained in 
approximately 70 minutes, and up to 96 samples could be processed in <2 hours. 
Conclusions: The performance of the Simplexa™ C. difficile Universal Direct assay 
was comparable to the other methods. With no requirement for nucleic acid extraction, 
the assay provides significantly reduced turnaround time without compromising 
detection sensitivity.  
 
ID28. Evaluation of a Molecular Diagnostic Method for the Clinical Detection of 
Hepatitis B Virus 
S. Kim1, W. Koo1, J. Park1, J.W. Kim1, H. Park1, H. Kim2, Y. Cha3 
1Bioneer Corporation, Daejeon, Republic of Korea ; 2Hallym University Hospital, Seoul, 
Republic of Korea; 3Chung-Ang University Hospital, Dongsak-Ku, Seoul, Republic of 
Korea. 
Introduction: During the past few years, pathogen detection by molecular diagnostic 
methods has become a staple in countless clinical laboratories. Yet, as usage and 
implementation of the foundational technology expands, the fundamental rigidity with 
current vendor solutions has yet to be solved. Here we develop a novel molecular 
diagnostic workflow that offers flexibility in sample type input while preserving 
throughput and performance. Methods: HBV-specific primers and fluorescent probes 
were designed from Hepatitis B virus Surface Antigen S gene by bioinformatics 
analysis. The primer and probe set for the internal positive control (IPC) DNA were 
designed from a Tobacco Mosaic Virus movement protein gene that does not exhibit 
any cross-reactivity toward the target gene. The optimization procedures of real-time 
PCR assay were performed using DNA template synthesized de novo. In order to 
improve specificity, chemical hot-start method using specific enzyme instead of 
antibody using in conventional hot-start method was developed. For convenience of 
use, all components required for PCR reaction, including thermo stable DNA 
polymerase, dNTP, as well as primers and probes, were aliquoted for one reaction per 
tube and lyophilized. We evaluated the sensitivity and specificity with a standard control 
for calculating the limit of detection, HBV genotype performance panel (PHD201), and 
68 clinical samples. Results: Basic performance metrics of the Hepatitis B Virus kit 
were analyzed. The limit of detection was 50 IU/mL, and dynamic range was 5X101 
IU/mL to 5X1010 IU/mL. The coefficient of variation in the dynamic range was <2%(Ct 
value). Comparison analysis against Roche TaqMan96 HBV system showed 
0.9272(R2) concordances. To evaluate the method effectiveness and throughput, 
published data of current vendor platforms were analyzed and compared against actual 
workflow measurements. Analysis revealed that processing 48 samples of a single 
sample type took on average 4.17 hours with the ExiStation platform, compared to 
calculated times of 8.45 and 6.67 hours for Roche and Abbott platforms, respectively. 
Varying input sample types (serum, plasma) did not add additional time in ExiStation 
processing a total of 48 samples. Additionally, processing 96 samples took only 5.25 
Conclusions: Our novel molecular diagnostic workflow, ExiStation, has overcome the 
input sample rigidity associated with current solutions available on the market while 
decreasing total assay time and preserving throughput. We believe that ExiStation will 
be able to expand the applicability of molecular diagnostic methods in clinical 
laboratories and accelerate its adaptation.  
 
ID29. Results of a Pilot Internet-Based, Peer-Group Quality Control Program for 
HIV-1 Viral Load Testing 
W. Dimech 
NRL, Fitzroy, Victoria, Australia. 
Introduction: Many laboratories performing HIV-1 viral load by nucleic acid testing 
routinely monitor results of quality control (QC) samples other than those provided by 
the manufacturer. However, this is done independently without sharing of QC data 
between laboratories. In 2001, NRL (Melbourne, Australia) developed an Internet-based 
QC monitoring program specifically designed for molecular and serological infectious 
disease testing. This program (EDCNet; http://www.nrlqa.net) allows laboratories 
testing the same QC sample in the same test system to compare results and 
investigate abnormal QC test results in real time. Methods: A total of 15 U.S. 
laboratories were enrolled in the pilot study comprising of Veterans Affair, private and 
major public health laboratories that performed HIV-1 viral load testing using the Abbott 
RealTime HIV-1 RNA PCR (Abbott) and/or Roche COBAS AmpliPrep/COBAS TaqMan 
HIV-1 Test version 2.0 assays (Roche). Each laboratory tested the same batch of a low 
AMP Abstracts    000
JMD November 2011, Vol. 13, No. 6
741
0_Bring_Pages_Into_Quark_2  10/7/11  2:56 PM  Page 741
and medium positive, independent QC sample, OptiQual (Life Technologies, 
AcroMetrix, Benicia CA). Results of the QC samples, along with reagent lot numbers, 
date of testing, operator and instrument identification were entered into EDCNet. 
Results: A total of 137 QC test results for the two levels of OptiQual were submitted to 
EDCNet; 87 from the Abbott assay and 50 from the Roche assay. The mean log10 viral 
load result for the OptiQual low positive QC was 2.56 (Abbott; n=44) and 2.68 (Roche; 
n=26). The mean QC result for the OptiQuant medium positive QC was 3.88 (Abbott; 
n=43) and 4.21 (Roche; n=24). The percentage coefficient of variation for the low and 
medium OptiQual QC tested on the Abbott and Roche assays was 5.08, 4.64, 4.48 and 
2.38% respectively. Conclusions: Testing QC samples independent of those provided 
by the assay manufacturer is recommended by many regulatory authorities worldwide. 
As testing QC samples is relatively expensive, peer-to-peer comparison of QC data 
allows laboratories to obtain the greatest possible value from QC testing and to 
maximize the number of data points available for investigation of unusual results. The 
collection of additional information such as kit lot number, instrument and operator 
details further aids investigations. EDCNet is used by more than 700 laboratories in 
over 30 countries. It underpins national QC programs for infectious disease testing in 
Australia, Canada, Poland and Malaysia. This pilot study demonstrated the utility of 
EDCNet to collect, store and analyze OptiQual QC test results from US-based 
laboratories testing for  
HIV-1 viral load.  
 
ID30. Detection of Human Papillomavirus from Cervical Specimens by Five 
Different Assays 
Y. Park1, J. Choi1, E. Lee2, D. Hong1, S. Shin1, H. Kim1 
1Yonsei University College of Medicine, Seoul, Republic of Korea; 2Green Cross 
Reference Laboratory, Seoul. 
Introduction: Repeated cervical infection with Human papillomavirus (HPV) is a well-
known risk factor for cervical cancer, thus early detection of cervical HPV infection is an 
important mean to prevent cervical cancer. We evaluated five assays utilizing different 
principles for the detection of cervical HPV infection. Methods: A total of 230 cervical 
swab specimens were collected from subjects with cytologic results of normal (group 1, 
n=78), ASCUS (group 2, n=51), LSIL (group 3, n=46), and HSIL (group 4, n=55). DNA 
was extracted from all samples and tested for following assays: two real-time PCR 
assays (RealTime High Risk HPV by Abbott, reporting 16, 18 and other 12 high risk 
genotypes; AdvanSure HPV by LG Life Science, detecting 16, 18 and other 39 high and 
low risk genotypes), hybrid-capture assay (Digene, detecting 8 high risk genotypes), 
liquid beads microarray (GeneFinder HPV by Innomeditech, reporting 43 detailed high 
and low risk genotypes), and DNA microarray (PANArray HPV by Panagene, reporting 
32 detailed high and low risk genotypes). Results: Among the 230 specimens, 15 
(6.5%) were negative and 70 (30.4%) were positive for all the five assays. Remaining 
145 (63.0%) showed different results according to the assays. Genotype 16 and 18 
were detected in around 13% and 5% regardless of assays performed. Positive rate 
was 44.3% for the Hybrid Capture (high risk genotypes: 10.3%, 25.5%, 65.2% and 
92.7% in group 1 to 4), 42.2% for the RealTime High Risk HPV (high risk genotypes: 
14.1%, 27.5%, 50.0% and 89.1% in group 1 to 4), 85.7% for the AdvanSure (high and 
low risk genotypes: 88.5%, 70.6%, 93.5% and 89.1% in group 1 to 4), 75.2% for the 
GeneFinder (high risk genotypes other than 16/18: 24.4%, 19.6%, 50.0% and 56.4%; 
low risk genotypes: 28.2%, 9.8%, 26.1% and 18.2% in group 1 to 4), and 49.1% for the 
PANArray (high risk genotypes other than 16/18: 3.8%, 15.7%, 41.3% and 34.5%; low 
risk genotypes: 3.8%, 9.8%, 13.0% and 7.3% in group 1 to 4). Genefinder detected 62 
(79.5%) cases coinfected with different HPV genotypes, while PANArray and RealTime 
High Risk HPV assays respectively detected 19 (24.4%) and 11 (14.1%) coinfection. 
Conclusions: Recently developed assays for the detection of HPV showed high 
positive rates. All the five assays showed similar positive rates in detecting genotype 16 
and 18, although overall concordance between the results for other HPV genotypes 
was not high. These assays may be sufficiently used for HPV testing. 
 
ID31. Verification of the COBAS® AmpliPrep/COBAS® TaqMan HIV  
Test ver. 2.0  
K.A. Lebel1, C.L. Bissaillon1, H.B. Steinmetz2, G.J. Tsongalis2, F. Moore1 
1Baystate Health, Springfield, MA; 2Dartmouth Hitchcock Medical Center, Lebanon, NH. 
Introduction: Verification of quantitative test systems in the clinical laboratory is 
essential in providing quality patient care. Recently, Roche obtained approval for a 
COBAS® AmpliPrep/COBAS® TaqMan HIV Test Version 2.0. Here we present data for 
verification of this new version of the assays as it claims a linear dynamic range of 20-
10,000,000 copies/ml and additional detection of HIV-1 Group O species. Methods: 
Verification studies were performed in two independent laboratories following the Roche 
Assay Verification Activities Plan. The Optiquant HIV-1 RNA quantitative panel 
(Acrometrix, Benicia, CA) was used to assess accuracy, linearity, precision and limit of 
detection. This panel consists of six samples spanning the range of 0-5x106 HIV-1 
copies/ml. Accuracy and precision was assessed using a high and low control run in 
triplicate over a 5 day span. Linearity was assessed by testing the Optiquant panel in 
triplicate within a single run. Limit of detection was assessed using a panel member at 
the lower limit of detection for the assay (20 cp/ml) within a single run in 20 replicates. 
In addition, 40 de-identified, frozen clinical samples were tested to assess method 
correlation. Results were compared to previously obtained results using the COBAS® 
AmpliPrep/COBAS® TaqMan HIV Test ver. 1.0. Results: The interlaboratory results 
were nearly identical. Precision was assessed at 2% and 1% Total (Log 10) %CV for 
low and high controls, respectively. Accuracy measured at two levels over 5 days 
yielded a mean Log 10 difference (expected to observed) at -0.13. Linearity studies 
resulted in a regression of y=0.9928x+0.023, with a correlation coefficient (r2) of 
0.9989. The limit of detection was demonstrated to be accurate within 95% confidence. 
Conclusions: Analysis of data obtained with the COBAS Ampliprep/COBAS Taqman 
HIV-1 Test ver. 2.0 verified manufacturers’ claims stated in the package insert. 
Furthermore, correlation of results ensures accurate assessment of HIV-1 viral load in 
patients can continue without the need for re-baselining. The decreased lower limit of 
detection and detection of Group O will enable laboratories to better assist in the care of 
HIV infected patients. The verification process, although timely, provides a precise 
mechanism to establish the parameters necessary to deliver high quality of care. 
 
ID32. Classification of E. coli Based on the Pathogen Genes in Amniotic Fluid  
B. Han1, O. Kwon1, H. Park1, H. Lee2 
1YeBT.Co. Ltd., Seoul, Republic of Korea; 2Seoul National University College of 
Medicine, Seoul. 
Introduction: Bacterial contamination of amniotic fluid (AF) can lead to a preterm 
delivery or rupture of membrane. Some of the Escherichia coli strains have toxin and 
can work as a pathogen in AF. E. coli consists of four major phylogenetic groups 
designated as A, B1, B2, and D. Usually, the commensal strains are placed into the 
phylogenetic groups A and the extraintestinal pathogenic strains into group B1, B2 and, 
to a lesser extent, group D. Amniotic fluid infection is usually detected by bacterial 
culture or bacterial 16S rDNA PCR assay. Because of PCR regents such as Taq 
polymerase containing E. coli DNA, it is difficult to detect E. coli from amniotic fluid in 
16s rDNA PCR assay. In this study, we have developed a detection method to find 
pathogen E. coli in the amniotic fluid Methods: TotalPlex PCR-amplified biotinylated  
E. coli genes (chuA, TspE4.C2, yjaA) were hybridized to bead. Based on the present or 
absent of the E. coli toxin gene, E. coli were classification into group A, B1, B2 and D. 
Results: Among the tested 30 AF samples, the classification results are as follow; 6 for 
group A, 5 for group B1, 12 for group B2 and 1 for group D. Conclusions: TotalPlex 
amplification and bead array system can precisely figure out the present or absent of 
the E. coli toxin gene.  
 
ID33. A Bead-Based Multiplex Assay for the Detection of Pathogens Causing 
Bloodstream Infections 
M. Shennan, H. Zhang 
Luminex Molecular Diagnostics, Toronto, Canada. 
Introduction: Bloodstream infections (BSI) are severe infections caused by a variety of 
bacterial and fungal species. BSI are usually diagnosed through the use of blood 
cultures (BC), a process that can take up to two days (or longer for fastidious 
organisms) to specifically identify the causative agent. Recently, DNA-based 
approaches have offered an alternative to traditional BC and provide results in 
significantly less time (i.e. hours as opposed to days). In this study, a bead-based 
multiplex assay (the xTAG® Bloodstream Pathogen Panel or BPP) under development 
by Luminex Molecular Diagnostics (LMD) was evaluated. This multiplex panel is 
designed to target 20 of the most common pathogens causing BSI (7 Gram-positive 
and 8 Gram-negative bacterial targets and 5 Candida species), 3 common resistance 
markers (mecA, vanA and vanB) and 1 internal/run control and provide an answer 
within 3 hours. Methods: The xTAG BPP was evaluated for both specificity and 
sensitivity using purified pathogen isolate DNA obtained from the American Type 
Culture Collection (ATCC). Additionally, preliminary limit of detection (LoD) studies 
using diluted DNA specimens were performed. Finally, DNA extracted from de-identified 
positive blood cultures provided by University of Pittsburgh were analyzed and the 
results compared to traditional typing methods. Results: Thirty-five DNA isolates were 
tested using the BPP, 23 representing the specific targets of the assay and 12 potential 
cross-reacting species. All positive samples tested were correctly identified (23/23, 
100% sensitivity) and there were no false positive results observed within the multiplex 
for specific targets, nor in any of the potential cross-reacting isolates (35/35, 100% 
specificity). Preliminary LoD performed using Staphylococcus aureus-MRSA strain 
FPR3757 (ATCC BAA-1556D-5) suggests that for this target in a purified system, 
single-genome copy (i.e. <10 fg) detection is possible. Twelve blood cultures (including 
one negative growth control) were also evaluated using the BPP; all 12 were in 
agreement with the phenotypic results provided by the site. Additionally, the multiplex 
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panel detected possible unreported co-infections in two of the twelve samples. 
Conclusions: This study showed that the xTAG BPP is highly specific and sensitive for 
the detection of bacteria and fungi known to cause bloodstream infections. This 
warrants future evaluation of the xTAG BPP for its utility in patient management.  
 
ID34. Evaluation of 16S rDNA Sequencing Analysis for the Identification of 
Vibrio vulnificus Species 
G. Park, D. Moon, Y. Park, S. Jang 
Chosun University College of Medicine, Gwangju. 
Introduction: To evaluate the usefulness of 16S rDNA sequencing analysis for the 
differentiation of V. vulnificus and V. navarrensis, we tested 57 Vibrio strains by several 
molecular techniques. Methods: Fifty-two clinical and environmental strains and 5 
Vibrio reference strains were used in this study. We performed 16S rDNA sequencing 
analysis, gyrB V. vulnificus-specific PCR (gyrB Vvu PCR), gyrB V. navarrensis-specific 
PCR, (gyrB Vna PCR), V. vulnificus-specific PCR (vvh PCR), and DNA J sequencing 
analysis. We determined final consensus identification of 57 Vibrio strains by comparing 
the results of each tests. We evaluated the usefulness of 16S rDNA sequencing 
analysis based on the final identification. Three methods of bacterial allocation criteria 
for species identification by 16s rDNA sequences are as follows: The bacterial 
allocation method 1 is to allocate the bacterial species showing highest % similarity with 
tested sequence as its identification. The method 2 is based on the mimicking criteria of 
CLSI guideline for interpretive criteria for identification of bacteria by DNA target 
sequencing (99.0% identity for species identification with greater than 0.8% separation 
between different species). The method 3 is based on the phylogenetic tree analysis. 
Results: The composition of final identification of 57 Vibrio strains were 50 (78.1%) V. 
vulnificus, 3 (4.7%) V. navarrensis, 2 (3.1%) V. parahaemolyticus, 1 (1.6%) V. cholerae, 
1 (1.6%) V. mimicus. By bacterial allocation method 1, 9(18%) and 39(78%) of 50 V. 
vulnificus were identified as V. vulnificus and V. navarrensis, respectively. One (33.3%) 
of 3 V. navarrensis was identified as V. navarrensis. Only 9 strains of Vibrio were 
identified by method 2, of which six were V. vulnificus. Fourty-eight of 57 strains could 
not meet the criteria of method 2. By method 3, 33(66%) of 50 V. vulnificus strains, 
each one of V. cholerae and V. mimicus was correctly identified. Conclusions: The 
result of 16S rDNA sequencing analysis was not satisfactory for the species 
identification of Vibrio. The method 3 was the best method among three methods of 
bacterial allocation criteria. 
 
ID35. Molecular Assay to Determine the Cervicovaginal Microflora Composition 
in Healthy Women and Individuals with Bacterial Vaginosis 
S. Balashov1, E. Mordechai2, M.E. Adelson2 
1Femeris Women’s Health Research Center, Hamilton, NJ; 2Medical Diagnostic 
Laboratories LLC, Hamilton, NJ. 
Introduction: Bacterial vaginosis (BV) is an imbalance in vaginal microflora 
characterized by a depletion of normal lactobacilli and overgrowth of various facultative 
anaerobic bacteria. Clinical symptoms include an increase in vaginal pH, vaginal 
discharge and unpleasant fishy odor. BV is associated with increased risk of sexually 
transmitted infections and serious pregnancy complications. BV is very common in 
women of reproductive age and is one of the most common reasons that women seek 
treatment from health care providers. The etiology of this condition remains largely 
unknown. Laboratory diagnosis of BV is mainly based on Gram staining of vaginal 
smears, microscopic evaluation and manual counts of bacterial morphotypes. This 
approach is time consuming, subjective, and substantially outdated. We have 
developed a molecular assay for identification of the major vaginal bacterial species 
presented in both healthy and disturbed vaginal microflora, which can serve as a 
reliable test for BV. Methods: DNA is extracted from a cervicovaginal sample and 
subjected to a panel of PCR assays targeting four Lactobacillus species: L. crispatus,  
L. gasseri, L. jensenii, and L. iners, and five BV-associated pathogens: Gardnerella 
vaginalis, Atopobium vaginae, Megasphaera type1 and type 2, and BVAB2. PCR data 
are combined and computed together generating an accurate relative evaluation of 
bacterial species composition in a given clinical sample. Results: We have processed 
189 cervicovaginal samples collected from BV carriers as well as healthy individuals. 
BV conditions were diagnosed by participating OB/GYN providers according to 
established clinical criteria. We have found substantial correlation between our new 
molecular PCR test results and the health status of sample donors. The vaginal 
microenvironment of BV patients was generally dominated by mixed populations of  
G. vaginalis, A. vaginae, Megasphaera spp., and/or BVAB2, whereas the vaginal milieu 
of healthy women was preoccupied by one or less frequently two Lactobacillus species 
in complete agreement with the literature data. Conclusions: We have developed an 
assay for relative assessment of major bacterial species present in normal and 
abnormal vaginal microflora. This molecular test may offer a significant advantage for 
clinical BV management. 
 
ID36. Genotype Specific HPV Detection from Formalin-Fixed, Paraffin- 
Embedded Tissue Samples in an Academic Institution 
A. Snow, J. Laudadio 
Wake Forest Baptist Medical Center, Winston-Salem, NC. 
Introduction: Identification of HPV using molecular techniques is employed to assess 
risk for gynecologic malignancy, characterize cutaneous lesions, localize primary sites 
from metastatic lesions, and enhance prognostic assessment of squamous cell 
carcinomas of the head and neck. This task is accomplished by detecting the presence 
or absence of the virus and categorizing the positive results based on high or low risk 
genotypes. The purpose of this study is to determine the HPV positivity rate and 
genotype distribution within formalin-fixed, paraffin-embedded tissues tested for routine 
clinical care. Methods: DNA was extracted and PCR amplified using consensus 
primers directed at the L1 region of the HPV genome. Positive samples were then 
subjected to restriction enzyme digestion for genotype discrimination. HPV results were 
correlated with tissue site and pathologic diagnosis if available. Data were 
retrospectively collected for all routinely tested specimens over an 18 month period. 
Results: Overall, 92 samples (52 head and neck cases, 35 anogenital biopsies, and 5 
other samples) were tested. 55 cases (59.8%) were positive for HPV: 32 (58.2%) high 
risk, 15 (27.3%) low risk, and 8 unknown risk. 10 separate HPV subtypes were 
identified. 6 samples contained a coinfection in which two distinct subtypes could be 
identified. Type 16 was the most prevalent high risk genotype detected and type 6 was 
the most prevalent low risk type. Of interest, rare genotypes detected included 45, 57, 
58, 62, and 66. 55.8% of head and neck cases were HPV positive with 8 genotypes 
identified. The most prevalent genotype was 16 (58.6%) followed by types 33 (10.3%) 
and 6 (10.3%). Type 16 was identified in 78.9% of HPV positive samples in this 
category with a pathologic diagnosis of in situ or invasive squamous cell carcinoma. Of 
the anogenital biopsies, 64.7% were HPV positive with 5 genotypes identified. 50% of 
positive samples contained type 6 and 22.7% contained type 16. Conclusions: HPV 
testing was predominantly requested on two groups of tissue samples: head and neck 
specimens and anogenital biopsies. HPV positivity rate in head and neck specimens 
was 56% with high risk types 33, 45, 58, 62, and 66 being detected in addition to type 
16. HPV positivity rate in anogenital samples was 65% with types 57, 58, 61, and 66 
being detected in addition to type 16. The only low risk types detected in all specimens 
were 6 and 11. No positive cases were identified as type 18 or 52. 
 
ID37. Evaluation of FFPE Tissue Specimens with a 24-Plex Luminex Fungal 
Panel Using the MagPix Instrument 
K. Walker, M. Lopez, R. Beissner, A. Rao 
Scott and White Hospital, Temple, TX 
Introduction: Fungal infections are often associated with suppurative or non-
suppurative necrosis, abscess, granulomatous or erosive inflammation. 
Histopathological diagnosis can be limited by the degree or type of inflammatory 
infiltrate, the number of fungal organisms and problems with morphological 
identification. Molecular based detection in formalin-fixed, paraffin-embedded (FFPE) 
samples can be nonspecific secondary to the reagent contamination or contaminant 
and commensal fungal spores. We investigated the Luminex fungal ASR panel on 
formalin-fixed tissue specimens (FFPE) with known fungal infections as also tissue 
specimens with necrosis and no documented fungal infections to validate and 
determine the specificity of the ASR panel. Methods: 40 positive and 13 negative 
formalin-fixed, paraffin-embedded tissue sections were selected and fungal elements or 
necrotic areas were isolated using the Arcturus Laser Capture Microscope and were 
incubated in the presence of proteinase K and lyticase enzyme. Additionally, evaluation 
was also performed using whole tissue curls (10 sections of 5 µm thickness) and 
extracted with a modified protocol using the Qiagen DNA Mini kit. The samples were 
amplified with Luminex ASRs in a Multiplex PCR format with a 24-plex primer mix to 
detect Candida species C. albicans, C. glabrata, C. lusitaniae, C. tropicalis,  
C. parapsilosis, C. guilliermondii and C. krusei, Aspergillus species A. terreus,  
A. fumigatus, A. flavus and A. niger, H. capsulatum, C. immitis, C. neoformans,  
B. dermatitidis, S. apiospermum, S. prolificans, Fusarium, R. microsporus, R. arrhizus, 
M. indicus, C. bertholletiae, and P. Jirovecii on the MagPix system after nucleic acid 
extraction with the plate heated to 45°C; 100 beads/set were collected. Results were 
correlated with histology and culture results. Results: Tissue curls were the specimen 
of choice and sensitivity was improved with the size and thickness of the specimen 
submitted. 12 of 13 necrotic specimens with no fungal elements identified by culture or 
histology were negative. One specimen was positive for C. albicans. Three specimens 
were positive for organisms not identified by histology (Candida and Cunninghamella 
spp identified instead of Histoplasma and Aspergillus). Organisms correctly identified 
included Aspergillus, Cryptococcus, Histoplasma, Pneumocystis, Candida and 
Coccidioides with a specificity of 98%. Co-infections included A. fumigatus with  
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C. albicans. Conclusions: The Luminex ASR panel had good specificity and sensitivity. 
The rapid detection in a multiplex format is very helpful in the fast and accurate 
diagnosis of fungal infections in histological specimens. 
 
ID38. Detection of Bordetella pertussis and Bordetella parapertussis by a Real-
Time PCR in a Community Hospital 
K. Norton, R. Cordery, C.A. Gleaves, B. Jensen 
SW Washington Medical Center, Vancouver, WA. 
Introduction: Whooping cough or B. pertussis continues to be an important cause of 
morbidity in this country despite the availability of a vaccine. The goal of this evaluation 
was to confirm the use of a 2-target real-time PCR assay that would detect B. pertussis 
and B. parapertsusis from patient samples. Methods: A total of 625 patient samples 
submitted for B. pertussis were tested. DNA extraction was performed using the Qiagen 
EZ1 Advanced XL. Following extraction, 5µl of the sample was tested for the IS481, 
plS1010, and the ptxS1 targets for B. pertussis and B. parapertussis. Real-time PCR 
was performed using the AB 7500 fast DX instrument. Results: Of the 625 samples 
tested, 28 were positive for B. pertussis, 7 were positive for B. parapertsussis and 24 
samples were considered indeterminate. Of the indeterminate samples 1 tested positive 
for B. holmesii by PCR and one sample was considered indeterminate for  
B. parapertussis. Of the remaining 22 indeterminate samples, 13 were siblings of 
patients that tested positive for B. pertussis. Conclusions: Real-time PCR is an 
invaluable tool for the rapid diagnosis of B. pertussis and B. parapertussis and can 
affect patient management. Additionally, this 2-target real-time PCR assay can enhance 
the epidemiological surveillance of B. pertussis. 
 
ID39. The Identification of Clinically-Important Yeasts in Blood Cultures Using 
Pyrosequencing 
M.J. Tuohy, G.W. Procop 
Cleveland Clinic, Cleveland, OH. 
Introduction: Our laboratory has developed a method of rapid, selective sequencing of 
a variable region of the 28S rRNA gene for the identification of clinically-important yeast 
species using PCR followed by pyrosequencing. In this study, we expanded our current 
in-house database that includes C. albicans , C. glabrata, C. parapsilosis complex,  
C. tropicalis, C. lusitaniae, C. krusei, C. dubliniensis, C. guilliermondii complex, 
Cryptococcus neoformans, and Cryptococcus laurentii complex and evaluated 
pyrosequencing and our updated database to perform direct yeast identification from 
blood cultures. Methods: Twenty-three well-characterized yeast isolates representing 
C. kefyr, Rhodotorula sp. and Saccharomyces cerevisiae were tested for addition to our 
database. Forty-four positive blood cultures from a frozen collection were tested as 
unknowns. Extracts for isolates and blood culture broths (BactALERT£ 3D Fan bottles) 
were processed using glass beads in lysis buffer, heating at 100qC, then extraction with 
the MagNA Pure LC or EasyMag System. Real-time PCR was performed on the Rotor-
gene 6000 targeting a variable region of the 28S rRNA gene. Pyrosequencing was 
performed according to the manufacturer's instructions, using a conserved sequencing 
primer that was adjacent to a variable region. Pyrograms were evaluated by the 
instrument software and sequences were manually verified if questionable. Forty bases 
were used for isolate categorization and results were compared to our updated 
database. Results: Seven C. keyfr, 6 Rhodotorula sp. and 10 S. cervisiae, when 
blasted against GenBank, were correctly assigned to their respective molecular group, 
however, for Rhodotorula sp. and S. cervisiae, identification was possible only to the 
genus level.  For 44 blood cultures, 39/44 (88.6%) had a correct match in our database 
including one specimen that required repeat testing. These 39 included 12 C. albicans, 
13 C. glabrata, 6 C. parapsilosis complex, 3 C. tropicalis, 2 Cryptococcus neoformans, 
1 Rhodotorula sp. and 2 Saccharomyces sp.  Of the 5 remaining samples that did not 
match our database, 4 blood cultures containing C. albicans had a 39/40 (97.5%) match 
in GenBank for C. albicans. One blood culture containing C. lusitaniae and coagulase 
negative Staph sp. resulted in a pyrosequence that did not have a match in GenBank or 
our database with only 29 readable bases. The yeast isolate was tested directly and 
matched the blood culture pyrosequence result. Conclusions: Pyrosequencing using 
our expanded in-house database can be used to identify yeast directly from blood 
cultures. 
 
ID40. Clinical Evaluation of the BD MAX™ MRSA Assay, the BD GeneOhm™ 
MRSA ACP Assay and Conventional Culture for the Rapid Detection of MRSA 
Directly from Nares Swabs 
D.D. Fuller, J.D. Talbott, R.J. Buckner, K.L. Newcomer, A. June, T.E. Davis 
Wishard Health Services-Indiana University School of Medicine, Indianapolis, IN. 
Introduction: Staphylococcus aureus (SA), a major cause of nosocomial infections, is 
commonly found in the nose or on the skin of healthy individuals (asymptomatic 
carriers). Methicillin-resistant strains of SA (MRSA) are frequently encountered in 
health-care settings, and the prevalence continues to increase. Development of 
sensitive molecular amplification techniques allows for detection of only a few copies of 
bacterial DNA in clinical specimens in a few hours. The combination of sensitivity and 
rapidity allows for the prompt isolation of MRSA carriers and thus prevention of the 
spread of antibiotic resistant SA. This study evaluated two molecular methods (BD 
MAX™ MRSA Assay and BD GeneOhm™ MRSA ACP Assay) and conventional culture 
for direct detection of MRSA from nasal swab specimens. Both the BD MAX™ MRSA 
Assay (BD MAX™) and the BD GeneOhm™ MRSA ACP Assay (ACP) utilize real-time 
PCR for the amplification of MRSA DNA and fluorogenic target-specific hybridization 
probes for the detection of amplified DNA. The BD MAX™ is a fully automated sample-
to-result platform that is currently investigational use only. The ACP assay is performed 
on the Cepheid SmartCycler® instrument and is commercially available. Methods: A 
total of 96 paired-nares specimens were collected in Liquid Stuart media. One swab 
was tested using the ACP assay according to package insert instructions. The second 
swab was inoculated on to a CSA and blood agar media and then broken into a sample 
buffer tube, vortexed, and analyzed using the BD MAX™ instrument/assay. 
Additionally, an aliquot of the sample buffer was inoculated into an enrichment broth 
(TSB with 6.5% NaCl). Direct and broth-enriched cultures were identified using 
standard and chromogenic media, latex agglutination, and cefoxitin disk diffusion 
methods for MRSA. Specimens were analyzed within 5 days of collection. Results from 
ACP, BD MAX™ and culture were used to calculate sensitivity/specificity using patient 
infectivity status (PIS) with true positives defined as any two out of three positive 
results. Results: Of the 96 subjects tested to date, 29 yielded true positive results and 
62 yielded true negative results based on PIS. Both ACP and BD MAX™ exhibited 
100% sensitivity and 98% specificity respectively, while culture yielded 83% sensitivity 
and 97% specificity based on PIS. Conclusions: Both BD MAX™ and ACP exhibited 
excellent sensitivity/specificity for direct detection of MRSA from nasal swab specimens. 
The fully-automated BD MAX™ accommodates up to 24 specimens and returns results 
in ~3h allowing rapid decisions affecting patient management. 
 
ID41. Establishment of an IL28B Genotyping Assay for Clinical Use 
M.A. Cervinski, H.B. Steinmetz, C.L. Lefferts, B. Wood, G.J. Tsongalis 
Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: Chronic hepatitis C (CHC) infection currently affects approximately 170 
million people worldwide and is the leading cause of cirrhosis in North America as well 
as an important risk factor for hepatocellular carcinoma. Standard of care treatment for 
HCV infection, pegylated interferon alpha and ribavirin (PegIFN/RBV), fails to achieve 
sustained viral response (SVR) in >50% of the HCV genotype 1 infected individuals. 
Recently, numerous studies have identified two allelic variants, rs12979860 and 
rs8099917, upstream of the interleukin-28B (IL28B) gene that are correlated with the 
rate of SVR following PegIFN/RBV therapy. CHC patients with the favorable CC 
genotype of rs12979860 have a 2- to 3-fold greater rate of SVR following PegIFN/RBV 
therapy than individuals with the CT or TT genotype. Similarly, patients with the TT 
genotype of rs8099917 have higher rates of SVR following combination PegIFN/RBV 
therapy as compared to GT or GG genotype individuals. We report on our initial 
validation of a clinical genotyping assay for the rs12979860 and rs8099917 
polymorphisms in the IL28B locus. Methods: Genomic DNA was extracted from 100 
de-identified residual EDTA whole blood samples with the EZ1 DNA Blood kit on the 
Qiagen EZ1 BioRobot. Genomic DNA was analyzed for yield and purity by absorbance 
spectroscopy. The extracted DNA was then analyzed using TaqMan® real-time PCR 
primers and probes on the Applied Biosystems 7500 Fast Real-Time PCR System with 
probes specific for the C and T alleles of rs12979860 and the G and T alleles of 
rs8099917 in the IL28B locus. Results: All 100 samples analyzed generated clinically 
usable results. In this set of de-identified patient samples 41/100 had the favorable CC 
genotype, 50/100 were CT and 9/100 were TT at rs12979860: overall allele frequency 
was 66% C and 34% T. For the rs8099917 polymorphism, 60/100 were the favorable 
TT genotype, 36/100 were GT and 4/100 were GG: overall allele frequency was 22% G 
and 78% T. The allelic frequency is similar to that reported in the HapMap project for a 
Caucasian population (rs12979860 C=74.2% T=25.8%; rs8099917 G=16.7%, 
T=83.3%). Conclusions: Our initial validation studies of a laboratory developed IL28B 
genotyping assay using TaqMan primers and probes demonstrates that this assay will 
be readily applicable to clinical testing, demonstrating allelic frequencies that are 
comparable with previous reports. Clinical availability of this assay will allow the 
clinician, in conjunction with other clinical factors, to predict the individual patient’s 
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ID42. Evaluation of the Focus Diagnostics SimplexaTM Flu A/B & RSV Direct 
Real-Time PCR assay 
M. Nair, H. Mai, L. Jacky, M. Young, E. Eleazar, J. Chen, S. Dempsey, Y. Xie, M. Aye, 
M. Tabb, M. Exner 
Focus Diagnostics, Cypress, CA. 
Introduction: Influenza A (Flu A), influenza B (Flu B) and respiratory syncytial virus 
(RSV) are clinically important viral pathogens that cause respiratory illness in millions of 
individuals worldwide each year. The Simplexa Flu A/B & RSV Direct assay is in 
development for the differential detection of Flu A, Flu B and RSV from nasopharyngeal 
swabs (NPS) without extraction. The goal of this study was to compare the performance 
of the Simplexa Flu A/B & RSV Direct assay to culture, and to a real-time PCR 
methodology that uses automated nucleic acid extraction. Methods: Performance of 
the Simplexa Flu A/B & RSV Direct assay was assessed with panels of clinical NPS 
specimens, and the results were compared to previous culture and/or qualitative real-
time PCR results. Specificity studies were performed using a contrived panel of 31 
respiratory pathogens and normal flora. Limit of detection (LoD) studies were performed 
using serially diluted viral stocks, and the LoD was determined as a concentration 
where 95% replicates were detected. In addition, assay inhibition/interference was 
determined by spiking relevant concentrations of potentially interfering substances. 
Results: The Simplexa Flu A/B & RSV Direct assay showed 100% agreement for all 
clinical specimens that were reported positive by both culture and the comparator real-
time PCR assay. Negative agreement for Flu A, Flu B and RSV were 98.4% (186/189), 
99.5% (187/188) and 100% (202/202) respectively. The multiplexed assay was specific 
and no cross-reactivity was observed with other organisms. The assay detected 
geographically diverse strains of Flu A including the H1 and H3 subtypes and the 2009 
pandemic H1N1 strain. It was also capable of detecting all tested strains of Flu B, RSV-
A and RSV-B, and the analytical sensitivity for each of the three targets was less than 
30 TCID50/mL. Studies using clinically relevant interferents did not show any inhibition 
of target detection. Conclusions: The sample-to-answer Simplexa Flu A/B & RSV 
Direct can provide results from 8 samples in approximately 1 hour with minimal hands-
on manipulation. The assay displays similar performance to conventional detection 




ID44. Lack of a BK Virus DNA International Standard Complicates Comparison 
of Results Between Laboratories and Development of a Lab-Developed 
Quantitative Assay  
C. Gentile1, A. Greer2, A. Valsamakis2, C.D. Watt1, V.M. Van Deerlin1 
1University of Pennsylvania Health System, Philadelphia, PA; 2The Johns Hopkins 
Hospital, Baltimore, MD. 
Introduction: BK virus (BKV)-induced nephropathy causes allograft loss in 
approximately 5% of renal transplant patients. Risk of allograft loss increases with high 
viral load (VL); monitoring plasma VL is used to detect viremia and allow for 
immunosuppression reduction to prevent allograft loss. Cut-off values for use in this 
monitoring paradigm have been recommended but have been difficult to implement due 
to quantification variability between different assays in the absence of an international 
standard that can be used as a uniform calibrator. Assay-dependent quantitative 
variability is particularly problematic for laboratories transitioning from reference 
laboratory testing after developing their own assays and for patients monitored at 
multiple laboratories. Methods: Split plasma samples (n= 136) were tested by the 
Qiagen artus BK Virus RG PCR Kit (artus) and at least one other method including 
Eragen Multi-code BK Primer ASR (Eragen), a reference laboratory (RefLab1) using 
Nanogen ASR reagents, reference lab 2 (RefLab2) using Focus ASR reagents, or in-
house testing using Focus ASR reagents. Calibrators included artus QS standards, 
Zeptometrix BK Virus Linearity Panel, Acrometrix Quantification Panel, serially diluted 
Applied Biotechnologies BK Viral DNA (ABI), and linearized plasmids (RefLab1 and 
RefLab2 only). Selected samples were genotyped by direct sequencing. Results: BK 
VL measured by artus were about 1-log lower than RefLab1, with excellent linear 
correlation; similar bias was observed with commercial panels. Plasmas (N=40) were 
tested by 4 methods: artus using 4 different standard curves, Eragen with Zeptometrix 
standard curve, RefLab1, and RefLab2. No bias was observed between artus and 
Eragen results or between RefLab1 and RefLab2. However, a 0.5-2.2 log bias was 
observed between artus and both reference labs. The artus results quantified using 
different standard curves were similar, except with ABI calibrators that showed a bias of 
0.5-log. A subset of samples was genotyped by sequencing including those with the 
largest and smallest observed bias. Samples with genotypes 1a, 1b1 and 1b2 showed a 
1-log bias between artus and RefLab1; while no quantification bias was observed for 
genotype 4 suggesting that RefLab1 method under-quantifies genotype 4. 
Conclusions: Comparison of several BKV DNA quantification methods demonstrated 
quantitative bias, but overall good correlation. Quantitative bias was likely due to the 
use of different calibrators for each assay although some assay designs may under-
quantify genotype 4. The observed bias highlights the need for BKV international 
standards. Inability to standardize quantification complicates validation of laboratory 
developed tests and clinical management of patients monitored in multiple labs.  
 
ID45. Mupirocin Resistance in Methicillin-Resistant Staphylococcus aureus 
(MRSA) Colonized Residents in Long-Term Care Facilities (LTCFs) 
C.M. Hines1,4, S. Boehm2, D. Burdsall3, K. Schora2, P.A. Patel2, P. Nagwekar2, 
 A. Grayes2, A. Robicsek2, L. Peterson2 
1Glenview Terrace, Glenview, IL; 2NorthShore University Health System, Evanston, IL; 
3Lutheran Life Communities, Arlington Heights, IL; 4Whitehall of Deerfield, Glenview, IL. 
Introduction: One approach to MRSA control is surveillance for asymptomatic carriers 
and then decolonization of those found MRSA positive using intranasal mupirocin. The 
goal of this study is determine the prevalence of mupirocin resistance in LTCFs. 
Methods: This study is part of a cluster randomized trial to control MRSA disease in 12 
nursing units at 3 different LTCFs. A pre-moistened double swab of both nares was 
obtained from all residents for a point prevalence survey. Real-time PCR (qPCR) was 
performed using one of the nasal swabs and if the PCR test was positive for MRSA, the 
second swab was cultured onto agar and the recovered MRSA tested using another 
qPCR test for mupirocin resistance and the presence of PVL (as a marker for 
community-associated MRSA). A commercial qPCR system was used to detect MRSA 
and an in-house qPCR assay was for identifying mupirocin resistance and the presence 
of PVL. Results: Overall, 680 residents were tested and 111 MRSA positive 
(prevalence = 16.5%). Mupirocin resistance was detected in 16 (14.4%) and PVL in 4 
(3.6%). Importantly, the two LTCFs serving an acute care system that actively 
decolonizes MRSA carriers as part of a comprehensive surveillance program had 
mupirocin resistance rates of 20% and 39% in their MRSA colonized residents. The 
LTCF not serving this same acute care organization had 2% mupirocin resistance (p = 
0.008 and 0.001 comparing the two LTCFs with high resistance to the one with 2% 
resistance, respectively) Conclusions: qPCR can rapidly detect MRSA as well as 
mupirocin resistance and PVL in the residents of LTCFs. Mupirocin resistance may be 
significantly increased for LTCF residents coming from acute care facilities with an 
active MRSA decolonization program. Additional therapeutic agents are needed for 
decolonization if mupirocin continues to be used in MRSA control programs. The 
prevalence of community-associated MRSA remains low in many LTCFs, suggesting 
most of their strains arise from the healthcare system and not the community.   
 
ID46. Comparison of Hybridization Probe-Free and Hybridization Probe-Based 
Assays for the Quantitative Detection of Cytomegalovirus 
I. Montalvan, P. Tsang, Z. Jobbagy 
Newark Beth Israel Medical Center, Newark, NJ. 
Introduction: Cytomegalovirus is a member of the Betaherpesviridae family capable of 
establishing lifelong persistent and latent infection after the primary exposure. CMV can 
reactivate leading to asymptomatic viral shedding or disease development. In 
immunocompetent individuals the infection is held under control by the host’s immune 
system, CMV infections are rarely serious and cause only mild symptoms resembling 
those of mononucleosis lasting up to a few weeks. Serious CMV disease is generally 
restricted to immunologically immature or immunocompromised hosts. CMV is a major 
cause of lung, liver, gastrointestinal renal and retinal disease in solid organ transplant 
patients and hematopoietic stem cell transplant patients. Monitoring CMV load is 
important to assess response to therapy, to identify patients who are likely to have 
recurrent disease and to optimize pre-emptive treatment. During the last decade real-
time PCR based quantitative DNA assays has became the method of choice for CMV 
viral load monitoring. These assays employ a wide variety of PCR chemistries and differ 
in the modes of the detection of amplified products. Methods: We compared the 
parameters of a probe–free real-time PCR assay (MultiCode RTx CMV Primers, 
EraGen Biosciences) with those of a probe based assay (CMV UL54 
Primer/Hybridization Probes, Roche) using OptiQuant CMV calibration panels 
(AcroMetrix) and de-identified patient serum samples. Viral DNA was extracted using a 
QiaCube automated nucleic acid extractor (Qiagen), and real-time PCR reactions were 
performed and he amplifications detected on the LightCycler 2.0 (Roche) platform. . 
Statistical analysis and correlation was calculated using MedCalc biostatistical software 
(MedCalc). Results: The linear range for both assays exceeded 5 logs. The low limit of 
detection of the probe-based assay was 1000 copies/ml (92% confidence n=23), while 
that of the probe-free assay was 250 copies/ml (100% confidence, n=20). Testing 
clinical samples, the positive agreement between the two assays was 100% with good 
correlation between the quantitative results (r=0.9123, n=27), while the negative 
agreement was 87% (n=15). The results of reproducibility, specificity and cross-
reactivity studies were similar for both reagent sets. Conclusions: The probe-free CMV 
assay appears to have higher sensitivity than the probe-based assay. Other assay 
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parameters including reproducibility, clinical specificity and assay linearity are 
comparable.   
 
ID47. Impact of Pap + HPV Co-Testing: Data from the First Year 
D.I. Quigley, M. Plaut, L.A. Dworkin, R.J. Krum 
Kaiser Permanente NW, Portland, OR. 
Introduction: High risk human papilloma virus (HPV) subtypes have been implicated 
as the causative agent in cervical cancer. As such HPV testing has long been 
performed on cervical pap samples with atypical cytopathology results (ASCUS), 
concerning for risk of cancer. Recently, pap + HPV co-testing has been recommended 
as a screening test for individuals age 30 and up for early identification of risk. 
Furthermore, a double negative result carries a very high negative predictive value. Due 
to the increased sensitivity of pap + HPV co-testing over pap screening alone, a 
lengthened testing interval of 3 years is recommended. We proposed a three-year 
interval for pap + HPV co-testing for patients age 30 and pap alone for patients age 
21-29. We predicted that this testing guideline would improve care by providing a test 
with increased sensitivity to the population at the highest risk for cervical cancer and 
decreasing the incidence of “over-papulation” in younger patients, which by extension 
should reduce over treatment of this group. With the lengthened screening interval we 
also expected a decrease in our pap volume. Methods: Clinicians collecting pap smear 
samples were educated about the implementation of the new pap + HPV co-testing 
guideline for individuals age 30. Samples for pap analysis and HPV testing were co-
collected for the appropriate population. Pap analysis was continued as previously 
performed. High risk HPV testing was performed using the CervistaTM HR HPV method. 
Results: During the first 10 months after implementation of co-testing, over 33,000 
HPV test have been performed. The overall incidence of high risk HPV was 5.71%. For 
individuals with normal cytology, the HPV incidence was 3.55% and for individuals age 
30 years with normal cytology, 3.45%. Pap testing data showed a 13.5% decrease in 
testing since the implementation of the new screening guidelines. Conclusions: The 
incidence of high risk HPV in individuals age 30 years with normal cytology is 
comparable to other reported studies. We have observed an expected decrease in pap 
volume with implementation of the new screening guidelines and have also seen a 
decrease in pap testing for individuals under age 21. Preliminary data suggest that the 
new screening guidelines are following expected results.  
 
ID48. Multiplex Respiratory Virus PCR: A Comparison of the xTAG® and 
FilmArray® Respiratory Virus Panel on Brochoalveolar Lavage Specimens 
J. Balada Llasat, C. Kelly, W. Zhang, H. laRue, P. Pancholi 
The Ohio State University Medical Center, Columbus, OH. 
Introduction: Children, the elderly, and immunocompromised patients are susceptible 
to respiratory viruses that cause acute local or systemic infections. The clinical 
presentation may be similar, therefore identification of the causative agent(s) aids in the 
selection of the appropriate treatment and infection control measures. Several multiplex 
PCR based assays have been developed for the detection of respiratory viruses. 
Among these are the FilmArray® (Idaho Technology Inc.) and the xTAG® (Luminex) 
assays. Performance of these assays was addressed using brochoalveolar lavage 
(BAL) to detect viruses within each specimen. Both assays detect influenza A (Flu A; 
seasonal H1 and H3) and influenza B (Flu B), adenovirus, parainfluenza 1-3 (Para 1-3), 
respiratory syncytial virus (RSV), human metapneumovirus (HMPV) and human 
rhinovirus/enterovirus (HRV/E). The FilmArray additionally detects coronaviruses (NL63 
and HKU1), Para 4, and Flu A subtype 2009 H1. The xTAG also differentiates RSVA 
and RSVB. Methods: 114 BALs were collected from hospitalized patients during winter 
of 2010-2011. One aliquot was processed with the xTAG and a second previously 
frozen aliquot was tested by the FilmArray. For the xTAG, viral nucleic acids were 
extracted using the EasyMag®, reverse transcribed (RT), amplified, and analyzed with 
Luminex technology. For the FilmArray, BALs were processed in a closed RT-PCR 
system that isolates, amplifies, and detects the viral targets. Results: The xTAG was 
positive for 24 Flu A (negative for H1/H3), 2 Flu A H3, 2 adenovirus, 2 Para2, 6 Para3, 
8 RSVA, 5 RSVB, 39 HRV/E, 7 HMPV and 19 BAL’s were negative. The FilmArray was 
positive for 22 Flu A 2009 H1, 2 Flu A H3, 1 Flu A non-typeable, 2 adenovirus, 2 Para2, 
7 Para3, 13 RSV, 35 HRV/E, 7HMPV and negative for 23 BALs. Of the 6 discrepant 
results, upon repeat testing 3 were positive for HRV/E, and 1 was negative by FilmArray 
One BAL positive for Flu A by the xTAG was consistently invalid by the FilmArray. One 
BAL positive for Para 3 by FilmArray was negative by xTAG. Co-infection was found in 
5 BALs with the FilmArray (4 with coronavirus and 1 with HRV/E-Para 3). Conclusions: 
Both assays performed comparably with BAL specimens for the majority of the viruses 
included in both assays. The FilmArray system offered a broader virus detection range 
and greater ease of use. However, the xTAG allows for greater specimen throughput. 
 
ID49. [WITHDRAWN] 
ID50. Improved Performance of Cervical Cancer Screening Using HPV E6, E7 
mRNA Quantification with Polygonal Gating and Cellular Normalization 
M.C. Schwab1, V. Padmanabhan2, V.E. Johncox2, L.J. Tafe2, G.J. Tsongalis2,3 
1Dartmouth Medical School, Dartmouth-Hitchcock Medical Center, Lebanon, NH; 
2Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH; 
3Dartmouth Medical School, Hanover, NH. 
Introduction: Abnormal cervical cytology has low sensitivity for CIN 2+ disease on 
biopsy. HPV DNA has been used to help triage abnormal cytology specimens 
especially ASCUS. HPV DNA, however, is positive in >50% of ASCUS samples yet 
<10% of ASCUS samples have CIN 2+. Similarly, HPV DNA is positive in >80% of LSIL 
cases yet <20% have CIN 2+ on biopsy. In this study, we show improved cervical 
cancer screening test performance by cellular quantification of HPV E6, E7 mRNA 
simultaneously with measures of cellular size (forward scatter) and complexity (side 
scatter). Methods: Thinprep liquid-based cervical cytology was performed on a total of 
115 samples. Residual liquid (1.0 mL) was used to perform E6, E7 mRNA quantification 
on a cell-by-cell basis using the HPV E6 and E7 mRNA reagents (IncellDx, Inc., Menlo 
Park, CA). Cell size and complexity were simultaneously assessed using forward and 
side scatter, respectively. Results: Thirty-six ASCUS samples were analyzed and 
16.67% showed overexpression of E6, E7 mRNA; 27 LSIL samples were analyzed and 
29.6% demonstrated overexpression of E6, E7 mRNA; 5 HSIL samples were analyzed 
and 40% overexpressed E6, E7 mRNA. Forty-seven NILM samples were analyzed 
demonstrating a specificity (based on PAP) of 93%. One endocervical adenocarcinoma 
confirmed by colposcopy and biopsy was detected using E6, E7 mRNA quantification 
on gated endocervical cells. Conclusions: The results presented in this study are in 
agreement with previous reports (Massad LS, Gynecol Oncol. 2001) demonstrating 9% 
CIN 2+ in ASCUS cytology, 17% CIN 2+ in LSIL, and 42% CIN 2+ in HSIL cytology 
specimens. The HPV  E6, E7 mRNA reagents offer a robust and user friendly method 
that can be performed from routine liquid cytology specimens. 
 
ID51. Development of MRSA/MSSA Independent NAT Run Controls for Multiple 
Test Platforms 
C. Huang, R. Vemula, J. Wu, B. Anekella 
SeraCare Life Sciences, Inc., Gaithersburg, MD. 
Introduction: Methicillin resistant (MRSA) and Methicillin-sensitive (MSSA) 
Staphylococcus aureus are leading causes of hospital acquired infections. A number of 
molecular tests have been approved by the FDA to screen hospital patients for MRSA 
and/or MSSA. An unmet need exists for independent run controls that can be used to 
monitor test performance and validate test systems using patient-like samples without 
introducing infectious bacteria into the hospital laboratory. SeraCare has developed 
ACCURUN® 530 MRSA positive control and ACCURUN® 550 (MRSA and MSSA 
combination pack) for use in quality control and method evaluation for nucleic acid 
based surveillance testing. Methods: Methicillin resistant (MRSA ATCC# 43300) and 
methicillin sensitive (MSSA ATCC# 29213) strains were used to formulate these 
controls. The bacteria are heat inactivated as part of the manufacturing process. These 
liquid controls are provided with a flocked COPAN® swab. The user dips the provided 
swab into the liquid, and the swab is then processed in the same manner as a patient 
sample. The controls have been evaluated with the Cepheid Xpert® SA Nasal 
Complete assay, the Roche LightCycler® MRSA Advanced Test, and the BD 
GeneOhm™ MRSA Assay. Results: The ACCURUN 530 and 550 controls are 
formulated to be low positives in order to monitor assay sensitivity; therefore, 
experiments were performed to determine the lower limits of detection for two popular 
test platforms. Dilution series of heat inactivated MRSA and MSSA cultures were 
produced and tested with the Cepheid and Roche assays. The lower limit of detection 
for the Cepheid assay was estimated to be 5.0x102 colony forming unit equivalents 
(CFU)/mL (100% positivity for 6 replicates across 3 testing days). The lower limit of 
detection for the Roche test was similarly estimated to be 1.0x103 CFU/mL. The target 
concentrations for SeraCare’s ACCURUN controls were set at 2.75x104 CFU/mL to 
allow for detection even with variability in swab use. These controls are designed for 
storage at 2-8ºC. Testing on the Cepheid platform indicates the products are stable for 
at least 6 months. Real-time and accelerated stability studies are on-going. 
Conclusions: The ACCURUN 530 and 550 controls provide tools for laboratories to 
monitor the performance of MRSA surveillance testing and can be used as daily run 
controls as well as for kit lot acceptance testing, validation activities, and technician 
competency evaluations. 
 
ID52. Detection of Toxigenic Clostridium difficile: Comparison of the Cell 
Culture Neutralization, Xpert® C. difficile and the IllumigeneTM C. difficile Assays 
P. Pancholi, C. Kelly, M. Raczkowski, J. Balada-llasat 
The Ohio State University Medical Center, Columbus, OH. 
Introduction: Clostridium difficile (CD) is the most important cause of nosocomial 
acquired diarrhea. The disease caused by CD ranges from mild, self-limited illness to a 
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severe, life-threatening colitis. The incidence of CD associated disease has risen 
dramatically over the last several years. Several laboratory techniques are available to 
detect CD in fecal specimens. Because questions have been raised about the reliability 
and turn-around time of the cytotoxin (toxin B) in the cell culture neutralization assay 
(CCNA), a study was performed comparing the performance of CCNA with two 
molecular assays. The detection of the toxin B gene (tcdB) by real-time PCR (Xpert®  
C. difficile; Cepheid, CA), and the detection of toxin A gene (tcdA) by loop-mediated 
isothermal amplification (IllumigeneTM, Meridian Bioscience, Inc.) were evaluated. The 
isolation of C. difficile in culture followed by CCNA on the isolate (toxigenic culture -TC) 
was used as the gold standard for discrepant testing. Methods: Two hundred 
prospectively collected stool specimens were tested simultaneously by the CCNA, 
Xpert® C. difficile and the IllumigeneTM C. difficile assays. Additionally, 50 retrospective 
stool specimens (previously positive by CCNA) were included in the study. Discrepant 
results were tested by TC. Results: Of the 200 prospective stools tested, 10.5% (n=23) 
were positive by CCNA, 17.5% (n=35) by IllumigeneTM, and 21.5% (n=43) by Xpert®. Of 
the 50 retrospective stools, previously positive by CCNA, 94% (n=47) were positive by 
IllumigeneTM and 100% (n=50) by Xpert®. Of the 11 discrepant results (negative by 
IllumigeneTM but positive by Xpert®), 10 tested positive by TC and for one specimen, 
we were unable to isolate C. difficile from the stool. Conclusions: The Xpert® was the 
most sensitive, rapid and easy to use assay for the detection of toxigenic C. difficile in 
stool specimens. 
 
ID53. Combined Morphology, Nuclear-to-Cytoplasmic Ratio and E6, E7 mRNA 
Quantification in Suspension Improves Cervical Cancer Screening Performance 
B. Patterson, B. Lack, K. Shults 
Incelldx, Inc, Menlo Park, CA. 
Introduction: Novel technology presented here can combine cell morphologic analysis 
as routinely done on slides by PAP smear with biomarker detection while the cells 
remain in suspension thus maximizing workflow and throughput. Methods: The 
objective of this study was to develop a non-subjective means for cervical cancer 
screening that includes biomarkers used in separate assays in a single slideless 
analysis. Using the HPV OncoTect3Dx assay performed on an image cytometer, we 
used bioinformatics to choose from 600 cellular and molecular parameters that 
distinguish normal, low grade, and high grade cells and samples from the others. We 
compared the results from standard liquid-based cytology (Pap smear) with the results 
from the HPV OncoTect 3Dx assay. Results: The combination of nuclear-to-
cytoplasmic ratio (N/C ratio) and E6, E7 mRNA defined with 97% accuracy the cytology 
result on 200 liquid-based cytology samples (NILM, LSIL, and HSIL). Of the six 
discrepant samples, Four HSIL samples were downgraded to LSIL and two LSIL 
samples were more likely to be high grade based on marker expression. Conclusions: 
This highly automated analysis that combines and digitizes the criteria used by 
pathologists to determine cytologic abnormalities in liquid-based cytology specimens 
with E6, E7 mRNA quantification/cell and DNA ploidy analysis may lead to less 
subjective means of cervical cancer screening while incorporating the molecular 
quantification of HPV-encoded oncogenes. 
 
ID54. Performance Evaluation of the Quantitative Real-Time PCR artus® BK 
Virus RG RUO Kit Using the QIAsymphony SP/AS Module and Rotor Gene® Q 
Instrument 
M. Sabato, T. Annang, L. Mulder, C.I. Dumur, D. Wilkinson, A. Ferreira-Gonzalez 
Virginia Commonwealth University Health System, Richmond, VA. 
Introduction: BK viral load measurement plays a key role in the management of kidney 
transplant patients. Today, the majority of clinical testing is performed using laboratory-
developed tests (LDTs). There is a need for a standardized test to further evaluate the 
clinical use of BK viral load in clinical practice. We report here the performance 
characteristics of the artus® BK Virus RG PCR RUO kit for the detection and 
quantification of BK Virus (BKV) in plasma using the QIASymphony SP/AS module and 
the Rotor Gene® Q instrument (Qiagen system). Results were compared to our 
laboratory-developed assay (LDT) for correlation and agreement. Methods: Linear 
range and lower limit of quantification (LOQ) were evaluated using a commercial BKV 
panel with additional dilutions. In addition, eight replicates each of a pool of anonymized 
patient specimens with high (6.05 log10 copies/mL) and low (3.49 log10 copies/mL) 
levels of viral load were tested in 4 different runs for reproducibility. Correlation and 
agreement studies were performed on 122 anonymized patient specimens previously 
tested with the LDT. Results: The assay was linear from 2.00 to 6.00 log10 copies/mL 
(based on an SD of 0.20 log10 copies/mL) with an R2 value of 0.9989 (y=1.0801x - 
0.4005). High level of reproducibility was obtained for the high and the low pooled 
patient specimens, with a CV of 1.16% and 2.87% in log10 copies/mL, respectively. A 
high level of inter-assay precision was also obtained when plasma specimen from 8 
patients were repeated in 2 runs performed on different days. Regression analysis 
showed a high correlation between the methods (R2= 0.9693) for the 92 positive 
specimens with viral loads ranging from 3.0 to 7.23 log10 copies/mL. A negative bias 
was obtained when both methods were compared for agreement. On average, the 
Qiagen reagents yielded BK viral load values that were -0.64 log10 copies/mL lower 
than the values obtained with the LDT and both methods agreed equally through the 
range with limits of agreement of -0.16 and -1.11, respectively. Thirty specimens were 
negative by both methods. Conclusions: The Qiagen Quantitative Real-time PCR 
artus® BK Virus RG RUO kit and QIAsymphony SP/AS module and Rotor Gene® Q 
instrument provided very good results and was in agreement with our LDT.  
 
ID55. Evaluation of the Walk-Away Multiplex FilmArray Respiratory Panel (RP) 
Test for Immunocompromised Patients in a Large Transplant Center 
D. Kohn, C. Starkey, S. Mossad, L. Danziger, R. Avery, B. Yen-Lieberman 
Cleveland Clinic, Cleveland, OH. 
Introduction: Recently, Respiratory Multiplex Viral Panel (RVP) tests have been used 
to detect more than 12-16 respiratory viral pathogens from a single nasopharyngeal 
swab (NP swab). These tests accurately detect viral infections in most patients with 
Influenza Like Illness (ILI) during respiratory season. Unfortunately, the current 
multiplex assays are labor intense with a long turnaround time for results (usually 
between 5-9 hrs). They also require expensive nucleic acid extractors and PCR 
instrumentation with large footprints. We evaluated a newly FDA cleared walk-away 
FilmArray RP Test (IdahoTechnology) using pre-characterized clinical samples 
collected from immunocompromised or severely ill patients with ILI symptoms from our 
large transplant services. Methods: Ninety-two samples sent for routine respiratory 
virus testing (includes PCR and DFA) were tested using the FilmArray RP test. In 
addition a respiratory viral control panel (NATRVP-3, Zeptometrix Corp) was tested with 
the FilmArray RP. Approximately 300 Pl of sample is inoculated into a lysis buffer. The 
lysed sample and hydration solution are then inoculated into the FilmArray reagent 
pouch that contains freeze-dried reagents necessary for sample preparation, RT-PCR, 
and detection. Results: The Film Array RP detected 53% (49/92) of the samples 
positive for one or more respiratory viruses. Positive results for RP are as follows: 15 
respiratory syncytial virus, 13 influenza A, 4 influenza B, 2 adenovirus, 6 parainfluenza, 
2 human metapneumovirus, 6 rhinovirus and 9 coronavirus. The RP also detected 9 
coinfections, 7 with 2 viruses and 2 with 3 viruses. Our routine methods detected 38% 
(35/92) with 14 respiratory syncytial virus, 13 influenza A, 3 influenza B, 1 adenovirus, 3 
parainfluenza and 2 coinfections with 2 viruses. The RP also correctly identified the 16 
respiratory viruses from the respiratory control panel. Conclusions: The FilmArray RP 
performed comparably to our methods on the eight respiratory viruses routinely tested 
for and in addition it detected a significant number of viruses that are not routinely 
tested for. The RP is a walk-away system that combines sample extraction , 
amplification, detection, and results analysis in an easy to use format that requires 2 
minutes of hands on time and has a total turnaround time of 1 hour. The FilmArray Test 
can be easily adopted in a busy hospital laboratory to better manage 
immunocompromised and very sick patients during the respiratory season. 
 
ID56. Specimen Handling Options for the Detection of Chlamydia trachomatis 
and Neisseria gonorrhea Using the Abbott Realtime CT/NG Assay 
I. Fung, A. Mezzacapo, A. Seth, H. Fernandes 
University of Medicine and Dentistry of New Jersey, Newark, NJ. 
Introduction: Nucleic acid amplification for detection of Chlamydia trachomatis (CT) 
and Neisseria gonorrhea (NG) is the gold standard for laboratory diagnosis. Automation 
in molecular assays reduces hands-on time, turn-around-time, potential contamination 
and facilitates implementation of assays in laboratories with limited technical expertise. 
We have compared specimen performance of the CT/NG assay on Roche COBAS 
Amplicor (COBAS) with the automated Abbott Realtime CT/NG (Realtime) assay. 
Methods: A total of 2040 swab and urine specimens were compared in the COBAS 
and the Realtime CT/NG assays. For COBAS, swabs were collected in M4 transport 
media and urine specimens were collected in polypropylene containers without 
preservatives. For comparison with the Realtime, these specimens were assayed in 
either of the following ways: i) 1696 swab specimens collected in M4 transport media 
were vortexed and poured into empty tubes without any stabilizing buffer; ii) 89 swab 
specimens were vortexed and 500ul was pipetted into the Abbott multi-Collect 
Specimen tube; iii) 200 swab specimens were directly collected using both the Abbott 
Specimen collection kit and the M4 transport media. 55 urine specimens were collected 
in clean, empty polypropylene tubes and poured into the multi-Collect tubes or directly 
in the multi-Collect tubes. Results: Of the 120 (7.1%) M4 swab specimens i) that were 
positive for CT in COBAS, 111/ 1696 (6.5%) repeated as positive in the Realtime assay. 
Similarly NG was detected in 2.0% of swabs tested in COBAS versus 1.53% in the 
Realtime assay. In studies in which selected M4 specimens were added directly to the 
multi-Collect collection tube with stabilizing buffer, ii) 26% and 10.1% that were positive 
for CT and NG in the COBAS resulted in 27% and 7.8%, respectively, in the Realtime. 
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When a direct comparison iii) of two different swabs was performed, 6.5% of the 
specimens were positive for CT in COBAS and 5.9% were positive in Realtime. In 
comparison 4.8% and 3.7% of the specimens were positive for NG in COBAS and 
Realtime, respectively. Analysis of 55 urine specimens yielded an increased number of 
positives: 2.1% for CT and 3.6% for NG in COBAS compared to the Realtime assay. 
Conclusions: The performance of both assays was comparable. Specimens collected 
in M4 viral transport media can be used directly or added to the specimen collection 
tube and tested on the Abbott Realtime CT/NG assay. Use of the Realtime automated 
assay results in a significant time savings in a laboratory. 
 
ID57. Development of a Rapid and Simple to Perform Isothermal Molecular 
Assay for the Detection of Group B Streptococcus from Lim Broth and Direct 
Specimens on a Noninstrumented Platform 
T.T. Stenzel1, T.A. Ranalli1, Y. Tong2, W. Tang2, T. Pack1, N. Nasser1, R. Lollar1,  
H. Kong2 
1Quidel Corporation, San Diego, CA; 2BioHelix Corporation, Beverly, MA. 
Introduction: Streptococcus agalactiae (GBS) is the leading cause of neonatal sepsis, 
pneumonia and meningitis and is present in as many as 35% of pregnant women, most 
of whom are asymptomatic. To reduce transmission, screening is performed around 35-
37 weeks in pregnancy; however, many women become re-colonized during the period 
of time between initial screening and delivery. Traditional methods for screening include 
culture, a less sensitive option, and molecular assays, which often are costly and/or 
difficult to implement.  Herein, we describe the development of a sensitive and specific 
molecular assay for the detection of GBS from Lim Broth and direct specimens using a 
novel isothermal instrument-free platform. Methods: Helicase-dependent amplification 
(HDA), an isothermal nucleic acid amplification platform that utilizes a helicase to 
separate strands of DNA or RNA, allows for target-specific amplification in the absence 
of thermocycling. The GBS assay combines HDA with a disposable self-contained 
detection device that allows for the rapid detection of amplicons generated by primers 
and probes specific for a region of the thiolase (atoB) gene. The assay is performed 
from Lim Broth culture as well as from direct vaginal/anogenital swabs. For the Lim 
Broth assay, an aliquot of the overnight culture is placed into a dilution tube, briefly 
heated to lyse the cells, and then transferred to a reaction tube containing lyophilized 
reagents. The sample is incubated at 64qC for 40 minutes and transferred to a cassette 
wherein the result is read via a lateral flow strip. For the direct assay, a patient swab is 
diluted and centrifuged. The supernatant is removed, lysed at 95qC and follows the 
above workflow for incubation and detection. Either assay is performed in less than 1.5 
hrs and “on-demand” eliminating the need to batch samples. Results: Analytical 
sensitivity testing has determined that the assay can detect as few as 10 copies of 
genomic DNA, does not cross-react with any non-GBS organisms that have been 
evaluated (31/31), and is capable of detecting each of the GBS serotypes evaluated 
(8/8). A preliminary clinical study performed with previously characterized frozen Lim 
Broth specimens has found that the assay identified 11/12 positive samples and 37/37 
negative samples. The one discrepant sample was confirmed as a true negative by 
alternate PCR. Conclusions: The HDA-based assay for the qualitative detection of 
GBS is a sensitive and specific assay that can be run in a wide variety of hospital 
settings without the need for costly instrumentation.  
 
ID58. Rapid Molecular Detection of Influenza A and H275Y Mutation Conferring 
Resistance to Oseltamivir 
P.M. Long1, K.A. Mangold1,2, K.L. Kaul1,2 
1NorthShore University HealthSystem, Evanston, IL; 2University of Chicago Pritzker 
School of Medicine, Evanston, IL. 
Introduction: Rapid molecular detection of influenza has become the standard for 
diagnosis and appropriate use of antiviral agents. However, the rapid emergence of 
oseltamivir-resistant seasonal H1N1 in the United States during the 2008-2009 
influenza season revealed the additional need for direct detection of the nucleotide 
change causing resistance. We developed robust real-time amplification assays for 
influenza A and oseltamivir-resistant seasonal and pandemic influenza A viruses using 
redundant primer cocktails to withstand viral sequence drift. Methods: To reliably 
detect all subtypes of influenza A and withstand viral sequence drift, a highly conserved 
region within the M gene was targeted using a cocktail of primers that collectively 
provided 99.9% coverage of more than 9,200 sequences analyzed in silico. Similarly, 
oseltamivir resistance was detected via multiple forward primers specific to the 
seasonal and 2009 pandemic strains and a single reverse primer specific for the H275Y 
SNP of the neuraminidase gene. The assays include a spiked-in internal control (MS2 
bacteriophage). Viral RNA was prepared from nasopharyngeal swab samples 
(easyMag, Biomerieux, France). The two-step single capillary RT-PCR assays using 
Plexor detection chemistry (Promega, Madison, WI) were performed in parallel using 
identical thermocycling conditions on the Roche LightCycler 2.0 (Indianapolis, IN). The 
assay was validated analytically using seven standard influenza isolates obtained from 
ATCC and CDC, and used to study 65 archived nasopharyngeal swabs from 2007-10 
that had previously been examined using both Eragen (Madison WI) ASR influenza A/B 
reagents and a lab-developed assay for influenza A subtyping. Results: The MS2 
target amplified in all retrospective samples. The pan-FluA assay was negative in 10 of 
10 negative retrospective samples, and detected 52 of 55 samples positive by routine 
clinical PCR testing. Of these 52 FluA positive samples, the H275Y assay was negative 
in 9 archived seasonal H3N2 samples, in 10 seasonal H1N1 samples collected in 2007 
(prior to the emergence of oseltamivir resistance), and 10 pandemic influenza H1N1 
samples, and was positive in all but one seasonal H1N1 sample collected during the 
2009-2010 influenza season, as expected. The three influenza positive samples that 
were negative using the pan-FluA assay, and the single H275Y negative 2010 seasonal 
H1N1 sample are under further investigation. Conclusions: We have designed and 
validated robust RT-PCR assays that utilize multiple primers to withstand sequence drift 
to detect influenza A and the H275Y SNP conferring resistance to oseltamivir in the N1 
subtype, with results available in less than 45 minutes. 
 
ID59. Detection and Identification of Ehrlichia and Other Vector-Borne 
Pathogens by PCR/ESI-MS 
M. Rounds1, M. Eshoo1, J. Friesen2, C. Crowder1, C. Quinn2, H. Matthews1, D. Ecker1, 
Y. Tang2 
1Ibis Biosciences, Carlsbad, CA; 2Vanderbilt University, Nashville, TN. 
Introduction: Ehrlichiosis presents with non-specific, flu-like symptoms, which makes 
accurate diagnosis difficult. Ehrlichia chaffeensis and E. ewingii are the two main 
species relating to different clinical outcomes in humans. Here we use a PCR 
electrospray ionization mass spectrometry (PCR/ESI)-based technique for the detection 
and identification of Ehrlichia species from whole blood. Methods: Specimens of whole 
blood were collected from patients with suspected tick–associated febrile illness. 
Nucleic acids from clinical specimens were extracted using a combination of 
mechanical and chemical lysis and magnetic bead purification. The specimens were 
then tested with a multi-locus assay utilizing 11 multiplexed primers targeting different 
loci that detect a wide range of vector-borne pathogens, including bacteria, protozoa, 
and viruses. ESI-MS of the PCR amplicons on an Abbott PLEX-ID was used to 
determine their base compositions that were subsequently used to identify the 
organisms found in the specimens. Results: In our study, specimens from patients with 
tick-associated febrile illness from the 2010 tick season in central Tennessee were 
analyzed. In 263 whole blood specimens tested, E. chaffeensis was detected in 18 
(6.84%). E. ewingii was detected in 2 samples (0.76%). Rickettsia rickettsii and 
Plasmodium vivax were detected in one specimen each (0.38%). Conclusions: We 
demonstrated that our vector-borne microbial detection assay can detect pathogens 
from a whole blood using the same extraction method. This assay could provide 
physicians with actionable results for a broad range of pathogens, including 
unculturable species such as Ehrlichia and Rickettsia that would not have been 
detected by culture methods. 
 
ID60. Characterization and Evaluation of a Novel Multiplexed Molecular Assay 
for the Detection of RSV and hMPV 
J. Stockwell, J. Carpenter, V. Armendarez, R. Kelly, R. Lollar, N. Nasser, T.A. Ranalli, 
T.T. Stenzel 
Quidel Corporation, Athens, OH. 
Introduction: Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) 
are significant respiratory pathogens of the very young and the elderly in both 
developed and developing countries. Further, these viruses present with the same 
symptoms during overlapping months, thereby confounding unaided clinical diagnosis. 
Molecular testing provides a sensitive and specific method for the detection and 
differentiation of these two upper respiratory pathogens. Utilizing proprietary 
chemistries and processes, we have developed novel room temperature stable 
reagents for use in our multiplex real-time RT-PCR assay for the detection of RSV and 
hMPV. This assay provides a simplified workflow and significantly reduces the number 
of steps required for testing. The objective of this study was to characterize the 
performance of the Quidel Molecular RSV+hMPV assay on 2 real-time PCR 
instruments and to evaluate this assay for the direct detection of leftover clinical 
specimens. Methods: RNA was extracted on the NucliSENS® easyMag® and 5 Pl of 
each sample was added to reconstituted master mix and evaluated by real-time PCR. 
Preliminary performance characteristics of the RSV+hMPV assay, including analytical 
sensitivity, specificity and reactivity, precision and interference were determined. 
Extracted RNA and Kit stability parameters were also investigated. Testing on leftover 
patient specimens established the initial performance of this assay. Results: The 
Analytical Sensitivity of the RSV+hMPV assay was determined to be <5TCID50/mL for 
RSV and <55 TCID50/mL for hMPV. The RSV+hMPV assay detected RSV A, RSV B 
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and the 4 major sub-types of hMPV using reference virus strains. No cross reactivity or 
interference was observed with greater than 50 non-RSV and non-hMPV respiratory 
and non-respiratory viruses and other micro-organisms. Blood, mucin, and common 
prescription and over-the-counter cold, allergy and asthma medications studied did not 
interfere with the RSV+hMPV assay. Results from a 12 day inter-operator precision 
study showed that all positive samples had CV% values of <5% for all concentrations 
and conditions studied. Stability studies showed that extracted RNA was stable at all of 
the conditions studied. Leftover patient specimens were analyzed in the RSV+hMPV 
assay for the presence of either RSV or hMPV and were able to detect 23/23 RSV and 
26/26 hMPV positive samples. Specificity was 100% for all samples evaluated. 
Conclusions: Results from these preliminary studies indicate that the RSV+hMPV 
assay is robust, simple to perform and sensitive and specific for the detection of RSV 
and hMPV. 
 
ID61. Timing of the Appearance of HBV Mutants after HBV 
Nucleoside/Nucleotide Analogue Treatments by Analyzing with Massively Parallel 
Pyrosequencing Method 
Y. Sohn, C. Ihm 
Eulji University Hospital, Daejeon, Daejeon, Republic of Korea. 
Introduction: It is well known that the mutations of HBV polymerase are causative of 
the resistance during HBV nucleoside/nucleotide analogue treatment. Although it is 
considered that these mutations were appeared before DNA breakthrough, the definite 
time of their appearance is obscure. We studied for the timing of the appearance of 
mutant clones and their sequential change as analyzing serial serum samples from the 
chronic HBV patients experienced DNA breakthrough after nucleoside/nucleotide 
analogues treatment by massively parallel ultra-deep pyrosequencing method. 
Methods: Six patients with chronic HBV hepatitis who had DNA breakthrough after 
receiving the nucleoside/nucleotide analogue treatment at Eulji Medical Center in Korea 
were enrolled. Their serial serum samples were acquired with 3 or 6 month intervals 
during treatment. After DNA extraction, all samples were analyzed for HBV polymerase 
gene by massively parallel ultra-deep pyrosequencing using Roche GS FLX system 
Results: For 5 of 6 patients the small amount of drug-resistant mutations were 
observed before DNA breakthrough, at nadir state or before. The proportion of these 
mutant clones was variable with range of 1.0 to 24.2%. At DNA breakthrough the 
mutant clones had been dominant in all 6 patients. Other many kinds of mutations were 
also shown but their amounts were very small and not changed before and after 
breakthrough. Conclusions: It was identified that HBV mutations associated drug 
resistance were already present at nadir state. It was helpful for HBV treatment 
because early detection of mutant clones at nadir state can anticipate DNA 
breakthrough.  
 
ID62. Comparison Between Two Methods for HCV Genotype Detection  
A. Maj, L. Mazur, L. Ma, M. Michalov 
ACL Central Laboratory, Rosemont, IL. 
Introduction: Hepatitis C is an infectious disease that causes chronic liver disease 
such as cirrhosis, liver failure, or liver cancer. Hepatitis C virus (HCV) is an enveloped 
single-stranded positive sense RNA virus. The most common genotypes present in 
North America and Europe are 1 through 6 and their subtypes. HCV genotyping has 
been used to assess disease prognosis and the likelihood of therapeutic response, 
HCV genotyping can be used to identify the source of infection, particularly for 
geographically distinct subtypes. Determination of HCV genotypes has been made 
using a variety of technical methods, including line blot hybridization, RFLP analysis, 
real-time PCR, and direct nucleic acid sequencing. Methods: This study compared two 
different reagent kits and instrumentation configurations. The first method (M1) was 
ASR Versant HCV Genotype 2.0 Assay (LiPA) by Siemens Healthcare Diagnostics that 
was run on EasyMag, ABI 9700 thermal cycler, and Autoblot 3000. The LiPA assay is a 
PCR-based assay with detection utilizing line probe and reverse hybridization. The 
second method (M2) was Abbott RealTime HCV Genotype II RUO from Abbott 
Molecular that included m2000sp and m2000rt. The Abbott HCV assay is a real-time 
PCR method that utilizes MGB probes. Both methods were run using known HCV 
positive samples in plasma and serum matrix. Results: In the study, the following 
parameters were determined: workflow duration (M1 = 7hrs, M2 = 5hrs), hands-on time 
(M1 = 160min, M2 = 70min) LIS Interface (M1 = none, M2 = available), analytical 
performance (M1 = 1-6 genotypes, multiple subtypes, LOD 5000IU/mL and M2 = 1-6 
genotypes, 1a and 1b subtypes, LOD 500IU/mL), sample tracking capability (M1 = 
manual, M2 = automated), laboratory contamination risk (M1 = high/open system, M2 = 
limited/closed system), assay regulatory status (M1 = ASR, M2 = RUO) and sample 
batch size (M1 = 18+2, M2 = 22+2). Conclusions: We concluded that both methods 
have comparable analytical and clinical utility. Siemens assay was able to detect more 
subtypes but requires a minimum viral load of 5000IU/mL. In comparison, Abbott assay 
detects 1a and 1b subtypes but needs a lower viral load of 500IU/mL. Advantages of 
using the Abbott system include shorter turnaround time, less hands-on time, 
interfacing capability, automatic specimen tracking, significantly reduce the risk of 
contamination, and finally analysis software standardizes analysis and interpretation 
process.  
 
ID63. Comparison of Efficiencies for HR-HPV Detection of Hybrid Capture 2 and 
COBAS4800 in High Grade Lesions 
J. Kaspirkova 
Medical Faculty Hospital, Plzen, Czech Republic. 
Introduction: The causal relationship between persistent high-risk human 
papillomavirus (HR-HPV) infection and cervical cancer is widely accepted. In addition, 
recent findings support theory that also substantial part of dysplastic lesions of 
anogenital area, e.g. vagina, anus, or penis, is connected in etiology with persistent HR-
HPV infection. Nowadays, HR-HPV DNA testing either in triaging cytological diagnosis 
or in primary screening is a helpful tool in cervical cancer prevention. Characteristics 
and efficiency of the longest FDA approved and most common commercial method for 
HR-HPV DNA testing, Hybrid Capture 2 HR-HPV DNA test (HC2), have been verified in 
thousands of studies. HC2 is a sandwich capture molecular hybridization assay utilizing 
whole genome probe detecting 13 types of HR-HPV. Recently, new FDA- approved 
assays have arisen on the market. Some of them are PCR based targeting L1 region of 
HPV genome. However, during the process of HPV integration into human genome 
parts of HPV genome could be lost. As this process is likely to occur in high grade 
lesions, it might result in false negative finding of PCR based HR-HPV DNA test there. 
To assess the risk of such a false negative finding, we focused on comparison of testing 
efficiency of PCR based assay Cobas4800 (Roche) and HR-HPV DNA HC2 (Digene, 
Qiagen) in samples with high grade lesion. Methods: 90 samples including negative 
and positive controls were tested by both, Cobas4800 and HC2 assays. Discrepant 
samples were further analyzed by sets of PCR methods targeting more genes in HR 
HPV types. Results: We compared results of analysis of patient’s samples, and 
positive and negative controls obtained by both methods, e.g. HC2 and Cobas4800. As 
expected, HPV cell lines controls known to be lacking the L1 region of HPV genome 
has been marked negative by Cobas4800 and positive by HC2. Furthermore, we have 
revealed discrepancy in 5 patient’s samples. Genotyping assays have shown 
Cobas4800 missing HPV in 4 samples, and 1 case of false positive HPV finding by 
HC2. Conclusions: L1 deletion of HR-HPV may be quite frequent process in 
progression towards high grade lesions in anogenital area, particularly in cervical 
cancer. In countries with well organized long term cervical cancer screening only few 
patients could be missed by HPV testing targeting L1 gene of HPV. However, in other 
countries, more patients with high grade lesion are present in screening population and 
therefore endangered by false negative finding in L1 targeting PCR screening test.  
 
ID64. Evaluation of the Gen-Probe APTIMA Trichomonas vaginalis Assay with 
the APTIMA Combo 2 Assay for Detection of Chlamydia trachomatis (CT) and/or 
Neisseria gonorrhoeae (GC) 
J.T. Hill, T. Starr, V.D. Ash, R.S. Liao 
PeaceHealth Laboratories, Springfield, OR. 
Introduction: The APTIMA Trichomonas vaginalis Assay is an in vitro qualitative 
nucleic acid amplification test (NAAT) for the detection of rRNA from T. vaginalis to aid 
in the diagnosis of trichomoniasis using the TIGRIS DTS System. The assay is 
approved to be used to test for T. vaginalis in the following specimens from 
symptomatic or asymptomatic women: i) clinician-collected endocervical swabs, ii) 
clinician-collected vaginal swabs, iii) female urine specimens, and iv) PreservCyt 
Solution liquid Pap specimens (i.e. ThinPrep). Methods: This study evaluated the 
accuracy of the APTIMA Trichomonas vaginalis Assay and studied the clinical 
usefulness of testing for T. vaginalis in patients co-infected with CT or GC. Results: 
There was 100% agreement when the accuracy of the APTIMA Trichomonas vaginalis 
Assay was assessed by testing 20 clinician-collected vaginal swabs (5 positive and 15 
negative) and 27 female urine specimens (all positive). These specimens were all 
previously evaluated using the APTIMA Trichomonas vaginalis Assay through 
interlaboratory exchange. Ninety-four patients (72 female and 22 male) with a mean 
age of 23.7 yr that were determined to be positive for CT (90 patients) or GC (4 
patients) with the APTIMA Combo 2 Assay were also tested for the presence of  
T. vaginalis in urine, vaginal specimens, ThinPrep, and penile specimens. Two of the 94 
patients (2%) were also positive for T. vaginalis. Seventeen of the 92 specimens that 
tested negative for T. vaginalis were independently confirmed to be true negatives with 
the BD Affirm VPIII Microbial Identification Test that uses DNA probes. Three patients 
with GC or CT were determined to also have HSV-1 or HSV-2 by PCR or viral culture. 
Conclusions: The APTIMA Trichomonas vaginalis Assay is an accurate test and can 
easily be added to the testing of patients with the APTIMA Combo 2 Assay for GC and 
CT. In our study of 94 patients positive for GC or CT, 2% were co-infected with  
T. vaginalis.      
AMP Abstracts    000
JMD November 2011, Vol. 13, No. 6
749
0_Bring_Pages_Into_Quark_2  10/7/11  2:56 PM  Page 749
ID65. Software Guided Assay Validation: Use of EZValidationTM in the 
Determination of the Performance Characteristics of a Real-Time PCR Assay 
Using MultiCode®-RTx for BKV Quantification 
A. Greer1, A. Valsamakis2 
1The Johns Hopkins Hospital, Baltimore, MD; 2Johns Hopkins Medical Institutions, 
Baltimore, MD. 
Introduction: The experimental design and execution of studies to define performance 
characteristics of nucleic acid tests for pathogen nucleic acid quantification (qNATs) can 
be challenging. The aim of this study was to determine the utility of assay validation 
software (EZValidation, Life Technologies) while defining the performance 
characteristics of an assay for quantification of BKV DNA using MultiCode-RTx analyte-
specific reagents (ASR, Eragen). Methods: The validation study was guided by the 
software and was comprised of design, definition, execution (results), analysis, and 
approval phases. The analyte, published assay validation “guideline,” and 
instrumentation are entered in the design phase. The validation was performed using 
QIAsymphonySP extractor and ABI 7500 real-time PCR system. Acrometrix BKV 
panels were used as assay calibrators and test material. In the definition phase, 
accuracy, linearity, limit of detection (LOD), repeatability and reproducibility experiments 
were planned. Results were imported via electronic spreadsheet, analyzed by software, 
and determined to be acceptable as per user-defined criteria. The software did not 
support a quantitative comparison study using patient plasma specimens and a second 
real-time PCR assay; this experiment was performed separately using residual samples 
between 3.0-6.0 log10 copies/ml as quantified by an artus RUO-based assay. Results: 
Accuracy data fell within acceptable range of 0.3 log10 copy/mL difference (expected 
vs. observed). Linearity characteristics (slope delta < 0.1, intercept delta < 0.5, and R2 
delta <0.1) also passed. LOD was estimated at 65 copies/mL (95% confidence interval, 
48-88) using probit regression. Acceptance criteria for repeatability and reproducibility 
(<40% CV) were met at the three tested levels (3.7 log10, 4.5 log10, and 5.0 log10 
copies/mL). The study summary including documentation of all phases was available as 
a printable report. Conclusions: Validation software provided an easy to use format for 
designing, organizing, executing, analyzing, and approving the results of validation 
studies. This could therefore be very useful for laboratories with little experience in 
assay validation. The data suggest that the MultiCode-RTx ASR-based assay has 
performance characteristics that are acceptable for quantification of BKV in clinical 
samples. One disadvantage that was encountered was the lack of sufficient software 
flexibility to enable study modification once experiments were designed and defined; 
correlation studies are also not presently supported.  
 
ID66. Adaptation of the BD-Geneohm Cdiff Assay: Implementation of 
Automated Nucleic Acid Extraction from Stool Using the Nordiag Arrow 
Instrument 
A. Valsamakis1, L. Gluck2, S. Shulder2, W. Babiker2, K.C. Carroll2 
1Johns Hopkins Medical Institutions, Baltimore, MD; 2The Johns Hopkins Hospital, 
Baltimore, MD. 
Introduction: Clostridium difficile is a major cause of diarrhea in patients with a history 
of recent antibiotic treatment and hospitalization; most disease is caused by bacteria 
expressing the toxin B gene (tcdB). The gold standard detection method is toxigenic 
culture, a laborious and lengthy test. Real-time PCR assays that amplify tcdB have 
been increasingly adopted to improve the diagnostic utility of testing. The goal of this 
study was to determine the effectiveness of automated nucleic extraction of stool using 
the Nordiag Arrow instrument for use with the BD-Geneohm Cdiff assay, a real-time 
PCR test FDA cleared for use with manually extracted nucleic acid. Methods: 
Randomly selected stool samples (n= 378) that had been tested by standard BD-
Geneohm method were de-identified after the initial real-time PCR result was recorded. 
0.25 mL (~30 mg) of stool were dissolved in 1 mL proprietary stool stabilizer buffer, 
vortexed, incubated for 1 min at room temperature, then centrifuged for 5 minutes at 
6000 rpm. 0.5 mL of dissolved stool was extracted using the Stool DNA 039 protocol 
and DNA was eluted in 0.1 mL. Three microliters of eluate were used in the BD-
Geneohm Cdiff assay as per standard protocol. Discrepant results were adjudicated 
with toxigenic culture. The institutional prevalence of 15% was used for statistical 
analysis; calculations were performed with SISA (http://www.quantitativeskills.com/sisa/ 
statistics/diagnos.htm). Results: Compared to the FDA cleared method, the modified 
method had the following performance characteristics (95% confidence intervals): 
overall agreement, 98.1% (96.4%-99.9%); kappa, 0.93 (0.8-1.06); positive percent 
agreement, 93.1% (84.8%-101%); negative percent agreement 99.1% (98%-100%); 
positive diagnostic likelihood ratio, 99.3 (23-418); negative diagnostic likelihood ratio, 
0.07 (0.02-0.23). Seven discordant results were observed (3 positive by Arrow but 
negative by manual extraction, 4 negative by Arrow but positive by manual extraction); 
results of discordant analysis are pending. Conclusions: Automated extraction on the 
Nordiag Arrow is a suitable replacement for manual extraction of stool for use with the 
BD-Genohm Cdiff assay. 
ID67. Evaluation of APTIMA Trichomonas vaginalis Assay 
S. Merritt1, V. Kasinathan2, A. Fothergill2, Y. Wang1,2 
1Grady Memorial Hospital, Atlanta, GA; 2Emory University School of Medicine, Atlanta, 
GA. 
Introduction: Trichomonas vaginalis (TV) is one of agents causing sexually transmitted 
disease (STD). Detection of TV with the traditional method such as wet-mount 
preparation (wet prep) has been used in clinical setting. T. vaginalis APTIMA assay is a 
nucleic acid amplification method (NAA) that can potential used in the same way for 
detection of Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT). This study is 
to evaluate if TV can be detected by NAA in the same way as for detection of NG and 
CT. Methods: 484 randomly selected clinical samples sent for NAA by APTIMA TMA 
(Gen-Probe) for N. gonorrhoeae and C. trachomatis were used for the prevalence study 
of T. vaginalis. The results of wet prep and NAA by APTIMA (Gen-Probe) for TV were 
used for assay validation. Results: Of 484 samples tested, 107 (22.1%) were positive 
for TV and 377 (77.9%) were negative for TV. Among 484 samples tested, 21 were 
positive for NG, 66 for CT, and 22 for NG and CT, thus total of 109 (23%) were positive 
for NG or CT. Of 107 tested positive for TV, there were 24 samples tested positive by 
NAA test for NG or CT (1 NG, 16 CT, and 7 NG and CT). There were 125 samples that 
had the wet prep test ordered in addition to the NAA for NG and CT. Among 125 
samples tested, 54 were tested positive by APTIMA for TV, 71 were negative for TV. 
Among 54 APTIMA-positive samples, 37 were positive by wet prep. Thus the sensitivity 
of wet prep for TV could be 68.5% among those samples. Among 37 wet-prep and 
APTIMA confirmed samples for TV, one sample was positive for NG, 6 for CT, and 1 for 
NG and CT. There were 8 samples (21.6%) tested positive for infection with TV, NG or 
CT.  Among 71 APTIMA-negative samples, 2 were reported positive by wet prep. Thus 
the false positive rate of NAA could be 2.8%. Among 65 TV-negative samples by both 
wet-prep and APTIMA, 4 were positive for NG, 10 for CT, and 4 for NG and CT. There 
were 18 samples (27.7%) tested positive for NG or CT. Conclusions: The preliminary 
data demonstrate the need and capability of NAA test by APTIMA in detection of  
T. vaginalis along with the detection of N. gonorrhoeae and C. trachomatis. 
 
OTHER (EDUCATION, ETC.) 
 
OTH02. The Rapid Expansion of a Molecular Pathology Laboratory  
K.A. Lebel1, G. Surprenant1, J. Newmark1, V. Johari1, R. Friedberg1, G.J. Tsongalis2 
1Baystate Health, Springfield, MA; 2Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: As our knowledge of the molecular mechanisms underlying human 
disease continues to increase, the transition of this knowledge into the clinical setting 
becomes critical to patient management. Pathology departments must be prepared to 
meet the increasing demands for new molecular based testing that has become 
standard of care. Our department committed to the creation of a core molecular facility 
to perform molecular testing across many disciplines. Here we demonstrate the 
effective and rapid expansion of the laboratory to meet the needs of the clinicians and 
combat the rising cost of reference lab testing. Methods: In 2008, Baystate Health 
committed to expanding the operating space and budget of their small and limited 
molecular pathology laboratory. This included the design and creation of a laboratory 
suited to the unique needs of molecular testing. In addition, new equipment was 
selected that would optimize technical resources and allow for rapid expansion of a test 
menu. Training, re-distribution of workload, streamlining of workflow, and coding/billing 
were all consider as part of this process. Results: The purchase of innovative variable 
platforms gave the laboratory the ability to provide a variety of different tests across 
different medical disciplines. The introduction of the AB 7500 Fast real-time PCR 
instrument, AB 3130 Genetic Analyzer, Roche COBAS Ampliprep/COBAS Taqman, 
and the Luminex 200 gave the laboratory significant flexibility and endless opportunities 
to maximize their use. A rapid expansion of the test menu from 5 tests to 15 tests was 
achieved with a team of 7 technologists, all of whom re-trained on new instruments and 
validation processes. Conclusions: A combination of FDA cleared assays and LDT’s 
were used to develop needed testing to support clinical needs in oncology, virology, 
inherited disease and pharmacogenomics. Eighteen months after the doors opened, the 
core molecular laboratory has been able to add 10 tests to its menu and increase its 
volume by more than 8,000 tests annually.  
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ST01. Progression to Esophageal Adenocarcinoma in Barrett’s Esophagus 
Patients with a Polysomy versus Nonpolysomy Fluorescence in Situ 
Hybridization (FISH) Result 
S. Brankley, M. Campion, E. Barr Fritcher, S. Jenkins, L. Lutzke, D. Minot, J. Voss,  
K. Wang, K. Halling 
Mayo Clinic, Rochester, MN. 
Introduction: Identification of patients with Barrett’s esophagus (BE) who will progress 
to esophageal adenocarcinoma (EA) is a challenge. Fluorescence in situ hybridization 
(FISH) has been shown to be useful for the detection of dysplasia and EA in 
endoscopic brushing specimens from patients with BE. The aim of this study was to 
determine if FISH can be used to predict which high-risk BE patients are most likely to 
develop EA. Methods: Endoscopic esophageal brushing specimens from 281 high-risk 
BE patients (86% had a history of high-grade dysplasia) without a previous diagnosis of 
EA (240 males and 41 females, median age of 66 years, range 22-90 years) were 
collected in conjunction with surveillance biopsy (four quadrant biopsies every 
centimeter of affected mucosa). Specimens were examined with FISH probes to 8q24 
(MYC), 9p21 (CDKN2A), 17q12 (ERBB2), and 20q13.2 (ZNF217) (Abbott Molecular 
Inc., Des Plaines, IL). Specimens exhibiting 4 polysomic cells (3 signals for 2 loci) 
were considered polysomic while specimens with all other genetic findings (e.g. 9p21 
loss, single locus gain, disomy/normal) were placed into the non-polysomic group for 
statistical analysis. Follow-up intervals (median 29.0 months) for progression to EA 
were calculated as the time between FISH and the first histologic diagnosis of EA or to 
the last endoscopy for patients who did not present with EA during follow-up 
surveillance. The risk of EA was compared between polysomy and non-polysomy 
groups with the logrank test and estimated using the Kaplan-Meier method. Results: 
Histology results at the time of FISH analysis included 117 (42%) high-grade dysplasia, 
71 (25%) low-grade dysplasia, 53 (19%) intestinal metaplasia and 40 (14%) benign 
squamous epithelium. Twenty-one of the 281 (7.5%) patients were found to have EA on 
follow-up. Of the 98 patients (median follow-up 21.1 months) with a polysomic FISH 
result, 17% developed EA while 2% of the 183 patients (median 38.2 months) with a 
non-polysomic FISH result developed EA (p=0.0001, Logrank test). The estimated risk 
of developing EA in three years from baseline was 21.3% among patients with a 
polysomic FISH result (95% CI: 11.1% to 31.5%) as compared to 0.6% among patients 
with a non-polysomic FISH result (95% CI: 0% to 1.8%). Conclusions: These data 
indicate that patients with a polysomic FISH results are at greater risk for developing EA 
compared to those without polysomy. Further studies are needed, but these findings 
suggest that FISH could be used to modify the frequency of endoscopic surveillance for 
patients with BE. 
 
ST02. BRAF Mutation Testing in Malignant Melanoma: Pitfalls of Allele-Specific 
PCR 
J. Willman, M. Roh, S. Knoepp, K. Hookim, H. Weigelin, K. Elenitoba-Johnson,  
B. Bryan 
University of Michigan, Ann Arbor, MI. 
Introduction: BRAF is commonly deregulated in human malignancies, including 
colorectal cancers, papillary thyroid carcinoma, and malignant melanoma. The recent 
introduction of therapeutic agents targeting mutated BRAF, especially in melanoma, 
has increased the need for accurate diagnostic assays. A single nucleotide hotspot 
mutation (NM_004333:c.1799T>A, p.V600E) accounts for a large percentage of 
described mutations; however, in malignant melanoma other mutations in this region, 
including V600K, V600R, and V600D, constitute a significant minority of up to 20%. 
Commonly used commercial and home-brew clinical assays for BRAF mutations 
employ methods to detect the V600E mutation but may not correctly classify other 
BRAF mutations. We studied the performance of our home-brew BRAF V600E allele 
specific PCR (AS-PCR) assay on fine-needle aspirates (FNAs) of metastatic melanoma 
as compared to Sanger sequencing. Methods: Air dried Diff-Quik stained cytologic 
smears from 15 FNAs of metastatic melanoma were studied. Areas enriched with tumor 
cells were identified by a cytopathologist, microdissected, and tumor DNA was 
extracted.  AS-PCR for BRAF V600E with capillary electrophoresis detection was 
performed. A control PCR reaction targeting BRAF exon 15 was performed in parallel 
for all samples. Sanger sequencing of BRAF exon 15 was also performed on all cases. 
Results: By AS-PCR, 14/15 samples yielded adequate amplification. 5/15 samples 
tested positive for the V600E mutation and 6/15 samples were wild type. In these 
cases, Sanger sequencing confirmed the V600E strong positive and wild type results; 
however, one V600E positive sample harbored an alternate V600E mutation 
(c.1799_1800delinsAA). 3/15 samples yielded weak AS-PCR products for V600E, 
which were much less than typically seen in V600E positive samples. On repeat 
analysis these peaks were consistently below or minimally above the threshold for a 
positive V600E interpretation. These three samples with small amplification peaks on 
V600E AS-PCR demonstrated V600K mutations (c.1798_1799delinsAA) by 
sequencing. Conclusions: Allele-specific PCR detects BRAF V600E mutations in 
malignant melanoma; however, variant BRAF mutations commonly found in melanoma, 
such as V600K, can confound assay interpretation leading to inaccurate test reporting. 
In our series, 4/8 BRAF mutant melanomas harbored variant BRAF mutations that, 
depending on assay design, may be inaccurately detected or not detected at all. The 
correct distinction and reporting of variant BRAF mutations is critical for trials that are 
evaluating BRAF-targeted therapies in melanoma. 
 
ST03. Implication of BRAF V600E Mutation Status for Prognosis in Colorectal 
Cancer 
Y. Xue1, L.J. Tafe2, 4, J.A. Lefferts3, A.A. Suriawinata2,4, M. Lisosvsky3, J. Pipas2,  
G.H. Ripple2, G.J. Tsongalis2,4 
1Dartmouth Hitchcock Medical Center, Lebanon, NH; 2Dartmouth Hitchcock Medical 
Center and Norris Cotton Cancer Center, Lebanon, NH; 3Dartmouth Medical School 
and Dartmouth Hitchcock Medical Center, Lebanon, NH; 4Dartmouth Medical School, 
Hanover, NH. 
Introduction: BRAF V600E mutations are frequently found in several cancer types 
including melanoma and thyroid carcinomas. This mutation can also be found in a 
smaller percentage of colorectal cancers. Although this mutation is found in 10% of 
colorectal cancers, recent evidence highlights the potential prognostic value of BRAF 
gene alteration in patients with colorectal cancers. In this study, we assessed the 
impact of BRAF V600E mutation on patient survival in KRAS negative colorectal 
cancers. Methods: DNA was extracted from 25 FFPE tumor tissues (one 10 µm 
section) from patients with colorectal cancer treated with resection and chemotherapy. 
Percentages of tumor tissue in total tissue were estimated for each block and ranged 
from 15% to 70%. Each DNA sample was previously tested with KRAS mutation 
specific TaqMan assays and now subjected to a SYBR Green real-time PCR assay 
consisting of separate amplifications with wild-type and V600E-specific primers. 
Amplification curves of the wild-type and mutant PCRs were compared using delta CT 
analysis and compared to a 1% mutant control used to set the limit of detection for the 
assay. For each test run, NTC, negative and positive controls gave the expected 
results. Results: The 25 tumors were previously genotyped as KRAS wild type. Of 
these 25 tumors, 18 (72%) were also BRAF wild type and 7 (28%) harbored the BRAF 
V600E mutation. The BRAF wild-type patients were treated between 2003-2006, while 
the patients with BRAF V600E mutations were treated between 2007 and 2010. Of the 
18 BRAF wild-type patients, 4 (18%) patients were deceased, while 4/7 (57%) of the 
BRAF mutant patients were deceased. The mean survival of the BRAF wild-type 
patients was approximately 6 years, while the survival of patients with BRAF V600E 
mutations was 1-2 years. The surviving BRAF V600E mutated patients all had 
metastatic disease detected within less than 2 years of diagnosis. In all patients with 
BRAF V600E mutations, the primary tumors were located in the right colon. 
Conclusions: Our data show that BRAF V600E mutation status appears to be 
associated with poorer outcomes in colorectal cancer patients, suggesting that BRAF 
mutation analysis should be included in the prognostic assessment of these patients. In 
addition, our findings suggest that BRAF mutation testing in patients with right-sided 
colon cancer may be useful in identifying individuals with a worse prognosis who would 
benefit from individualized therapy. 
 
ST04. qPCR Analysis of MicroRNA Expression Differences in Formalin-Fixed, 
Paraffin-Embedded Pancreatic Ductal Adenocarcinoma, Intraductal Papillary 
Mucinous Neoplasm, and Pancreatitis Tissues 
N.M. Patel1,2, M. Regner1, K. Mangold1, H. Du1, C. Hall1, K.L. Kaul1,2 
1NorthShore University HealthSystem, Evanston, IL; 2University of Chicago,  
Evanston, IL. 
Introduction: Pancreatic ductal adenocarcinoma (PDA) is an aggressive disease with 
low survival rates. Diagnosis can be difficult, as it may resemble pancreatitis both 
radiologically and histologically. Previous studies have demonstrated differential 
expression of microRNAs in these diseases as compared to normal pancreas (NP). The 
goal of this study was to differentiate pancreatic adenocarcinoma, intraductal papillary 
mucinous neoplasms (IPMN), and pancreatitis on the basis of microRNA qPCR of 
formalin-fixed, paraffin-embedded (FFPE) tissue cores, as histologic diagnoses are 
often made utilizing tissue cores from fine needle aspirations. Methods: Tissue cores 
were obtained from FFPE tissue blocks from pancreatectomy specimens carrying 
diagnoses of PDA, IPMN, and pancreatitis. After re-embedding, sections were used for 
total RNA (including miRNA) isolation (FFPE RNA Purification Kit, Norgen Biotek Corp., 
Thorold, ON, Canada).  MiRNA expression levels for 10 miRNA were analyzed using 
qPCR (Taqman microRNA assay, Applied Biosystems, Carlsbad, CA). Statistical 
analysis was performed using ǻCt values normalized to miR-16, which was previously 
shown to have consistent expression among pancreatic tissues types, rather than 
rRNA. A total of 27 PDA and adjacent NP, 10 IPMN and adjacent NP, and 10 
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pancreatitis samples were evaluated. Results: Analysis of miRNA expression levels 
yielded multiple miRNA with discriminatory abilities.  MiR-21, -24, -155, and -203 were 
significantly differentially expressed based upon the histology of the sample, and 
discriminated between pancreatitis, IPMN, and pancreatic cancer. Mir-191, -301, -210,  
-221, -375 and -376a showed no discriminatory capabilities.  Reduced mir-24 
expression alone was able to effectively discriminate pancreatitis from IPMN, PDA, and 
normal tissues. Significantly increased expression of mir-155 was seen in PDA 
compared to adjacent normal tissue. There was increased expression of mir-21 in all 
disease states compared to normal pancreatic tissues. Mir-203 showed significantly 
increased expression in PDA. Conclusions: qPCR of microRNAs has potential as an 
ancillary test in differentiating pancreatic lesions. From a set of 10 miRNA targets, a 
subset of 4 (miR-21, -24, -155, and -203) could be used to discriminate the majority of 
PDA, IPMN, and pancreatitis. The use of a single miRNA (miR-24) was able to 
discriminate pancreatitis from neoplasia (IPMN and PDA).  Further testing using an 
expanded sample set is underway to fully demonstrate the utility of miRNA quantitation 
in assessment of pancreatic lesions. 
 
ST05. A Novel Internal Tandem Duplication of KIT Exon 11 Confers 
Responsiveness to Imatinib 
J.P. Segal, J. Edwards, R.T. Sharkey, K.T. Montone, A.R. Sepulveda, L.A. Fecher,  
C.D. Watt, V. Van Deerlin 
Hospital of the University of Pennsylvania, Philadelphia, PA. 
Introduction: KIT, a proto-oncogene located on human chromosome 4q, codes for a 
type III receptor tyrosine kinase critical for development of multiple cell types. KIT 
activating mutations have been identified in various malignancies, including 
gastrointestinal stromal tumors (GISTs) and approximately 2% to 3% of malignant 
melanomas (MM) (most commonly the acral, mucosal and ocular subtypes). Greater 
than 95% of melanoma KIT mutations are found within exons 9, 11, 13 and 17. In 
contrast to exon 11 insertion/deletion mutations commonly found in GISTs, MM most 
commonly shows point mutations or small deletions. However, the full spectrum of 
mutations in MM is unclear, and data is only beginning to emerge regarding which 
melanoma mutations are susceptible to KIT-targeted therapy. Methods: 76 cases of 
MM seen at the Hospital of the University of Pennsylvania since 2010 (all confirmed 
negative for the BRAF V600E mutation) were reviewed by staff surgical pathologists. 
Selected tumor-enriched areas were macrodissected and genomic DNA was isolated. 
Exons 9, 11, 13, and 17 of KIT were amplified by PCR and labeled using BigDye 
Terminator v3.1/Xterminator reagents (ABI). Samples were electrophoresed using a 
3130xl Genetic Analyzer (ABI) and analyzed using Mutation Surveyor V3.97 software 
(SoftGenetics). Confirmatory testing was performed at a reference laboratory. Results: 
KIT activating mutations were seen in 8 of 78 cases of MM (10.2%), with mutations 
most frequent in acral (3/8) and mucosal (2/8) melanomas as previously described. 
Mutations were observed in exon 11 (6/8) and exon 17 (2/8). Missense mutations 
comprised 7/8 cases. One patient with metastatic acral melanoma showed a novel 54 
bp internal tandem duplication (ITD) mutation within exon 11, resulting in an 18 amino 
acid insertion in the juxtamembrane domain. Conclusions: KIT mutations in melanoma 
occurred most frequently in exon 11 and consisted mainly of point mutations, as 
previously described. Missense mutations ranged from common (L576P, 3 cases) to 
relatively rare (N822Y, one case). A novel 54 bp exon 11 ITD was found in a patient 
with acral melanoma who showed an excellent response to imatinib, with resolution of 
inguinal and pulmonary metastases and lack of progression following 8 months of 
treatment. One other patient with vulvar mucosal melanoma (L576P mutation) shows 
stable disease after 9 months of dasatinib treatment. Our findings highlight the lack of 
complete knowledge regarding the spectrum of KIT mutations in melanoma, and 
suggest that KIT mutational assays for melanoma should not be designed to target only 
particular classes of mutations. 
 
ST06. IDH1 Mutation Is a Favorable Prognostic Factor for Type 2 Gliomatosis 
Cerebri 
M. Kwon1, Y. Choi2, S. Kang2, S. Park3, D. Nam2, S. Kim2, Y. Suh2 
1Hallym University Sacred Heart Hospital, Hallym University College of, Anyang; 
2Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, 
Republic of Korea; 3Gil Medical Center, Gachon University of Medicine and Science, 
Incheon. 
Introduction: Recent studies have demonstrated the prognostic significance of IDH1 
mutations in glioma. However, it is unclear whether IDH1 mutation is also a prognostic 
factor in gliomatosis cerebri (GC). Primary GCs can be grouped into Type 1 GCs, which 
represent classical lesions with diffuse neoplastic growth without mass formation, and 
Type 2 GCs, which have obvious neoplastic masses in addition to diffuse lesions. Type 
1 and Type 2 GCs are thought to have different molecular features and prognostic 
factors. Methods: Here we evaluated the prognostic relevance of IDH1 mutation on 
overall survival (OS) and progression-free survival (PFS) in 74 GCs including 43 Type 1 
and 31 Type 2 GCs. IDH1 and IDH2 alterations of the mutational hotspot codons R132 
and R172 were assessed by bidirectional Sanger sequencing and PNA-mediated 
clamping PCR. Results: We detected 33 IDH1 mutations in 74 GCs (44.6%), and no 
IDH2 mutations. The percentage of two-year OS for wild-type IDH1 patients was 46% 
versus 72% for patients with IDH1-mutated tumors. Multivariate analyses revealed that 
IDH1 mutation was an independent favorable prognostic factor predicting OS in GC. In 
further analyses according to growth type, IDH1 mutation was strongly correlated with 
favorable prognostic outcomes of Type 2 GCs, but not of Type 1 GCs. Conclusions: 
IDH1 mutation may be useful prognostic factor in GC, especially for Type 2 GC. In 
addition, Type 1 and 2 GCs appear to have different molecular features.  
 
ST07. Quality Assessment of Lung Fine Needle Aspirates (FNA) for Mutational 
Analysis  
G.S. Mantha, M. Miller, N. Parish, R. King, S. Dacic, M. Nikiforova 
University of Pittsburgh Medical Center, Pittsburgh, PA. 
Introduction: Personalized therapy based on tumor molecular testing is evolving 
rapidly. The need to provide molecular results quickly with limited specimen material is 
becoming a constant challenge. At our institution, computed tomography (CT)-guided 
fine-needle aspirations (FNA) are routinely used for diagnostic assessment of lung 
tumors. In order to guide patient therapy, mutation results for EGFR and KRAS are 
often requested on this limited specimen type. In this study we evaluated the utility of 
lung Fine Needle Aspirates (FNAs) for mutational analysis when compared with 
routinely performed testing of surgically resected specimens. Methods: 101 lung 
formalin-fixed FNA specimens were used for molecular analysis. At least 50% of tumor 
cells were required to be present in the specimen. After manual microdissection and 
DNA extraction, optical density (OD 260/280) readings were obtained and DNA 
concentration was measured using the Nanodrop 1000. Detection of EGFR exons 19 
and 21 and KRAS codons 12 and 13 and was performed with Sanger sequencing. 
Results of FNA analysis was compared to mutational analysis of 1467 surgically 
removed FFPE lung tumor tissues tested for the presence of mutations from Jan 2007 
to April 2011 at the University of Pittsburgh Medical Center. Results: In lung FNA 
specimens, 93% of samples were informative for KRAS and EGFR mutational analysis, 
while 7% (7/101) demonstrated absence or low level of PCR amplification and were 
considered as indeterminate for molecular testing. The average DNA concentration for 
indeterminate FNAs was low (1.7 ng/Pl, range=0.2-4.4 ng/Pl) as compared to cases 
informative for analysis (8.5 ng/Pl, range=1.5-27.5 ng/Pl). In addition, in 100% (7/7) 
indeterminate cases with low concentration of DNA had OD ratio measurements out of 
acceptable range (1.8-2.0). In surgical specimens, only 2% (25/1467) were 
indeterminate for molecular analysis. Interestingly, in these indeterminate surgical 
specimens, the quantity of DNA was acceptable for molecular testing (average: 10.8 
ng/Pl), however OD 260/280 readings were out of range in 60% of cases. EGFR and 
KRAS mutations were detected in 30% of FNAs and 25% of resected cases. 
Conclusions: Lung FNA samples were informative for mutational analysis using 
Sanger sequencing in 93% of cases and demonstrated a mutation detection rate similar 
to resected tumor specimens. For all specimens indeterminate for molecular analysis, 
OD ratio, 260/280, was a better predictor of the quality of PCR amplification as 
compared to DNA concentration.  
 
ST08. Heterogeneous Staining for DNA Mismatch Repair Proteins Encountered 
During Lynch Syndrome Tumor Screening: A Somatic Phenomenon?  
S.E. Kerr, K.C. Halling, K.M. Rumilla 
Mayo Clinic, Rochester, MN. 
Introduction: Immunohistochemical staining (IHC) for DNA mismatch repair (MMR) 
protein expression is used alone or in combination with microsatellite instability testing 
(MSI) in tumor screening for Lynch Syndrome. Abnormal screen results often prompt 
further tumor testing (MLH1 promoter methylation, BRAF mutation analysis) or germline 
sequencing of MMR genes to differentiate between Lynch Syndrome and sporadic MSI-
high (MSH-H) tumors. While IHC interpretation is usually straightforward, rare tumors 
display unequivocal heterogeneity of expression for one or more MMR proteins, the 
significance of which is uncertain. We describe a series of such cases. Methods: 
Reports and IHC slides were reviewed to find examples of heterogeneous IHC staining. 
Heterogeneous loss (HL) was defined as areas of loss of DNA MMR staining in tumor 
nuclei in contrast to positive staining of internal controls (i.e., stroma, lymphocytes) and 
positive nuclear staining in separate areas of the same tumor. Results: Twenty cases 
showed HL of one or more MMR proteins. Eleven were colorectal adenocarcinomas 
and 9 were endometrioid-type endometrial adenocarcinomas. The most common 
staining pattern in the cohort was HL of MLH1 and PMS2 with normal staining for MSH2 
and MSH6 (n=11). The second most common pattern was MSH6 HL with complete loss 
(CL) of MLH1 and/or PMS2 (n=7). Of the 11 cases showing HL of MLH1, 5 tested 
cases exhibited MLH1 promoter methylation and 1 did not. Of 16 cases tested for 
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microsatellite instability, 14 were MSI-H and 2 were microsatellite stable (MSS). The 
two MSS cases exhibited MLH1 promoter methylation and were in the MLH1 HL group. 
Only 2 patients had follow-up germline testing (MLH1), and a mutation or deletion was 
not detected. Conclusions: The significance of heterogeneous MMR staining in tumors 
remains unclear; however, it seems likely that it represents a somatic event since it is 
not present in all tumor cells. The finding of MLH1 promoter methylation in some of the 
cases provides support for this contention. HL of DNA MMR protein expression may 
lead to discordant MSI testing results if the area of tumor used for MSI testing is 
different than the area of tumor that shows loss of MMR expression. Reporting of HL is 
probably warranted both to explain discordant MSI results and to direct potential 
germline testing until a more systematic study can prove the somatic nature of the 
finding.  
 
ST09. Verification of a Laboratory Developed Assay (LDA) for Detection of 
KRAS and BRAF Mutations from Formalin-Fixed Paraffin-Embedded (FFPE) 
Tumor Tissues 
J.A. Woolworth, L. Zhang, J. Morris, M.H. Romano, M.S. Richardson, D.J. Wolff,  
F.S. Nolte 
Medical University of South Carolina, Charleston, SC. 
Introduction: Identification of allele-specific mutations in tumor samples from FFPE 
tissues has increasingly become important in the clinical management of cancer due to 
development of gene-specific anti-cancer therapies. Here, we report the clinical 
verification of a laboratory developed real-time PCR KRAS/BRAF mutation panel using 
commercially-available research use only reagents (EntroGen Inc., Tarzana, CA). 
Methods: Tumor samples from thirty-one patients (12, lung cancer; 11, melanoma; 6, 
colon cancer; and 2, not specified) were retrospectively collected and compared to 
results obtained from reference laboratories (Clarient, Genzyme, and ARUP) with 9 
positive for KRAS mutations, 3 positive for BRAF V600E and 20 negative for KRAS and 
BRAF mutations. The LDA consists of 12 individual real-time PCR assays designed to 
detect KRAS mutations on codons 12, 13, and 61 and the BRAF mutation V600E on 
codon 599. FFPE tissue samples were collected in two ways from FFPE blocks: three 
10 micron sections, or 1.5 mm circular cores. The core method was used on solid tumor 
samples to preserve sample in the tissue block for future use. Results: The percent 
positive and negative agreements between the LDA and reference laboratory assay 
results were both 100%. The KRAS and BRAF LDAs were found to detect 2.5% and 
20% of mutant DNA in the presence of wild-type DNA extracted from FFPE cell pellets, 
respectively. The inter-run coefficients of variation of the LDA cycle threshold values for 
KRAS G12V and the BRAF V600E mutations were 0.46% and 7.8%, respectively. The 
core method was found to be comparable to sectioning in concentration and quality of 
extracted DNA, but simpler and less labor intensive. Conclusions: The LDA was 
accurate, reproducible, and robust for detection of KRAS mutations in lung and 
colorectal cancers and the identification of BRAF V600E in colorectal cancers and 
melanoma. Local availability of molecular oncology tests can reduce turn-around-times 
for results, save costs, and provide for better stewardship of often limited tumor tissue.   
 
ST10. Design and Initial Validation of a Next-Generation Sequencing-Based 
Assay for Detecting Somatic Mutations in Clinically Actionable Cancer Genes 
D. Spencer, C. Lockwood, J. Payton, M. Watson, J. Pfeifer 
Washington University, St. Louis, MO. 
Introduction: Molecular testing is becoming standard-of-care for some cancers 
because certain mutations provide information about prognosis and treatment. Current 
methods for mutation detection are only capable of interrogating selected regions of 
individual genes, which is inefficient when testing multiple genes is clinically indicated. 
We are conducting a pilot study using Agilent solution-based genomic enrichment and 
Illumina sequencing for comprehensive mutation analysis of multiple cancer genes in a 
single assay. We have designed and completed initial validation for an assay that 
targets 28 genes frequently mutated in solid and hematologic malignancies. Methods: 
Baits for Agilent solution-based capture were designed to target exons +/- 200bp and 
+/- 1000bp of each gene. Initial validation was performed using DNA from three 
HapMap individuals with known single nucleotide polymorphism (SNP) genotypes, and 
DNA derived from frozen and formalin-fixed specimens from two lung adenocarcinoma 
tumors, also with previously-generated SNP array data. Multiplex Illumina sequencing 
of validation samples was performed following library construction and Agilent solution-
based capture. Reads were mapped using novoalign and sequence differences were 
identified and annotated using samtools and a custom analysis pipeline. Sensitivity and 
specificity for detecting single-nucleotide variants was assessed by comparing 
sequencing basecalls to array-based SNP genotypes. Results: The assay was 
designed to target 437,694 base-pairs across the 28 cancer genes in our panel, 
although some positions were not covered by capture baits because of repetitive 
sequence. Hybridization capture and multiplex sequencing of initial validation samples 
produced 4-6 million reads per sample, of which ~70% were unique reads that mapped 
to the target region. Average coverage depth across all target regions was 800- to 
1000-fold per sample. Read count, on-target percentage and error rates were similar 
between the three sample types. Consensus basecalls from the seven validation 
samples were 96% concordant with array-based genotypes at 106 sites for the tumor 
samples and 344 sites for the HapMap samples. In addition, a missense mutation was 
identified in the KRAS gene in one of the tumor samples at a position known to be 
mutated in non small cell cancer. Conclusions: Initial validation of a targeted next-
generation sequencing-based assay for somatic mutations revealed excellent 
enrichment for targeted regions and accurate identification of previously-known 
genotypes in seven samples. Additional validation is necessary to characterize the 
performance of this assay, but our preliminary studies suggest it will be an efficient 
alternative to established methods for detecting somatic mutations in cancer, 
particularly when testing multiple genes is indicated. 
 
ST11. Deep Sequencing of Target Genes in Solid Tumors Reveals New 
Deletions and Insertions in Microsatellite Sequences 
J.X. Yu, T. Jatkoe, J. Jiang, Y. Zhang, Y. Wang 
Ortho Clinical Diagnostics, Raritan, NJ. 
Introduction: Multiple genetic changes occur in cancer cells, including activation of 
oncogenes and inactivation of tumor suppressor genes. Mutations that disrupt gene 
functions that are important to cell growth and development could contribute cancerous 
development. Similarly, deletions or insertions in coding regions can result in either 
deletion or insertion of amino acids or reading frame shift with a truncated protein. 
Methods: To identify such deletions and insertions, we selected 276 genes that had a 
high tendency to mutate in breast, colorectal, lung, or prostate tumors for deep 
sequencing. DNA BAITs of 120 nucleotides were designed to cover all exons of the 
target genes and corresponding RNA BAITs were generated for target enrichment. By 
coupling Illumina GA II sequencing system with multiplexing and Agilent SureSelect 
target enrichment system, we achieved ~ 60x coverage deep sequencing on the exons 
of the target genes in 29 breast, 22 colorectal, 22 lung and 7 prostate tumors. After 
assembling paired sequence reads to human genome, small deletions and insertions 
were detected in the samples. After a series of filtering steps and computational 
analyses, followed by visual examination of sequence assembly at the mutation sites, 
deletions and insertions in these tumors were identified. Results: Ten deletions and 
insertions were identified and confirmed by Sanger sequencing. Among them, 4 cause 
reading frame shift, 5 cause 1-6 amino acids deletion, and 1 results in 2-amino acid 
insertion. Most of the mutated genes are known to play important roles in tumor 
development. Interestingly, 8 of the 10 mutations occur in microsatellite sequences. 
These mutations either increase or decrease the number of the repetitive units and are 
believed the products of microsatellite instability (MSI) in tumors due to impaired 
mismatch repair system. In addition, 7 of the microsatellite mutations were detected in 
colorectal cancers, and 4 are detected in colorectal cancers only. Conclusions: This 
study indicates that MSI in sporadic colorectal cancers may be more prevalent than 
currently believed 15%. It also suggests that MSI is present in breast, lung and prostate 
cancers, to less extent, and could lead to identification of new diagnostic markers for 
cancer development and progression. 
 
ST12. Oligonucleotide-Based in Situ Hybridization for the Detection of EGFR 
Variant III in Glioblastoma  
S. Akhavanfard1, L. Fazlollahi1, S. Han2, N. Nguyen 2, Q. Nguyen2, Y. Ma2, L.P. Le1,  
D.R. Borger1, M. Rivera1, A. Iafrate1 
1Massachusettes General Hospital, Boston, MA; 2Affymetrix, Santa Clara, CA. 
Introduction: The Epidermal growth factor receptor (EGFR) gene is commonly altered 
in a wide range of human tumors including Glioblastoma (GBM). EGFR variant III 
(EGFRvIII) is a common alteration in GBM, and results from in frame skipping of exons 
2-7 of the wild-type EGF receptor. This is often coupled to amplification of the EGFR 
locus. In this study we developed an oligonucleotide based mRNA in situ hybridization 
(ISH) assay to detect both wild type and vIII mRNA expression status of the EGFR 
gene in previously diagnosed GBM patients. Methods: 15 GBM formalin-fixed, paraffin-
embedded (FFPE) tissue blocks were selected from the records of the Massachusetts 
General Hospital Department of Pathology based on EGFR fluorescence in situ 
hybridization (FISH) results. These included 8 cases with EGFR amplification and 7 
cases with normal DNA copy numbers. An oligonucleotide based mRNA ISH assay was 
developed with two sets of probes. The first set detects normal EGFR expression with 
oligonucleotide probes in exons 2-7. The second set detects EGFRvIII expression using 
oligonucleotide probes that recognize the exon 1 and 8 fusion sequence after skipping 
of exons 2-7 (Quantigene View RNA ISH, Affymetrix, CA). EGFRvIII RT-PCR and 
oligonucleotide lysate detection (QG 2.0 lysate assay, Affymetrix, CA) were also 
performed using RNA extracted from the same cases as gold standards. Results: 5 out 
of 8 EGFR amplified GBM cases (62.5%) showed EGFRvIII mRNA expression with the 
developed QuantiGene View RNA ISH Assay. The signals were strong, cytoplasmic, 
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discrete and specific to tumor cells. None of the GBM cases with normal EGFR copy 
number showed vIII expression. Oligonucleotide lysate detection confirmed the same 
results. EGFRvIII RT-PCR applied to tissue lysates showed positive bands in 4 out of 5 
detected positive cases. Our internal control assay, GAPDH, showed very low level of 
signals in the 5th case, suggesting the sample with degraded RNA. Although RT-PCR 
was negative in this case, our assay, because of its oligo based nature and being in 
situ, was able to detect the signals in a small number of intact cells left in the tissue. 
Conclusions: We have developed an oligonucleotide-based mRNA ISH assay for 
EGFRvIII that performs comparably to RT-PCR in FFPE samples. Being oligo based 
and using multiple probes per target make this assay very sensitive and specific. Given 
the absence of specific antibodies for this aberration, this provides a unique tool to 
detect this aberration in situ in GBM and potentially other tumors. 
 
ST13. Validation of a FISH Assay to Identify JAZF1 Rearrangements in Primary 
and Metastatic Endometrial Stromal Tumors 
P.P. Bedroske, W.R. Sukov, K.E. Pearce, J.C. Hodge 
Mayo Clinic, Rochester, MN. 
Introduction: Endometrial stromal sarcoma (ESS) is a rare uterine malignancy with the 
potential for aggressive behavior that frequently shows variable histologic and 
immunophenotypic features making diagnosis difficult. In addition, metastatic ESS often 
presents with a long latency (20 years or greater) or without a previously identified 
primary lesion. Endometrial stromal nodule (ESN) is histologically similar to ESS but 
without infiltrative growth into the myometrium. Also, high grade lesions previously 
included in the ESS diagnostic spectrum are now classified as the histologically distinct 
entity undifferentiated endometrial sarcoma (UES). Rearrangements of JAZF1 at 7p15 
resulting in fusion with partner genes JJAZ1 at 17q11.2 or PHF1 at 6p21 reportedly 
occur rarely in UES but are present in greater than 70% of classic ESS and ESN. 
Therefore, we developed a fluorescence in situ hybridization (FISH) assay using a 
break-apart strategy (BAP) to detect rearrangements of JAZF1 to aid in the diagnosis of 
these tumors. Methods: Lab developed FISH probes were constructed using bacterial 
artificial chromosome (BAC) clones covering 658 kb adjacent to the 5’ end of JAZF1 
(labeled in SpectrumGreenTM) and 635 kb adjacent to the 3’ end of JAZF1 (labeled in 
SpectrumOrangeTM). The FISH probe was evaluated in a blinded fashion by two 
reviewers scoring 50 nuclei each (100 total). Thirty-seven paraffin-embedded tissue 
samples of primary or metastatic tumor from patients suspected or diagnosed with ESS, 
ESN, or UES and 26 normal endometrium/myometrium control specimens were tested. 
The specimens were processed and scored using standard culture and FISH 
procedures. Results: The BAP probe identified JAZF1 rearrangement in 17 of 37 (46%) 
of sarcoma specimens. These include JAZF1 rearrangement in 7 of 11 (64%) primary 
ESS, 6 of 9 (67%) metastatic ESS, 3 of 8 (38%) ESN, and 1 of 9 (11%) UES tumors. 
The 26 control specimens were confirmed to be normal and were used to establish 
false positive cutoff values for recurrent signal patterns of this probe. Conclusions: A 
lab developed FISH assay was validated to detect JAZF1 rearrangement in a subset of 
ESS, ESN and UES. This FISH probe will be useful in the diagnosis of endometrial 
stromal sarcomas, particularly when ESS occurs as a metastatic lesion or exhibits 
variant morphology. 
 
ST14. Evaluation of the OpenArray Platform for a Noninvasive Melanoma 
Detection Assay 
S. Chang1, T. Palmer1, W. Wachsman2,3 
1DermTech International, San Diego, CA; 2VA San Diego Healthcare System, San 
Diego, CA; 3UC San Diego, San Diego, CA. 
Introduction: When detected and diagnosed early, melanoma is highly curable. 
However, the current means for melanoma detection depends upon visual and optical 
cues that, although sensitive, have low specificity. Only 3% to 10% of lesions biopsied 
for suspicion of melanoma are found upon histopathologic evaluation to harbor the 
disease. In addition, 10% to 35% of such biopsies can have discordant pathology 
readings. We recently identified a multi-gene genomic classifier by means of epidermal 
genetic information retrieval (EGIR) (Brit J Dermatol 2001 164:797) that was found to 
be 100% sensitive and 88% specific for detection of both in situ and invasive 
melanoma. The microarray assays to discover this classifier used sub-nanogram 
amounts of RNA, non-invasively harvested by adhesive tape stripping of stratum 
corneum overlying a lesion deemed suspicious for melanoma. The objective of this 
study is to determine whether the OpenArray (OA) platform (Applied Biosystems, Inc.) 
has adequate sensitivity and reproducibility to enable translation of an EGIR-based 
melanoma detection assay into the clinic. Methods: Pigmented skin lesions, suspicious 
for melanoma, were tape stripped and then biopsied as per standard of care. Total RNA 
isolated from the tape by EGIR was pre-amplified by 14 cycles of PCR and then 
assayed on a custom OA plate, using TaqMan real-time PCR (qPCR). The custom OA 
plate contained 15 gene targets, based on our discovery research for a melanoma 
classifier, as well as 3 internal control gene targets. Results: Using this OA platform, 
we determined that as few as 100 copies of target mRNA can be detected in EGIR-
harvested specimens. In addition, OA qPCR assays exhibited > 4-log linear dynamic 
range (LDR) and had a coefficient of variation (CV) < 3%. Some 118 EGIR specimens 
(57 in situ and invasive melanomas, 61 nevi) were analyzed and, following 
normalization, assessed by means of the TreeNet algorithm (Salford Systems, Inc.) for 
class prediction. This 15-gene classifier was found to be 100% sensitive and 85% 
specific with a ROC AUC > 0.912 for discrimination of in situ and invasive melanoma 
from nevi. Conclusions: These results demonstrate that the OA qPCR platform 
provides sufficient sensitivity, reproducibility, and LDR for assay of picogram quantities 
of RNA present in EGIR-harvested skin specimens. In addition, our initial testing of this 
technology shows that it is highly accurate for melanoma detection and suitable for 
further development and implementation in the clinical setting. 
 
ST15. Development of a MicroRNA-Based Classification Model for Differential 
Diagnosis of Pancreatic Ductal Adenocarcinoma in Fine Needle Aspirates: 
Results from a Multi-Center Study 
A.E. Szafranska-Schwarzbach1, A.T. Adai1, M.B. Lloyd1, M.S. Sanders2, R.E. Brand2, 
L.S. Lee3, G. Rateb4, C. Menard4, B.A. Centeno5, M. Hartleb6, A. Wiechowska-
Kozlowska7, L. Stefanczyk8, C.L. Lefferts9, J.B. Mundig10, A. Tannapfel10,  
D.C. Whitcomb2, D.C. Conwell3, J.A. Morisset4, S. Vignesh5, G.J. Tsongalis9,  
S.A. Hahn10, B.F. Andruss1 
1Asuragen, Inc., Austin, TX; 2University of Pittsburgh Medical Center, Pittsburgh, PA; 
3Brigham and Women’s Hospital, Boston, MA; 4University of Sherbrooke, Fleurimont, 
QC, CA; 5H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; 6Medical 
University of Silesia, Katowice, PL; 7Hospital of the Ministry of Internal Affairs and 
Administration, Szczecin, PL; 8Medical University of Lódz, Lódz, PL; 9Dartmouth 
Hitchcock Medical Center, Lebanon, NH; 10University of Bochum, Bochum, DE. 
Introduction: Differential diagnosis between chronic pancreatitis (CP) and pancreatic 
ductal adenocarcinoma (PDAC) can be difficult. PDAC can arise in the background of 
CP and can cause secondary inflammatory changes due to obstruction of the 
pancreatic duct. PDAC also shares many of the microscopic and imaging features with 
CP. Endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA), the most 
accurate preoperative diagnostic modality for pancreatic masses, has a reported false-
negative rate of up to 30%. In this disease setting, an inaccurate diagnosis can result in 
a delayed surgery for a potentially curable lesion. Thus, molecular markers, such as 
microRNAs, may be valuable in resolving challenging, ambiguous or indeterminate 
cases. Herein, we will discuss three different strategies that were applied in the 
development of a miRNA-based classification model for the differential diagnosis of 
PDAC in EUS-FNAs. Methods: Total RNA from fresh frozen, FFPE and EUS-FNA 
specimens preserved in RNARetain (Asuragen) was extracted using methods 
optimized for recovery of small RNAs. miRNA candidates were initially selected using 
commercially available high throughput miRNA expression microarray platforms 
(Ambion, Agilent) and their expression was verified using TaqMan miRNA Assays 
(Applied Biosystems). Three classification models were constructed to achieve a 
differential diagnosis of PDAC using EUS-FNA. Model 1 contains miR-196a and miR-
217 (previously published work on high tumor content FFPE samples). Model 2 
comprises of miR-196a, miR-210 and miR-375 and was developed using low tumor 
content fresh frozen, FFPE and FNA samples. Model 3, which consists of unique 
miRNAs, was developed using microdissected fresh frozen and low tumor content 
FFPE samples. Initial performance of the models was evaluated on different FFPE 
sample sets, but validated on a common set of EUS-FNAs. Results: In the 
development phase using FFPE specimens, all models tested (Model 1, 2, 3) showed 
promising performance with Area Under Curve (AUC) ranging from 0.96-0.99. During 
model migration to EUS-FNA specimens, only Model 3 retained its accuracy to 
distinguish PDAC from CP showing an AUC of 0.88. Conclusions: Although all three 
classification models were expected to perform differently when applied to EUS-FNA 
specimens as compared to FFPE specimens, it was not clear a priori which model 
would perform best. The results herein reinforce the importance of considering sample 
type and bias in discovery and development of biomarkers. Furthermore, the results 
indicate that miRNA-based classification models are able to aid in differentiation 
between PDAC and CP using EUS-FNA specimens. 
 
ST16. Analysis of BRAF and EGFR Mutations in Thyroid Carcinomas 
K.E. Fisher, C. Cohen, C. Foulks, J. Sharma, C.J. Weber, C.E. Hill 
Emory University School of Medicine, Atlanta, GA. 
Introduction: The worldwide incidence of thyroid carcinoma is steadily rising with an 
expected concomitant increase in disease-associated mortality. Four major subtypes of 
thyroid carcinoma are recognized: papillary (PTC), follicular, medullary, and anaplastic, 
each with a unique histologic and molecular signature. Activating mutations (TĺA 
1799; V600E) in the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase 
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are associated with aggressive disease in PTCs. Epidermal growth factor receptor 
(EGFR) is an upstream receptor in the BRAF signaling pathway. In certain lung 
adenocarcinomas, EGFR exon 19 deletions (del 2235-2259/2236-2250; del E746-
A750) or activating mutations in exon 21 (TĺG 2573; L858R) are associated with poor 
clinical outcomes. Given that BRAF mutations are present in only a subset of thyroid 
carcinomas and that oncogenic BRAF and EGFR mutations are mutually exclusive, we 
investigated the contribution of BRAF and EGFR mutations in different subtypes of 
thyroid carcinoma. Methods: 60 cases of thyroid carcinoma from a single academic 
institution from 2002-2008 were tested. The histologic carcinoma subtypes tested 
included PTC (18), follicular (33), medullary (2), anaplastic (6), and an unclassifiable 
poorly-differentiated carcinoma (1). Metastatic carcinoma was present in 20 cases. A 
single paraffin block for each case was selected for mutational analysis. DNA was 
extracted using a Qiagen DNA Mini Extraction Kit. Mutational analysis was performed 
by pyrosequencing using a Qiagen Pyromark Q96. Results: DNA was successfully 
extracted from 59 of 60 paraffin blocks. The DNA yields ranged from 12.7 – 2661 ng/µl. 
One case of follicular carcinoma yielded only 4.4 ng/µl of DNA and was insufficient for 
analysis. 10% (6/59) of the carcinomas tested positive for the V600E BRAF mutation 
while none (0/59) of the carcinomas tested positive for either EGFR exon 19 deletions 
or exon 21 activating mutations. Of the six carcinomas that harbored the V600E BRAF 
mutation, there were four cases of metastatic PTC and two cases of anaplastic 
carcinoma. Conclusions: Our data confirm the aggressive nature of carcinomas with 
V600E BRAF mutations as 100% of cases were either metastatic PTC or anaplastic 
carcinoma. No E746-A750 deletions or L858R EGFR mutations were identified 
suggesting that alternate EGFR mutations or other oncogenic mutations are involved in 
the carcinogenesis of these malignancies. With the paucity of current 
chemotherapeutics for progressive metastatic thyroid carcinoma and the advent of 
selective inhibitors for cancer treatment, further investigation of molecular thyroid 
carcinogenesis is warranted.  
 
ST17. Beyond V600E: Comprehensive Genotyping of BRAF Codon 600 
S.M. Hafner, E.E. Bruening, C.S. Spittle, C.D. Galderisi, S. Wong 
MolecularMD Corp., Portland, OR. 
Introduction: BRAF mutations at codon 600 occur in 70% to 90% of metastatic 
melanomas and somewhat less frequently in colorectal, ovarian, thyroid and other 
tumors. The V600E (T1799A) activating mutation occurs with highest frequency across 
all tumor types, while lower frequency variants are of emerging importance. Pan-RAF 
and mutant-specific BRAF inhibitors have shown promising results in clinical trials. 
Lower frequency variants such as V600K (10% to 15%) have displayed differential 
responses to inhibitor therapies, demonstrating the importance of distinguishing 
between these variants. We have developed a robust semi-quantitative allele specific 
PCR assay that categorizes the codon 600 variants for identification of patients that 
may benefit from targeted therapies. To complement these AS-PCR assays, clinical 
samples with high mutant allele percentage (>10%) are reflexed to our validated 
Sanger sequencing assay. Together these assays allow complete characterization of 
high frequency V600E/K and the rarer variants R, M, and D, and de-novo mutations that 
may arise. Methods: Genomic DNA was extracted from immortalized human 
melanoma cell lines and FFPE tumor tissues using internally validated protocols. 
Primers were designed and optimized to distinguish mutant variants and functionally 
evaluated to determine specificity. Sensitivity was evaluated using serial dilutions of 
mutant BRAF into wild-type DNA. Precision and accuracy were determined using a 
blinded set of remnant clinical samples of known genotype. The AS-PCR assay utilizes 
3 primer sets and a common TaqMan-MGB probe to generate an overlapping control 
amplicon and two allele-specific codon 600 amplicons that categorize E and K type 
variants. The Sanger sequencing assay provides bi-directional coverage spanning 
nucleotides 1742-1860 of exon 15 using standard PCR amplification and capillary 
electrophoresis. Results: The AS-PCR assays were designed with reference control 
and mutant specific amplicons of equivalent amplification efficiency. The relative 
sensitivity was determined to be ~0.2% mutant allele (~10 copies) in a wild-type 
background with absolute sensitivity approaching single copy detection by dilution to 
extinction of the V600E and V600K mutants. The absence of amplification from mutant 
specific primers on wild-type templates is required for single copy detection and 
achieved. Rare variants V600R, M, and D will also be detected by these assays and 
further characterized by the Sanger sequencing assay when present at ~ 10% to 20% 
mutant allele. These assays were validated using FFPE tissues from metastatic 
melanoma for reproducibility, precision, and accuracy with 100% concordance. 
Conclusions: The BRAF assays are validated for detection of common and rare codon 
600 mutations in solid tumors. 
 
ST18. Blood Cell Origin of Circulating MicroRNAs: Implications for Cancer 
Biomarker Studies 
C.C. Pritchard1, E. Kroh2, B. Wood1, J.D. Arroyo2, K.J. Dougherty1, M.M. Miyaji1,  
J. Tait1, M. Tewari2 
1University of Washington, Seattle, WA; 2Fred Hutchinson Cancer Research Center, 
Seattle, WA. 
Introduction: Recent studies have reported endogenous plasma miRNAs as 
biomarkers for solid tumors, yet little is known about the cellular origin of plasma 
miRNAs or mechanisms that influence circulating miRNA levels. Methods: We used 
qRT-PCR to examine expression of 85 proposed circulating miRNA biomarkers of non-
hematopoietic cancers in purified sub-populations of blood cells and matched cell-free 
plasma from healthy individuals. To determine if blood cell counts influenced circulating 
miRNA biomarker levels, we correlated plasma miRNA levels to blood cell counts in a 
cohort of 42 consecutive residual plasma specimens collected from an academic 
hospital hematology laboratory and in serial plasma specimens from a patient 
undergoing autologous stem cell transplant. Results: We found that 47/85 (55%) of 
literature-reported solid tumor biomarkers are highly expressed in one or more blood 
cell type, and that 43/47 (91%) of these blood-cell expressed biomarkers were also 
present at considerable basal levels in healthy donor plasma (>50th percentile among 
all miRNAs detected), suggesting that blood cells could be a major source for these 
plasma miRNAs. Plasma levels of myeloid (miR-223, miR-197, miR-574-3p, let-7a) and 
lymphoid (miR-150) expressed biomarkers were tightly correlated with white blood cell 
counts, with greater than 50-fold differences between patients with the highest and 
lowest overall cell counts.  Plasma biomarkers expressed in red blood cells (miR-486-
5p, miR-451, miR-92a, miR-16) were not influenced by blood cell counts, but were 
significantly increased in hemolyzed specimens (20- to 30-fold plasma increase; 
p<0.0000001). Finally, in a patient undergoing autologous hematopoietic cell transplant, 
plasma levels of myeloid- and lymphoid-restricted miRNAs (miR-223 and miR-150) 
closely mirrored changes in corresponding blood counts. Conclusions: Blood cells are 
a major contributor to circulating miRNAs. Perturbations in blood cell counts can alter 
plasma miRNA biomarker levels by at least 50-fold, which raises concerns regarding 
prior studies that have attributed small miRNA differences (2 to 5-fold) to specific 
cancers. Future studies of circulating miRNA biomarkers for solid tumors and other non-
hematopoietic diseases may be most effective if focused on miRNAs that are not highly 
expressed in blood cells. 
 
ST19. Reevaluation of HER2 Status in Breast Cancer Patients According to the 
2011 Guidelines 
E.O. Ote, O. Ozer, Z. Yilmaz, F.A. Bolat, F. Sahin 
Baskent University Faculty of Medicine, Ankara, Ankara-Turkey. 
Introduction: HER2 amplification is detected in about 20% of breast cancer patients. 
The mechanism underlying HER2 overexpression is amplification and HER2 
overexpression effects clinical outcome, treatment and prognosis of these patients. 
HER2 positive patients have poor prognosis and they are resistant to endocrine 
therapies mostly. The agents targeting HER2, like trastuzumab, are more effective in 
these patients. Methods: In our study we reevaluated formalin-fixed, paraffin-
embedded (FFPE) tissue sections of 54 breast carcinoma patients admitted to our 
department between the years 2008 and 2011. We reviewed our FISH analysis results 
according to the 2011 ASCO guidelines. These patients had invasive ductal carcinoma 
histopathologically. All patients had 1 or 2+ IHC results and have been evaluated for 
estrogen and progesterone receptor status. Results: We detected HER2 amplification 
in 22 of 54 patients. Previously, we reported  2 signal ratio as no gene amplification 
whereas ratios 2-4 and >4 were regarded as amplification. According to the 2011 
guidelines from both ASCO and NCCN, we accepted patients with a signal ratio <1.8-
2.2 as borderline. We reported these results as amplification as the algorithm in the 
ASCO guidelines suggests patients with 2 ratio are eligible for trastuzumab treatment. 
Four of 22 positive (18.2%) patients in the study were in the intermediate or equivocal 
group according to the ASCO guidelines. In addition, we suspected aneuploidy in three 
patients; two of them were amplification-positive and the other was amplification-
negative. Our results with intermediate or equivocal FISH results seem to be similar to 
the literature. Conclusions: HER2 status is important in targeted therapy of breast 
carcinoma patients as well as other cancers. Therefore, standardization of analysis and 
reporting parameters is important both for the patient and the clinician. We believe the 
new guidelines reached the aim in improving the accuracy of HER2 amplification and 
it’s utility as a predictive marker. 
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ST20. Protein Signatures for Classification and Prognosis of Gastric Cancer: A 
Signaling Pathway-Based Approach 
F. Ye1, D. Wang2, Y. Sun2, W. Li2, W. Zhang1, J. Suo2, D. Zhang1 
1Mount Sinai School of Medicine, New York, NY; 2The First Hospital, Jilin University, 
Changchun, Jilin, China. 
Introduction: Worldwide, gastric cancer is the fourth most common malignancy and 
ranked as the second leading cause of cancer death. Unlike other common cancers, 
the prognosis for most gastric cancer is poor and has improved little over the past 
several decades. Current methods have limited accuracy in predicting survival and 
stratifying patients with gastric cancer for appropriate treatment. We aim to identify 
protein signatures of gastric cancer for classification, prognostication as well as 
stratification for appropriate treatment. Methods: Protein Pathway Array (initial study) 
and Western Blot (confirmation) were used to assess the protein expression in a total of 
199 fresh frozen gastric samples. Fifty-six paired samples were divided into a training 
set (n=37) and a validation set (n=19) for the identification differentially expressed 
proteins between tumor and normal tissues. Fifty-six tumor samples were used to 
identify proteins correlating with tumor and nodal staging. All of the 93 tumor samples 
were used to identify candidate proteins for predicting survival. An additional cohort of 
gastric cancer samples (n=50) was used to confirm the survival prediction of the 
candidate proteins. Results: Twenty-two proteins were differentially expressed 
between normal and tumor tissues. Nine proteins were selected to build the predictor to 
classify normal and tumor samples by cross-validation analysis. Ten proteins were 
differentially expressed among different T stages and 4 of these were able to separate 
the tumors into 2 groups (less invasive group and more aggressive one). An additional 
4 proteins were associated with lymph node metastasis. Two proteins (AKT and CDK2) 
were identified as independent risk factors for overall survival. Conclusions: This study 
indicated that some dysregulated signaling proteins could be selected as useful 
biomarkers for tumor classification and predicting outcome in gastric cancer patients. 
 
ST21. Germline Mutational Analysis of SDHB, SDHC, and SDHD Genes in 196 
Subjects with Paragangliom/Pheochrocytoma  
F. Li, J. Wang, E.S. Schmitt, L. Wong 
Baylor College of Medicine, Houston, TX. 
Introduction: Paraganglioms are tumors arising in paraganglion tissues associated 
with autonomic nervous system. Pheochromocytomas and extra-adrenal 
paragangliomas involve the sympathetic nerves and are also called sympathetic 
paragangliomas. The mitochondrial SDH complex II subunit genes, SDHB, SDHC and 
SDHD, are classically considered to be involved in tumorigenicity of paragangliomas/ 
pheochromocytomas although the mechanism is still unclear. Germline mutations in 
these genes result in highly increased risk for paraganglioma/pheochrocytoma. The 
predisposition to tumor is inherited in an autosomal dominant mode, with loss of 
heterozygosity in tumors. Methods: Peripheral blood DNA samples from 196 
independent subjects affected with paragangliomas/pheochromocytomas were 
analyzed for the entire coding regions of the SDHB, SDHC and/or SDHD genes. 
Oligonuclceotide microarray comparative genome hybridization (aCGH) analyses were 
performed in 44 subjects without identifiable mutations in these 3 genes from sequence 
analysis. Results: A total of 37 different mutations/missense variants were identified in 
56 unrelated families. Thus, the overall mutation detection rate is ~29% (56/196). In 
these 56 families, 30 had mutations/missense variants in the SDHB gene, 1 in the 
SDHC gene and 25 in the SDHD gene. Among the mutations/missense variants 
identified, 6 and 4 in the SDHB and SDHD gene, respectively, are novel. Intragenic 
deletions and duplications involving SDHB, SDHC and SDHD genes were not detected 
in all 44 samples analyzed. Interestingly, one subject affected with severe Leigh 
syndrome, typical of a mitochondrial disorder harbored a homozygous c.143A>T 
(p.D48V) missense pathogenic variant in the SDHB gene. Transmission of SDHD 
associated tumor was hypothesized to be paternally imprinted. However, we observed 
an SDHD case whose disease appeared to be transmitted from an asymptomatic 
mother. Conclusions: Our data demonstrated that mutations in SDHC is least 
represented among the three SDH genes. The c.380T>G (p.I127S) mutation is the 
most common mutation in the SDHB gene (4/30) and the c.242C>T (p.P81L) is the 
most common one (7/25) in the SDHD gene. Germline deletion of the SDH genes in 
paraganglioma/pheochrocytoma may be rare. Autosomal recessive mutations in the 
SDHB gene may cause a typical mitochondrial disorder, while heterozygosity may 
increase susceptibility for paragangliom/pheochrocytoma. Exceptions to paternal 
imprinting of the SDHD gene are worth investigating.  
 
ST22. E-Cadherin (CDH1) Gene Mutation Could Explain at Least in Part the 
Pathogenesis of Korean Patients Presenting with Signet Ring Cell Gastric 
Cancers 
S. Kim1, S. Kim2, H. Lee2, S. Chun2, W. Min2, J. Chung3, H. Jung2, W. Lee2 
1Ilsan Paik Hospital, Inje University College of Medicine, Goyang-si, Republic of Korea; 
2University of Ulsan College of Medicine and Asan Medical Center, Seoul,; 3Gachon 
Medical School, Gil Medical Center, Inchon. 
Introduction: The relationship between germline mutations in CDH1 gene, encoding E-
cadherin, and hereditary diffuse gastric cancer has been well defined in the Western 
population. However, the impact of CDH1 gene mutation, despite the higher prevalence 
of stomach cancer, has not been well described in Asians, especially Korean 
population. In this study, we tested the CDH1 gene mutation status of Korean patients 
with diffuse gastric cancer with familial tendency. Methods: We tested the mutation 
status of CDH1 gene in 42 Korean gastric cancer patients with familial tendency. PCR-
direct sequencing was performed for all the 16 exons and flanking regions and Multiplex 
Ligation-dependent Probe Amplification (MLPA) was done for the subjects with negative 
sequencing results using a commercial kit. The included patients all satisfied the 
following criteria: presence of at least two gastric cancer patients within first-degree 
relatives or diagnosed before the age of 40 years. For the patients with negative results 
for CDH1 gene mutation and negative for P53 immunohistochemistry performed for the 
tumors, TP53 gene mutation testing was done by direct sequencing method. Results: 
Two (4.8%) patients had the same known nonsense mutation (c.1003C>T, p.Arg335X) 
in exon 7. One was 40-year-old female and had no familial cancer history. The other 
was 43-year-old female and her brother and sister died due to stomach cancer at the 
age of 41 and 21 respectively. Although one patient had unclassified missense variant 
(c.715G>A, p.Gly239Arg), it was predicted as ‘benign’ or ‘tolerate’ on in silico prediction 
algorithms such as PolyPhen and SIFT. MLPA results were normal for all the patients. 
No patients had TP53 mutation. Conclusions: Although some E-cadherin gene 
mutations were found in Korean patients, they cannot fully explain the possible 
relationship between CDH1 mutation and hereditary diffuse gastric cancer. It implies 
that there might be another genetic mechanism underlying diffuse gastric cancer with 
familial tendency especially in Koreans. Also relatively old age of the subjects suggests 
that the clinical criteria for hereditary diffuse gastric cancer should not restrict the 
subject to younger age group only and we should pay attention to familial nature of the 
subjects. 
 
ST23. Pyrosequencing Is a Highly Sensitive Method for Assessment of MGMT 
Promoter Methylation Status in Glioblastoma Multiforme in Specimens with 
Significant Tumor-Associated Necrosis  
N.L. Steidler1, R. Medina-Flores1, J.M. Gale2, M.A. Vasef1,2 
1University of New Mexico, Albuquerque, NM; 2TriCore Reference Laboratories, 
Albuquerque, NM. 
Introduction: Assessment of methylation status of the O6-methylguanine 
methyltransferase (MGMT) gene promoter in high-grade astrocytomas provides 
valuable information including prognosis as well as prediction of response to 
chemotherapeutic alkylating agents such as temozolomide. Tumors with methylated 
MGMT have increased susceptibility to temozolomide and longer survival. High-grade 
astrocytomas often display necrosis, accompanied by variable numbers of reactive 
microglia. Typically, the hypercellular areas that include neoplastic cells intermixed with 
reactive microglia are assessed indiscriminately for determination of MGMT promoter 
methylation status. The purpose of this study is to determine the limit of a highly 
sensitive MGMT methylation assay utilizing various sized tissues with varying 
proportions of microglia/necrosis. Methods: From archival files in the department of 
Pathology at the University of New Mexico, 27 cases of glioblastoma multiforme, 
diagnosed between January 1, 2009 and December 31, 2010, were selected for this 
study. Representative paraffin-embedded tissue blocks containing large areas of 
necrosis or scant biopsies were selected for analysis of MGMT methylation status as 
well as for dual-immunohistochemical staining using glial fibrillary acidic protein (GFAP) 
and CD163 antibodies. DNA was extracted from paraffin-embedded tissue sections, 
treated with bisulfite, and subjected to PCR amplification, followed by pyrosequencing 
for analysis of eleven CpG sites in the MGMT promoter region. Methylation of eleven 
CpG sites was averaged and for each sample, an average greater than 5% was 
considered hypermethylated (based on previous validation studies). Proportions of 
tumor and microglia/necrosis were analyzed based on staining patterns of GFAP and 
CD163 respectively by Aperio® Color Deconvolution v9 algorithm. Results: The area of 
tissue analyzed ranged from 1.1 mm2 to 260.7 mm2 (median=78.04 mm2), and the 
percent of necrosis/microglia infiltration ranged from 12% to 84% (median=42.3%) of 
tissue analyzed. 15 of 27 (56%) cases showed hypermethylation of the MGMT 
promoter region. The highest percentage of necrosis in a sample with hypermethylation 
of the MGMT promoter was 72%. The smallest tissue area with hypermethylation of the 
MGMT promoter (38.1%) was 4.3 mm2, which consisted of 2.5 mm2 of 
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microglia/necrosis and 1.8 mm2 of tumor. Conclusions: Our study demonstrates that 
pyrosequencing is a highly sensitive method for reliable detection of MGMT promoter 
methylation status in biopsies with significant necrosis (up to 72%) or scant tumor tissue 
(down to 1.8mm2). This robust, highly sensitive MGMT promoter methylation 
pyrosequencing assay provides valuable information to patients and clinicians even in 
the presence of low-level methylation, necrosis or scant specimen.  
 
ST24. Comprehensive Approach for Molecular Testing of Thyroid FNA Samples 
M.N. Nikiforova, G. Mantha, J. Murphy, M. Durso, Y.E. Nikiforov 
University of Pittsburgh Medical Center, Pittsburgh, PA. 
Introduction: The recently revised American Thyroid Association’s management 
guidelines recommend testing for a panel of somatic mutations (BRAF, RAS, RET/PTC, 
PAX8/PPARg) for nodules with indeterminate FNA cytology to help guide clinical 
management. We developed a comprehensive approach for testing for these mutations 
in thyroid FNA samples that includes a specific method for collection of thyroid cells and 
novel control for assessment of adequacy of FNA samples. Methods: Thyroid FNA 
samples were collected during an ultrasound guided FNA procedure; cells that 
remained in the FNA needle after preparation of a cytology smear and needle washings 
were collected into a nucleic acid preservative solution (Roche) and stored at -20°C 
until molecular testing was requested. Controlling adequacy of collected FNA sample: 
Due to common contamination of thyroid FNA with non-thyroid cells (blood cells, 
stromal cells, etc.), assessment of thyroid cell quantity is important prior to molecular 
analysis. The method we developed is based on detecting difference in expression of 
GAPDH, which is uniformly expressed in all cells types, and the cytokeratin gene KRT7, 
which is expressed only in few distinct types of epithelial cells including thyroid cells. 
Expression of both genes was detected by real-time RT-PCR on the ABI7500. CtKR7 - 
CtGAPDH <3.5 was used as a cut off. Detection of mutations: The BRAF, NRAS, 
HRAS, KRAS, RET/PTC1, RET/PTC3, and PAX8/PPARg mutations were detected by 
real-time PCR and RT-PCR techniques. Results: For the past two years, 1715 freshly 
collected thyroid FNAs with indeterminate cytological diagnosis or suspicious for 
malignancy were tested using this approach at the at the UPMC Molecular Anatomic 
Pathology laboratory. We found insufficient amount of nucleic acids in 3% and 
insufficient amount of thyroid cells in 9% of FNA samples, and these samples were 
rejected for mutational analysis. In the remaining samples, 181 mutations (80 BRAF, 56 
NRAS, 21 HRAS, 2 KRAS, 11 RET/PTC1, 3 RET/PTC3, and 8 PAX8/PPARg) were 
identified. When corresponding surgical material was available for mutational analysis, 
a 95% correlation in mutational status was found between the FNA and resected 
specimens. Conclusions: We report a comprehensive approach for detection of 
mutations in thyroid FNA samples that allows high accuracy of molecular testing. 
Collection of residual thyroid FNA material directly into preservative solution provides 
high quality of nucleic acids and does not compromise cytological examination. The 
addition of KRT7 control is useful for assessment of proportion of thyroid cells in FNA 
samples and helps to eliminate false negative results.  
 
ST25. Cancer Subclones and Treatment Prediction: Mutation Detection on FFPE 
Tissue Sections in Situ by Padlock Probes and Rolling Circle Amplification 
J. Botling, I. Grundberg, J. Imgenberg-Kreuz, K. Edlund, P. Micke, M. Sundström,  
S. Kiflemariam, M. Nilsson 
Uppsala University, Uppsala, Sweden. 
Introduction: Activating oncogene mutations are targets for a new generation of 
cancer drugs. The standard assays for mutation diagnostics are based on DNA-extracts 
from crude tumor sections that often contain a mixture of distinct neoplastic cell 
populations – dysplasia, in situ cancer, well differentiated and poorly differentiated 
invasive carcinoma. However, little is known about the impact of tumor heterogeneity 
with regard to mutation status in different subclones during tumorigenesis, and if this is 
important for treatment response and prognosis. Methods: We have developed an 
RNA-based mutation assay that can target a set of oncogene mutations in a multiplex 
fashion in situ on routine tumor tissue slides by use of multiple mutation specific 
padlock probes and rolling-circle amplification. Results: The distribution of wild-type 
(green rolling-circle products) and mutated (red rolling-circle products) alleles were 
determined for single cancer cells in different parts of heterogeneous tumors without the 
use of microdissection. We demonstrate reliable detection of KRAS and EGFR 
mutations in colon and non-small cell lung cancer samples, on cytologic tumor imprints 
as well as on fresh-frozen and formalin-fixed, paraffin-embedded tissue sections. 
Conclusions: This in situ method offers single cell mutation detection for prediction of 
response to targeted therapy, such as EGFR-inhibitors, and holds great promise as a 




ST26. Utility of SNP Array for Distinguishing Independent Primary Tumors from 
Metastases 
G. Sharma, U. Chandran, M.B. Durso, L. Kelly, Y.E. Nikiforov, G. Mantha,  
M.N. Nikiforova 
University of Pittsburgh Medical Center, Pittsburgh, PA. 
Introduction: Cancer can present at two or more sites as independent primary 
tumor(s) or as metastatic disease. Distinguishing between these conditions is critical in 
the diagnosis, staging and management of patients. Currently, loss of heterozygosity 
(LOH) analysis may help in determining the clonality of these lesions but it is often 
limited due to small number of loci used for analysis. In this study we present the utility 
of single nucleotide polymorphism (SNP) microarray for distinguishing new independent 
primary tumors from metastases. Methods: Formalin-fixed, paraffin-embedded tissues 
from seven patients who had been previously analyzed with LOH clonality studies at 
our institution were retrieved. Seven cases, comprising of fifteen tumors and seven 
matched normal tissues were microdissected and DNA was isolated using a Qiagen kit 
and analyzed by the Affymetrix 250K Nsp SNP microarray. SNP array data was 
analyzed using CNAG v.3.2.0.0. Results: By SNP array, 4 of 7 patients had the 
secondary lesions being a metastasis from primary tumor and 3 had independent 
primary tumors. By LOH analysis, in 5 of 7 patients the secondary lesions were found to 
be metastases and 2 were independent primaries. Concordance rate was 87% and the 
discrepant case represented a lung adenocarcinoma presenting in three different sites 
with varying differentiation. SNP array showed high correlation in detection of deletions 
found by LOH. In addition, SNP array was able to detect additional regions of deletion, 
amplification, and uniparental disomy (UPD), which increased power of the analysis. 
Conclusions: Utilization of SNP microarray analysis allows for characterization and 
distinguishing independent primary tumor(s) from metastases. This technique has high 
correlation with the existing LOH analysis and provides higher confidence in 
interpretation by including regions of amplification and deletions in context of the whole 
genome. A larger study to confirm our findings as well as explore statistical methods to 
support the use of this technology in clinical practice is in progress.  
 
ST27. Evaluation of the Prognostic Utility of miRNA and Commonly Proposed 
Genetic Markers in Stage II Colon Cancer 
E. Mambo1, T. Sanford1, K. Buddavarapu1, A.T. Adai1, P. LeBourgeois1, K. Rasmussen2 
1Asuragen Inc., Austin, TX; 2Maine Medical Center, Portland, ME. 
Introduction: The standard form of treatment for stage IIA colon cancer is surgery 
alone, however, there is variable prognosis, indicating that other factors apart from 
clinical stage influence the outcome. Several markers have been proposed to contribute 
to this variation in prognosis, among which include mutational status of KRAS gene, 
microsatellite instability (MSI), expression of mismatch repair proteins and, more 
recently, microRNA (miRNA). To date, most of these markers have been evaluated at 
an individual level. Due to the complexities of tumor biology, we evaluated the multiple 
parameters indicated above in retrospectively collected colon cancer samples with 
known clinical outcome. This work extends our previous results suggesting the 
prognostic utility of miRNA in stage II colon cancer. Methods: We examined the 
association of mutant KRAS, MSI status, expression of MSH2, MSH6, MLH1, PMS2 
and p27, and miRNA in 95 FFPE tumors consisting of 50 non-recurrent and 45 
recurrent colon cancer cases. The expression of 835 miRNAs was examined using the 
Affymetrix Gene Chip V1.0 microarray and select individual miRNAs were further 
examined using RT-qPCR assays. MSI status was examined using a fluorescent PCR-
based assay and capillary electrophoresis for fragment size determination. Mutations in 
KRAS codons 12 and 13 were determined using direct sequencing on PCR products 
amplified from DNA isolated from FFPE tissues. The expression of MMR proteins 
MHS2, MHS6, MLH1, PMS2 and p27 were determined by IHC analysis. Results: 
KRAS mutations in codons 12 and 13 were detected in 26% of cases. Of the mutant 
KRAS cases, 91.6% were MSS, making mutant KRAS and MSI almost mutually 
exclusive. 41.6% of the mutant KRAS had no recurrence, while 58.3% had disease 
recurrence within 5 yr, suggesting that mutant KRAS is not associated with disease 
recurrence. Within the MSI cases, 66.7% had no disease relapse while 33.3% had 
relapse within 5 years. Absence of MLH1 and PMS2 was highly associated with MSI-H 
and good prognosis. The majority of the recurrence cases 36/45 (80%) had MSS, 
suggesting that microsatellite stability is associated with poor prognosis. We observed 
differential miRNA expression based on tumor location, MSI status, KRAS status and 
recurrence status Conclusions: Multi-marker evaluation may provide a more accurate 
assessment of prognosis in stage IIA colon cancer and may lead to improved disease 
management. We are currently performing larger validation studies in independent 
sample cohorts to evaluate the clinical utility of these miRNA in combination with other 
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ST28. Validation of KIT Assay in New Mexico Cancer Center Patients 
C.F. Kletecka1,2, J.M. Gale2, M.A. Vasef1,2 
1UNM, Albuquerque, NM; 2TriCore Ref Laboratories, Albuquerque, NM. 
Introduction: KIT gene encodes a receptor tyrosine kinase that plays a major role in 
cellular proliferation and survival. Activating KIT gene mutations have been identified in 
multiple malignant neoplasms, including gastrointestinal stromal tumors (GIST), 
melanoma, acute myelogenous leukemia (AML) and mastocytosis. The mutational 
status of KIT has important clinical implications, including targeted therapy, prognostic 
indicator, and predictor of response to tyrosine kinase inhibitor therapy. In this study, we 
successfully identified clinically relevant KIT mutations in exons 9, 11, 13, and 7 using 
high resolution melting (HRM) curve analysis and pyrosequencing platforms in New 
Mexico Cancer Center patients. Methods: KIT mutations analysis was performed on 
DNA extracted from paraffin-embedded diagnostic tissue blocks from 81 GISTs, 70 
melanomas, 10 AML with inv(16), 9 AML with t(8;21) and 16 mastocytosis, using HRM 
curve analysis on the Light Scanner 32 and pyrosequencing analysis on the PyroMark 
Q24 System. Mutations identified on screening using HRM were further characterized 
by direct sequencing on the ABI3130 Genetic Analyzer. Exons 9, 11, and 13 were 
targeted for KIT mutations in GIST and melanoma, using HRM. Mutations of codons 
816, 820, 822, and 823 of exon 17 of KIT were targeted using pyrosequencing. 
Results: KIT mutations were identified in 56 of 81 (69%) GIST specimens including 6 in 
exon 9, 43 in exon 11, 2 in exon 13, and 5 in exon 17 (4 with N822Y and 1 with Y823H). 
Direct sequencing revealed multiple novel mutations in exon 11including 575-577del, 
V560-L576 del, and 566-571del in GIST cases. KIT mutations identified in 3 of 70 (4%) 
melanoma including 2 in exon 11 and 1 in exon 17 with N822Y. Exon 17 KIT mutations 
were found in 4 of 19 (21%) AML cases including D816V in 1 AML with inv(16), N822S 
in 3 AML with t(8;21), and D816V in 9 of 16 (56%) mastocytosis cases. Conclusions: 
Our results indicate that HRM assay for exons 9, 11, and 13 in conjunction with 
pyrosequencing for exon 17 of KIT gene accurately identify KIT mutations in clinically 
relevant neoplasms. Most mutations that were identified in our study are similar to those 
described previously. However, we identified several novel mutations in exon 11 that 
have not been described previously. Although the prevalence of mutations in GIST, 
AML, and mastocytosis in our study appear similar to those described previously, the 
incidence of KIT mutation in melanoma among New Mexican patients appear to be 
slightly lower.  
 
ST29. Predicting Response to Combined Biologic Therapy in Metastatic Non-
Small Cell Lung Cancer by Differential Expression of MicroRNAs from Serum 
S. Truong1, R. Bastien2, L. Egbert3, N. Hu1, W. Akerley1, P. Bernard1 
1University of Utah, SLC, UT; 2ARUP Institute for Clinical and Experimental Pathology, 
SLC, UT; 3Huntsman Cancer Institute, SLC, UT. 
Introduction: Prognosis in metastatic Non-Small Cell Lung Cancer (NSCLC) is poor 
with an average overall survival of only 10-12 months. Targeted biologic agents, such 
as bevacizumab (anti-VEGFR pathway) in combination with chemotherapy or erlotinib 
(anti-EGFR pathway) as a single agent, demonstrate improved survival, but their 
combination as first-line treatment is only now being tested. These agents are 
expensive and are effective in only a fraction of the patients treated, so technologies 
that can predict benefit are needed. MicroRNAs (miRNA) are small (~22 nucleotides) 
RNAs that silence genes through post-transcriptional regulation that involves either 
repression of translation or mRNA degradation. Although there is limited understanding 
about the targets of miRNAs, they have already shown utility in distinguishing different 
types of tissues, including non-cancer from cancer. MicroRNAs are also abundant in the 
blood where they circulate within microvesicles (50—90nm) called exosomes. The main 
objective of this study was to identify a panel of circulating miRNAs from exosomes that 
could be used to predict tumor response to first-line biologic therapy. Methods: Blood 
serum was obtained from four metastatic NSCLC patients enrolled into a single-arm 
phase II study of bevacizumab (anti-VEGFR pathway) and erlotininib (anti-EGFR 
pathway). Serum samples collected before and after six weeks treatment from two 
responding patients (tumor size decreased with treatment) and two patients who 
progressed (non-responders) were evaluated. Exosomes were isolated from each 
serum sample using ExoQuick Exosome Precipitation Solution, followed by RNA 
extraction using the QIAGEN miRNeasy Kit. The expression of microRNAs within each 
sample was then analyzed using Agilent miRNA Expression Microarray. MicroRNAs 
with significant changes in responders versus non-responders were identified using a 
pairwise analysis in GeneSifter. Results: We identified 37 miRNAs that displayed 
significant (p<0.01) changes in expression between responders and non-responders 
using pre- and post-treatment (6 weeks) samples. There were sets of miRNAs that 
changed significantly between pre- and post-treatment in responders compared to 
progressors, and miRNAs that were significantly different between responders and 
progressors either before or after initiation of therapy. Conclusions: In this pilot study, 
we found circulating miRNAs in the sera of metastatic NSCLC patients that appear to 
distinguish responders from non-responders receiving biologic therapy. Further 
investigation of these markers is needed to determine how early the change in 
biomarker profile can be detected, whether the pre-treatment signature is indicative of 
post-treatment changes and response, and whether these changes are due to a 
systemic reaction to the drugs or directly related to tumor burden. 
 
ST30. GNAQ and GNA11 Q209 Mutation Analysis in Uveal Melanoma 
S. Dogan1, K. Le 2, A.E. Maria1, M. Hameed1, C. Hedvat1, K. Busam1, M. Rosenblum1, 
D. Abramson1, G. Schwartz1, R. Carvajal1, B. Bastian1, K. Nafa1 
1Memorial Sloan-Kettering Cancer Center, New York, NY; 2Thomas Jefferson 
University, Kimmel Cancer Center, Philadelphia, PA. 
Introduction: Recent studies have identified activating mutations at codon Q209 in 
exon 5 of either the GNAQ or GNA11 gene in 83% of uveal melanoma. Both GNAQ 
(guanine nucleotide-binding protein alpha-q) and GNA11 (alpha-11) can activate the 
MAP kinase pathway in melanoma. Mutations in GNAQ/GNA11 provide new insights 
into uveal melanoma pathogenesis and are currently evaluated as predictive biomarker 
of response to MEK inhibitors in uveal melanoma. Here, we report the MSKCC 
experience with GNAQ/GNA11 Q209 testing in metastatic melanoma using a wild-type 
blocking PCR assay to increase the sensitivity of direct DNA sequencing. Methods: To 
carry out this validation, we obtained 12 uveal melanoma DNA samples with known 
GNAQ/GNA11 exon 5 mutation status. Because of the sensitivity of detecting mutations 
was only 50% by conventional PCR-sequencing, PCR amplification of GNAQ/GNA11 
exon 5 was also performed in the presence of a locked nucleic acid (LNA) 
oligonucleotide. This LNA was designed to suppress amplification of the wild-type 
GNAQ/GNA11 DNA, leading to preferential amplification of the mutant allele. The PCR 
products of both standard and LNA-PCR were purified and sequenced. Multiple 
concentrations of LNA-oligonucleotide were tested to determine the concentration 
required for optimum assay performance. Between June 2010 and May 2011, 38 uveal 
melanoma (predominantly metastatic) samples were analyzed for GNAQ/GNA11 Q209 
mutations by direct DNA sequencing. Samples were routinely macro-dissected to enrich 
for tumor. Results: Concordant results were obtained for all validation samples. In the 
sensitivity study, an optimal result was obtained with a concentration of 0.4uM of LNA 
oligo-nucleotide, which improved the technical sensitivity of GNAQ and GNA11 Q209 
direct sequencing from 50% to 6.25% in both directions. Ten GNAQ (5 Q209P, 5 
Q209L) and 17 GNA11 Q209L mutations were identified in 22 metastatic melanomas, 4 
in melanoma, and in one melanocytic tumor of the CNS (71%). Conclusions: The 
technical sensitivity of the LNA-PCR sequencing assay is well beyond that of standard 
PCR-sequencing. This assay was approved by the New York State Department of 
Health. GNAQ/GNA11 Q209 mutations were found in 71% (27/38) of predominantly 
metastatic melanoma samples. Prospective genotyping for GNAQ/GNA11 mutations in 
melanoma is of increasing interest in terms of selecting patients for treatment with 
targeted agents. 
 
ST31. Quantitative Methylation Analysis of H19 and IGF2 Regions in Breast, 
Colon, Cervical, and Ovarian Cancer Tissues 
M. Poulin, A. Meyer, S. Lei, J. Xu, L. Yan 
EpigenDx, Inc, Worcester, MA. 
Introduction: H19 and IGF2 are reciprocally imprinted genes found on chromosome 
11. Epigenetic gene deregulation is increasingly shown to play a role in many types of 
cancer. Imprinted genes are especially susceptible to epigenetic regulatory changes 
because of silencing of one allele and the dependence on proper methylation for normal 
function Methods: Quantitative Pyrosequencing methylation assays were developed for 
different regions of the IGF2 and H19 genes.  Distal promoter, DMR0, DMR1, and 
proximal promoter regions of the IGF2 gene and ICR1, ICR2, and promoter regions of 
the H19 gene were studied on four different types of cancer tissue DNA (breast, 
colorectal, cervical, and ovarian). DNA was isolated from ten samples from each of 
these cancers along with their corresponding normal tissue. The DNA was bisulfite 
treated and methylation analysis was performed. Results: There was a significant trend 
that DNA isolated from the tumor tissues was hyper-methylated in non-imprinted 
regions of the genes, while a hypo-methylation was more commonly observed in the 
imprinted regions, such as the ICR region of H19 and the DMR0 region of the IGF2 
gene. Different cancer types showed different methylation patterns. Breast cancer DNA 
showed a significant increase of methylation in the proximal promoter region of IGF2, 
while colorectal cancer DNA showed no change in methylation when compared to 
adjacent normal DNA. There are similar trends in the H19 gene. Conclusions: Loss of 
imprinting (LOI) is an epigenetic alteration involving loss of parental origin-specific 
expression at normally imprinted genes. The differences in methylation patterns 
between DNA isolated from tumor and normal adjacent tissue across 4 different tumor 
types in the H19 and IGF2 genes indicates the critical influence of epigenetic regulation 
in this region on the progression of cancer. The combination of LOI and methylation 
changes in the promoter regions could be used as potential biomarkers for detecting 
breast cancer, cervical cancer, and ovarian cancer. The correlation of LOI and 
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methylation level change and their effect on IGF2 and H19 gene expression will be 
further investigated. 
 
ST32. [WITHDRAWN]  
 
ST33. Identification of Mispriming in Amplification Refractory Mutation 
Screening (ARMS) Used with Scorpions Technologies for the Detection of EGFR 
Mutations in Exons 18 to 21 
C.I. Dumur, P. Morris, J.A. Almenara, D.S. Wilkinson, A. Ferreira-Gonzalez, C.N. 
Powers 
Virginia Commonwealth University, Richmond, VA. 
Introduction: EGFR mutations in exons 18 to 21, encoding for the tyrosine kinase 
domain of the receptor, have been found to be related to the response to tyrosine 
kinase inhibitors (TKI) in chemotherapy-refractory advanced non-small-cell lung cancer 
(NSCLC). EGFR mutations are found in approximately 10 to 19% of patients with 
NSCLC, and studies have shown that most EGFR mutants have constitutive tyrosine 
kinase activity and, therefore, a greater sensitivity to EGFR-targeted therapies. 
However, certain mutations, such as T790M, may confer resistance to TKI treatments. 
During molecular testing, tissue heterogeneity may mask the gene mutation status, 
misleading the oncologist during treatment decisions. Commercially available kits using 
real-time PCR aim at increasing the sensitivity of mutant DNA detection in a wild-type 
(WT) DNA mixture by limiting the amplification to only mutant DNA sequences. 
Methods: Here, we assessed the analytical validity of Scorpions and ARMS® 
technologies on DNA isolated from cell lines and FFPE sample mixtures ranging from 
1% to 100% mutant DNA. These were used to establish the analytical sensitivity of the 
assay. In addition, WT DNA was further used to assess the mispriming phenomenon 
and to develop metrics to avoid false positive results. Results: From a total of 35 FFPE 
samples and 3 different cell lines we were able to determine a cutoff value for the 
difference between the cycle threshold (ǻCt) values obtained for mutant DNA in 
different proportions. Using the ǻCt metric we were able to detect EGFR mutations with 
86.54% accuracy (PPV: 100.00% and NPV: 83.33%). This less than optimal 
performance was due to false positive results caused by mispriming-driven 
amplification. To better identify non-specific amplification, for each individual reaction, a 
second parameter (ǻCt2) was established from a set of negative samples. This metric 
alone was able to significantly (p = 1.92E-18) distinguish true positives from false 
positive results. Thus, using an algorithm that takes into account both metrics, we were 
able to detect as little as 1% mutant DNA with 100.00% accuracy (PPV: 100.00% and 
NPV: 100.00%). Conclusions: Scorpions and ARMS® technologies present a highly 
sensitive and specific method for detecting low-level mutant alleles of EGFR in FFPE 
specimens, provided that mispriming is easily identified in order to avoid false positive 
results. This phenomenon is enhanced when using samples with low tumor content or 
with limited amounts of DNA, such as those obtained from laser capture 
microdissection intended to enrich for tumor cells. 
 
ST34. KIT and PDGFRA Mutation Analysis: MSKCC Clinical Testing Experience 
K. Nafa1, C. Moung1, A. Oultache1, I. Yilmaz2, A.E. Maria1, C. Antonescu1, C. Hedvat1, 
M. Ladanyi1, M. Hameed1 
1Memorial Sloan-Kettering Cancer Center, New York, NY; 2Gulhane Military Medical 
Academy, Haydarpasa Training Hospital, Istanbul. 
Introduction: Oncogenic mutations of KIT and PDGFR-alpha (PDGFRA) lead to 
constitutive receptor activation and downstream signaling. KIT mutations have been 
mainly detected in gastrointestinal stromal tumors (GIST) and mastocytosis, and at 
lower frequency in melanomas, AML, seminomas and thymomas/thymic carcinomas. 
Mutations in PDGFRA are predominantly seen in GIST. The availability of targeted 
therapy for the receptor tyrosine kinase mutations has led to development of molecular 
diagnostic tests that are being utilized in clinical practice. Here we report the MSKCC 
experience with KIT and PDGFRA clinical testing. Methods: Based on KIT mutation 
frequencies in COSMIC database, an algorithm for testing of each of the 5 type of 
neoplasms was developed as follows: i) GIST: exons 9,11,13,14,17; ii) Melanomas: 
exons 9,11,13,17,18; iii) thymomas/thymic carcinomas: exons 8,9,11,13,14,17;  
(iv) AML: exons 17,8,9,11,18; (v) Mastocytosis: exons 17,11. GISTs were also tested 
for PDGFRA exons 12 and 18 mutations. Between September 2009 and May 2011, 217 
solid tumors (105 GISTs, 90 melanomas, 9 thymomas, 11 other tumors) and 74 
hematological cases (58 AML, 9 MDS, 5 mastocytosis and 2 others) were analyzed for 
KIT and/or PDGFRA mutations, first by fragment analysis (KIT exons 9 and 11 and 
PDGFRA exon 18 for GIST only) and then, if fragment analysis was negative, by direct 
DNA sequencing (KIT exons 8,11,13,14,17,18, and PDGFRA exons 12,18). Results: 
We identified KIT and/or PDGFRA mutations in 90 GISTs (74 KIT, 16 PDGFRA) of 
which 60 were in frame deletions or insertions (indels) in KIT exons 9 (13 cases), 11 (42 
cases) or PDGFRA exons 12 (1 case), 18 (4 cases), and 30 missense mutations. Nine 
GIST cases had second site KIT mutations associated with acquired resistance to 
Gleevec or other KIT inhibitors, including 4 in exon 17, 4 in exon 13, one in exon 14. 
Five melanomas, one thymic carcinoma, 2 AML, and one mastocytosis were positive for 
KIT mutations. Conclusions: KIT mutations were found in 70.5% (74/105) of GIST 
cases and PDGFRA mutations in 15.2% (16/105). Following our algorithm, fragment 
length analysis detected indels in KIT exons 9 and 11 and PDGFRA exon 18 in 56% 
(59/105) of GIST cases. This reduces the amount of DNA sequencing by half. KIT and 
PDGFRA mutation analysis is an adjunct tool in GIST diagnosis and is important in 
assessment of sensitivity to kinase inhibitors. 
 
ST35. Molecular Profiling of Colorectal Cancer: Correlation with Histopathologic 
Findings and Microsatellite Instability Status 
D. Itani, Z. Su, D. Lai, W. Pao, C. Vnencak-Jones 
Vanderbilt University Medical Center, Nashville, TN. 
Introduction: Two primary molecular pathways have been implicated in the 
pathogenesis of colorectal cancer (CRC). The majority are microsatellite stable (MSS) 
with chromosomal instability (CIN) while others display microsatellite instability (MSI) 
due to alterations in DNA mismatch repair genes. Mutations in various oncogenes are 
also common in CRC and are associated with disease progression or response to 
treatment. We have performed molecular profiling on a cohort of CRC specimens to 
detect somatic mutations frequently altered in CRC and have correlated the results with 
histopathological findings and MSS/MSI status. Methods: 100 ng of DNA representing 
16 MSI-H and 35 MSS CRC samples were screened using the SNaPshot multiplex kit 
(Applied Biosystems). The lab developed test enables detection of 64 mutations in 8 
genes and includes: BRAF, KRAS, NRAS, AKT1, PIK3CA, PTEN, SMAD4 and 
TGFBR2. Results: 24/51 cases had detected mutations with 3/24 having 2 mutations 
identified. KRAS was most commonly observed (10/51) with 8/10 associated with MSS. 
3/4 BRAF and 4/5 SMAD4 mutations were associated with MSI-H tumors. 3/4 NRAS 
mutations were in MSS tumors. PTEN and PIK3CA mutations were exclusive to MSI-H 
and MSS tumors, respectively. 2/3 PIK3CA mutations were observed with a second 
driver mutation. Mutations in AKT1 or TGFBR2 were not detected. 12/16 MSI-H cases 
were located in the proximal colon while 4/16 were distributed along the transverse and 
distal colon. 3/16 cases were medullary carcinomas with a driver mutation detected in 
each and 1 with both a BRAF and PTEN mutation. 5/16 were poorly differentiated 
adenocarcinomas (PDA) with 4 displaying a driver mutation. The remaining 8 MSI-H 
tumors were moderately differentiated adenocarcinomas (MDA), with 7 having a 
mucinous component and 1 having no mucin but an extensive intratumoral lymphocytic 
infiltrate; 3 of these showed SMAD4 mutations. 27/35 MSS cases were MDA with 5 
containing a mucinous component and 10/27 demonstrating driver mutations. 8/35 MSS 
cases were PDA; 4/8 had histologic features typically associated with MSI with 3/4 
having a driver mutation. 4/8 MSS PDA had no MSI associated histologic features and 
no mutations. Conclusions: Driver mutations were detected in 10/16 (62%) MSI-H and 
16/35 (46%) MSS tumors. Most MSI-H cases (7/8) with medullary and high grade 
features harbored at least 1 driver mutation. In this cohort, MSS and MSI-H CRC 
tumors appear to display distinct molecular profiles. Studies such as these will facilitate 
genetically-informed treatment plans for the optimization of patient management.  
 
ST36. New miRNA Markers in Follicular-Patterned Thyroid Tumors 
M. Durso1, M. Dettmer1, H. Moch2, G. Mantha1, L.M. Kelly1, Y.E. Nikiforov1,  
M.N. Nikiforova1 
1University of Pittsburgh Medical Center, Pittsburgh, PA; 2University Hospital Zurich, 
Zurich, Switzerland;  
Introduction: The most difficult thyroid tumors to be diagnosed by cytology are 
follicular carcinomas (FC), oncocytic or Hürthle cell carcinomas (HCC) and follicular 
variants of papillary carcinomas (PTC,FV). Several miRNAs were previously reported 
as reliable markers in conventional papillary thyroid carcinoma, however, limited 
information is available for FC, HCC and PTC,FV. The aim of this study was to find 
candidate miRNA markers that can be used in diagnostically challenging thyroid FNA 
samples. Methods: Forty-three thyroid carcinomas (15 FC, 13 HCC, 15 PTC,FV), 2 
benign hyperplastic nodules and 6 normal thyroid tissues were studied for expression of 
380 miRNAs using Human Microarray Assays (Applied Biosystems) on ABI 7900. 
miRNAs were isolated using Trizol reagents from frozen thyroid tissue (n=28) and using 
RecoverAll Total Nucleic Acid kit (Ambion) from FFPE tissue specimens (n=23). The 
data analysis was performed with StatMiner v.4.2 (Integromics) and Data Assist v2.0 
(Applied Biosystems) programs. Ten thyroid FNA samples were studied for expression 
of individual miRNAs. Results: miRNA expression was different between follicular 
variant of papillary carcinomas and follicular carcinomas demonstrating individual 
clusters on the unsupervised hierarchical clustering analysis. The most consistently up-
regulated miRNAs in PTC,FV were miR-221, -222, -146b-3p, -146b-5p, -187, -155, and 
miR-375 and down-regulated miRNAs were miR-138 and miR-199a. Expression of 
these miRNAs was confirmed in 10 FNA samples derived from PTC,FV tumors. Both, 
follicular carcinomas of conventional type and oncocytic or Hürthle cell carcinomas 
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showed up-regulation of miR-182, -183, and -520e and down-regulation in miR-199,      
-411, -455. In addition, up-regulation of miR-221 and miR-222 was detected in HCCs. 
Conclusions: We identified specific up-regulated and down-regulated miRNAs in 
thyroid follicular carcinoma and follicular variant of papillary carcinoma, tumors that 
create diagnostic difficulties on preoperative evaluation of thyroid nodules. Further 
studies are necessary to validate their diagnostic use in thyroid fine needle aspiration 
samples.  
 
ST37. Distinct Molecular Subtypes of Gastric Adenocarcinoma are Revealed by 
Expression Profiling of Viral and Human RNAs in Paraffin-Embedded Tissue 
W. Tang1, D.R. Morgan1, M.O. Meyers1, R.L. Dominguez2, N. Banet1, H. Muallem1,  
M.L. Gulley1 
1University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Western Regional 
Hospital, Santa Rosa de Copan, Honduras. 
Introduction: Gastric adenocarcinoma is the second leading cause of cancer death 
worldwide, and it is uniquely associated with Helicobacter pylori and Epstein-Barr virus 
(EBV) infections. Methods: To define molecular subtypes of gastric cancer, we 
designed an assay to measure 89 RNAs (20 viral, 69 human) chosen because they 
were shown in prior studies to be dysregulated in virus-associated cancer and/or in 
gastric cancer. The Nanostring nCounter system was used to quantify expression of 
these 89 RNAs as well as 4 housekeeping RNAs and 3 ERCC control RNAs that were 
spiked into 500ng of total nucleic acid extracted from macrodissected paraffin sections 
using the Roche HighPure miRNA Isolation Kit. Results: When applied to a series of 14 
well characterized cell lines that had been paraffin embedded, the assay successfully 
distinguished infected from uninfected cells, and epithelial from lymphoid lineages. 
When applied to 102 cancers (86 gastric adenocarcinomas and 16 lymphoepithelioma-
like cervical cancers) as well as 61 matched non-malignant gastric or uterine mucosa 
from the same surgical specimens, unsupervised hierarchical clustering revealed 
patterns of expression largely differentiating gastric from cervical lineages, and reactive 
from malignant diagnoses. None of the cervical cancers expressed EBV RNAs, in 
keeping with negative results by the gold standard EBER ISH histochemical assay. 
Interestingly, among the 86 gastric adenocarcinomas were 8 cases (9%) that expressed 
virtually all of the latent and lytic EBV RNAs on the panel and that also had distinct 
human gene expression profiles, implying that EBV is not an innocent bystander when 
present in gastric cancer cells. Surprisingly, 31% of reactive gastric mucosae expressed 
two or more EBV RNAs, suggesting that active viral infection is prevalent in stomach 
tissue adjacent to cancer, regardless of whether the cancer itself is infected. 
Conclusions: EBV-infected cancers represent a distinct biologic subtype of gastric 
adenocarcinoma. Further studies are warranted to explore the role of EBV in gastric 
cancer pathogenesis and tumor maintenance. This work illustrates the power of RNA 
expression profiling for exploring cancer biology and for molecular classification of 
disease.  
 
ST38. Role of Laser Capture Microdissection and Real-Time, Allele-Specific 
PCR in Determining Clonality in Biphasic Tumors 
J.R. Pettus, A. Srivastava, L.J. Tafe, G.J. Tsongalis, J.A. Lefferts 
Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: Clonality studies using molecular techniques in solid tumors can be 
useful in situations where the origin of tumors or specific tumor features is in question. 
Some tumors including fibroadenomas and phyllodes tumors of the breast, pancreatic 
mucinous cystic neoplasms with ovarian type stroma, and colonic fibroblastic polyps 
(CFP) are consider biphasic due to the presence of both epithelial and stromal 
components in the tumor. It is unclear whether the stromal component is actually part of 
the same clone in these tumors or is a reactive response to the epithelial component. 
Since CFPs have been shown to harbor the BRAF V600E mutations, we evaluated a 
series of CFPs to assess the feasibility of clonality studies utilizing laser capture 
microdissection with a real-time, allele-specific PCR assay for this BRAF mutation. 
Methods: Six cases of CFPs were reviewed by examining H/E stained slides of FFPE 
tissue to confirm the correct histology and to select cases containing ample stromal 
tissue suitable for microdissection from surrounding epithelial tissue. Genomic DNA 
was extracted from both whole FFPE tissue sections of each polyp and stromal tissue 
that had been obtained by laser capture microdissection using a PixCell II system (Life 
Technologies). BRAF V600E mutation analysis was performed by real-time, allele-
specific PCR for both wild-type and mutant sequences. Delta CT values (CT(wt)-
CT(V600E) ) were obtained for relative quantitative analysis and compared to a 1% 
V600E control (V600E DNA diluted in wild-type DNA). Results: The BRAF V600E 
mutation was present in all six (100%) of polyps tested. Laser capture microdissection 
yielded adequate stromal DNA for 5/6 polyps as determined by wild-type BRAF 
detection. All five BRAF V600E-postive polyps with successful DNA extraction from 
laser capture microdissected stroma showed either an absence (n=3) or a relative 
decrease (n=2) in BRAF V600E detection in the stroma. Conclusions: Our findings 
confirm the feasibility of using laser capture microdissected FFPE tissue for clonality 
studies. This method can be applied to biphasic tumors where the pathogenesis of the 
stromal component is controversial. Low-level detection of the BRAF mutation in two 
cases suggests inadvertent contamination of the microdissected stromal tissue with 
epithelium and further refinements in technique are likely to prevent this in the future. 
 
ST39. Clinical Validation of HER2 Testing in Gastric Cancer: A Pilot Study 
M. Sabbath-Solitare1, L. Tafe2, G.J. Tsongalis2, J.F. Lara1, T.C. Redondo1 
1St. Barnabas Medical Center, Livingston, NJ; 2Dartmouth Hitchcock Medical Center, 
Lebanon, NH. 
Introduction: In 2010, the ToGA (Trastuzamab for Gastric Cancer) trial showed that a 
combination of chemotherapy with trastuzumab (Herceptin) in patients with advanced 
stages of HER2 positive gastric carcinoma resulted in an improvement in survival. 
Guidelines for scoring HER2 gene amplification or overexpression for this tumor type 
have not yet been fully validated. In this study, an interlaboratory comparison of assay 
performance for HER2 status by IHC and FISH in patients with both a biopsy and 
resection was performed. Methods: Formalin-fixed, paraffin-embedded gastric 
carcinoma (paired biopsy and resection) tissue specimens were selected after review of 
Surgical Pathology reports. H&E slides and blocks were retrieved from the Saint 
Barnabas Medical Center archives (2003 to 2011). FISH analysis was performed at two 
independent laboratories using the FDA-approved Abbott-Vysis PathVysion DNA probe 
kit. Amplification of the HER2 gene was defined as a ratio (HER2:17cen) of 2.2 in 60 
or more cells counted. IHC was performed using a monoclonal c-erbB-2/HER2/neu 
antibody from BioGenex, clone CB11 at a 1:40 dilution. Results were scored as 0-1+ 
(negative), 2+ (equivocal) and 3+ (positive). Scoring and interpretation of results were in 
accordance with the ASCO/CAP guidelines presently established for breast carcinoma. 
In addition, age, gender, histologic type and TNM stage were recorded. Results: 
Results from nine patients (6 females/3males - ages ranging from 56 to 95 years) are 
as follows: i) Nine paired biopsy/resections (18 specimens) were negative by FISH; 
however, heterogeneity (defined as amplification in 1/20 cells) was observed in two 
biopsies and one resection each from different patients. ii) Seven of nine paired 
biopsy/resections (14 specimens) were negative by IHC. Two remaining: one patient’s 
biopsy and resection were both equivocal by IHC and one patient’s biopsy was 
negative, but the resection was equivocal. iii) Correlation between FISH and IHC was 
89% (8/9) in biopsies and 78% (7/9) in resections. Discrepant results were due to 
equivocal IHC results. Conclusions: We present the results of a pilot study between 
two collaborating institutions addressing the clinical application of HER2 testing in 
gastric carcinomas (using paired biopsy/resection specimens). Correlation between IHC 
and FISH results was implemented to clinically validate HER2 testing in this tumor type. 
This study highlights the need for further evaluation of test performance and scoring 
criteria for HER2 in gastric carcinoma.  
 
ST40. Optimization and Validation of EGFR Testing on FNA Cytology and Core 
Biopsy Samples on the Qiagen PyroMark Q24 and Rotor-Gene Instruments 
R. Khode, S. Walker, B. Culbreath, D.S. Parish, K. Walker, L. Sayage-Rabie, A. Rao 
Scott and White, Temple, TX. 
Introduction: EGFR-directed therapies in lung cancer patients include tyrosine-kinase 
inhibitors, gefitinib and erlotinib, and the monoclonal antibody cetuximab. EGFR 
mutations are important in determining selection of patients for multi-agent 
chemotherapy or gefitinib and testing is performed by sequencing or PCR based testing 
on small biopsy or fine-needle aspiration samples. Very few comparative or optimization 
studies have been performed on different sample types. We present an optimization 
study for FNA and biopsy tumor samples on the Qiagen RotorGene and the PyroMark 
Q24 platforms. Methods: 60 formalin-fixed (FFPE) biopsy, FNA and cytology tissue 
blocks and 35 air-dried direct smears were used in the studies. Laser capture 
microscopy was used to enrich for tumor in FFPE and cell block samples. Air-dried 
direct FNA smears were prepared and stained using the Diff-Quick (modified Giemsa 
protocol) method and cells identified with a marker pen. DNA was extracted from FFPE 
samples using the Arcturus PicoPure DNA Extraction Kit and from the Diff-Quick 
smears using the Zymo Research Pinpoint Slide DNA Isolation System. Quantitative 
measurement of mutations in codons 719, 768, 790, 858, 861 and deletions and 
complex mutations in exon 19 of the EGFR gene was performed on the Pyromark Q24 
and compared with the qualitative measurement of 19 deletions in exon 19, 3 insertions 
in exon 20 and mutations in codons 719, 768, 790, 858 and 861 on the RotorGene 
instrument with the EGFR RGQ PCR Kit that utilizes ARMS and Scorpions 
Technologies. Results: DNA extracted from smears ranged from 0.31 ng/Pl to132 
ng/Pl and from FFPE samples ranged from 5.22 ng/Pl to 127 ng/Pl. All reactions from 
smears were valid on both the PyroMark Q24 and RotorGene while there were 2 
invalids from the cell blocks and cores on the PyroMark Q24 and 4 invalids on the 
RotorGene. Eight positive mutations were observed from smear samples and 14 from 
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cell block samples. A 5% mutation cut-off limit (PyroMark Q24) was used as the limit of 
detection.  Ten matched smear and biopsy samples showed identical results. Five 
samples showed discrepant results between the PyroMark Q24 and the RotorGene. 
Conclusions: Direct extraction and analysis of EGFR mutations from Diff-Quick 
smears is a convenient and robust method for FNA obtained samples. The method has 
been optimized for both the PyroMark Q24 and RotorGene platforms. 
 
ST41. Evaluation of Three Different Methods for the Detection of Mutations in 
Exons 18 to 21 of the EGFR Gene 
M. Ramanathan1, D.L. Aisner2,3, A. Baisre1, A. Seth1, H. Fernandes1 
1UMDNJ/New Jersey Medical School, Newark, NJ; 2University of Colorado Denver, 
Denver, CO; 3Colorado Molecular Correlates Laboratory, Denver, CO. 
Introduction: Somatic mutations in the Tyrosine Kinase (TK) domain of the epidermal 
growth factor receptor (EGFR) gene in lung cancers are associated with variable 
response to small-molecule TK inhibitors (TKIs). About 90% of mutations with favorable 
responses in non-small-cell lung cancer (NSCLC) occur as in-frame deletions in exon 
19 or a L858R mutation in exon 21. Mutation T790M in exon 20 is the most common 
mutation associated with acquired resistance to TKIs. Using a sensitive assay that is 
reproducible and easy to interpret is key to providing accurate results for detection of 
EGFR mutations. Methods: DNA from 35 new and previously analyzed formalin-fixed, 
paraffin-embedded tissue specimens belonging to patients with NSCLC were used for 
EGFR mutation analysis by three methods; fragment analysis, pyrosequencing and 
Sanger sequencing. DNA from lung cancer cell lines, H1650 with an Exon 19 deletion 
and H1975 harboring the L858R and T790M mutations, served as positive control. 
EGFR mutations were detected using a laboratory-developed PCR with fragment 
analysis on the ABI 3130 genetic analyzer, pyrosequencing using the EGFR Pyro Kit 
(Qiagen), and Sanger sequencing. In the fragment analysis assay exon 19 deletions 
were detected by differences in the amplicon sizes and the L858R mutation was 
detected by an RFLP assay. Discrepancies were resolved by repeat sequencing in a 
different laboratory. Results: Out of 35 specimens tested for exon 19 deletions, 7 
specimens showed deletions by all three methods. On closer analysis, 6 specimens 
tested by fragment analysis and pyrosequencing had a 15bp deletion and one 
specimen had an 18bp deletion, whereas Sanger sequencing detected five 15bp and 
two 18bp deletions. The L858R activating mutation in exon 21 was detected in 6 
specimens using all three methods. Three specimens positive for exon 20 mutations 
(T790M and S768I) and one specimen identified with the G719A mutation by Sanger 
sequencing were confirmed by pyrosequencing. Conclusions: Pyrosequencing and 
fragment analysis are easy to perform and interpret, and showed good specificity and 
sensitivity for the detection of mutations in exons 18-21. Since the clinical utility of 
specific size deletions in exon 19 is not yet documented, the length of the deletion may 
not be pertinent. Performance characteristics of all three assays for the detection of 
EGFR mutations were comparable. Implementation of the assay is dependent on 
availability of instrumentation and experience.  
 
ST42. Identification of CpG Promoter Methylation Gene Targets in 
Gastrointestinal Stromal Tumors (GISTs) 
D.L. Aisner1, Y. Yao2, J. Easler2, S. Harada3, T. Uehara2, P.J. Zhang2, N.A. Ahmad2,  
A. Sepulveda2 
1University of Colorado Denver, Denver, CO; 2University of Pennsylvania, Philadelphia, 
PA; 3Johns Hopkins University School of Medicine, Baltimore, MD. 
Introduction: The role of promoter CpG methylation in GISTs is poorly understood, 
with few genes having been reported to be altered by CpG methylation in these tumors. 
We hypothesize that GISTs may be characterized by unique CpG methylation patterns 
and there may be increased CpG methylation of selected gene loci in higher risk GISTs. 
Methods: DNA methylation at 1,505 CpG sites in 807 cancer-related genes was 
evaluated using Illumina GoldenGate methylation arrays. Forty gastric GISTs (17 >5cm 
and 23 <5cm) were studied. DNA was extracted from paraffin sections of tumor areas. 
Bisulfite modified DNA was used for quantitative SYBR green methylation specific PCR 
(QMSP) and array studies. Methylation levels of the promoter regions of DHCR24 
(previously shown to be altered in human cancers) and PTCH2 (hedgehog signaling 
pathway) genes were determined in 38 tumors by QMSP. Methylation levels of each 
CpG locus were measured and reported as a% of the reference actin gene. Results: 
Methylation array data showed that methylation of CpG regions represented on the 
array is frequent in GISTs. The methylation values (beta) in the array range from 0 to 1. 
The mean methylation values for all targets of GISTs < 5cm and >5cm, excluding 
background methylation values <.1 were 0.29 (+0.18) and 0.34 (+0.2), P<.001, 
respectively. Methylation values >.2 were seen in 67% of >5cm GISTs and 54% of <5 
cm GISTS. To identify individual genes that may be useful to differentiate between high-
grade vs. low-grade GISTs, genes with significantly higher methylation in >5cm and >5 
mitoses/50 HPF GISTs were identified. Two selected genes (DHCR24 and PTCH2) 
showed increased methylation in high-grade (>5cm) GISTs (17 cases) vs. low-grade 
(<5cm) GISTs (21 cases), by QMSP. Although the difference was not statistically 
significant (P>.05), the mean% methylation levels of DHCR24 were 7.9 (+24.3) and 2.6 
(+5.5), and mean% methylation levels of PTCH were 1.9 (+3.5) and 0.1 (+0.3) for high-
grade vs. low-grade GISTs, respectively. There was a positive correlation between 
methylation levels detected by the array and by QMSP for DHCR24 (P=3.75E-10) and 
PTCH (P=.036). Conclusions: This study shows frequent methylation of GISTs at CpG 
targets among 807 genes represented in the Golden Gate methylation array. Frequency 
and levels of methylation of two selected genes correlated with the array data. Our 
studies provide support for a role of CpG methylation in the molecular mechanisms 
underlying GISTs.  
 
ST43. Evaluation of Molecular Prognosticators in a Subset of Gliomas 
A. Seth, A. Baisre, M. Ramanathan, H. Fernandes 
UMDNJ/New Jersey Medical School, Newark, NJ. 
Introduction: Studies indicate that IDH mutations are early events in gliomagenesis 
and that mutated IDH1 and IDH2 are involved as oncogenes in the progression to 
Grade II and III gliomas. Molecular markers such as 1p/19q co-deletion in 
oligodendrogliomas, MGMT promoter hypermethylation,  10q (PTEN) loss in 
glioblastomas, and mutations in IDH1 and IDH2 in diffuse gliomas are frequently used 
for diagnosis, subclassification and prognosis of gliomas. Recent studies have 
suggested that assessment of 1p/19q codeletions in combination with IDH mutations in 
anaplastic oligodendroglial tumors offer additional prognostic information. We have 
evaluated the presence of these markers together with MGMT hypermethylation in our 
patient specimens. Methods: A total of 38 formalin-fixed, paraffin-embedded gliomas 
were used for analysis. Twenty-six specimens from patients with an initial 
histopathological diagnosis of oligodendroglioma or mixed oligoastrocytoma, 4 with 
astrocytoma and 8 with GBM or other glial tumors were assessed for allelic status of 
chromosomes 1p, 19q and 10q by capillary electrophoresis Mutational status of IDH1 
and IDH2 was assessed using real-time PCR and melt curve analysis. The presence of 
mutations was confirmed by sequence analysis on the ABI 3130. MGMT promoter 
methylation was assessed by pyrosequencing. Results: Eighteen of the 26 (69%) 
oligodendrogliomas and mixed oligoastrocytomas showed 1p/19q co-deletions. One 
astrocytoma, 1 GBM, and a third classified as a GBM with oligodendroglial features also 
had loss of heterozygosity (LOH) at 1p/19q.  In comparison only 3/12 (25%) diagnosed 
as astrocytomas or GBMs had evidence of 1p/19q LOH.  Of the 38 specimens 
analyzed, only 1 showed LOH at 10q. This astrocytoma was also observed to have the 
1p/19q co-deletion. 25/ 37 (68%) specimens analyzed were observed to have the IDH1 
mutation, and 18/25(72%) of these specimens were oligodendrogliomas/mixed 
oligoastrocytomas. Only 1 specimen (astrocytoma) that was IDH1 wild type was found 
to have the IDH2 mutation. Hypermethylation was present in 52% of the specimens 
analyzed and 50% of these were oligodendrogliomas with the 1p/19q deletion. 
Conclusions: Analyzed collectively, 69% of the oligodendrogliomas and mixed 
oligoastrocytomas had the1p/19q co-deletion; 73% of these identified gliomas were 
observed to harbor the IDH mutation indicating that there is a significant correlation 
between the two prognosticators. The results further indicate that methylation status 
may not be a favorable indicator in the classification of tumors with oligodendroglial 
features. 
 
ST44. Evaluation and Optimizing Test Sensitivity in BRAF Mutation Analysis 
M. Cuaresma, L. Ma, L. Mazur, M. Michalov 
ACL Central Laboratory, Rosemont, IL. 
Introduction: BRAF V600E encodes a RAS-regulated Kinase that mediates cell growth 
and malignant transformation kinase pathway activation. BRAF V600E is the 
predominantly occurring mutation in colorectal cancer, melanomas and thyroid cancer. 
More than 30 different BRAF mutations have been identified. BRAF V600E constitutes 
about 90% of all activating BRAF mutations and is the mutation commonly tested for in 
clinical laboratories. Because of the limited amount of tumor tissue available for testing 
(FFPE is the sample of choice), sensitivity and accuracy are central to this test. The aim 
of this study was to evaluate and implement the most sensitive and reliable method for 
routine BRAF laboratory testing. Methods: In this evaluation, we use three different 
technologies: i) real-time PCR with high resolution melting (HRM) curve analysis, ii) 
real-time allele-specific PCR with ǻǻCp mutant vs wild type analysis (both methods are 
SYBER-GREEN based) and iii) pyrosequencing (Qiagen) to analyze BRAF mutations 
from dilution of cell line and 38 patient specimens positive for BRAF V600E mutation. 
Results: We found that real-time PCR with HRM (2%) and real-time allele-specific PCR 
(2%) are more analytically sensitive than pyrosequencing (3%). When we tested 38 
clinical samples all three methods have comparable clinical sensitivity (5%). Successful 
detection of BRAF mutation is dependent upon quality and percent tumor% present on 
the FFPE slide. For the purpose of the study, our cut-off was determined to be 30% of 
the tumor cell in a background of normal cells. Conclusions: This study suggests that 
all three test methods have comparable analytical sensitivity, down to 2% (real-time 
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PCR), which is in agreement with other publications, (3) and 3% (pyrosequencing). 
Clinical sensitivity is greatly dependent on the tumor cell content in the background of 
normal cells. In all three methods, tumor cell content <20% to 30%, increases the risk of 
false negative interpretation. Although none were seen here, the two real-time PCR 
methods may, theoretically, produce false positive results due to complex mutations 
present in V600E hot spot location. This risk is limited in case of pyrosequencing, where 
interpretation is based on detection of single base change and does not require 
additional confirmation. Based on above study ACL Molecular Pathology implemented a 
real-time PCR/HRM assay for initial screening (as a lower-cost option) with reflex to 
Pyrosequencing to confirm BRAF V600E mutation. 
 
ST45. KRAS and Fluorescence in Situ Hybridization (FISH) Results in 
Pancreatobiliary Stricture Brushings Based on Tumor Localization  
N.S. Kip, B. Kipp, E.B. Fritcher, M. Campion, M. Keeney, S.E. Roellinger,  
R.G. Hofmeister, J. Voss, K. Halling 
Mayo Clinic, Rochester, MN. 
Introduction: We recently demonstrated that KRAS mutations can be detected by 
quantitative PCR (qPCR) in pancreatobiliary stricture brushings and the combination of 
FISH with KRAS mutation analysis increases the detection rate of cholangiocarcinoma 
(CCA) over conventional cytology alone. The aims of the current study were to evaluate 
the sensitivity of KRAS mutation analysis for the detection of malignancy in 
pancreatobiliary brushings based on tumor localization (intrahepatic CCA; extrahepatic 
CCA or adenocarcinoma of the pancreas (AOP)), and to determine the relative 
sensitivity of KRAS and FISH testing. Methods: Pancreatobiliary brushing specimens 
(n=217) obtained during endoscopic retrograde cholangiopancreatography (ERCP) had 
previously been assessed for malignancy by routine cytology and FISH analysis. 
Residual brushing specimens from these patients were analyzed for KRAS mutations 
using the qPCR DxS KRAS mutation test kit. Five cases were excluded due to test 
failure (n=2) or non-diagnostic cytology or FISH results (n=3). Subsequent 
clinicopathologic follow-up of the 212 patients revealed intrahepatic CCA (n=27); 
perihilar extrahepatic CCA (n=54); distal extrahepatic CCA (n=11); AOP (n=17); other 
malignancies (n= 18); and benign strictures (n= 85). There were 101 patients (48%) 
with primary sclerosing cholangitis (PSC). Results: AOP had the highest KRAS 
mutation rate (71%), which was more sensitive than polysomy FISH (41%). Polysomy 
FISH alone had higher sensitivity than KRAS for all other malignancy types. Combined 
FISH and KRAS mutation analyses were complementary and demonstrated better 
sensitivity than FISH alone for intrahepatic CCA (59% vs. 44%, p=0.046), perihilar 
extrahepatic CCA (63% vs. 37%, p=0.0002), and AOP (82% vs. 41%, p=0.008). The 
combined sensitivity was not significantly greater than FISH alone for distal extrahepatic 
CCA (91% vs. 82%, p=0.32) or ‘other’ malignancies (72% vs. 67%, p=0.32). The 
combined specificity of KRAS and FISH was significantly lower than FISH alone (87% 
vs. 95%, p=0.008). Interestingly, both methods revealed a lower sensitivity for PSC-
associated CCA than for sporadic CCA. Of the 35 patients with equivocal FISH results 
(i.e. trisomy 7 or tetrasomy), 13 (37%) showed KRAS positivity and all patients had 
malignancy on follow-up, as opposed to 20 cases (57%) with wild-type KRAS results in 
whom 50% of cases had malignancy. Conclusions: The findings of this study suggest 
that the combined sensitivity of KRAS and FISH is higher than FISH alone in ERCP 
pancreatobiliary brushings despite tumor sub-type. KRAS mutation analysis may be 
especially helpful for cases with equivocal FISH results, despite the limitation of 
decreased specificity.  
 
ST46. Comparability of Sensitivity Study in KRAS Mutation Analysis 
L. Ma, L. Mazur, E. Katz, M. Cuaresma, A. Maj, M. Michalov 
ACL Central Laboratory, Rosemont, IL. 
Introduction: The presence of mutation in the KRAS (Kirsten ras) gene has been 
associated with poor response to anti-EGFR (epidermal growth factor receptor) 
therapies for metastatic colorectal cancer (mCRC), and most (>90%) mutations occur in 
codons 12 and 13 of exon 2 of the KRAS gene. The KRAS mutation test will become an 
important aspect of mCRC patient therapy management. Because of the limited amount 
of tumor tissue available for testing, sensitivity and accuracy are central to this test. 
Methods: In this study, we use three different technologies: i) real-time PCR with 
melting curve analysis, ii) modified traditional Sanger sequencing (ABI), and iii) 
Pyrosequencing (Qiagen). When analyzing KRAS mutations from three cell lines (3 
known mutations) and 63 patient specimens positive for KRAS mutation, 10 different 
mutation types were seen. Results: Cell lines SW-480 (G12V), LoVo (G13D), A549 
(G12S) were diluted with a known wild-type sample in serial dilution of 50%, 20%, 10%, 
5% and 1% mutant and analyzed by all three methods. All levels were detected in 7-9 
repeats down to 1% mutant by real-time PCR/MT and down to 5% by sequencing 
assays. A total of 63 KRAS samples (predominantly colon, liver and lung FFPE tissues) 
were run by all three methods. Out of the 63 positive samples all were detected. Tested 
samples contained percentage range of tumor cells (75-<30). Additionally 10 samples 
with tumor cell 30% were run in repetition all of them were detected, therefore we 
determined our cut-off to be around 30% tumor cells. All of the 63 samples showed the 
same KRAS type of mutation by all three methods. Conclusions: This study suggests 
that all three test methods have comparable analytical sensitivity (LOD): down to 1% for 
real-time PCR/MT and 5% for both modified Sanger and pyrosequencing. Although 
clinical sensitivity of all three methods is 100%, we chose to utilize PCR/MT as a 
screening method to accurately and more economically identify the negative cases 
requiring no further analysis. Positive cases are then reflexed to pyrosequencing for 
confirmation and proper identification of individual nucleotide mutation. In this process, 
the pathologist plays a crucial role in selecting appropriate tumor specimens for testing 
and result confirmation. 
 
ST47. Comprehensive Next Generation Sequencing from Formalin-Fixed Tissue 
Representing a Range of Specimen Ages and Tissue Types 
M. Jarosz1, F. Juhn1, K. Brennan1, D. Lipson1, R. Yelensky1, S. Downing1, A. Donahue1, 
S. Balasubramanian1, G. Frampton1, T. Bloom1, Z. Zwirko1, J. Curran1, A. Parker1,  
J.S. Ross1,2, M. Cronin1 
1Foundation Medicine, Inc, Cambridge, MA; 2Albany Medical College, Albany, NY. 
Introduction: Comprehensive cancer genomic testing using Next-Generation 
Sequencing (NGS) technology identifies many more mutations than traditional methods. 
Some of these mutations, whether previously known or novel, may aid therapeutic 
decision making. To realize its full potential to help inform clinical cancer treatment, an 
NGS-based test must perform well on clinically relevant tissue specimens, principally 
formalin-fixed, paraffin-embedded (FFPE) surgical resections, needle biopsies, or fine 
needle aspirates that may vary significantly in age. Furthermore, detection of somatic 
mutations in impure and heterogeneous tumor specimens requires high depth of 
coverage, in contrast to that of germline variants. This is challenging in that formalin 
fixation degrades nucleic acids, making molecular analyses challenging for such 
samples. Here we present a targeted NGS-based test that delivers high quality 
sequencing results from FFPE specimens representing four tissues of origin and 
ranging from one to eleven years old. Methods: DNA was isolated from three 20ȝm 
sections each from 54 FFPE specimens (9 breast, 14 colon, 18 lung, and 13 renal 
tissues) ranging from one to eleven years old. Indexed, ligation-based sequencing 
libraries were constructed using 200ng of DNA from each specimen. Solution-based 
hybrid capture was used to enrich for ~200 cancer-related genes and the selected 
libraries were paired-end sequenced on an Illumina HiSeqTM 2000 platform. Results: 
All 54 samples produced successful (>500ng) libraries, with 52/54 yielding more than 
2ȝg, and were then successfully hybrid captured and sequenced. After removing PCR 
duplicates, the median coverage across all 54 samples averaged 1,000 with a range of 
390 – 1,500. The library yields and median coverage were similar across all specimen 
ages and tissue types. This high depth of coverage allows for high sensitivity to detect 
mutations present at frequencies as low as 5%. Mutations consistent with expectations 
for each tissue type were observed, including mutations in APC, PIK3CA, KRAS, and 
TP53. Additionally, error rates for the FFPE samples were comparable to those of cell-
line sample controls from the same sequencing run. Conclusions: Our study 
demonstrates that high quality NGS data routinely can be obtained from the small 
amounts of tumor present in FFPE cancer tissue specimens representing a wide range 
of sample ages and tissue types. We believe these results indicate that comprehensive 
NGS-based testing should emerge as a routine part of cancer clinical trials and patient 
care. 
 
ST48. EGFR Mutation Analysis in Non-Small Cell Lung Cancers (NSCLC): 
Experience from a Southern Taiwan Molecular Diagnosis Core Center 
Y. Chen1, W. Huang2, W. Su2, C. Ho2, C. Lu2 
1National Cheng Kung University, Tainan, Taiwan; 2Cheng Kung University Hospital, 
Tainan. 
Introduction: Epidermal growth factor receptor (EGFR) mutation analysis detects 
EGFR gene mutations in tumor specimens of patients with non-small cell lung cancer 
(NSCLC). EGFR, when activated, plays a role in cellular tumor growth and proliferation 
and is the target of tyrosine kinase inhibitors (TKI). Recent studies have indicated that 
EGFR mutations are associated with clinical response to gefitinib. Interestingly, all of 
these mutations occur within EGFR kinase domain. These mutations resulted in 
increased tyrosine kinase activity and were sensitive to gefitinib treatment. Methods: 
Paraffin-embedded tissues and needle biopsies of lung specimens (255 total) were 
collected from Cheng-Kung University Hospital between September 2009 and March 
2011. The TK domain of EGFR coding sequence, from exons 18 to 21, was amplified 
by PCR and nested PCR conditions. PCR products were purified by QIAmp Tissue 
FFPE purification kit (Qiagen) and sense and antisense sequences were obtained by 
using forward and reverse internal primers, respectively. Each exon was sequenced 
using the BigDye Terminator Cycle sequence following the PE Applied Biosystem 
strategy and Applied Biosystems ABI PRISM 3500 DNA Sequencer (Applied 
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Biosystem, Forster City, CA). All mutations were confirmed by performing two 
independent PCR amplifications. Results: The 255 samples include 160 
adenocarcinomas, 23 of non–small cell lung cancers/carcinoma 4 squamous cell 
carcinomas (SCC), and 57 cases whose pathology reports are not available. Among 
255 samples, 53% (142/255) of the samples were found to harbor mutations. Most 
mutations were detected in exons 19 (45.7%) and 21 (45.7%). The mutation rates in 
adenocarcinoma, NSCLC/carcinoma, SCC and cases with no pathology report were 
57% (91/160), 35% (8 /23), 0% and 49% (28/57), respectively. For the 17 patients 
treated with gefitinib, 10 of the 11 responders had EGFR mutation; the remaining six 
responders have no mutations. The mutations are rather complex in that altogether 23 
different mutations were observed, and 8 tumors carried 2 mutations. The EGFR 
mutation rate in patients was associated with female than in man (61% vs.39%; 
p=0.004), never smoking history than smoking (79% vs. 20%; p=0.023), but not 
associated with age or cancer stage. Conclusions: The EGFR mutation rate detected 
in this study is 53%. The high mutation rate found in this study is in agreement with 
previous studies that EGFR mutations were more prevalent in Asian subjects with 
adenocarcinoma, are associated with non-smoking history and female than their 
counterparts.  
 
ST49. Activating EGFR Mutations among Patients with Non-Small Cell Lung 
Cancer from India 
R. Pai, A.G. Nehru, A. Singh, A.D. Bhatt, S. Suganthi, A. Korula, R.T. Chacko 
Christian Medical College, Vellore, India. 
Introduction: Tyrosine kinase inhibitors (TKIs), targeting the epidermal growth factor 
receptor (EGFR), have replaced chemotherapy as the first line treatment of choice for 
advanced non-small cell lung cancer (NSCLC). However, not all patients respond to 
therapy. In this context, somatic mutations in the EGFR gene (exons 18-21) have 
proven to be reliable predictors of response to therapy. But there is limited data on 
EGFR mutations among patients with NSCLC from India. In this study, we analyzed the 
frequency of these mutations by PCR-sequencing and also attempted to determine the 
utility of bi-directional PCR amplification of specific alleles (Bi-PASA) in detecting EGFR 
mutations. Methods: DNA was extracted from formalin-fixed, paraffin-embedded 
(FFPE) tissues of 46 cases of NSCLC obtained during the period January 2008 to 
March 2011, after manually microdissecting from areas that had ~40% tumor. The DNA 
was amplified targeting exons 18-21 of the EGFR gene and the products were 
sequenced using the ABI PRISM BigDye Terminator Cycle Sequencing Kit. Bi-PASA 
was performed on a subset of 20 samples using previously published allele specific 
PCR primers targeting exons 19 and 21, including DNA from NCI-H-1650 and NCI-H-
3255 as controls respectively. Results: Of the 46 cases included, 43% were positive for 
mutations, with deletion in exon 19 (del E746-A750) being most frequent (70%). 
Mutations were also seen in exons 21 (L858R), exon 20 (mutation H773 ins NPH) and 
at exon 19 (del L747-P753 ins A and del L747-P753 ins S). Fifty-four percent of the 
women (n=13) included in the study had mutations while only 39% of men (n=33) 
carried mutations. The Bi-PASA assay was performed on a subset of 20 samples and 
primers AQ, which amplify the wild-type sequence of EGFR 19 was positive only in 
15/20 samples. Primers PB that are designed to detect nucleotide deletions at E746-
A750, amplified only 4/5 samples with this deletion. Similarly the G reaction specific for 
L858R mutation in exon 21 was positive only in 2/3 cases with this mutation. 
Conclusions: The frequency of EGFR somatic mutations among patients with NSCLC 
in our study population is higher than the incidence in the western world but similar to 
the reports from the Asian region. Allele specific PCR, though easy to perform and 
useful in resource limited settings, will have to be assessed on a larger data set to 
determine its true utility.  
 
ST50. EGFR Gene Amplification and MGMT Gene Promoter Methylation in 
Gliosarcomas: Series of 31 Cases with Clincopathological Features 
S. Epari, S. Ahmed, R. Jalali, A. Moyiadi, T. Gupta, P. Shetty, M. Bal 
Tata Memorial Centre, Mumbai, India. 
Introduction: Gliosarcomas (GS) are rare WHO grade IV primary biphasic brain 
tumors composed of high grade glial and mesenchymal components with either similar 
or worse prognosis than glioblastomas. Methods: Archives of the departmental files of 
the last nine years were reviewed and cases of gliosarcoma, where paraffin blocks and 
reasonable clinical information were available were included for the study. All these 
cases were evaluated for EGFR gene amplification by fluorescence in situ hybridization 
and MGMT gene promoter methylation by gel-based methylation PCR assay, in 
addition to routine histomorphological and immunohistochemical evaluation. Results: 
Total 31 cases with age range of 12-70 yrs (median: 50yrs and mean: 47.4 yrs) and sex 
ratio: 6.75:1(M- 27; F-4) were noted. Commoner sites were temporal (n-12) and frontal 
(n-10); while other sites were parietal (n-4), occipital (n-2), intraventricular, 
cerebellopontine angle and pineal (one case each). One case each occurred in treated 
patients of medulloblastoma and adenoid cystic carcinoma of lip. One case showed an 
extracranial direct contagious extension into the temporal fossa and one showed 
systemic metastasis to iliac bone. Histologically, all except for one case showed an 
intricate admixture of glial and mesenchymal components. One case (known treated 
case of adenoid cystic carcinoma) showed a predominantly sarcomatous component 
with very scant (<5%) glial component. Myogenic differentiation was noted in six cases, 
one case showed chondrosarcomatous differentiation and in rest of the cases no 
specific differentiation of the sarcomatous component identified. Additionally, three 
cases showed admixed population of small undifferentiated small cell component. TP53 
immunopositivity was noted in 27 cases and negative in 4 cases. MIB-1 LI was 15% to 
40% (10% to 15% - 17, 15% to 20% -8, 20% to 30% -3 and 30% to 40% - 3). EGFR 
gene evaluation could be interpreted in 26 cases, of which one case showed 
amplification; while the rest of the 25 cases were non-amplified. MGMT gene promoter 
methylation results were available in two cases and both were non-methylated. The 
remainder are being evaluated. Conclusions: EGFR gene amplification is an 
uncommon molecular abnormality in GS. In addition, this series also documents the 
occurrence of these tumors at rare sites (intraventricular and CP angle), uncommonly 
as second primary tumors, heterogeneity of dedifferentiation (undifferentiated, 
myogenic and rarely matrix producing chondrosarcomatous) and their potential for 
extracranial metastases. 
 
ST51. Sensitive Quantitative Methylation Analyses for Risk Assessment of 
Coexisting Dysplasia in Ulcerative Colitis Patients 
T. Uehara1, D.L. Aisner2, Y. Yao1, W. Yan1, M. Regueiro3, F. Fogt4, S.L. Jorge5,  
A. Sepulveda1 
1University of Pennsylvania, Philadelphia, PA; 2University of Colorado Denver, Denver, 
CO; 3UPMC Presbyterian, Pittsburgh, PA; 4Penn Presbyterian Medical Center, 
Philadelphia, PA; 5Veterans Administration Hospital, Philadelphia, PA. 
Introduction: Patients with ulcerative colitis (UC) may develop colon cancer after 
longstanding chronic colitis, followed by dysplasia and ultimately cancer. Dysplasia and 
cancer in UC develop through complex pathways, including epigenetic deregulation 
associated with CpG methylation of cancer related genes. The field defect in 
background colitis includes epigenetic changes that predispose to dysplasia and cancer 
development. In this study we aimed to determine whether background colitis of 
patients with co-existing dysplasia shows higher levels of methylation in cancer related 
genes MGMT, MLH1, P16 and TGFBR3, as compared to colitis of patients without 
dysplasia. Methods: CpG methylation levels of the promoter regions of MLH1, MGMT, 
P16 and TGBR3 were determined in the mucosa of Colectomy specimens from 33 UC 
patients (12 without dysplasia or cancer and 21 with co-existing low-grade dysplasia). 
DNA was extracted from paraffin sections from selected areas of colitic mucosa or low-
grade dysplasia. Bisulfite modified DNA was used for quantitative SYBR green 
methylation specific PCR (QMSP). Methylation levels of each CpG locus were 
measured and reported as a% of the reference actin gene. Results: CpG methylation 
of the four genes was negligible in colitic mucosa of UC patients without co-existing 
dysplasia or cancer, averaging 0.0 to 0.5% methylation, while CpG methylation of the 
four genes was significantly increased in dysplasia and associated background colitis of 
patients with co-existing dysplasia (mean: 4.6; 2.2; 5.1; and 1.6 in colitis and 11.2; 8.8; 
4.1; and 1.4% methylation in dysplasia, for MGMT, MLH1, P16 and TGFBR3, 
respectively, P<.001). In contrast, the methylation levels were not significantly different 
between matched background colitis and dysplastic lesions of UC patients with co-
existing dysplasia (P>.05 for each of the four genes). Multiple logistic regression 
analysis of methylation levels of the four genes in background mucosa was used to 
derive a probability for the presence of dysplasia with a sensitivity of 100% and a 
specificity of 86%. ROC analysis indicated that the area under the curve for the logistic 
regression-derived combined probability was 0.98, as compared to 0.91, 0.86, 0.83, 
and 0.74 for individual P16, MLH1, MGMT, and TGFBR3 levels. Conclusions: 
Sensitive quantitative methylation testing of a limited gene panel using mucosal 
biopsies may be a specific and sensitive test for the presence of dysplasia in patients 
with ulcerative colitis. Methylation test results may be used to refine the selection 
criteria for colonoscopic surveillance in ulcerative colitis patients.  
 
ST52. Rapid Identification of EGFR Pathway Somatic Mutations in Melanoma of 
Varying Subtypes 
H.M. Froehlich1, M.C. Schwab2, G.J. Tsongalis3,4, J.B. Brennick1,4 
1Dartmouth Hitchcock Medical Center, Lebanon, NH; 2Dartmouth Medical School, 
Dartmouth-Hitchcock Medical Center, Lebanon, NH; 3Dartmouth-Hitchcock Medical 
Center and Norris Cotton Cancer Center, Lebanon, NH; 4Dartmouth Medical School, 
Hanover, NH. 
Introduction: Multiple genes associated with signaling pathways, specifically the EGFR 
pathway, have become targets of interest in molecular therapies for treatment of 
melanoma. Somatic mutations in the EGFR pathway, particularly in the BRAF and 
NRAS genes, are frequently seen in primary and metastatic melanomas. Rapid 
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identification of a large number of somatic mutations in melanoma will likely become 
increasingly important due to the molecular heterogeneity of mutations in primary and 
metastatic melanomas. In this study, we evaluated melanomas of varying subtypes with 
a method for rapid identification of a large number of somatic mutations in the EGFR 
pathway. Methods: DNA from eleven primary and metastatic melanomas of varying 
subtypes was macrodissected and DNA was extracted using the Qiagen Gentra 
Puregene Blood Kit. Following DNA extraction, qPCR of each melanoma was 
performed using the Qiagen qBiomarker™ Somatic Mutation PCR Array, directed at the 
Human EGFR pathway, and run on the AB 7500 Fast Real-time PCR System. The 
average Ct method was used to determine the mutational status of each melanoma for 
85 somatic mutations across 9 genes. Results: Eleven melanomas were examined for 
85 somatic mutations within the human EGFR pathway. Two melanomas, both 
metastatic, were shown to have a single mutation in the NRAS gene (Q61R and Q61L). 
The remaining nine melanomas of varying subtypes (superficial spreading, nodular, 
acral lentiginous, spindle cell melanoma and additional metastatic melanomas) were 
shown to be wild type for genes known to harbor somatic mutations in the EGFR 
pathway. Conclusions: Somatic mutations in melanomas have molecular 
heterogeneity that can be time consuming and costly to evaluate and identify. Rapid 
identification of multiple mutations of interest are more efficient and cost-effective than 
traditional SNP genotyping techniques. As somatic mutations are increasingly targeted 
by molecular therapies for melanoma, the utility of such methods are becoming an 
optimal tool in research, and potentially in clinical settings. In addition, further evaluation 
of varying melanoma subtypes using rapid identification of a comprehensive number of 
mutations may reveal molecular signatures specific for most commonly seen 
melanomas. 
 
ST53. MGMT Promoter Methylation in Colorectal Cancer Is Associated with G>A 
KRAS Mutations and High Stage at Presentation 
C.E. Hagen, J.A. Lefferts, J.M. Pipas, C.E. Fadul, G.J. Tsongalis, L.J. Tafe 
Dartmouth Hitchcock Medical Center, Lebanon, NH. 
Introduction: Promoter methylation of O6-methylguanine-DNA methyltransferase 
(MGMT), a DNA repair enzyme, is seen as an early event in the progression of various 
types of cancer. In Glioblastoma, MGMT methylation predicts a positive response to 
alkylating chemotherapy agents such as temozolimide. In colorectal cancer (CRC), data 
supporting the prognostic significance of MGMT methylation has been limited. Recent 
data show that patients with metastatic CRC and loss of MGMT expression may 
respond to temozolmide. The goal of our study was to determine the prevalence of 
MGMT methylation in CRC patients and to associate these findings with KRAS 
mutation status, pathologic features, and patient outcomes. Methods: Thirty-five 
patients (mean age 61.7; M:F 18:17; average follow up 43 mos.) with a history of CRC 
were included. Tumor DNA previously extracted from FFPE for determination of KRAS 
status was used for analysis. The EpiTect Bisulfite kit (Qiagen) was used for bisulfite 
conversion. Converted DNA was then subjected to a real-time, methylation-specific 
PCR to detect MGMT promoter methylation and ACTB as an internal control. Four 
patients had ACTB Ct levels >35 and were excluded from analysis. Pathologic and 
clinical information were collected through chart Results: Ten patients (32%) were 
positive for MGMT methylation. The average age of the methylated group was 66.6 
(range 50-84) vs. 56.3 (range 35-81) in the unmethylated group. 50% of the methylated 
group had a coexisting KRAS mutation and of these 80% were codon 12 or 13 G>A 
mutations. Only 24% of the unmethylated group had a coexisting KRAS mutation; 60% 
were G>A mutations. Patients in the methylated group were more likely to have right-
sided CRC (30% vs. to 24%) and to present with stage IV disease (56% vs. 35%). All 
patients except 2 received an alkylating agent (oxaliplatin-based chemotherapy) during 
treatment; these two patients were in the methylated group, had stage IV disease, and 
were deceased at last follow up. Mortality in both groups was similar: methylated 60% 
(83% CRC-related) and unmethylated 62% (85% CRC-related). Conclusions: Here, 
MGMT methylation was present in 32% of CRCs, similar to previous reports. These 
patients were more likely to have KRAS codon 12 or 13 G>A mutations, older age of 
CRC onset, right-sided lesions, and higher pathologic stage at diagnosis than the 
unmethylated group. Although MGMT methylation did not confer a survival benefit, 
patients with high pathologic tumor stage and MGMT methylation may benefit from 
newer alkylating agents such as temozolomide.      
 
ST54. DNA Extraction Method for Formalin-Fixed, Paraffin-Embedded Breast 
Cancer Specimens and Quality Assessment Comparison to DNA Isolated from 
Matched Fresh Frozen Specimens for Array CGH 
T.J. Gliem, J.E. Eckel Passow, P.A. Decker, M.L. Kosel, J.C. Hodge 
Mayo Clinic, Rochester, MN. 
Introduction: Formalin-fixed, paraffin-embedded (FFPE) specimens are frequently the 
only available source of solid tumor tissue for analysis, particularly in a reference 
laboratory setting. Unlike fresh frozen (FF) tissue, the FFPE process induces DNA 
fragmentation that is not ideal for array comparative genomic hybridization (aCGH). 
aCGH identifies copy number changes and its application in tumors is of clinical interest 
to detect diagnostic and prognostic genetic markers. This study was designed to 
identify a method of isolating DNA from FFPE breast cancer samples that yields DNA of 
sufficient quality to produce concordant aCGH results to those of patient-matched FF 
samples. We demonstrate a statistical assessment to confirm comparable DNA quality 
between FFPE and FF samples. Methods: Following IRB approval, DNA was extracted 
from twenty patient-matched FFPE and FF invasive breast tumors using three QIAGEN 
kits. Extracted DNA was quantified on a NanoDrop and fluorometer and fragment size 
tested by PCR. DNA was labeled using the Genomic DNA ULS Labeling kit, hybridized 
to Agilent arrays with a fragmented normal blood reference sample, and analyzed using 
DNA Analytics. We compared patient-matched FFPE and FF samples with respect to 
precision of the base-2 logarithm transformed foreground intensities individually for the 
Cy3 and Cy5 median intensity values as well as for the LogR values. Additionally, we 
examined the reproducibility associated with replicate assays for a set of patient-
matched FFPE and FF samples. Results: The QIAamp kit, with protocol modifications, 
yielded the highest DNA concentrations and quality. Visual inspection of the data in 
DNA Analytics showed consistent trace alignment of the patient-matched FFPE and FF 
samples. Similar distributions of foreground intensities as well as derivative log ratio 
spread (DLRS) values were observed between matched FFPE and FF samples. The 
replicate FFPE assays resulted in a Pearson correlation of 0.96, 0.96 and 0.78 for the 
foreground Cy3, Cy5, and LogR values, respectively. Similarly, the replicate FF assays 
resulted in a Pearson correlation of 0.95, 0.94, and 0.61. Bland-Altman plots indicate 
that the discordance in the replicate assays is intensity-dependent such that higher 
intensity probes are more discordant than lower intensity probes. We hypothesize that 
the discordance is likely due to a technology limitation as both the replicate FFPE and 
frozen samples showed the same trend. Conclusions: A modified QIAamp kit method 
for DNA extraction from FFPE breast cancer tissue produced comparative quality and 
aCGH results to patient-matched FF samples as assessed by trace alignment, 
foreground intensity, DLRS, and concordance of replicate assays. 
 
ST55. Utility of Gene-Expression Profiling for Reporting Difficult-to-Diagnose 
Cancers 
M. Pollen1,4, G. Wellman2, M. Lowery-Nordberg2,3 
1University of Mississippi, Jackson, MS; 2Delta Pathology, Shreveport, LA; 3Feist-
Weiller Cancer Center, Shreveport, LA; 4Vanderbilt University, Jackson, MS. 
Introduction: Studies of primary and metastatic lesions of poorly differentiated 
malignancies find approximately 80% of lesions are identified with routine stains and 
immunohistochemistry (IHC). When examining only metastatic carcinomas of unknown 
primary, this figure drops to 65%. Limited clinical information further decreases this 
value. Inexperienced pathologists will arrive at erroneous conclusions more frequently. 
When the primary tumor site is ambiguous among three or more possibilities, there are 
no standard algorithms for IHC panels. Information from these stains is often 
indeterminate.  The appropriate use of targeted chemotherapy requires knowledge of 
tumor type. These expensive therapies have side-effects and are only effective for 
select patients. A determination of primary tumor is requisite for their use. Pathwork® 
Diagnostics offers a Tissue-of-Origin (TOO) microarray-based test as an adjunct to IHC 
to reduce ambiguity of stain interpretation and provide greater accuracy in 
determination of cancers of unknown origin. Methods: This is a retrospective study of 
cases referred to Genoptix® for Tissue-of-origin microarray testing from April 1, 2009 
through the present. Cases included: are considered difficult-to-diagnose carcinomas, 
have histopathology reports, have three or more possible sites of origin. Original 
diagnosis, TOO results, and difference, if any, between working and final diagnoses are 
compared. TOO relies on mRNA expression in 15 organs. Over 2,000 mRNA 
sequences comprise the expression profiles. Tumors are given a similarity score, 
ranging from 0-100, to a particular tissue based on gene expression pattern. The scores 
sum to 100 across all tissue types. A high score confidently assesses origin. Scores 
under 20 are non-contributory. Results: Nineteen cases of difficult-to-diagnose 
carcinomas were examined for original working diagnoses, gene-expression profiling 
and difference in final opinion based on gene-expression results. Of the nineteen cases, 
12(63%) revealed a different site of origin from the pathologist-favored site. Of these, 2 
did not yield high enough similarity scores to change the position of the pathologists. In 
2 cases, a clinically assumed primary lesion turned out to be metastatic. 2(10%) cases 
were not able to arrive at a similarity score above 20, the lowest meaningful score. The 
remaining 5(26%) cases had results that concurred with the original interpretation. 
Conclusions: The Pathwork® Diagnostics Tissue-of-origin test is a valuable adjunct to 
immunohistochemistry in determining site of origin for lesions that are poorly 
differentiated or show staining and morphology patterns that are inconsistent with 
expectation.   Given the current clinical need for origin determination, the Tissue-of-
Origin test can provide increased diagnostic acumen for challenging specimens.  
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ST56. Comprehensive Molecular Analysis of High Grade Invasive Urothelial 
Bladder Carcinomas by Whole Genome, Mate-Pair, and Whole Exome 
Sequencing 
L.M. Sabatini1, N.J. Nowak1,2, J.M. Conroy1, K. Head1, J.L. Jamison2, P. Liu3, D. Xiong3, 
P.T. Vedell4, M. You4, C. Morrison1 
1Roswell Park Cancer Institute, Buffalo, NY; 2State University of New York at Buffalo, 
Buffalo, NY; 3Medical College of Wisconsin, Milwaukee, WI; 4Cancer Center, Medical 
College of Wisconsin, Milwaukee, WI. 
Introduction: An estimated 386,000 new cases and 150,000 deaths from bladder 
cancer occur annually worldwide. There is a 14-fold variation globally and a 2- to 5-fold 
higher incidence in males. Primary contributors to bladder cancer incidence include 
smoking, occupational exposures, and chronic infections. Of patients with high grade 
invasive urothelial carcinoma, up to 70% develop recurrences, and stage progression 
and death due to disease are observed in as many as 65% of patients. We attempted a 
comprehensive genomic analysis of high grade urothelial carcinomas by whole 
genome, mate-pair, and whole exome sequencing in order to better define features that 
may assist in improved patient management. Methods: Five tumor genomes from high 
grade invasive urothelial carcinoma with matching normal DNA were sequenced on the 
Illumina HiSeq2000 with 30- to 40-fold average coverage. The same five tumors as well 
as two well characterized bladder cancer cell lines, one karyotypically complex and one 
near diploid, were analyzed by the Illumina mate-pair protocol (5Kb fragment size) to 
identify structural rearrangements. An additional 28 high grade urothelial carcinomas 
with matching normal DNA (14 node negative and 14 node positive) were analyzed by 
whole exome capture and sequencing using the Illumina TruSeq exome capture 
protocol (62Mb, covering 97.2% RefSeq coding exons). Results: After filtering data 
against the paired normal samples, deep sequencing of high grade urothelial 
carcinomas showed 103 to 104 somatically-acquired mutations per tumor. 10 to 102 
variants per tumor were predicted to be potentially deleterious by Ensemble Variant 
Effect Predictor and further mapped into cancer-related pathways. At least 12 genes 
were found to be mutated in more than one tumor. Some recurrent genes were known 
cancer-associated genes, while others likely represent passenger mutations. The mate-
pair protocol successfully identified structural rearrangements using a low-coverage, 
tumor only strategy as compared to deep sequencing. Whole exome analysis showed, 
for example, that FGFR3, TP53, and PIK3CA are commonly mutated in high grade 
urothelial carcinomas. Conclusions: Whole genome analysis provided, for the first 
time, a comprehensive picture of the genome complexity in high grade, invasive, 
urothelial carcinomas. In addition, all samples showed similar tumor-specific structural 
rearrangements by a low-coverage mate-pair protocol, which may provide a highly 
sensitive, cost-effective method for monitoring patients for recurrent disease. In whole 
exome analysis, some differences were observed between node negative and node 
positive tumors. A larger data set will be required to confirm these observations.  
 
ST57. Evaluation of HER2 FISH with Centromere 17 Probe Scores >2.9 
S.A. Tandy, J. Mabray, A. Womack, K. Huspen, J. Wagenfuehr, D. Cohen, R. Miller,  
C. Buresh, R. Oliai, K. Murphy 
ProPath, Dallas, TX. 
Introduction: Assessment of HER2 (ERBB2) gene copy number by Fluorescence In-
Situ Hybridization (FISH) is a standard method for identifying HER2 amplification in 
breast carcinoma. When using a single color FISH probe to HER2, amplification is 
defined as greater than 6 copies of HER2 per cell.  When using dual-color FISH probes 
to HER2 and centromere 17 (CEP17), HER2 amplification is defined as a ratio of HER2 
to CEP17 > 2.2. This calculation is designed to prevent misclassification of 
chromosome 17 polysomy as positive for HER2 amplification.  Recent data suggests 
that not all cases with increased signal from CEP17 are due to polysomy, potentially 
resulting in false negative HER2 ratio scores. We have reviewed our HER2 FISH data 
to identify cases with increased CEP17 signal to determine what percentage of cases 
would have been interpreted as negative, equivocal, or positive had the analysis been 
performed using a single probe assay. Methods: Paraffin-embedded tissues were 
processed per the PathVysion (Abbott, Inc.) protocol. All samples were analyzed using 
the PathVysion criteria and 2007 ASCO/CAP guidelines for HER2 testing in breast 
cancer. Negative (non-amplified) samples had HER2:CEP17 ratios of <1.8. Equivocal 
samples had ratios between 1.8 and 2.2, and the positive (amplified) samples had 
ratios of greater than 2.2. Tissue sections were also evaluated by 
Immunohistochemistry (IHC) for HER2 protein expression, using a HER2-specific 
antibody (clone SP3, 1:80), EDTA antigen retrieval (manual method), peroxidase-
conjugated polymer, and DAB chromogen. Results: We identified 38 cases with 
CEP17 signal > 2.9. HER2 IHC results were available for 23 of these cases. For one 
case, the HER2/CEP17 ratio was consistent with amplification. For the remaining 37 
cases, the HER2/CEP17 ratio was consistent with negative for amplification.  In the 
absence of the CEP17 signal, 23/37 (62.2%) would have been scored as negative, 
11/37 (29.7%) would have been scored as equivocal, and 3/37 (8.1%) would have been 
scored as positive for amplification. Although not statistically significant, there was a 
trend toward increased HER2 IHC scoring with increased HER2 FISH score. 
Conclusions: Our data indicates that 35% to 40% of cases with increased CEP17 
signal would have been reported as equivocal or positive for HER2 amplification if a 
single probe assay had been performed. These results are consistent with data 
reported by others. This type of discrepancy needs further investigation in order to 
avoid failing to treat patients who may benefit from HER2-targeted therapy. 
 
ST58. Whole Exome Analysis and Tumor Evolution of a Rare Malignant 
Myoepithelioma Tumor of Soft Tissue 
C. Morrison1, N.J. Nowak1,2, J. Conroy1, K. Head1, J.L. Jamison2, P. Liu3, D. Xiong3, 
P.T. Vedell4, M. You4, L.M. Sabatini1 
1Roswell Park Cancer Institute, Buffalo, NY; 2State University of New York at Buffalo, 
Buffalo, NY; 3Medical College of Wisconsin, Milwaukee, WI; 4Cancer Center, Medical 
College of Wisconsin, Milwaukee, WI. 
Introduction: Malignant myoepithelioma of soft tissue is a rare tumor, and little is 
known about best treatment practices. We report here whole exome analysis of a local 
recurrence of disease in the great toe, a metastatic lesion in an inguinal lymph node, 
and a lesion to the left lower lung, from a patient diagnosed with malignant 
myoepithelioma who universally failed radiation and chemotherapy. Whole exome 
sequencing provides an unbiased analysis of the recurrent and metastatic tumor 
genomes, which may illuminate mechanisms of tumor progression as well as identify 
molecular features that may guide patient care. Methods: DNA was extracted from 
fresh frozen tumor tissues and whole blood from a patient with metastatic malignant 
myoepithelioma. Indexed DNA libraries were prepared from fragmented genomic DNA 
and enriched by a 10-cycle PCR. Libraries were pooled and exomic fragments were 
captured using the Illumina exome enrichment protocol, designed to capture 62Mb of 
genomic DNA (97.2% RefSeq coding exons). Samples were sequenced on an Illumina 
HiSeq2000 (2X100 bp, paired-end reads). FASTQ files were aligned to the reference 
genome, filtered to identify somatically-acquired mutations, and annotated. A selection 
of 100 SNVs was validated by Sanger sequencing and included both a random 
selection of SNVs (50) and a selection of unique and common mutations between the 
three different tumor samples (50). Results: All four exomes were sequenced to an 
average depth of 100X coverage, enhancing the detection of low frequency variants. 
Most variants were common between the three tumor exomes, while a smaller number 
were unique. Validation studies showed high concordance with conventional Sanger 
sequencing, especially among those variants identified in two or three tumor 
specimens. Unique variants showed a higher false positive rate. Conclusions: Whole 
exome analysis has become a manageable approach to understanding tumor biology 
and tumor evolution in rare cancer subtypes, for which little information is available. 
Advantages include a comprehensive analysis of SNV and copy number alterations for 
protein coding regions. This approach does not currently identify structural 
rearrangements, mitochondrial variants, or regulatory regions, which may be important 
in tumor evolution and stage progression. As costs continue to decline and data 
analysis becomes standardized, whole exome sequencing may be a sensitive and cost-
effective approach to the analysis of rare tumor types. Molecular profiling will potentially 
provide critical information to effectively manage patient care. 
 
ST59. PTEN, KRAS, and PIK3CA Sequencing of Endometrioid and Non-
Endometrioid Type Endometrial Cancers 
L.M. Peterson, B.R. Kipp, F. Medeiros, K.C. Halling 
Mayo Clinic, Rochester, MN. 
Introduction: Endometrial cancer is associated with numerous gene alterations that 
activate oncogenes and inactivate tumor suppressor genes. Many studies have 
assessed endometrial cancer associated genes individually on endometrioid type 
endometrial cancer (ETC) or non-endometrioid type endometrial cancer (NETC), so it is 
difficult to discern whether these gene alterations are overlapping or mutually exclusive 
among the different histological subtypes. The aim of this study was to characterize a 
set of ETC and NETC for PTEN, KRAS, and PIK3CA alterations by sequencing and to 
assess for correlations between these common alterations. Methods: Genomic DNA 
was extracted from fresh-frozen tumor samples from 86 endometrial cancers including 
55 ETC (32 grade I, 12 grade II, and 11 grade III) and 31 NETC (17 carcinosarcoma, 9 
serous carcinoma, 2 clear cell carcinoma, and 3 mixed tumors). Sequencing was 
performed for the detection of alterations in PTEN (exons 1-9), PIK3CA (exons 9 and 
20), and KRAS (exons 2 and 3) genes. Results: At least one PTEN alteration 
(pathogenic mutation or variant of unknown significance) was identified in 48 (56%) 
specimens, including 41 (73%) ETC and 7 (23%) NETC. A PIK3CA alteration was 
observed in 16 (19%) specimens, including 8 (15%) ETC and 8 (26%) NETC. 
Interestingly, 56% of serous cancers had a detectable PIK3CA mutation, compared to 
only 14% of non-serous tumors. Twelve of 86 cases (14%) analyzed for KRAS 
mutations were found to have a mutation, including 8 (15%) EC and 4 (13%) NETC. 
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Eleven (23%) and 6 (13%) of the 48 specimens with a PTEN alteration also had a 
PIK3CA and KRAS mutation, respectively. This suggests that the co-existence of either 
a PIK3CA or a KRAS mutation with a PTEN mutation is not uncommon. None of the 16 
specimens with a PIK3CA alteration had a KRAS mutation, suggesting that these 
alterations are mutually exclusive. Conclusions: Our study has assessed a large 
cohort of diverse endometrial carcinomas for alterations in the PTEN, KRAS, and 
PIK3CA genes. The findings of this study suggest that endometrial cancers encompass 
a multitude of unique molecular profiles, and larger multi-gene testing studies are 
needed to better understand endometrial cancer pathogenesis. 
 
ST60. Identification of Rare Mutations in Cancers While Screening for High 
Frequency Mutations Using Sequenom® MassARRAY System 
H. Rahimi, R. Singh, A.N. Bartley, K.P. Patel, B.A. Barkoh, J. Manekia, R. Luthra 
The University of Texas M.D. Anderson Cancer Center, Houston, TX. 
Introduction: One of the important goals of personalized cancer therapy is to 
determine the mutational status of all therapeutically and prognostically relevant genes 
in the tumor. Routine screening for multiple mutations is hindered by the need for 
multiple platforms and limited sample. Consequently, routine screening focuses on the 
common mutations with the rarer, albeit clinically significant, mutations being neglected. 
We have employed a Sequenom® MassARRAY-based multiplex mutation detection 
panel as a high-throughput method to simultaneously screen for both high frequency 
and low frequency mutations in clinically important genes. We report the low frequency 
mutations identified so far. Methods: Following micro dissection, genomic DNA was 
isolated from formalin-fixed, paraffin-embedded (FFPE) tumor from several cancer 
types (N=425). A panel was developed to screen for mutations in 13 genes including 
rare mutations in four genes (AKT1, PIK3CA, GNAS and GNAQ) in addition to 
frequently mutated genes such as KRAS and BRAF. Briefly, 10ng DNA was subjected 
to PCR and single-base-primer extension using iPLEX Gold kit and samples were 
subjected to MALDI-TOF mass spectrometry (Sequenom®, CA). Results: The tumor-
type specific reported frequencies of mutations shown below in parenthesis were 
obtained from Catalog of Somatic Mutations in Cancer (COSMIC) database. In our 
study, in colon adenocarcinoma, five mutations were detected in PIK3CA (codon 
(reported number of cases in COSMIC)): p.C420R (8), p.N345K (2), p.E110K (0), 
p.H1047R (139) and p.N88Q (7). One mutation was detected each in AKT1 p.E17K (0), 
GNAQ p.Q209P (0) and GNAS p.R201C (0). In papillary thyroid cancer and breast 
carcinoma a single mutation p.N345K (0 for thyroid and 23 for breast)) was detected in 
PIK3CA with no mutations detected in other genes tested. In leiomyosarcoma and 
melanoma, a single mutation was detected in GNAQ p.Q209P (0 for both)). In thyroid 
carcinoma one mutation p.R201C (9) was detected in GNAS with no mutation detected 
in the other three genes tested. Overall, of 425 cases tested, only 19 cases were 
positive to at least one of the 12 mutations tested reflecting their rarity of occurrence. 
Conclusions: Sequenom® MassARRAY system can simultaneously detect frequent 
and rare mutations using limited sample. This approach can be applied as a convenient 
high-throughput technique to screen for rare mutations and obtain more comprehensive 
mutational profile using limited sample. 
 
ST61. Next Generation Sequencing from Formalin-Fixed, Paraffin-Embedded 
Tissue 
C. Baker1, R. Margraf1, J. Durtschi1, W.L. Donahue1, C.P. Vaughn1, K. Voelkerding 2, 
W. Samowitz1,2 
1ARUP Institute for Clinical and Experimental Pathology, SLC, UT; 2University of Utah, 
SLC, UT. 
Introduction: Formalin fixation and paraffin embedding (FFPE) is the standard for 
processing tumor tissue in pathology departments. Archived tissue blocks provide an 
important resource for molecular oncology studies, as tissue in this form and some 
degree of clinical follow-up is available from nearly all tumors. However, the fixation 
procedures that are necessary for tissue preservation compromise the quality of the 
DNA, making FFPE a challenging sample for many molecular applications. Clinical 
evaluation of FFPE tissue for oncogene mutations, such as those in KRAS, has been 
achieved, but this typically involves evaluation of a small number of nucleotides. 
Evaluation of an entire genome from FFPE tissue, as with next generation sequencing 
(NGS), is more challenging especially as compared to NGS on higher quality DNA, 
such as from peripheral blood leukocytes. We developed a protocol for NGS on 
routinely processed FFPE. Methods: We developed a protocol to prepare an NGS 
sequencing library from FFPE tissue from a melanoma sample. The sample was 
microdissected to enrich for tumor cells from a 5 µm slice of tissue. DNA was extracted 
using the Qiagen DNA extraction kit with an extended (4 days) Proteinase K incubation. 
DNA was then sheared to approximately 800 base pairs with the Covaris adapted, 
focused, acoustic technology. The SPRI-TE automated nucleic acid extractor was used 
for Illumina adaptor ligation. PCR was done across the adaptors and gel extraction and 
purification to select for a 400 bp fragment. Kapa Biosystems quantitative PCR was 
used to assess validated library quantity. The Illumina c-Bot generated clusters on 8 
lanes of a flow cell and the Illumina Hi Seq generated 2x100 paired end reads. Results: 
The entire genome of the melanoma was sequenced. Over 90% of the reads had Q 
scores greater than 30, corresponding to 99.9% base call accuracy. Average coverage 
of the genome was 30 reads per base. A BRAF c.1799A>T (V600E) mutation was 
detected in 17/29 reads (59%). BRAF mutation detection of the original DNA extraction 
before library preparation showed the same mutation at 57%. Conclusions: The 
protocol described here is a method for next generation sequencing of an entire tumor 
genome from FFPE. The Q scores and coverage were comparable to sequence from 
genomic DNA from whole blood or snap frozen tissue. Targeted sequencing, such as of 
the exome or kinome, when paired with this protocol, would likely provide adequate 
coverage for somatic mutation detection in FFPE samples.  
 
ST62. High Resolution Melt Analysis (HRMA), a Sensitive Screening Method to 
Detect Exonic Mutations in Phosphatase and Tensin Homologue (PTEN) Gene in 
Cancers 
N.G. Reddy, R. Singh, A.V. Paladugu, H. Rahimi, K.P. Patel, R. Luthra 
The University of Texas M.D. Anderson Cancer Center, Houston, TX. 
Introduction: PTEN encodes a tumor-supressor phosphatase capable of 
dephosphorylating both phospholipids and phosphoproteins. It dephosphorylates 
phosphotidyl inositol 3,4,5-triphosphate (PIP3), thus antagonizing the PI3K/AKT-PKB 
signaling cascade. PTEN functions are lost, in at least a subset of most cancers types, 
due to gene deletion or loss-of-function mutations. These mutations are scattered 
across all nine exons making mutational analysis for clinical purposes very labor 
intensive with routinely employed techniques like Sanger sequencing. Here we have 
explored the use of HRMA analysis as a screening tool to identify the exons with 
mutations for Sanger sequencing confirmation. Methods: DNA from 16 formalin-fixed, 
paraffin-embedded (FFPE) endometrial tumors was isolated following manual 
microdissection. PCR to amplify the 9 exons of PTEN was performed using 50ng of 
gDNA template and the amplicon sizes ranged from 147-244 bp. HRMA analysis was 
performed in Roche LightCycler 480 (Indianapolis, IN). Either DNA from patient 
samples or cell lines with known PTEN mutations was used for optimizing HRMA 
conditions. HRMA-PCR products from all cases were sequenced bi-directionally using a 
3730 Genetic Analyzer (Life Technologies, Carlsbad, CA). Serial dilution studies were 
performed using positive FFPE CAMA1 cell line (D92H) into negative FFPE HL60 cell 
line. Results: A total of 19 mutations were detected in 16 cases by Sanger sequencing, 
which included point mutations, insertions and deletions. Exon 5 (encoding 
phosphatase domain) (6/19 or 32%) and exon 8 (encoding protein-binding domain) 
(6/19 or 32%) had the highest number of mutations followed by exon 7 (4/19 or 21%), 
exon 1 (2/19 or 11%) and exon 6 (1/19 or 5%). No mutations were identified in exon 2-4 
or 9. HRM was able to detect all the mutations identified by Sanger sequencing 
exhibiting high sensitivity. However, 9 out of 96 (9.3%) Sanger mutation negative 
fragments were called variants (mutation positive) by HRM. The sensitivity of HRMA 
was 10% in serial dilution studies Conclusions: High concordance (100%) of mutations 
detected by HRM and Sanger sequencing demonstrated the reliability and sensitivity of 
the HRM analysis as a preliminary screening method. Though, there were few false 
positive calls by HRMA compared to Sanger sequencing, probably due to greater 
sensitivity of HRMA and/or software settings, there were no false negatives.  In a 
clinical setting, it could be a rapid and cost effective method to identify potentially 
mutated regions, which could subsequently be confirmed by Sanger sequencing thus 
avoiding the need to sequence the entire exonic region of PTEN. 
 
ST63. Somatic Deletions of the PolyA Tract in the 3Ǝ-UTR of EGFR Are Common 
in Microsatellite Instability-High Endometrial and Colorectal Carcinomas 
D. Ma1, Z. Chen2, C. Nero3, K.P. Patel2, E.M. Daoud2, H. Cheng2, B. Djordjevic2,  
R.R. Broaddus2, L.J. Medeiros2, A. Rashid2, R. Luthra2 
1University of Iowa, Iowa City, IA; 2The University of Texas M. D. Anderson Cancer 
Center, Houston, TX; 3Texas Children’s Hospital, Houston, TX. 
Introduction: Epidermal growth factor receptor (EGFR) is overexpressed in up to 80% 
colorectal and endometrial carcinomas. The EGFR gene contains a polyA tract 
polymorphism (A13/A14) in its 3ƍ-untranslated region (3ƍ-UTR). Deletions of this polyA 
tract have been reported in microsatellite instability-high (MSI-H) colonic carcinomas 
but its impact on EGFR expression and downstream oncogenic pathways, such as 
KRAS and BRAF, is unclear. Furthermore, 3ƍ-UTR polyA status and its correlation with 
EGFR expression have not been reported in other MSI-H tumors, such as endometrial 
carcinoma. In this study, we examined the length of the 3ƍ-UTR polyA tract of EGFR in 
both endometrial and colorectal carcinomas and the mutational status of downstream 
targets of the EGFR signaling pathway. Methods: Ninety-eight colorectal carcinomas 
(36 MSI-H, 22 MSI-low, 40 MSI-stable) and 17 endometrial carcinomas (7 MSI-H and 
10 MSI-stable) formalin-fixed, paraffin-embedded patient samples and 30 snap-frozen 
tissues (15 MSI-H and 15 MSI-stable) endometrial carcinomas were included in this 
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study. Genomic DNA was isolated and MSI status was determined using a panel of 7 
markers (BAT25, BAT26, D2S123, D5S346, D17S250, BAT40, and/or TGFBRII). EGFR 
3ƍ-UTR polyA status was detected by capillary electrophoresis and Sanger sequencing. 
EGFR gene expression and copy numbers were determined by quantitative qPCR 
reaction. KRAS and BRAF mutation status was analyzed by pyrosequencing. Results: 
The 3ƍ-UTR polyA tract was deleted in 18 of 23 (78%) MSI-H versus 0 of 24 MSI-stable 
(MSS) endometrial carcinomas (P= .001). Similar observations were seen in colorectal 
carcinomas in which 29 of 36 (81%) MSI-H, 1 of 62 (1.6%) MSI-low (MSI-L) and none of 
the MSI-stable (MSS) tumors harbored 3ƍ-UTR polyA deletions (P=.001). A moderate 
increase in EGFR mRNA level was observed in endometrial carcinomas with 3ƍ-UTR 
polyA deletions versus those with wild-type polyA tract. Amplification of the EGFR gene 
was not observed by qPCR based copy number analysis. Deletions in polyA tract do 
not seem to affect the frequency of KRAS and BRAF mutations. Conclusions: 
Deletions of EGFR 3ƍ-UTR polyA is frequent in endometrial and colorectal carcinomas. 
Deletions in the 3ƍ-UTR polyA tract of EGFR were confined almost exclusively to MSI-H 
tumors. PolyA deletion does not seem to affect the frequency of KRAS and BRAF 
(V600E) mutations. 
 
ST64. Sensitive and Rapid Detection of KRAS Mutations by Peptide Nucleic 
Acid (PNA) Clamp PCR in Endometrial Cancer 
C.L. Jackson1, V. Breese1, M. He2, J. Xiong2 
1Rhode Island Hospital and Brown University, Providence, RI; 2Women and Infants 
Hospital and Brown University, Providence, RI. 
Introduction: Somatic KRAS mutations are found in a wide variety of malignancies. 
Assessment of KRAS mutation status at codons 12 and 13 provides valuable guidance 
for cancer management, particularly with respect to targeted therapy. Direct sequencing 
from macro- or microdissected tumor cells has been traditionally used to identify 
mutations but this method has a low sensitivity. Peptide Nucleic Acid (PNA) clamp PCR 
is one approach to increasing sensitivity by enriching for mutant alleles. This study 
compares the sensitivity and specificity of PNA clamp PCR compared to direct 
sequencing for the detection of KRAS mutations in mucinous carcinoma (MC) and 
endometrioid carcinoma (EC), endometrioid carcinoma with significant Mucinous 
differentiation (ECMD) and serous carcinoma (SC) of the uterus. Methods: With IRB 
approval, 52 cases were selected from archives database at Women and Infants 
Hospital (Providence, RI). There were two cases with positive lymph nodes. Genomic 
DNA was extracted from microdissected formalin-fixed, paraffin-embedded sections 
and subjected to both direct sequencing and PNA clamp real-time PCR using a ¨Ct 
value calculation to determine the mutation status. Sequencing of the PNA PCR 
product was used to identify the specific KRAS mutation as well as resolve 
discrepancies with direct sequencing results. Results: KRAS mutations were detected 
in 23 cases (23/52, 44%) including 7 of 9 (78%) MC, 11 of 16 ECMD (69%), 4 of 16 EC 
(25%), and 1 of 11 SC (9%). Statistically significant differences in KRAS mutational 
status were noted between MC vs EC (P<0.05), ECMD vs EC (P<0.05), MC vs. SC 
(P<0.01), and ECMD vs. SC (P<0.01, Fisher’s exact test). Initially, 13/52 cases tested 
positive by PNA clamp PCR and negative by direct sequencing. Four of these cases 
may represent positive cases not detected by direct sequencing, four cases appear to 
be false positives and five cases are still under investigation. No cases were direct 
sequencing positive and PNA clamp PCR negative. PNA clamp PCR compared to 
direct sequencing is 100% sensitive and 75% specific. Conclusions: Compared to 
direct sequencing, PNA clamp PCR is able to rapidly screen for the presence or 
absence of KRAS mutations with high sensitivity. The specific point mutation in codon 
12 or 13 can then be identified in positive patients by sequencing the PNA PCR 
product. This reduces the amount of labor intensive sequencing needed to identify 
these mutations. 
 
ST65. Novel Mutations in KRAS Codons 12 and 13 Are Likely Informative 
Regarding Cetuximab or Panitumumab Treatment Choices  
M.A. Johnson, C. Richards 
Oregon Health and Science University, Portland, OR. 
Introduction: Colorectal cancer is the third most commonly diagnosed cancer and the 
second leading cause of cancer death in the United States. Approximately 101,700 
people in the United States will likely be diagnosed with colorectal cancer in 2011. 
Survival of metastatic colorectal cancer patients has nearly doubled in the past decade. 
This improvement is mainly due to the development of new combinations of standard 
chemotherapy and also to the introduction of monoclonal antibodies such as cetuximab 
or panitumumab against epidermal growth factor receptor (EGFR) or against vascular 
endothelial growth factor. Several studies demonstrate that patients with metastatic 
colorectal cancer, who have a KRAS mutation in codon 12 or 13, do not derive benefit 
from treatment with cetuximab or panitumumab. Additionally, the use of cetuximab or 
panitumumab therapies may result in increased toxicity. A KRAS mutation is present in 
approximately 40% of metastatic colon cancer tumors. Methods: Our laboratory, 
participating in the CERGEN study (Comparative Effectiveness Research in Genomics 
and Personalized Medicine for Colon Cancer funded by the National Cancer Institute) 
tested for variants in codons 12 and 13 in the KRAS gene in 367 individuals diagnosed 
with metastatic colorectal cancer. DNA from these individuals was extracted from 
formalin-fixed, paraffin-embedded (FFPE) tumor tissue on unstained slides; to aid in the 
enrichment of tumor-originating DNA, the specific location of tumor tissue on the slide 
was confirmed microscopically by a pathologist on a companion H&E slide, circled and 
percent tumor indicated. We used Sanger sequencing to determine genotypes using 
primers flanking the start and end of exon 2 (in which codons 12 and 13 are 
embedded). Results: Here we report two novel KRAS mutations (as determined by 
inspection of the COSMIC data base on June 1, 2011): c.36_47dupTGGCGTAGGCAA 
and c.38_39insTGG; additionally a previously unreported complex mutation was 
detected, c.[38G>A(+)40G>A]. Conclusions: All of these mutations are predicted to 
disrupt the phosphate-binding P-loop in the KRAS protein (encoded by codons 10-17), 
likely resulting in autoactivation of the KRAS protein. Due to this autoactivation, 
cetuximab or panitumumab are likely to be ineffective treatments.  
 
ST66. KRAS Mutation Analysis Is a Good Adjunct to Cytologic Evaluation of 
Pancreatic Cyst Fluids 
C. Ok, O. Walter, K. Tomaszewicz, L. Hutchinson, E. Belkin, W. Wassef, B. Woda,  
E.F. Cosar 
University of Massachusetts Memorial Health Care/University Massachusetts, 
Worcester, MA. 
Introduction: Cystic lesions of the pancreas have increasingly been detected due to 
advances in diagnostic endoscopy. Diagnostic approach includes cytologic examination 
and tumor marker analysis in cyst fluid. However this approach has its limitations and 
may further benefit from molecular testing. The objective of this study is to evaluate the 
utility of KRAS mutation analysis in pancreatic cyst samples. Methods: From 2008 to 
2011, we prospectively evaluated 44 patients (22 male, 22 female, median age 56.5) 
with pancreatic cyst(s) who underwent endoscopic ultrasound (EUS) guided fine needle 
aspiration (FNA) of cyst fluid. The median follow-up period was 92 days (range: 14 to 
540 days). A total of 47 FNA samples were collected. Based on the cytology diagnosis, 
the cases were categorized into four groups: non-diagnostic (group 0, 28%), negative 
(group 1, 53%), atypical/suspicious (group 2, 15%), and positive for malignancy (group 
3, 4%). KRAS mutation on codon 12 and 13 was tested by quantitative PCR (sensitivity 
0.1%). DNA quality/quantity was evaluated using multiple methods. Cyst fluid CEA and 
amylase levels were also measured. Clinical follow-up data was obtained. Results: 
Forty-six samples (98%) had adequate quality for PCR. KRAS mutation was detected in 
39% (18/46) of cases – 46% (6/13), 21% (5/24), 71% (5/7) and 100% (2/2) in group 0, 
1, 2 and 3, respectively. Surgical resection was performed in 5 patients – a mucinous 
cystic neoplasm with focal low grade dysplasia (group 0), a mucinous cystic neoplasm 
and a pseudocyst (group 1) and 2 intraductal papillary mucinous neoplasms (group 2). 
In group 3, patients were treated with neoadjuvant chemotherapy. The remaining 
patients had either observation or no follow-up data. Difference in cyst fluid CEA level 
was observed (249.1 vs. 25.1 ng/ml, median value), but no difference in quality or 
quantity of DNA and cyst fluid amylase levels were found between KRAS mutant and 
wild-type cases, respectively. Conclusions: Among patients with negative cytology and 
wild-type KRAS, 18 of 19 showed no evidence of neoplasm. By contrast, at least 4 of 7 
patients with atypical/positive cytology and mutant KRAS had a tumor. KRAS mutation 
was identified in 30% (11/37) of cytologically non-diagnostic or negative cases. Thus 
KRAS mutation testing can serve as a good adjunct to cytology. Further studies with 
additional molecular markers and long-term clinical follow-up are needed to assess the 
clinical specificity of mutation testing. 
 
ST67. Oncogene Mutation Analysis of Cholangiocarcinoma Using the 
OncoCarta Panel and MassArray Technology 
B.R. Kipp, L.M. Holtegaard, S.M. Kerr, J.S. Voss, E.G. Barr Fritcher, W.E. Highsmith,  
J. Zhang, K.C. Halling 
Mayo Clinic, Rochester, MN. 
Introduction: Cholangiocarcinomas (CCA) are rare and often lethal cancers of the 
biliary tract. Despite technologic advancements over the past decade, little is known 
about the somatic changes that occur in these tumors. The goal of this study was to use 
MassArray technology to identify common mutations in CCA specimens that could aid 
in the development of assays for early detection and/or provide potential therapeutic 
targets for patients diagnosed with CCA. Methods: Eight unstained, 10 micron sections 
were cut from formalin-fixed, paraffin-embedded tissue blocks from 100 CCAs. DNA 
was extracted from areas comprising >20% tumor as determined by a board certified 
pathologist. Specimens were then evaluated using the Sequenom OncoCarta™ 
Mutation Profiler Panel (Sequenom Inc., San Diego, CA). This MALDI-TOF mass 
spectrometry SNP genotyping panel evaluates 19 oncogenes for 238 somatic 
mutations. Results: Twenty-seven of the 100 CCA specimens tested in this study 
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harbored a mutation in 1 (n=24) or 2 (n=3) oncogenes. The 30 mutations included 
alterations of the following oncogenes: KRAS (n=12), PIK3CA (n=4), MET (n=4), EGFR 
(n=3), BRAF (n=2), PDGFRA (n=2), ERBB2 (n=1), NRAS (n=1) and RET (n=1). 
Mutations were identified in 11 of 31 (35%) extrahepatic CCAs and 16 of 69 (23%) 
intrahepatic CCA’s. MassARRAY also detected what appeared to be a homozygous 
EGFR G719S mutation in one specimen. However, fluorescence in situ hybridization 
testing demonstrated that this specimen had EGFR amplification of the G719S mutated 
allele. Conclusions: MassARRAY technology can be used to detect mutations in a 
wide variety of oncogenes using paraffin-embedded tissue. Twenty-seven percent of 
the evaluated CCAs harbored a mutation within at least one of the panel oncogenes. 
Because most of these mutations occur in oncogenes that encode proteins for tyrosine 
kinase receptors or proteins involved in currently targeted signaling pathways, clinical 
testing of CCA for these mutations may drive personalized therapy selection for these 
tumors in the future. The variety of mutations detected suggests that a multiplexed 
mutation detection approach is necessary for both diagnostic and theranostic 
algorithms for CCA.  
 
ST68. Prevalence of Microsatellite Instability and MLH1 Promoter Methylation 
Status among Hispanic and Caucasian Patients with Colorectal Cancer in New 
Mexico  
C.F. Kletecka1, J.M. Gale2, M.A. Vasef1,2 
1University of New Mexico, Albuquerque, NM; 2TriCore Ref Laboratories, Albuquerque, 
NM. 
Introduction: Microsatellite instability (MSI) occurs due to defective DNA mismatch 
repair and is associated with Lynch Syndrome (LS) as well as a proportion of sporadic 
colorectal cancer. LS-associated colorectal cancer (CRC), comprises approximately 5% 
of all CRC. The MSI in greater than 2 markers (MSI-H) is found in about 95% of LS 
associated CRC and in approximately 20% of sporadic CRC. Likewise, MLH1 promoter 
hypermethylation is found in sporadic CRC and not in LS-associated cancers.  
Therefore, MSI and MLH1 promoter methylation status testing are useful as screening 
tools to identify individuals with potential LS allowing them to benefit from increased 
cancer surveillance. There is only limited data in English literature addressing the 
prevalence of MSI-H in Hispanic patients with CRC versus Caucasian patients with 
CRC. In this study, we analyzed the MSI and MLH1 promoter methylation status in 
Hispanic and Caucasian patients with CRC. Methods: MSI analysis was performed on 
DNA extracted from paraffin-embedded tumor tissue in parallel with corresponding 
benign tissue on 21 patients including 12 Caucasians and 9 Hispanics. The age of the 
patients included in this study ranged from 25 to 85, with a median age of 49. The 
analysis was performed using Promega MSI kit (Marker panel: BAT-26, BAT-25, NR-
21, NR-24, MONO-27) followed by capillary electrophoresis for sizing on the ABI 3130 
Genetic Analyzer. MLH1 promoter methylation analysis was performed by 
pyrosequencing analysis of bisulfite-treated DNA on the PyroMark Q24 System by 
Qiagen. Results: Seventeen of 21 cases including 7 Hispanic (78%) and 10 
Caucasians (83%) showed MSI-H, defined by 2 or more loci demonstrating 
microsatellite instability. The remaining 4 patients were microsatellite stable, defined by 
absence of instability in any of the 5 loci analyzed. MLH1 promoter hypermethylation 
was identified in 7 cases, including 2 (29%) Hispanics and 5 (71%) Caucasians with 
MSI-H. None of the MSI stable cases demonstrated MLH1 hypermethylation. 
Conclusions: Our results indicate that the prevalence of MSI-H is similar among New 
Mexican Hispanic and Caucasians patients. This finding further confirms the results of 
prior studies. Although the number of cases in our study is low, the relatively high 
incidence of MLH1 promoter hypermethylation among Caucasian group with MSI-H 
compared to Hispanic group, may suggest that LS-associated MSI may be more 
common in individuals of Hispanic origin. 
 
ST69. Discrimination of Normal Lung, Squamous Cell Carcinoma, and 
Adenocarcinoma Using a Novel Panel of Five MicroRNAs to Analyze Archival 
Tissues 
Z. Wang, B. Evans, J. Navenot, R. Vadegipalli, S.C. Peiper, C. Solomides 
Thomas Jefferson University, Philadelphia, PA. 
Introduction: Noon-small-cell lung carcinoma (NSCLC) can be differentiated into 
squamous cell carcinoma (SCC) and adenocarcinoma (Ad), which have different 
treatments and prognosis. Therefore it is critical to establish an accurate pathologic 
diagnosis. Among the current available diagnostic tools, while this process can be aided 
by expert morphologic and immunohistochemical analysis, molecular characterization 
offers higher level of resolution. There is increasing evidence that different cell types 
have distinct microRNA (miRNA) expression profiles. Since miRNA can be efficiently 
extracted from formalin-fixed, paraffin-embedded (FFPE) archival tissues, we tested the 
ability to distinguish between normal lung (NL) and the malignant counter parts, SCC 
and Ad. Methods: With approval by the IRB for analysis of de-identified specimens, 61 
independent FFPE lung  specimens were analyzed for miRNA expression. Microarray 
analysis (Agilent) was performed on 16 specimens of different subtypes to determine 
the whole genome miRNA profile. Total RNA was extracted from paraffin blocks using 
Recover All total nucleic acid extraction kit (RNA protocol) from Ambion. RNA were 
labeled and hybridized to the microarray according to the manufacturer’s procedure. 
The median of the log2 transformed raw signal intensity data was normalized and 
processed through an invariant normalization. Among 34 miRNA differentially 
expressed in NL, SCC, and Ad, the expression levels of the 9 with the highest level of 
discrimination were verified by Q-PCR (Applied BioSystems) with additional specimens. 
A final panel of 5 miRNA (miR-205, -26b, -486-5p, -451, -21) was further selected to 
complete the Q-PCR analysis for all samples. Results: Microarray data demonstrated 
proper clustering of NL, Ad, and SCC subgroups with distinctive expression patterns. 
miR-451 and miR-486-5p were down regulated in the malignant specimens regardless 
the subtype. miR-21 was increased in cancer specimens as previously identified. These 
three microRNAs can be used to distinguish NL from SCC and Ad. Expression of miR-
205 was dramatically increased in SCC specimens as previously reported. miR-26b 
expression was modestly reduced only in SCC in comparison to Ad and NL. Combining 
the miR-205 and miR-26b expression data enabled us to differentiate SCC from Ad. 
These results were highly reproducible between different experiments using the delta 
Cp method to normalize total input RNA and assay conditions. Conclusions: We 
identified a panel of 5 miRNAs, including novel species, that can be used to distinguish 
NL from tumor and SCC from Ad. These findings demonstrate the potential clinical 
utility to distinguish between poorly differentiated cases of SCC and Ad. 
 
ST70. Comparison of Somatic Point Mutation Detection Methods in Colorectal 
Carcinoma: Addressing the Challenges of Analytical Sensitivity  
A.D. Bossler, S.S. Arbefeville, J.A. Pruessner, A.A. Stence, J.W. Heusel 
University of Iowa Hospitals and Clinics, Iowa City, IA. 
Introduction: The identification of somatic mutations affecting signal transduction of 
the epidermal growth factor receptor (EGFR) pathway, including activating missense 
mutations of KRAS and BRAF, is important for clinical decisions regarding targeted 
therapy in colorectal cancer, since these mutations confer resistance to anti-EGFR 
monoclonal antibodies. Reliable detection of somatic mutations with an analytic 
sensitivity <10% is challenging, and defining a minimum level at which a patient may 
still derive a positive benefit from targeted therapy is unknown. The aims of this study 
were to determine the limits of detection for two primer extension-based assays using 
clonal, mutation-specific reagents and compare performance between the two assays 
on formalin-fixed, paraffin-embedded (FFPE) colorectal adenocarcinomas. Methods: 
One primer extension assay is based upon the method of Lurkin et al (PLoS ONE. 
2010, 5:e8802) in which multiplex PCR amplification of the relevant KRAS and BRAF 
exons is followed by single nucleotide probe extension using the SNaPshot™ Multiplex 
Kit (Applied Biosystems, Foster City, CA) and detection of the products by capillary 
electrophoresis. The second assay, the Mutector kit (Applied Biosystems), follows the 
amplification step with a primer extension step using proprietary shifted termination 
assay reagents. KRAS and BRAF mutation-specific DNA fragment control reagents 
were PCR generated and cloned using the QuickChange® Lightning Site-Directed 
Mutagenesis kit (Stratagene) for plasmid and cell-based control reagents. All 
laboratory-derived positive control reagents were sequence verified. The two assays 
were used to evaluate a panel of colorectal adenocarcinomas FFPE tissue specimens 
for which the KRAS and BRAF mutation status was previously determined. Results: 
The assays showed 100% concordance between each other and 94% against the prior 
determination (also a primer extension based method) for the detection of the most 
common KRAS mutations from 17 patient specimens. This failure of both assays to 
detect a low-abundance G12D mutation in one tumor with infiltrating histology possibly 
emphasizes the need for more sophisticated tumor cell collection such as laser capture 
microdissection. The relative proportions of the mutant peak height to the wild-type 
peak height give an estimated analytical sensitivity of ~10%. The analytic sensitivity of 
both assays using dilution of KRAS mutation-specific clones was higher. Conclusions: 
The low analytical sensitivity of primer extension-based detection of somatic KRAS 
mutations denoted in this analysis demonstrate the need to further optimize these 
methods in order to address the important clinical issue of defining a lower threshold for 
reporting mutation-positive specimens. 
 
ST71. Molecular Mechanisms that Contribute to Heterogeneous Scanty Staining 
for MSH6 in Colorectal Carcinoma 
L. Zhang, R. Bacares, L. Chen, J. Ruggeri, M. Ladanyi, J. Shia 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: IHC for MMR proteins is a well-accepted approach to evaluate patients 
for Lynch Syndrome (LS). Rare MLH1- and/or PMS2-deficient CRCs as well as post-
treatment MMR proficient rectal cancers can show only scanty staining (i.e., near 
complete loss of staining) for MSH6. We have observed a scanty staining pattern with 
MSH6 antibody in a small proportion of our cases (9/420) that poses problems for 
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interpretation. This study aimed at elucidating the molecular mechanisms that 
contribute to this aberrant pattern of staining. Methods: DNA was extracted from 10 
formalin-fixed-paraffin-embedded (FFPE) tissue sections from colorectal tumors using 
the Qiagen DNeasy Tissue kit (Qiagen, 69504) from these 9 cases. The coding exon 
containing a mononucleotide repeat sequence, an 8-cytidine repeat, (C)8, was 
amplified and sequenced. DNA fragments with frameshift in the C8 region were cloned 
into pCR4 TOPO vectors (Invitrogen, Carlsbad, CA). DNA from colonies was amplified 
and subjected to direct DNA sequencing analysis. Results: Of the 9 cases, 4 cases 
had additional, unstable alleles in the C8 region in MSH6. We cloned PCR fragments 
into TOPO vectors for two cases. We observed C8 in about half of the colonies (45% 
(5/11) and 43% (3/7)). The remaining colonies had C7, C9 or C10 repeats, leading to 
frameshifts. In these 4 cases, MLH1 and/or PMS2 were absent in the tumor by IHC (a 
germline PMS2 R315X mutation was identified in one case). We did not observe any 
frameshift in the other 3 cases (MMR proteins were present). Two cases could not be 
studied because of insufficient amount of material. Conclusions: Secondary mutations 
in the mononucleotide repeat sequence, C8, in the MSH6 coding region explain the 
scanty staining for MSH6 in some MLH1- and/or PMS2- deficient cancers.  
 
ST72. IDH1 and IDH2 Mutation Detection by Melting Curve Analysis in Brain 
Specimens 
M.C. Hiemenz, D.H. Oliver 
UT Southwestern at Dallas, Dallas, TX. 
Introduction: Mutations in the genes encoding isocitrate dehydrogenase 1 (IDH1) and 
2 (IDH2) have been found in a majority of grade 2 and 3 astrocytomas as well as 
oligodendrogliomas and some glioblastomas, while the mutations are absent or very 
uncommon in tumors outside the central nervous system. Techniques used to assess 
IDH mutations have included pyrosequencing, Sanger sequencing, 
immunohistochemistry, and PCR-RFLP. Melting curve analysis after real-time PCR has 
also previously been applied to IDH testing in brain tissues and shown to correlate with 
results from Sanger sequencing. This study compares newly designed IDH1 and 2 
primers and probes to previously reported ones for use in melting curve analysis as a 
tool for detection of IDH mutations in glial neoplasms. Methods: Forty-two formalin-
fixed, paraffin-embedded tissues were analyzed, including neoplastic brain lesions 
(n=20), benign brain tissue (n=10), and non-nervous system tissue (n=12). Nucleic 
acids were extracted using Qiagen QIAamp DNA FFPE Tissue kits. DNA was amplified 
and subjected to melting curve analysis using previously published IDH1/IDH2 primers 
and FRET probes on a Roche LightCycler, following the authors' protocol. The same 
sample DNA was then analyzed using an optimized protocol and unique primers and 
LightCycler probes designed in our lab. In both assays mutations (heterozygous) 
manifested as second peaks in the melt curve. Parameters addressed when comparing 
the assays included robustness of DNA amplification and ability to discriminate wild 
type from mutant based on differences of melting temperatures (TM). All mutations 
detected by melting curve analysis were verified by Sanger sequencing of forward and 
reverse strands. Results: More robust amplification was achieved with the newly 
designed primers compared to those used in the published assay. Overall there was no 
significant difference in the ability of the previously published and newly designed FRET 
probes to differentiate between mutant and wild type based on the TM spread. DNA 
sequencing was in agreement with mutation assessment by melting curve analysis. 
Conclusions: Our results show further optimization of melting curve analysis as a 
sensitive and viable method for the analysis of IDH1 and IDH2 mutations in glial 
neoplasms. IDH1 and IDH2 melting curve analysis represents a powerful adjunct 
method for diagnosis of glial neoplasms from brain biopsies in complex or otherwise 
challenging cases.  
 
ST73. Comparison of Peptide Nucleic Acid (PNA)-Mediated PCR Clamping, 
COLD-PCR, and Direct Sequencing in Detection of PIK3A, BRAF and KRAS 
Mutations in Colorectal Cancers  
Y. Choi1, M. Kwon2, S. Kang1 
1Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul; 
2Hallym University Sacred Heart Hospital, Hallym University College of Medicine, 
Anyang. 
Introduction: KRAS, BRAF, and PIK3CA mutation testing before anti-epidermal growth 
factor receptor therapy of metastatic colorectal cancer (CRC) has become important. 
However, considerable uncertainty exists as to which methods for detection can be 
applied in a reproducible, sensitive, and simple manner in the routine diagnostic setting. 
Methods: We compared the detected rate of KRAS, BRAF, and PIK3CA mutations in 
92 routine paraffin tissues of CRC specimens by three discrete methods of direct 
sequencing, co-amplification-at-lower denaturation-temperature PCR (COLD-PCR) and 
peptide nucleic acid (PNA)-mediated PCR. Results: The KRAS, BRAF, PIK3CA 
mutations were detected 21%, 3%, and 1% by direct sequencing. The use of COLD-
PCR raised the percentage of mutated CRCs by 6%, 4%, and 2% for KRAS, BRAF, 
and PIK3CA compared than the detection rate of regular PCR followed by direct 
sequencing (p = 0.031, p = 0.250, and p = 0.250, respectively). PNA-mediated PCR 
clamping also increased the percentage of KRAS, BRAF, and PIK3CA mutation up to 
7%, 2%, and 6% compared than the detection rate of regular PCR followed by direct 
sequencing (p = 0.039, p = 0.250, and p = 0.031, respectively). Conclusions: COLD-
PCR and PNA-mediated PCR clamping method are similarly more sensitive for the 
clinical diagnosis of KRAS, BRAF, and PIK3CA mutations. 
 
ST74. Evaluation of Real-Time PCR Assay Options for Detection of MGMT 
Promoter Methylation 
Z.B. Moses1, J.A. Lefferts2, C.E. Fadul2, G.J. Tsongalis2 
1Dartmouth Medical School, Hanover, NH; 2Dartmouth-Hitchcock Medical Center, 
Lebanon, NH. 
Introduction: O6-methylguanine-DNA-methyltransferase (MGMT) gene silencing by 
promoter hypermethylation is associated with improved survival and increased 
response in patients with glioblastoma to alkylating agents, such as temozolomide. 
Methylation-specific PCR (MSP) was used in several clinical trials that established 
MGMT methylation as a positive predictive and positive prognostic marker. In addition 
to a lengthy bisulfite conversion of genomic DNA, MSP methodology requires two 
rounds of nested PCR followed by gel electrophoresis. This is a labor-intensive assay 
that can result in amplicon contamination and be difficult to score since it is entirely non-
quantitative. Methods: Two sets of previously published primer and probe sequences 
for MGMT and ACTB (TaqMan and MGB-TaqMan) were used along with two different 
commercially-available PCR master mixes to develop a robust real-time, quantitative 
methylation-specific PCR (qMSP) assay that would allow for detection of methylated 
MGMT promoter from genomic DNA isolated from formalin-fixed, paraffin-embedded 
(FFPE) tumor tissue. All DNA samples were isolated from FFPE tissue and subjected to 
the EpiTect Bisulfite kit (QIAGEN). The bisulfite-treated DNA was then subjected to 
real-time PCR amplification on a 7500 Fast Real-time PCR System (Life Technologies) 
using either TaqMan Universal PCR Master Mix (Life Technologies) or EpiTect 
MethyLight master mix (QIAGEN). Human genomic DNA controls (methylated and 
unmethylated) were used to assess assay performance and to produce standard 
curves. Results: With both primer/probe sets the EpiTect MethyLight master mix 
outperformed the TaqMan Universal PCR master mix with respect to sensitivity. This 
can be observed by the detection of diluted control samples and FFPE samples that 
were either not detected with the Universal master mix or detected at much lower levels 
than the EpiTect master mix. When both sets of primer/probes were compared using 
the Epitect master mix, PCR efficiencies were all near 100%, although the linear range 
of the assay with the MGMT Taqman probe did not extend as low as the assay with the 
MGMT MGB-TaqMan probe. Conclusions: Methylation-specific real-time PCR assays 
have an increased potential to serve as clinical diagnostic assays due to their 
quantitative nature and the decrease potential for PCR contamination. The qMSP 
methods described in the literature are much less robust in our hands when testing 
DNA from FFPE tissues instead of fresh tissue. Modifying qMSP protocols by using an 
alternative PCR master mix results in a marked increase in assay performance 
 
ST75. Validation of the Agilent High-Resolution Array-CGH Platform and 
Comparison of aCGH to FISH in Diagnostic Evaluation of Cutaneous Melanoma  
L. Wang, M. Rao, K. Busam, Y. Fang, A. Viale, S.C. Jhanwar 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: Benign melanocytic nevi and cutaneous malignant melanomas can be 
difficult to distinguish from each other by routine microscopic analysis. Recent evidence 
has suggested that cytogenetic analysis may be a useful ancillary method for 
diagnostically difficult melanocytic proliferations. Melanomas tend to carry recurrent 
unbalanced chromosomal aberrations, while melanocytic nevi usually do not contain 
detectable chromosome aberrations by CGH analysis, except for a subset of Spitz nevi. 
Therefore, we validated Agilent Human 244K aCGH platform for clinical diagnosis of 
melanocytic tumors, and compared aCGH results with a four-probe FISH assay in 
diagnosis of melanoma. Methods: We studied 33 FFPE samples from our melanocytic 
tumor archive, including 28 melanomas and 5 benign nevi. The aCGH raw data were 
analyzed by Agilent Cytogenomics software and a list of aberration findings (CNVs, 
Copy Number Variations) was generated for each sample. CNVs identified in regions 
contained no annotated genes or fully overlapped by known benign CNVs, were filtered 
out from the aberration finding list. The remaining CNVs with more than 100 probes 
involved (i.e. >700Kb in size) were considered as solid findings and thus weighed in 
favor of the diagnosis of melanoma. Four-probe FISH assay (RREB1/MYB/CEP6 and 
CCND1), approved by NYS as an adjunct clinical diagnostic method for Cutaneous 
Melanoma, was performed on 22 melanoma samples with sufficient materials. aCGH 
findings and FISH results were interpreted independently in a blinded fashion. 
Results: No solid finding was noticed in any of the 5 benign nevi by aCGH analysis. In 
contrast, significant unbalanced genomic aberrations were revealed in 27 melanomas 
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(96%), 26 of which exhibited complex unbalanced genomic aberrations. Positive results 
were obtained in 15 melanomas (70%) by four-probe FISH analysis, and negative 
results in five cases; two cases were uninformative. In addition, major aCGH findings of 
focal homozygous deletions/amplifications were also verified by FISH. The overall 
concordance in aberration detection between the two methods was 95%. Conclusions: 
Copy number analysis of FFPE tumor samples by aCGH is a sensitive and reliable 
method in diagnosis of melanoma. The evaluation of the whole genome by aCGH is in 
particular valuable for cases in which the histopathologic features alone do not permit 
definitive diagnosis and the four-probe clinical FISH assay is uninformative (normal 
results, equivocal findings due to poor quality of the FFPE section, or failure).  
 
ST76. Targeted Screening of Colorectal Cancers for a Novel BUB1B Mutation 
J.A. Lefferts, H. Chen, G.J. Tsongalis, A.A. Suriawinata 
Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: The BUB1B gene encodes the spindle-assembly checkpoint regulator 
protein, BUBR1. Mutations in the BUB1B gene have been reported in cases of mosaic 
variegated aneuploidy syndrome, an extremely rare cancer susceptibility syndrome with 
autosomal recessive inheritance. Symptoms of mosaic variegated aneuploidy include 
growth deficiency, microcephaly, and cancer (often by age 2). In a recent case report, a 
homozygous, intronic BUB1B mutation resulting only in reduced BUBR1 expression 
was discovered in a patient with a history of multiple gastrointestinal cancers, but 
lacking the typical clinical features of mosaic variegated aneuploidy. This patient was 
initially suspected of having Lynch syndrome, but cytogenetic testing indicated mosaic 
variegated aneuploidy syndrome. A population of 590 unaffected individuals was 
screened for this mutation, resulting in a single heterozygote. In order to further 
elucidate a potential significance for this BUB1B mutation beyond the proband 
described, we tested DNA samples from two groups of colorectal patients to see if the 
frequency of this mutation might be higher in a more targeted population Methods: 
DNA samples were isolated from archived FFPE tissue of two groups of colorectal 
cancer patients. A “KRAS negative” group consisted of 23 cases that had been 
submitted for KRAS mutation testing and found to be negative for the codon 12 and 13 
mutations and a “MMR intact” group consisted of 19 colorectal cancer patients 
suspected of Lynch syndrome but found not to be deficient in MLH1, MSH2, MSH6, or 
PMS2 by immunohistochemistry. A TaqMan genotyping assay was designed to detect 
the c.2386-11A>G mutation and corresponding wild-type sequences in BUB1B. Wild-
type and mutant oligonucleotide controls were constructed to confirm assay 
performance. Results: The TaqMan assay was able to discriminate between 
homozygous wild-type, heterozygous and homozygous c.2386-11A>G control samples. 
All 23 DNA samples from the “KRAS negative” group and all 19 samples from the 
“MMR intact” group were found to be wild type with respect to the c.2386-11A>G 
mutation. Conclusions: The absence of the BUB1B c.2386-11A>G mutation in the two 
groups of colorectal cancer patients examined in this study indicate that this mutation is 
not commonly correlated with colorectal cancer. While larger studies may show 
additional cases of gastric or colorectal cancer resulting from mosaic variegated 
aneuploidy syndrome and BUB1B mutations, these cases would be expected to be 
infrequent. 
 
ST77. Highly Sensitive Molecular Assay for the Detection of Circulating Cell-
Free BRAF V600E Tumor DNA in the Serum and Plasma of Melanoma Patients 
S. Manjeshwar1, N. Keo1, M. Carter1, N. Amitina1, S.N. Markovic2, L. Van Der Ploeg1,  
D. Knauer1, I. Ichetovkin1 
1Nant Holdings, LLC, Costa Mesa, CA; 2Mayo Clinic, Rochester, MN. 
Introduction: V600 mutations of the BRAF gene have been described in approximately 
8% of all solid tumors, with the frequency exceeding 50% in melanomas. Several 
BRAF-specific inhibitors are currently undergoing Phase II/III trials in late stage V600E 
BRAF-positive melanoma patients with promising results, such as vemurafenib, which 
has shown better than 80% response rate. However, non-invasive and highly sensitive 
techniques for BRAF mutation detection and monitoring therapeutic efficacy are 
currently lacking. This study describes the development and validation of a sensitive 
and highly specific molecular assay for the detection of BRAF V600E mutations in 
circulating cell-free (cf) tumor DNA in plasma/serum utilizing the MassARRAY® MALDI-
TOF platform. Methods: Plasma and serum DNA were isolated from Stage IV 
melanoma patients and healthy volunteers. Plasma spiked with DNA extracted from cell 
lines containing either the wild-type (wt) BRAF gene (PANC1) or the BRAF V600E 
mutation (SK-MEL28, HT29), served as controls. Cell line DNA was fragmented to 200-
1000bp in size prior to spiking to emulate circulating cfDNA. PCR amplification with 
concurrent digestion of wtBRAF using thermostable TspRI endonuclease resulted in 
preferential amplification of mutant BRAF DNA. The amplified DNA was then subjected 
to single base mutation detection using iPLEX® technology on the MassARRAY® 
platform (Sequenom Inc. San Diego, CA). Results: The assay was shown to reliably 
detect V600E BRAF in plasma spiked with 50pg/mL of mutant cell-line gDNA 
(equivalent to 3-5 copies of the V600E BRAF gene per reaction). The presence of up to 
500ng of additional wild-type genomic DNA per reaction was well tolerated and did not 
affect the detection of the mutant allele. Clinical performance was assessed on a 
blinded panel of plasma samples and tissue biopsies from 31 stage IV melanoma 
patients. Fourteen of 31 patient tumors had V600E mutant DNA present. BRAF V600E 
mutations were detected in circulating cfDNA extracted from the plasma of 11/14 
patients, demonstrating 79% sensitivity (95%CI 0.52-0.94, NPV 0.64-0.95). Plasma 
matched to all of the 17 wtBRAF tumors tested negative, demonstrating 100% 
specificity (95%CI 0.82-1.00, PPV 0.74-1.00). Serum from 50 healthy volunteers all 
tested negative for V600E cfBRAF. Conclusions: We present a novel method to 
specifically detect extremely low levels of circulating cell-free mutant BRAF DNA of 
tumor origin in patient plasma or serum. This test can be potentially used to stratify 
patients to BRAF inhibitor therapy and to monitor tumor status non-invasively following 




TT01. Two Complementary and Scalable PCR-based Workflows Enable Next 
Generation Sequencing of Cancer-Associated Genes in FFPE Tumor DNA 
G.J. Latham, E. Mambo, L. Chen, A. Hadd, J. Houghton, L. Garmire, T. Sanford,  
K. Buddavarapu, A. Adai, A. Choudhary 
Asuragen, Inc., Austin, TX. 
Introduction: Advances in next generation sequencing (NGS) technologies have 
enabled an unprecedented view of the genetic events and molecular pathways 
associated with cancer initiation and progression. These technologies, combined with 
the armament of nearly 1000 anti-cancer drugs approved or in development, provide a 
compelling opportunity to empower cancer personalized medicine by matching patient-
specific molecular abnormalities and dysfunctional cellular pathways with targeted 
therapies. NGS of clinical specimens, however, has been largely restricted to analyses 
of high quality DNA from fresh frozen tissues rather than the modified DNA from FFPE 
samples that represent the majority of tumor biopsies. In addition, the heterogeneous 
nature of cancer specimens requires “deep” sequencing (eg, 5,000-10,000X read 
depth) to reveal low abundance mutations, such as those involved in drug resistance, 
that may be clinically relevant. Methods: Two FFPE-compatible PCR-based 
enrichment panels were developed. The first was a multiplexed PCR assay that 
targeted 35 amplicons in 16 cancer genes, including the most common mutations in the 
MAPK/ERK and PI3K/AKT pathways. The second included nearly 1000 amplicons from 
52 cancer genes. Primers were designed to avoid known SNPs, repetitive sequences, 
and psuedogenes whenever possible, and included adaptor sequences to enable direct 
sequencing on either the Ion Torrent PGM or the Illumina GAIIx. Results: We optimized 
target enrichment methods based on PCR that are scalable from dozens to thousands 
of amplicons, and are compatible with NGS of FFPE DNA. These methods can identify 
“actionable” mutations in 50 or more cancer-associated genes, including both 
oncogenes and tumor suppressor genes, and can enable the detection of nearly all of 
the known mutations from these genes indexed in databases such as COSMIC. The 
procedures can detect as few as 1% to 2% variants using PCR enrichment strategies 
that, in the case of the Illumina GAIIx, can be barcoded at up to 36 samples per lane. 
Identified mutations can be confirmed using one of several orthogonal methods, 
including an independent target enrichment method that is compatible with the Ion 
Torrent PGM. Conclusions: The combination of two NGS approaches can 
accommodate both large-scale, whole exon mutation assessments across 48-96 
samples per run, as well as “hotspot” mutation analyses across 15-20 genes with a 
rapid turnaround time (~1 week). Consequently, this strategy addresses current unmet 
needs for unbiased and high sensitivity mutation detection in FFPE tumor specimens, 
and can accelerate both basic and clinical cancer research.  
 
TT02. Detection of Expression Levels of LincRNAs in Human Whole Blood Over 
Time: A High-Potential Future Diagnostic Tool? 
I.C. Herz, T. Voss 
QIAGEN GmbH, Hilden, NRW, Germany. 
Introduction: With a size of up to several kilobases, long intergenic non-coding RNAs 
represent the larger counterparts to small regulatory RNAs like microRNAs. Former 
scientific studies suggest that lincRNAs play an essential role in a diverse set of 
functions like the regulation of chromatin states or their involvement in epigenetic 
inheritance. Links to many diseases like cancer are assumed, too. Therefore, we were 
interested in the detection of these regulatory RNA species in human blood that may 
become useful in the future for many diagnostic applications. We have successfully 
provided evidence for their detectability in blood and also compared the transcription 
levels over a period of time from 2 to 48 hours after blood collection for 12 different 
lincRNAs. Methods: Blood was collected in PAXgene® Blood RNA tubes from 
consented healthy adults. Afterwards, RNA was isolated manually using the PAXgene 
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Blood miRNA protocol. The qualitative analysis of the extracted RNA was performed 
using a Spectramax photometer to measure the optical density and an Agilent 
Bioanalyzer to check for the RNA integrity. Quantitative analysis of the purified RNA 
was accomplished by duplex qRT-PCR using 18S rRNA as an internal standard. In 
addition, long-range PCRs were conducted in order to demonstrate the full length of the 
transcripts. Results: Most lincRNAs were well detectable in the blood samples with 
only few exceptions like XIST and TSIX. HAR1A, NEAT1 and SNHG8 displayed 
constant CT-values for all donors at each point in time. In contrast to this, expression 
levels of other lincRNAs like HOTAIR fluctuated over the assigned time frame. The 
missing signal of, for example, XIST is easily explicable as this lincRNAs is involved in 
the X-chromosome-inactivation only during the embryonic stage. In general, false-
positive signals from gDNA contamination can be excluded due to a low overall gDNA 
contamination and tests with a second DNA digest. Furthermore, with the help of long-
range PCRs the existence of full-length transcripts was verified. Conclusions: To our 
knowledge, the analysis of lincRNA expression profiles in human whole blood was 
performed for the first time. This provides researchers with a new powerful tool for the 
development of new biomarkers. The PAXgene Blood miRNA kit and the described 
PCR assays are for research use only. Not for use in diagnostic procedures. 
 
TT03. Direct Molecular Characterization and Enumeration of Circulating Tumor 
Cells in Lung Cancer Blood by Digital Sample Enrichment and RT-CastPCR 
Technology 
D.X. Deng, F. Wang, Y. Bao, D. Merrill, P. Brzoska, C. Chen 
Life Tech, Foster City, CA. 
Introduction: Enumeration and molecular characterization of circulating tumor cells 
(CTCs) promise to be valuable for cancer diagnosis, survival prognosis, and treatment 
guidance. However, current methods require extensive enrichment process before 
analyzing rare CTCs in human blood. Methods: We reported a new approach for direct 
CTC detection in blood samples without cell sorting by using digital sample enrichment 
and reverse transcription competitive allele-specific TaqMan PCR (dRT-castPCR) for 
rare mutations and qRT-PCR for cancer-specific genes. CastPCR is capable of 
detecting 1 mutant in 1 million wild-type molecules. Blood samples from lung cancer 
patients or normal individuals with spiked-in known lung cancer cell lines were 
partitioned in aliquots of 5 - 50 µL onto 96-well plates, such that each well contained 
either one cancer cell or none in the presence of 50 – 500 thousand normal white blood 
cells. Genetic mutations and panel of cancer-specific markers including CK19 and CEA 
for CTC identification and enumeration were determined by using both dCastPCR and 
qRT-PCR assays. Results: The sample partition process resulted in a digital 
enrichment of 20- to 200-fold (the relative ratio of CTC to normal cells) in a CTC-
positive well. Digital castPCR accurately identified known mutation and CK19 in spiked-
in samples of ~10 - 60 cells per mL whole blood by two cell lines, but there was no 
positive well in the absence of spiked-in cells. Furthermore, cell type specific markers 
(CK19) and known EGFR mutations were identified in the same sample wells, 
indicating that identified mutation was specifically derived from cancer cells.  In five 
blood samples from lung cancer patients of stage I - IV, EGFR mutation (p.L858R) was 
detected in all samples. CTC numbers in 3 early- stage lung cancers (I and II) were 11 - 
32 cells/mL blood. Much higher CTCs were detected in stage IV patients (>96 CTCs). 
For those sample wells with negative detection of EGFR mutation, corresponding wild-
type sequences were detected in all sample wells. Conclusions: In conclusion, our 
data suggest that combination of digital sample enrichment with d-castPCR and qRT-
PCR could be used to directly enumerate CTCs and detect cancer mutations in whole 
blood cells in early lung cancer patients without prior biophysical sample enrichment.  
 
TT04. Detection of Clonality Using the InVivoScribe Technologies Assays for 
IGH, TCRB, and TCRG Gene Rearrangements by Capillary Electrophoresis on the 
Applied Biosystems® 3500 
L.J. Tafe1, H.B. Steinmetz2, G.J. Tsongalis 1,3 
1Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH; 
2Dartmouth-Hitchcock Medical Center, Lebanon, NH; 3Dartmouth Medical School, 
Hanover, NH. 
Introduction: Gene rearrangement studies have been routinely used in the detection of 
clonal populations of B and T cells for the confirmation of diagnosis and detection of 
minimal residual disease. Many laboratories utilize capillary electrophoresis systems as 
the means for post-PCR detection of amplicons with the added ability of being able to 
accurately size these products. Here, we describe the use of the InVivoscribe Clonality 
kits on the new Applied Biosystems 3500. Methods: In the present study, we analyzed 
10 specimens for IGH rearrangements and 6 specimens for TCRB and TCRG 
rearrangements. For IGH the specimens included 6 formalin-fixed, paraffin-embedded 
(FFPE) tissue samples (4 GI biopsies, 1 lymph node, 1 bone marrow (BM)), 1 BM 
aspirate, 2 peripheral bloods and 1 frozen BM tissue. For TCR studies the specimens 
included 1 BM aspirate, 1 peripheral blood and 4 FFPE skin biopsies. DNA was 
extracted using established protocols. After PCR amplification, capillary electrophoresis 
was performed on the AB 3500 at 60ºC using the POP-7™ polymer. The data were 
analyzed using GeneMapper 4.1 software. The reportable range was determined by 
analyzing a dilution series of positive controls for each primer set in concentrations of 
200 ng, 100 ng, 50 ng and 10 ng total DNA template. Analytical sensitivity was 
determined using InVivoscribe sensitivity panels. Precision and accuracy were also 
evaluated. All specimens had previously been evaluated using the Beckman-Coulter 
Videra NsD. Results: In comparison with the Videra, 9/10 samples were concordant for 
IGH and 5/6 for TCR with the AB 3500. The IGH discordant case showed a clonal peak 
in FR2 with the AB 3500 (polyclonal in FR1 and FR3) that was not detected with the 
Videra. The discordant TCR case showed a clonal peak in tube TGA that was 
polyclonal on the Videra. The majority of samples were run in duplicate at 50 and 200 
ng/µl concentrations and on multiple runs/days with the same results. For all IGH and 
TCR primer sets, all positive control concentrations (200ng to 10ng) were detected and 
with the sensitivity panels, all dilutions (100% to 1%) were detected. Conclusions: We 
have shown that the B cell IGH and T cell TCRB and TCRG InVivoscribe clonality kits 
can be used with excellent results on the AB 3500. The AB 3500 is able to detect clonal 
gene rearrangements with small amounts of DNA (10 ng/µl) with an analytical 
sensitivity of 1% in a variety of specimen sample types. 
 
TT05. Comparison of the Performance of the Qiagen BRAF RGQ PCR and 
Autogenomics INFINITI® BRAF Assays Using DNA Extracted from FFPE Lung 
Tumor Biopsies 
V.K. Rajagopal, C. Tutt, A.D. Light, V. Michel-Treil, T.E. Schutzbank 
Covance Central Laboratory Services, Indianapolis, IN. 
Introduction: Mutations in the BRAF oncogene are common in melanomas and 
papillary thyroid cancers (PTC) and also found in other cancers of the lung and colon. 
The most common mutations, at codon 600, can result in constitutive activation of the 
EGFR-activated protein kinase signaling pathway. Testing for such mutations may be 
useful for staging patients with PTC and possibly melanoma, and for determining 
candidacy for treatment of specific cancers using monoclonal antibodies targeting the 
epidermal growth factor receptor. The purpose of this study was to evaluate two 
different commercial methods for detecting mutations in codon 600 of the BRAF gene. 
Methods: DNA was extracted from 10 ȝm FFPE lung tissue sections prepared from 
non-small-cell lung cancer (NSCLC) tumors using the Qiagen QIAamp DNA FFPE 
Tissue Kit. BRAF testing was performed using both the Qiagen BRAF RGQ PCR (real-
time scorpion probe PCR) and the AutoGenomics (AGI) Infiniti BRAF (DNA microarray 
chip) assays, according to the manufacturer’s instructions. The Qiagen method detects 
the V600E, V600D, and V600K mutations but does not differentiate which is being 
detected. The AGI method detects the V600A, V600E, V600D, and V600KRM 
mutations, and reports the specific mutation found.  Real-time PCR for the Qiagen 
method was performed using the RotorGene Q platform (RGQ). Initial PCR 
amplification for the AGI test, and final mutation analysis, were performed with the 
Applied Biosystems 9700 thermocycler, and the AGI Infiniti Analyzer respectively. 
Results: Tissue sections from 25 NSCLC tumors, with known BRAF V600E mutation 
status, were analyzed by the Qiagen and AGI tests. BRAF testing results were in 
agreement for 24 of the 25 samples with both methods. One sample, positive for V600E 
with the Qiagen scorpion probe method, was wild type (WT) by the AGI microarray. 
This sample had been previously reported as WT by the laboratory that supplied the 
tissue sections, using Applied Biosystems SNaPshot® methodology. The Ct value of 38 
for the discordant sample with the Qiagen assay was close to the cutoff of 40, 
suggesting that the percentage of cells carrying the mutation in the tumor may have 
been very low. Conclusions: Both BRAF mutation analysis methods tested are 
suitable for use in the clinical laboratory. The Qiagen and AGI methods have testing 
capacities of 30 and 22 samples per run, respectively, including controls. The 
advantage of the Qiagen BRAF test is rapid time-to-result, while that of the AGI method 
is greater coverage of codon 600 mutations, and reporting which mutation is detected. 
 
TT06. Quality of DNA from Patients at Autopsy Varies with Collection Time and 
by Organ 
A. Church, X. Zhang, J. Squire, D. LeBrun, H. Feilotter 
Queen's University, Kingston, Canada. 
Introduction: The authors have embarked on a study to investigate potential 
differences in genomic copy number variations between organs from a single patient. 
We collected several tissue samples from patients at autopsy. The quality of the 
extracted DNA and its suitability for microarray analysis is an important issue for our 
study and allows us to investigate the wider issue of the quality and suitability of all 
samples extracted at autopsy, which is a fairly common practice. Much attention has 
been paid to the quality of nucleic acid derived from formalin-fixed, paraffin-embedded 
tissues, but few, if any, articles discuss the quality of DNA from fresh autopsy-derived 
tissue, particularly between organs from a single individual. Methods: Five patients 
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who died within 48h of autopsy examination and for whom the families could give 
consent, were selected for study. All patients died in hospital and were transferred to a 
cool (5˚C) room within 3 hours of death. Ten organs plus peripheral blood from each 
patient were sampled: skin, cardiac muscle, skeletal muscle, lung, colon, stomach, 
spleen, pancreas, kidney, and brain. Solid tissue samples were collected without media, 
peripheral blood was collected in PAX DNA tubes; all samples were frozen within one 
hour of collection. DNA was isolated using Qiagen kits, and quality was assessed by 
agarose gel electophoresis. The patients’ hospital charts were reviewed for 
demographic data as well as past medical history, history of presenting illness and 
cause of death. Results: The DNA quality was highly variable between organs and 
patients. Representative gel images of genomic DNA from each organ and each patient 
will be presented. The interval between time of death and time of autopsy examination 
varied from 7 to 45 hours; longer intervals correspond to poorer DNA quality. The 
variability between organs was not consistent between patients, but spleen, stomach 
and pancreas-derived DNA were generally of the worst quality. Skin and skeletal 
muscle samples were generally the best. Conclusions: The finding that DNA quality 
may be negatively correlated with the time between death and autopsy is consistent 
with published data, and detailed examination of a larger number of subjects may allow 
us to develop guidelines for tissue sampling. The variability in DNA quality between 
organs from the same individual is interesting and suggests that some tissues may be 
superior for collection when DNA studies or banking are required. We intend to attempt 
to correlate the internal variability with each patient’s medical history. 
 
TT07. Rapid Identification of Somatic Mutations in Melanoma Cell Lines 
M.C. Schwab1, S. Jung1, J.L. Fisher1, M.S. Ernstoff2,3, G.J. Tsongalis2,3 
1Dartmouth Medical School, Dartmouth-Hitchcock Medical Center, Lebanon, NH; 
2Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer center, Lebanon, NH; 
3Dartmouth Medical School, Hanover, NH. 
Introduction: Signaling pathways, including MAPK and KIT, are known to regulate cell 
proliferation and intracellular processes in multiple cancer types, including malignant 
melanoma. Malignant melanomas are known to have activating mutations within 
several of these pathways that may serve as potential therapeutic targets yet making 
the identification of multiple mutations a financial and time limiting step. In this study, we 
evaluated a method for rapidly identifying somatic mutations of interest in melanoma 
cell lines. Methods: Eleven experimental and one control cell lines were grown in 
culture until log phase had been reached. Cells were then harvested and DNA was 
extracted using the Qiagen QIAamp DNA Mini Kit. Following DNA extraction, qPCR of 
each cell line was performed using the Qiagen qBiomarker™ Somatic Mutation PCR 
Array, directed at the Human KIT pathway, and run on the AB 7500 Fast Real-time 
PCR System. The array includes mutational analysis of the AKT, BRAF, EGFR, KRAS, 
HRAS, NRAS, MEK1, PIK3CA, and PTEN genes. The mutational status of each 
experimental cell line was determined using the ¨¨Ct method. The control cell line 
(human fibroblasts) was run on the array in triplicate, and the ¨Ct for each run 
averaged for use in the analysis. Results: Eleven experimental cell lines were 
examined for somatic mutations of genes within the human KIT pathway. Three of the 
cell lines (HMCB, WC00062 and WC00080) examined were wild type for the 85 
mutations tested. Eight (72%) cell lines were shown to have a mutation in the BRAF 
(V600E) gene, and of these eight, three showed additional mutations. In the cell lines 
with multiple mutations, HS294T and VMM12 harbored a mutation in the KIT (M541L) 
gene while WCOO46 harbored two unique mutations in the KIT gene (M541L and 
L576E). Conclusions: Identifying somatic mutation in cell lines used in in vitro 
experiments is an important step in identifying potential therapeutic targets of malignant 
melanoma. Here we identified somatic mutations in eight cell lines of interest. Using the 
qBiomarker™ Somatic Mutation PCR Arrays allowed us to rapidly identify these 
mutations with limited hands on time required and at a reduced cost compared to 
traditional SNP genotyping methods. 
 
TT08. Taking Ultra-Deep Sequencing to the Extreme: COLD-PCR Transforms 
the Mutation-Detection Capability of Next Generation, Targeted Amplicon 
Resequencing 
C.A. Milbury, M. Correll, J. Quackenbush, G. Makrigiorgos 
Dana-Farber Cancer Institute, Boston, MA. 
Introduction: There is tremendous interest in the application of next generation 
sequencing (NGS) for the analysis of individual cancer specimens for personalized 
treatment-guidance, prognosis, and therapy follow-up. A major obstacle with many 
classes of clinical specimens is that tumor cells are mixed with normal/stromal cells; 
thus the resulting low-level DNA mutations fall below the current NGS detection limit 
(i.e., false positives predominate in such samples). Because low-level tumor mutations 
can have profound implications on the development of metastasis, prognosis, choice of 
treatment, follow-up or early detection strategies, it is imperative to ensure their 
detection. Methods: Herein, we amplify the genomic DNA of serially-diluted mutation-
containing human cell-lines into wild-type DNA, as well as clinical tumor specimens, 
using COLD-PCR (a PCR technology that enables enrichment of unknown mutations at 
any sequence position), as well as conventional PCR for comparison. Following the 
amplification of several TP53, KRAS and EGFR regions with mutations, PCR products 
were pooled and multiplexed through library preparation, and we analyzed the mutation 
detection sensitivity of targeted amplicon resequencing on the Illumina HiSeq2000 next 
generation sequencing platform. Results: Regardless of sequence depth, we observed 
a mutation-detection limit of approximately 1% to 2% mutation abundance in 
conventional PCR amplicons; in contrast, COLD-PCR amplicons encompassed 
mutation enrichment exceeding the sequence noise levels, and enabled ultra-deep 
identification of mutant abundances of as little as 0.02% in wild-type DNA. Through the 
analysis of clinical tumor specimens, we have demonstrated that several low-
abundance mutations cannot be detected in next generation sequencing of 
conventional amplicons, yet are clearly detectable in the COLD-PCR amplicons. 
Conclusions: We have observed that increased depth of sequence analysis does not 
overcome background noise using Illumina next generation sequencing, and thus does 
not allow for the detection of mutation abundances below ~1% to 2% in clinical 
specimens. However, combining COLD-PCR with amplicon resequencing magnifies the 
mutations and enables reliable NGS sequencing of mutation spectra. It is anticipated 
that COLD-PCR will facilitate the reliable application of NGS for many clinical 
specimens such as: infiltrating, diffuse-type tumor specimens; sub-optimally micro-
dissected or heterogeneous tumor samples; DNA from circulating nucleic acid, 
circulating cells, sputum or other bodily fluids; tumor margins; stromal cells; and 
generally facilitate the broad inter-phasing of NGS with clinical practice. 
 
TT09. Validation of Cytochrome p450 2D6 Genotyping by the Luminex xTAG® 
2D6 v3 IVD/LX200 Detection System  
K.C. Chao1, K. Weck2 
1UNC Healthcare, Chapel Hill, NC; 2UNC-CH, Chapel Hill, NC. 
Introduction: The cytochrome p450 2D6 enzyme is important for metabolism of many 
exogenous drugs in clinical use, including activation of the breast cancer hormone 
modulator tamoxifen. The CYP2D6 gene exhibits significant inter-individual variability, 
which is associated with altered response to medications metabolized by CYP2D6. We 
evaluated CYP2D6 genotyping using the Luminex xTAG® CYP2D6 Kit v3, which 
detects 17 different CYP2D6 alleles including gene duplication, deletion, frameshift 
mutations, and point mutations that result in increased, decreased, or no enzymatic 
activity. Methods: A total of 46 DNA specimens containing a variety of CYP2D6 allele 
combinations were used for validation of the Luminex xTAG® CYP2D6 genotyping 
method. The samples included 20 DNA samples from a previous clinical study, two 
samples from the Coriell cell repository, two samples from LabCorp, and six samples 
from Luminex. In addition, 16 randomly selected whole blood specimens were tested to 
validate use with different DNA extraction methods. Genotyping was performed as per 
manufacturer instructions with an input of approximately 50 ng of genomic DNA. 
Results were compared to prior genotyping results from the Roche AmpliChip CYP450 
test or the Coriell database. Samples with discrepant results were further analyzed by 
DNA sequencing in order to identify the correct genotypes. Results: Concordance for 
CYP2D6 genotype was obtained for 24 of the 30 comparison samples. Discrepancies 
were observed for six of the validation samples. Four samples were homozygous for 
CYP2D6*17 (*17/*17) on the Roche AmpliChip, but were called CYP2D6*17 
heterozygous (*2/*17) by Luminex. Two samples were compound heterozygous for a 
gene deletion and CYP2D6 *17 (*5/*17) on the AmpliChip but received no call by 
Luminex. Further analysis by DNA sequencing using primers flanking CYP2D6 exon 2 
confirmed homozygous or hemizygous presence of the *17 variant nucleotide 1023C>T 
for all six of the discrepant samples, confirming previous genotyping results. Analysis of 
the raw Luminex data revealed a high signal with the *17 wild-type probe for each of 
these samples, resulting in either a no-call or *17 heterozygous miscall. All 16 in-house 
extracted DNA samples were successfully genotyped. Conclusions: The Luminex 
xTAG® CYP2D6 v3 genotyping method was able to identify 25 different allele 
combinations of CYP2D6. Correct genotyping calls were made for all alleles analyzed 
with the exception of samples homozygous or hemizygous for the CYP2D6 *17 
1023C>T variant. The Luminex method was robust and easy to use with a short 
turnaround time and reasonable hands-on time. 
 
TT10. COLD-PCR in Emulsion Magnifies Low-Level Mutations Prior to 
Sequencing 
E. Castellanos Rizaldos1, C. Milbury1, P. Liu1, G. Makrigiorgos2 
1Dana Farber Cancer Institute, Boston, MA; 2Dana Farber Cancer Institute and Harvard 
Medical School, Boston, MA. 
Introduction: Reliable sequencing of low-level mutations in certain classes of clinical 
samples (infiltrating, diffuse-type tumor specimens; tumor-margins; stromal cells; DNA 
from circulating-nucleic acids, circulating-cells, sputum or other bodily samples) is of 
AMP Abstracts772
JMD November 2011, Vol. 13, No. 6
0_Bring_Pages_Into_Quark_2  10/7/11  2:57 PM  Page 772
paramount significance for personalized medicine based upon mutational profiling of 
individual patients. Nevertheless, Next-Generation-Sequencing (NGS) technologies are 
not sufficiently reliable for the discovery or validation of low-level mutations in clinical 
samples, and thus NGS integration within Clinical Molecular Diagnostics cannot be 
exploited effectively. Employing COLD-PCR, a technology that magnifies mutations at 
any sequence position of a given amplicon, enables enrichment of low-level mutations 
such that NGS technologies can easily identify them (see Abstract TT08 by Milbury et 
al, AMP 2011). Despite this advantage, COLD-PCR requires individualized optimization 
for each DNA target amplicon, and thus COLD-PCR is laborious and technically 
challenging for large-scale analyses. We examined the feasibility of simultaneously 
performing COLD-PCR in several sequences, by adapting COLD-PCR to operate in 
nano-PCR emulsion-based reactions in the presence of several copies of a distinct 
DNA target sequence. Accumulation of the target sequence within individual emulsions 
was enabled by creating magnetic beads coated with specially designed Reference 
Sequences (COLD-PCR-beads). Methods: COLD-PCR-beads were prepared using 
streptavidin-coated beads possessing several copies of a single-stranded Reference 
Sequence. The COLD-PCR-beads capture numerous copies (both mutant and wild 
type) of target sequences from a diverse DNA population. Genomic DNA from human 
cell-lines that harbor TP53 mutations (c.847C>T, p.R283C and c.818G>A, p. R273H 
respectively), were serially-diluted into wild-type DNA for subsequent experiments. 
Single-stranded target DNA, generated with an asymmetric PCR approach, was used 
for magnetic hybridization capture (MHC) on COLD-PCR beads. Following the capture 
of target sequences, COLD-PCR-beads were emulsified such that each emulsion 
contains at most one bead. Fast-COLD-PCR was performed at a denaturation 
temperature determined experimentally. Results: COLD-PCR performed within 
emulsion (eCOLD-PCR) resulted in the enrichment of mutations in all three sequences 
examined. Mutations located in different regions of TP53 exon 8 showed an average 7-
fold mutation enrichment during eCOLD-PCR. A second round of MHC and eCOLD-
PCR produced additional 5-fold mutation enrichment. eCOLD-PCR produces similar 
mutation enrichment to that produced in-solution and following eCOLD-PCR DNA target 
amplicons with mutations at the 1% level or below could be directly sequenced via 
Sanger-sequencing. Conclusions: eCOLD-PCR enables miniaturization of COLD-PCR 
and opens up the possibility for highly-parallel COLD-PCR reactions in several target 
sequences simultaneously, followed by reliable NGS-based detection of low-level 
mutations. eCOLD-PCR thus may facilitate broad inter-phasing of NGS with Clinical 
Diagnostics. 
 
TT11. A Milling Machine Based Meso Level Dissection Device for Accurate, 
Rapid, and Economical Recovery of Tissue from Slides 
N.B. Adey1, R.J. Parry1, C.N. Paxton2, M.G. Herrmann2, K.B. Geiersbach2 
1AvanSci Bio, Salt Lake City, UT; 2ARUP, Salt Lake City, UT. 
Introduction: Dissection of formalin-fixed, paraffin-embedded (FFPE) sections of solid 
tumors is required for most molecular oncology testing, since the analytical sensitivity 
depends upon the purity of tumor tissue obtained. Most pathology laboratories employ 
manual dissection due to the high cost and labor intensiveness of currently available 
microdissection instrumentation, such as laser capture microdissection (LCM) 
instruments. We have developed an inexpensive milling machine based mesodissection 
prototype instrument that provides an intermediate level of resolution. This 
mesodissection instrument employs a specialized milling tip that simultaneously 
dispenses and aspirates milling liquid in order to capture the milled fragments. This 
instrument is fast and easy to use, capable of transferring electronically indicated target 
regions between neighboring tissue sections, and leaves intact non-dissected tissue 
allowing improved documentation of the region that was sampled. This is the first report 
of the performance of this prototype mesodissection instrument. Methods: 
Performance criteria were developed for resolution, accuracy, purity, and efficiency. 
Resolution and accuracy were assessed by microscopic inspection of the dissected 
region; resolution is the smallest recoverable area and accuracy is the dissected region 
in comparison to the boundaries of the desired region. Purity is defined as the 
percentage of desired tissue retrieved from a mouse/human fusion FFPE block as 
determined by real-time PCR amplification of species-specific repetitive DNA elements. 
Efficiency is defined as total DNA recovered relative to manual methods, as quantified 
by PicoGreen fluorescence. Results: Currently, the working prototype is capable of  
0.5 mm resolution, accuracy better than 0.1 mm compared to a desired boundary, and 
efficiency comparable to manual methods. Improvements to the prototype and 
evaluation of performance criteria are currently ongoing. Conclusions: The 
mesodissection instrument provides an alternative to the limited resolution of manual 
dissection methods and the high cost and low recovery efficiency of LCM 
instrumentation for dissection of selected areas from FFPE specimens mounted on 
slides. Digitally targeted dissection using adjacent H&E-stained tissue sections marked 
by a pathologist allows for downstream dissection by a technologist without specialized 
training in histopathology. 
TT12. A Quantitative Real-Time PCR Based Approach for Resolution of HER2 
Amplification/Over-Expression Status in FISH and IHC “Double Equivocal” Breast 
Cancer  
B. Portier1, Z. Wang1, E. Downs-Kelly1, G. Budd2, C. Lanigan2, R. Tubbs2 
1Cleveland Clinic, Cleveland, OH; 2Taussig Cancer Center, Cleveland Clinic, Cleveland, 
OH. 
Introduction: This study assesses the feasibility of using Quantitative Real-Time PCR 
(qRT-PCR) to resolve HER2 amplification/over-expression status in invasive breast 
cancer cases that fail resolution via immunohistochemistry (IHC) and fluorescence in 
situ hybridization (FISH) testing following ASCO/CAP guidelines. The IHC and FISH 
equivocal patient population (Double Equivocal) represent a particularly problematic 
breast cancer sub-group that currently lacks standardized clinical management 
guidelines. Methods: Cases were selected from the Cleveland Clinic electronic records 
from 1/2008 to 12/2010. RNA extraction was performed following macro-dissection 
using High Pure RNA Paraffin Kit (Roche Applied Biosciences, Indianapolis, IN). qRT-
PCR was carried out using TaqMan® RNA-to-CT™ 1-Step Kit with primers and probes 
(HER2, B2M, GAPDH, ACTB, TFRC, Applied Biosystems, Foster City, CA). qRT-PCR 
was performed on a LightCycler 480 II (Roche Applied Biosciences, Penzberg, 
Germany) according to the manufacturer’s instructions. Results were expressed as the 
ratio of HER2 to reference gene copies, all normalized against calibrator RNA from 
MCF7. Results: qRT-PCR performed on two breast cancer control groups, HER2 
amplified (AMP) and non-amplified (Non-AMP) as defined by FISH and IHC, 
demonstrated 2 non-overlapping populations. ROC curve analysis, using a cut off of 
7.0, showed the qRT-PCR assay separates AMP from Non-AMP cases with 100% 
sensitivity and specificity. Applying the 7.0 RT-PCR cut off to a group of double 
equivocal cases resulted in resolution of HER2 amplification/expression status for all 
cases (10 AMP and 40 Non-AMP). Cases with heterogeneity of HER2 expression did 
not alter sensitivity of the RT-PCR assay. Conclusions: qRT-PCR analysis of HER2 
gene expression represents a viable approach to resolve cases with double equivocal 
HER2 status at the time of diagnostic biopsy. This molecular approach accurately 
determined HER2 status in a population that failed classification by both FISH and IHC. 
qRT-PCR combines the precision and high sensitivity of real-time PCR with the 
morphological specificity of histological evaluation and ultimately allows definitive HER2 
classification at the time of initial diagnosis. Further studies correlating response to anti-
HER2 therapy and HER2 status by qRT-PCR are warranted. 
 
TT13. Improvement of Pyrosequencing Assay for EGFR Exon 19 Deletions 
S. Shen, M. Chintalapudi, D. Qin 
Moffitt Cancer Center, Tampa, FL. 
Introduction: EGFR exon 19 mutation has different variants, which pose a challenge 
for pyrosequencing. To increase the capacity of the assay in detecting exon 19 
mutations, a restriction enzyme (MseI) digestion has been used to enrich mutant EGFR 
exon 19 in specimen. There are MseI restriction sites in EGFR exon 19. Most of exon 
19 deletions will eliminate one MseI restriction site. Therefore, the EGFR exon 19 
deletion mutant is more resistant to MseI digestion. After MseI digestion, the ratio of 
exon 19 deletion mutant in a specimen will be increased and easier to be detected and 
easier to be analyzed. Methods: The DNA from an EGFR exon 19 deletion mutant cell 
line PC9 was mixed with normal spleen cell DNA at different ratios to generate 5%, 
2.5%, 1.25%, 0.625% and 0.3125% preparations. A portion of the above preparations 
was subjected to MseI digestion before and after PCR amplification. (10 unit/10 µl, 37 
degrees for 3 hours). The rest is served as control. The preparations with or without 
digestion were pyrosequenced. Five consecutive EGFR exon 19 deletion positive 
samples were selected and de-identified from routine molecular test specimen. The 
sequencing results of these samples with or without digestion were also compared. 
Pyrosequencing reagents were purchased from Qiagen. Pyromark MD was used 
according to the manufacturer’s instructions. Results: Without MseI digestion, the exon 
19 mutation was detected in 5%, 2.5%, 1.25% samples, but not in 0.625% and 
0.3125% samples with quantitating results of 4.97%, 2.72%, 2.20%, 0%, 0%, 
respectively (see figure 2A). With MseI digestion, the exon 19 mutant was detected in 
all 5 preparations (5%, 2.5%, 1.25%, 0.625% and 0.3125%) with quantitating results of 
85.43%, 81.54%, 75.06%, 62.72% and 58.78%respectively. FFPE tissue was also 
tested with or without MseI digestion. After MseI digestion, the peak height from mutant 
increased. The negative cases were also tested. After digestion, the negative cases 
remained negative. Conclusions: MseI digestion could increase pyrosequencing assay 
sensitivity for EGFR exon 19 deletion approximately 20 to 200-fold. The enrichment is 
more effective when starting mutant gene percentage is low. The digestion also 
simplifies the data analysis and also works in FFPE specimen. 
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TT14. Multiplex Sequencing: Using Multiplex PCR Amplification and 
Pyrosequencing for KRAS/BRAF Mutation Analysis 
H. Takei, M. Szanyi, F. Monzon 
The Methodist Hospital, Houston, TX. 
Introduction: Novel targeted therapeutic approaches often require detection of a 
specific mutated gene in a patient’s tumor. In addition, mutations in downstream 
effectors of drug targets can impact therapeutic efficacy. Targeted agents to the 
epidermal growth factor receptor (EGFR) have improved outcomes for patients with 
metastatic colorectal carcinomas (mCRCs). However, activating mutations in the KRAS 
or BRAF genes confer resistance to anti-EGFR agents. KRAS mutation status of mCRC 
cases is now routine, but BRAF gene status is only recommended as an option if KRAS 
is wild type. In addition, mutation in the KRAS codon 61, although much less frequent, 
also confers resistance. Although PCR can be multiplexed to detect the most frequent 
mutations, sequencing is the method of choice to detect all possible mutations but 
needs to be done individually for each exon. Our goal was to develop a multiplexed 
sequencing assay that could be applied to KRAS/BRAF mutation detection. Methods: 
We designed a multiplex PCR protocol to amplify gene sequences containing KRAS 
codons 12/13, KRAS codon 61, and BRAF codon 600. Pyrosequencing was performed 
using the multiplex amplicon reaction. A KRAS (codon 13) mutant cell line (HCT116), a 
BRAF (codon 600) mutant cell line (HT29), and a wild-type control (placental DNA) 
were tested simultaneously. We also determined the lower limit of detection of KRAS 
and BRAF mutations. Results: The multiplex PCR yielded specific amplicons for each 
of the target sequences. The locus containing KRAS codon 61 was more efficiently 
amplified and appeared to negatively influence the yield of product from the less 
efficient locus containing KRAS codon 12/13. Pyrosequencing demonstrated expected 
sequencing patterns (i.e., mutated sequences c.38G>A (p.Gly13Asp) and c.1799T>A 
(p.Val600Glu) in KRAS and BRAF mutant cell lines, respectively, and wild-type 
sequences in control DNAs). However, there was slightly increased background noise 
compared to non-multiplex PCR reactions. The lower limit of detection was 8% (allele 
burden) for KRAS G13D mutation and 14% (allele burden) for BRAF V600E mutation. 
Conclusions: We have demonstrated that the clinically significant exons of KRAS and 
BRAF in CRCs can be tested simultaneously with our multiplex PCR reaction protocol. 
This approach could enable a single multiplex PCR reaction followed by sequential 
sequencing for multiple mutations (proceeding only to the next step if wild type) in other 
signaling pathways. Further optimization and validation with a large number of samples 
will be necessary for clinical implementation of our KRAS/BRAF assay.   
 
TT15. Automated DNA Extraction from FFPE Tissue Using a Xylene-Free 
Deparaffinization Method  
J. Uhlendorff, S. Angenendt, P. Scholtysik , D. Groelz, K. Beller 
QIAGEN GmbH, Hilden, Germany. 
Introduction: Formalin-fixed paraffin-embedded (FFPE) tissue samples are routinely 
used for immunohistochemistry and molecular analysis in cancer research. However, 
many methods for DNA extraction from FFPE tissue sections are manual procedures 
that are not standardized, time consuming and often include usage of hazardous 
materials like xylene. In this study, we describe an alternative xylene-free 
deparaffinization method that can be used in combination with automated DNA 
extraction on QIAsymphony sample preparation instrument. Performance is shown in 
comparison to DNA extraction using standard xylene deparaffinization method and 
manual sample preparation. Methods: Either rat FFPE tissue material was prepared 
freshly or human FFPE Tissue was purchased from Proteogenex. Up to eight tissue 
sections were used for DNA extraction. Deparaffinization of FFPE tissue was performed 
according to QIAamp DNA FFPE Tissue Kit by use of xylene and ethanol or by use of 
QIAGEN Deparaffinization solution. DNA was extracted by either using QIAsymphony 
DNA Mini Kit in combination with the Tissue Low content protocol or manual QIAamp 
DNA FFPE Tissue kit. Performance was compared by determining DNA yield, purity 
and integrity as well as mutational status of biomarker. Linearity of DNA extraction was 
assayed by using increasing amounts of FFPE tissue sections. Results: Hands-on-time 
for deparaffinization was significantly reduced from 20min to 5min by use of 
Deparaffinization solution. Data obtained by performance study using xylene-free 
deparaffinization showed a mean DNA yield that was comparable to standard xylene 
pre-treatment or manual method. DNA purity determined by the ratio A260nm/280nm 
was greater than 1.8 for all methods. Integrity of DNA was tested by multiplex endpoint 
PCR that showed the same spectrum of amplicon sizes and demonstrated the usability 
of DNA for PCR analysis. A plot of DNA yield vs. amount of FFPE sections revealed 
linearity for automated methods (regression coefficient of  0.9). Analysis of mutational 
status of biomarker KRAS, BRAF and EGFR lead to identical results, demonstrating 
functionality of extracted DNA. Conclusions: The QIAGEN Deparaffinization solution in 
combination with QIAsymphony DNA Mini Kit and the Tissue Low content protocol 
represents an efficient and fast method for automated DNA extraction from FFPE tissue 
without use of the hazardous material xylene.  
The applications presented here are for research purposes. Not for use in diagnostic 
procedures. 
 
TT16. Fluorescence-Based Multiplex PCR MSI Assay Optimized for the Applied 
Biosystems 3500 Genetic Analyzer 
M. Le, X. Chen, A.C. Mackinnon 
Medical College of Wisconsin, Milwaukee, WI. 
Introduction: Approximately 15% of colon cancers demonstrate high frequency 
microsatellite instability (MSI-H). As MSI-H patients have better overall survival 
compared to patients with microsatellite stable (MSS) colon cancer and do not respond 
as well to 5-fluorouracil-based adjuvant chemotherapy, identification of MSI-H colon 
cancer is clinically significant. MSI status is frequently determined by multiplex PCR of 
five mononucleotide alleles followed capillary gel electrophoresis. We describe a 
modified PCR protocol for MSI detection that is well-suited for the Applied Biosystems 
3500 Genetic Analyzer, which recently became available in the USA. Methods: 40 
paired normal and tumor DNA samples were purified from FFPE colon cancers. 0.4 to 
26.8 ng of template DNA was used to analyze NR27, NR21, NR24, BAT25, and BAT26 
mononucleotide microsatellite loci in multiplex PCR. Reverse PCR primers were labeled 
with 6FAM, VIC, or NED fluorescent dyes. The PCR products were resolved on an 
Applied Biosystems 3500 Genetic Analyzer and analyzed using GeneMapper 4.1 
software. Cases were also analyzed by immunohistochemistry (MLH1, MSH2, MSH6, 
and PMS2). 20 of the cases were analyzed in parallel using a commercially available 
multiplex PCR MSI Analysis System. Results: Total PCR time was 75 minutes. 
Fluorescent intensities of all markers were balanced allowing maximum sensitivity. 
Shifted peaks from a DNA sample containing 5% of MSI DNA were clearly identified. 
The minimum detection limit of template DNA was 0.4 ng. Robust PCR amplification of 
all mononucleotide loci in all samples was observed, and all results were confirmed by 
IHC. In marked contrast to our results, weak amplification of one or more loci was 
observed in 4 samples tested using conventional multiplex PCR methods in conjunction 
with an older-model capillary gel electrophoresis instrument. Consequently the MSS 
status of these cases could not be unambiguously established. Conclusions: The 
modified MSI assay described here is optimized for the Applied Biosystems 3500 
Genetic Analyzer. The assay is fast, robust, relatively inexpensive, and sensitive down 
to less than 0.5ng of purified template DNA. To the best of our knowledge, no MSI 
detection kits are commercially available for the Applied Biosystems 3500 Genetic 
Analyzer. When compared with an existing MSI Analysis System optimized for older 
model capillary gel electrophesis instruments, this modified MSI assay generates more 
intense peaks making subsequent interpretation less challenging while also reducing 
the turn-around-time for MSI results. 
 
TT17. Performance Evaluation and Comparative Simulation Modeling of 
LightCycler® MRSA Advanced and Xpert™ MRSA assay in a Multi-Center Trial 
A. Mohammad1, K. Walker1, R.C. Arcenas2, S. Spadoni3, R.C. Fader1, F.L. Kiechle2,  
F. Perdreau-Remington4, J. Osiecki5, O. Liesenfeld6, A. Rao1 
1Scott and White Memorial Hospital, Temple, TX; 2Memorial Regional Hospital South, 
Hollywood, FL; 3Edward Hines Jr. VA Hospital, Hines, IL; 4University of California, San 
Francisco, San Francisco, CA; 5Roche Diagnostic Corporation, Indianapolis, IN; 6Roche 
Molecular Diagnostics, Pleasanton, CA. 
Introduction: Rapid detection of nasal colonization with methicillin-resistant 
Staphylococcus aureus (MRSA) followed by infection control procedures can curtail 
MRSA infection and transmission. Universal screening imposes considerable demands 
on performing laboratories and optimization is key to achieving acceptable turnaround 
times. When tests have comparable sensitivity and specificity, the selection of one 
technology over other is usually based on determining laboratory efficiency parameters 
such as throughput, turnaround times, labor utilization and cost, which is best 
determined by simulation modeling. Methods: The performance and work-flow of two 
FDA approved tests, the LightCycler® MRSA Advanced test (Roche Indianapolis, IN) 
and Xpert™ MRSA test (Cepheid Sunnyvale, CA) was evaluated on 1202 specimens in 
a multi-center trial. It was noted that the mean hands on time for sample preparation 
(using all samples regardless of whether they had been tested in singlicate or in 
groups/batches) was actually less for the LightCycler® MRSA Advanced assay than the 
Xpert™ MRSA assay per sample (1:40 min vs 2:35 min). We used a discrete event 
simulator to simulate the processes and confirm without bias using iGrafx Process 2007 
for Six Sigma discrete event simulator software. Time and motion analysis was 
performed for all steps in the two processes. The models were validated by comparing 
the predicted turnaround times and test throughput with the experimental data. 
Results: Compared to directly-plated culture, the LightCycler® MRSA Advanced and 
Xpert™ MRSA assay showed similar relative sensitivities of 95.2 (95% CI 89.1-98.4%) 
and 99.0% (95% CI 94.8-100%), and specificities of 95.5 (94.1-96.7%) and 95.5% (95% 
CI 94.1-96.7%) respectively. The GeneXpert system is well suited when single samples 
are tested giving better turnaround times (73 min as compared to 112 min) as long as 
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number of samples tested per run is less than or equal to 8. However, when MRSA is 
tested in batch mode (n= 30) as was done at two of the sites, the LightCycler gives 
better throughput, shorter turnaround times (213 min compared to 286 min) and 
comparable percent labor utilization (17.9% and 16.6%). Conclusions: The low labor 
utilization clearly indicates that the rate limiting factor for test throughput is the number 
of GeneXpert modules available in the laboratory. The multiple sample processing 
capabilities of the LightCycler® offers advantages for batch mode processing. Such 
optimization models are clearly valuable for successful laboratory operations. 
 
TT18. Comparison of SNaPshot® Fluorescent Capillary Electrophoresis and 
Sequenom® MassARRAY Based Platforms for Multiplex Solid Tumor Mutation 
Screening 
B.A. Barkoh, R. Patel, J. Manekia, A.N. Bartley, Z. Zuo, K. Patel, R. Luthra 
The University of Texas M.D. Anderson Cancer Center, Houston, TX. 
Introduction: With increasing availability of targeted therapies for solid tumors, 
simultaneous assessment of the mutation status of multiple targetable genes in tumors 
has become critical for patient management. Limited availability of samples 
necessitates the use of multiplex approaches for testing. Current multiplex hotspot 
mutation screening approaches include primer extension assays followed by mass 
spectrometry (MS)-based (Sequenom® MassARRAY; Sequenom, San Diego, CA) or 
fluorescent capillary electrophoresis (FCE)-based (SNaPshot® multiplex system: Life 
Technologies, Carlsbad, CA) detections. As the FCE-based platform, which offers 
flexibility for multiple applications, is available in many molecular diagnostic 
laboratories, we validated a solid tumor mutation screening panel using this platform. 
Here, we present our assessment of the performance characteristics of the FCE-based 
mutation panel in comparison with our existing MS-based mutation panel. Methods: 
DNA was extracted from 7 formalin-fixed, paraffin-embedded (FFPE) cell lines (HL60, 
A375, H2122, H1437, HT1080, DLD1 and CAMA-1) and 120 manually micro-dissected 
FFPE solid tumor samples. A 9-well panel was developed to assess the mutation status 
of hotspot regions from 13 genes (AKT 1, AKT 2, AKT 3, BRAF, EGFR, GNAQ, GNAS, 
IDH1, IDH2, KRAS, MET, PIK3CA, and RET). DNA (10 ng) was PCR amplified and 
subjected in parallel to single-base-primer extension (SBE) using the SNaPshot® 
multiplex kit and iPlex® Pro kit (Sequenom). SBE products were genotyped by FCE-
based or MS-based detection. Assay sensitivities were determined for mutations for 
which positive cell lines were available. Results: Both FCE-based and MS-based 
panels successfully detected all previously published mutations in the control cell lines. 
Sixty-seven mutations (KRAS, N=21; NRAS, N=4; MET, N=8; PIK3CA, N=19; BRAF, 
N=9; IDH1, N=2; EGFR, N=1; GNAQ, N=2; and GNAS, N=1) were detected in 57 tumor 
samples. One hundred percent concordance was observed in the genotyping results 
between the two platforms. Depending on the level of multiplexing in a given well, the 
sensitivity of detection ranged from 3% to 7% for FCE-based panel and from 5% to 10% 
for MS-based panel. Conclusions: Both FCE and MS provide reliable high-throughput 
platforms that can be used to detect multiple mutations simultaneously using limited 
DNA. In our experience, FCE data were easier to interpret, especially in samples with 
low level mutations, as the visualization was aided by both color and fragment size. 
Further, the FCE-based panel can be easily incorporated into the workflow of most 
molecular diagnostic laboratories by using existing genetic analyzers that are already in 
wide-spread use for fragment analysis and Sanger sequencing. 
 
TT19. Verification of a Fully Automated Sample Preparation for SurePath™ 
Specimens Using the QIAsymphony SP 
K. Lindebaum1, C. Kupfer1, J. Giles2, R. Chendvankar2, J. Huff2, R. Mallonee2,  
M. Londono2, J. Wallace2, C. Papadopoulos1, Y. Lee1, T. Hartinger1, A. Schubert1,  
M. Sprenger-Haussels1 
1QIAGEN GmbH, Hilden, Germany; 2QIAGEN Inc., Gaithersburg, MD. 
Introduction: QIAGEN is currently developing a DNA extraction procedure based on 
pH-driven anion exchange sample preparation chemistry (AXpH) for use on the 
QIAsymphony SP. This work summarizes data generated using SurePath specimens 
on the QIAsymphony SP. Methods: To compare manual and automated sample 
preparation methods, DNA was isolated on the QIAsymphony using the AXpH 
SurePath protocol and as a reference, the manual sample conversion method. The 
QIAsymphony eluates and the corresponding manually converted pellets were tested 
with digene HC2 High-Risk HPV DNA Test®. HC2 testing was done using 352 residual, 
de-identified, cervical SurePath post-gradient specimens, retained after cytology 
screening. The automated DNA extraction procedure was evaluated for repeatability, 
precision, eluate stability and tested the effect of potentially interfering substances on 
the extraction procedure using either pools of de-identified SurePath samples, or 
individual cervical SurePath post-gradient specimens. To test repeatability, DNA was 
purified from 7 dilutions of HPV positive samples in two independent experiments using 
the QIAsymphony DSP AXpH DNA Kit. To test precision, inter-instrument and inter-day 
precision was determined on three different QIAsymphony instruments and on three 
different days using HPV positive samples. For eluate stability analysis, DNA extracted 
from positive and negative material was stored 4-8°C or at –20°C prior to analysis in 
HC2. The impact of potentially interfering substances on the AXpH chemistry were 
tested by adding varying amounts of blood, lubricating jelly, contraceptive jelly, 
spermicidal gel, douche, feminine spray, and antifungal cream to low positive samples. 
Results: The QIAsymphony AXpH SurePath protocol resulted in 92.9% total 
agreement with the manual conversion method (327 of the 352 results agreed, kappa = 
0.81), negative agreement was 96.6% (255 of the 264 results agreed), and positive 
agreement was 81.8% (72 of the 88 results agreed). (b) Initial evaluation of the 
automated procedure showed that the specifications for repeatability, precision and the 
effect of potentially interfering substances were met. Preliminary eluate stability results 
for up to two weeks at 2–8°C and up to four weeks at –20°C met the acceptance 
criteria. Conclusions: We successfully evaluated the automated QIAsymphony DSP 
AXpH DNA extraction procedure using SurePath™ samples. The QIAsymphony 
applications presented here are for research purposes. Not for use in diagnostic 
procedures. 
 
TT20. Implementation of IL28B rs12979860 Polymorphism Testing on the Abbott 
m2000 Platform 
J.H. Willman, L.J. Bischof, W.D. Lebar, D.W. Newton 
University of Michigan, Ann Arbor, MI. 
Introduction: Genome wide association studies have identified the single nucleotide 
polymorphism (SNP) rs12979860 as an important predictor of Hepatitis C virus 
treatment response and spontaneous viral clearance. rs12979860 genotype results are 
becoming an important component of HCV therapeutic planning and management. We 
implemented a rapid, robust real-time TaqMan PCR assay to determine the rs12979860 
genotype utilizing the Abbott m2000 platform. Methods: Genomic DNA was extracted 
from 50 de-identified EDTA whole blood samples utilizing the whole blood protocol on 
the Abbott m2000sp instrument. The extracted DNA was analyzed by real-time TaqMan 
PCR on the Abbott m2000rt real-time PCR System with hydrolysis probes specific for 
the rs12979860 C and T alleles. Results were correlated with genotypes obtained by 
Sanger sequencing and with results obtained from an outside reference laboratory. 
Results: Assay performance was excellent with all of the fifty samples generating an 
appropriate genotype result. There was 100% agreement with Sanger sequencing 
results and reference laboratory results. Allelic frequencies were 0.618 for the C allele 
and 0.382 for the T allele. Genotype frequencies were C/C 0.417, C/T 0.402, and T/T 
0.181. The allelic and genotype frequencies observed were similar to published 
frequencies, however the ethnic background of the patients tested was not available 
and the tested population likely represents a mixed ethnicity population. The genotype 
results were highly reproducible between runs, with repeat analysis (n=9) showing a CV 
of 1.5% for the Ct value of the C allele and CV of 0.2% for the Ct value of the T allele. 
Conclusions: Our implementation of a rs12979860 genotyping assay utilizing the 
Abbott m2000 platform is readily applicable to clinical testing and demonstrates 
excellent performance and reproducibility. Rapid determination of the rs12979860 
genotype will facilitate the planning and management of personalized treatment for 
HCV infected individuals. 
 
TT21. A Comparative Study of Methods for Determination of NPM1 Mutation 
Status in Diagnostic AML Specimens 
K.C. Behling, J. Edwards, V.M. Van Deerlin, C.D. Watt 
Hospital of the University of Pennsylvania, Philadelphia, PA. 
Introduction: Mutations in nucleophosmin (NPM1) are important for stratification of 
patients with cytogenetically normal acute myeloid leukemia (AML) with respect to the 
timing and use of induction chemotherapy and stem cell transplant. Mutations in NPM1 
are most commonly the result of a 4 bp insertion at a specific site in exon 12. Numerous 
mutations have been described; however, most mutation positive patients have one of 
three insertion mutations (types A, B, D). Several methods have been proposed for 
detection of NPM1 mutations in patient samples, including sequencing and liquid bead 
array based methods, each with inherent advantages and disadvantages with respect 
to analytical and clinical sensitivity and ease of interpretation. Methods: Diagnostic 
AML specimens (bone marrow and peripheral blood, N=64) from patients at the 
Hospital of the University of Pennsylvania were collected, and RNA and DNA were 
extracted using the QIAamp RNA Blood mini kit and QIAamp DNA blood mini kit 
(Qiagen, Valencia, CA), respectively. Each specimen was evaluated by Sanger 
sequencing (BigDye Terminator method, Applied Biosystems, Carlsbad, CA), 
pyrosequencing (Pyromark, Qiagen) and a liquid bead array assay (Signature NPM1 
Research Use Only Kit, Asuragen Inc., Austin, TX) to assess NPM1 mutation status. 
Clinicopathologic data were also obtained for correlation with NPM1 mutation status. 
Results: NPM1 mutations were detected in 20/64 specimens tested (31%). Forty-two of 
the patients had cytogenetically normal AML, and NPM1 mutations were detected in 17 
of these patients (40%). These results are comparable to those previously reported. 
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Overall concordance between the methods was excellent. Data on the performance of 
each method will be presented including 4 samples that upon sequencing presented 
interpretive challenges. Notably, the liquid bead array assay demonstrated 
commendable performance characteristics including 100% concordance with 
sequencing as well as an analytical sensitivity at least as low as 0.01% as determined 
by an admixture of OCL-AML3 cells and HL-60 cells. Conclusions: While multiple 
methods are available for the determination of NPM1 mutation status, the Signature 
NPM1 liquid bead array assay is a sensitive and straightforward method to asses for 
NPM1 mutations in diagnostic AML patient samples. This is in contrast to the potentially 
difficult analysis of data generated by less sensitive methods such as traditional Sanger 
sequencing and pyrosequencing. Although the liquid bead array assay cannot 
distinguish amongst the NPM1 mutations it is designed to detect, more than 90% of 
known NPM1 mutations are covered by the assay. 
 
TT22. Development and Validation of SNP Detection Assays Using Invader 
Plus® Reagents 
E. Romeo, T. Holscher, C. Ibarra, J. Lameh, J. Diver 
Genoptix, Inc., Carlsbad, CA. 
Introduction: Single Nucleotide Polymorphisms (SNPs) are often linked to the 
development of diseases such as cancer and resistance/sensitivity to specific 
chemotherapeutics. Detection of such gene alterations is fundamental in the diagnosis 
of cancer or in treatment management. We have designed, developed and validated 
two assays for the detection of BRAF V600E and DPD IVS14+1G>A. The BRAF V600E 
mutation may be associated with resistance to anti-EGFR drugs such as panitumumab 
and cetuximab in colorectal cancer (CRC), while in thyroid cancer patients, the BRAF 
V600E mutation correlates with poor prognosis. In melanoma, BRAF V600E mutation 
occurs in 60% to 80% of the patients; anti-BRAF therapy is being developed and 
recently it showed promising results in clinical trials. The IVS14+1G>A polymorphism 
occurs in the dihydropyrimidine dehydrogenase (DPD) enzyme; the first and rate-
limiting step in the catabolic pathway that metabolizes the drug 5-fluorouracil (5-FU). 
This polymorphism results in a protein with little to no activity, which can lead to severe, 
occasionally fatal, side effects in response to 5-FU treatment. Methods: The Invader 
Plus® chemistry consists of a limited cycle PCR followed by Cleavase®-driven allele-
specific signal amplification in a homogeneous single-tube format. Invader Plus® 
oligonucleotides were designed to the targeted regions of interest (BRAF and DPD) and 
the designs then ordered through a third-party oligonucleotide manufacturer. The 
Invader Plus® primers and probes were designed, and then tested to optimize the initial 
PCR conditions and the appropriate Cleavase®-dependent fluorescent detection time 
using a real-time PCR platform. Results: For BRAF V600E, the reaction was optimized 
for the semi-quantitative detection of the mutation in DNA extracted from formalin-fixed 
paraffin-embedded (FFPE) tumor specimens. The assay validation showed that the 
sensitivity of the assay is 1% on as little as 15 ng of DNA. The DPD IVS14+1G>A 
genotyping assay has three possible outcomes: homozygous negative (no 
polymorphism), homozygous positive (IVS 14+1G>A present) and heterozygous. The 
test was developed to clearly differentiate the three possible genotypes such that 
fluorescence ratio from the two probes would cluster in distinct non-overlapping ranges 
for each genotype. Conclusions: The analytical laboratory validation of the Invader 
Plus® developed assays demonstrated 100% concordance with results from an 
external laboratory using a different chemistry, on 20 FFPE specimens for the BRAF 
V600E assay and on 22 peripheral blood and FFPE specimens for the DPD 
IVS14+1G>A assay. 
 
TT23. Deparaffinization with Mineral Oil: A Simple Procedure for Extraction of 
High-Quality DNA from Archival Formalin-Fixed, Paraffin-Embedded Bone 
Marrow Trephine Biopsies 
N.M. Heikal, R.H. Nussenzveig, A. Agarwal 
University of Utah, ARUP Laboratories, SLC, UT. 
Introduction: Extracting DNA from formalin-fixed, paraffin-embedded (FFPE) archival 
samples represents a challenge for molecular testing due to nucleic acid degradation 
with often a variable yield results. Successful PCR with DNA extracted from FFPE 
samples are still very low. Methods: We extracted DNA from 12 archival FFPE bone 
marrow trephine biopsy samples (from 5, 10 and >18 years of storage) by using a 
simple protocol based on deparaffinization with molecular biology grade mineral oil 
followed by DNA extraction with the Qiagen FFPE kit. Comparison of this 
deparaffinization method with the xylene and hemo-D protocols was investigated. The 
quality and quantity of extracted DNA was tested by a combination of ultraviolet (UV) 
spectroscopy, analysis on a bioanalyzer, and real-time PCR combined with high 
resolution melt (HRM) analysis of different size amplicons. Results: DNA extraction 
yields for all three deparaffinization procedures were comparable. In contrast to 
extraction yields, high-quality FFPE DNA was not uniform for all procedures based on 
the bioanalyzer and UV spectroscopy results. Higher quality of extracted DNA was 
obtained with deparaffinization based on the mineral oil and xylene protocols. 
Moreover, results obtained by deparaffinization with hemo-D protocol suggested a 
carryover of a byproduct with absorbance at a wavelength of 230 nm. This result was 
confirmed by real-time PCR and HRM. Highest quality PCR amplifiable DNA was 
obtained by deparaffinization with the mineral oil protocol (100% for smaller products), 
while more variable results were obtained for the 2 other deparaffinization procedures. 
Conclusions: Besides improvement in quality of extracted DNA, the use of mineral oil 
for deparaffinization has the added benefit of decreased time (20 minutes vs. 75 
minutes) and a significant reduction of hands on labor (1 step vs. multiple hands-on 
centrifugation and decanting steps). Our results indicate that DNA extraction using 
mineral oil for deparaffinization is simple, fast, generates excellent quality extracted 
DNA and sufficient yields for retrospective studies and advocate for the adoption of this 
procedure in the diagnostic and research laboratories.  
 
TT24. Pyrosequencing Is a Highly Sensitive Technique for Detection of Point 
Mutations in Exon 17 of KIT Gene Involved in Gastrointestinal Tumors, 
Melanoma, AML and Mastocytosis 
C.F. Kletecka1, J.M. Gale2, M.A. Vasef1,2 
1UNM, Albuquerque, NM; 2TriCore Ref Laboratories, Albuquerque, NM. 
Introduction: KIT mutations have been identified in gastrointestinal stromal tumor 
(GIST), melanoma, acute myeloid leukemia (AML), and mastocytosis. The mutational 
status of KIT receptor tyrosine kinase has important clinical implications in targeted 
therapy, as a prognostic indicator and predictor of response to tyrosine kinase inhibitor 
therapy. The most commonly used methods for mutation identification are high 
resolution melting curve analysis and/or direct sequencing. We successfully identified 
KIT mutations in codons 816, 820, 822 and 823 of exon 17 using a pyrosequencing 
technique. Methods: Exon 17 KIT mutation analysis was performed on DNA extracted 
from paraffin-embedded tissue blocks including 81 GISTs, 70 melanomas, 16 mast cell 
disease, and on DNA extracted from banked cell pellets of 10 AML cases with inv(16) 
and 9 AML cases with t(8;21). The extracted DNA was subjected to PCR amplification 
followed by pyrosequencing analysis on the PyroMark Q24 System. Mutations involving 
codons 816, 820, 822 and 823 were analyzed. Results: Exon 17 KIT mutations were 
identified in 5 of 81 (6%) GIST cases including a N822Y mutation in 4 and a Y823H 
mutation in 1. One out of 70 (1%) melanoma cases demonstrated a N822Y mutation. 
One of 10 (10%) AML cases with inv(16), revealed a D816V mutation. Three of 9 (33%) 
AML cases with t(8;21) demonstrated a N822S mutation, and 9 of 16 (56%) mast cell 
disease cases, showed a D816V mutation. Conclusions: Based on our study, 
pyrosequencing assay is a preferred technique in reliable detection of clinically 
significant point mutations involving exon 17 of KIT gene in various types of cancer 
specimens. The pyrosequencing technique has a higher sensitivity, shorter turnaround 
time and is cost effective compared to other techniques such as high resolution melting 
curve and direct sequencing.  
 
TT25. A Utility Comparison of Clinical DNA Samples Before and After 
Dehydration with GenTegraTM for Use on Several Common Molecular Platforms 
C.L. Bissaillon1, K.A. Lebel1, S.A. Marconi1, R.L. Flaherty1, G.J. Tsongalis2 
1Baystate Health, Springfield, MA; 2Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: Long term DNA storage has become a cumbersome, space consuming 
and costly venture for many clinical laboratories. With increased volumes of molecular 
testing, the number of archived DNA samples has risen, posing a storage space issue 
for many laboratories. In this study, we evaluate the feasibility of using the GenTegraTM 
DNA system (GenVaultTM), where DNA is stored in a water free environment, 
preventing damage from hydrolysis, oxidation and microbial growth.  Previously isolated 
and tested clinical samples were dehydrated using the GenTegraTM DNA system and 
then re-hydrated and retested for the same genetic markers. Methods: De-identified, 
previously isolated and tested clinical samples were dehydrated using the GenTegraTM 
DNA system. Forty-five DNA samples and 5 no target controls (NTC) were used. DNA 
(or Tris-EDTA for the NTC) was added to the GenTegraTM DNA tube and mixed 
according to the manufacturer’s recommendation. . The samples were dried in a 
desiccant bag, capped and stored at room temperature. The samples were re-hydrated 
to their original volume using molecular grade water, incubated at room temperature for 
15 minutes, and vortexed for 1 minute. The re-hydrated DNA was then analyzed on the 
NanoDrop 2000 spectrophotometer and tested utilizing the AB 7500 FAST, AB 3130, 
Luminex and Hologic platforms. Results: The re-hydrated GenTegraTM DNA performed 
as well as original clinical samples on the various testing platforms. 10 coagulation 
panel, 10 Cystic Fibrosis, 10 KRAS and 15 fragile X samples all gave concordant 
results after rehydration using the respective platforms. The 260/280 ratios and DNA 
concentration obtained from spectrophotometer analysis were similar to those 
previously obtained. Conclusions: The GenTegraTM DNA system appears to be a 
viable option for storage of clinical DNA samples. Its performance on multiple platforms 
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indicates the integrity of the DNA was not altered during the dehydration and hydration 
process. The GenTegraTM DNA matrix did not interfere with these testing systems. 
 
TT26. The Optimization of Copy Number Analysis of FFPE Tumor DNA by Array-
CGH for Implementation into a Clinical Diagnostic Laboratory 
L. Dias1, A. Guttapalli1, J. Teruya-Feldstein2, L. Wang3,4, J. Houldsworth1 
1Cancer Genetics Inc, Rutherford, NJ; 2Memorial Sloan-Kettering Cancer Center, New 
York, NY; 3Chilton Hospital, Pompton Plains, NJ; 4Mountainside Hospital, Pompton 
Plains, NJ. 
Introduction: Array comparative genomic hybridization (aCGH) has evolved as a 
valuable tool for the identification of genomic copy number alterations in tumors. 
Reliable aCGH analysis requires tumor cell enrichment of specimens; therefore the 
ideal specimen would have a high percentage of tumor cells. While genomic DNA 
(gDNA) extracted from fresh frozen tissue is of high integrity and easier to label, 
formalin-fixed, paraffin-embedded (FFPE) material allows for the assessment of tumor 
cell content within the specimen and subsequent sampling of tumor rich areas for 
aCGH analysis. The goal of this study was to optimize a procedure for the isolation and 
labeling of gDNA from tumor enriched areas of FFPE specimens for subsequent aCGH 
analysis. Methods: DNA was extracted from six pairs of matched FFPE (5x20-Pm 
sections) and fresh frozen specimens representing a variety of lymphoma types. The 
six FFPE DNAs were labeled chemically using the Agilent Technologies Oligo aCGH 
Labeling KIT (ULS) or enzymatically using the Enzo Life Sciences CGH Labeling Kit 
(Enzo), while gDNAs extracted from the fresh frozen specimens and tumor enriched 
FFPE cores (1.5x2-Pm cores) were labeled enzymatically. All DNAs were hybridized on 
a custom designed, targeted oligonucleotide array. Data from scanned arrays was 
extracted and analyzed using Agilent software. Agilent’s “Genomic Workbench Lite” 
was used to visualize, detect, and analyze copy number changes. Aberrations detected 
in fresh or FFPE specimens were confirmed via QPCR using a candidate mapped 
gene. Results: A comparison of the quality of hybridizations for the six FFPE 
specimens across labeling methods, and to those obtained for matched fresh tissue 
revealed higher signal to noise ratios for Enzo-labeled FFPE gDNA compared to the 
ULS-labeled gDNA, and values comparable to those obtained for fresh frozen tissue. 
DLRSpread for Enzo-labeled FFPE gDNAs was substantially lower than that for ULS-
labeled FFPE gDNAs, which was comparable to those obtained for fresh frozen tissue. 
The log ratio profiles for Enzo-labeled FFPE gDNAs exhibited overall lesser scatter than 
for ULS-labeled FFPE gDNAs such that aberration detection was more challenging for 
the latter. The isolation and labeling protocol was successfully used to identify copy 
number changed in gDNA isolated from tumor enriched FFPE cores using aCGH. 
Conclusions: We optimized a protocol for the isolation and labeling of FFPE gDNA 
from sections and tumor enriched cores for aCGH analysis. The enzymatic method of 
FFPE gDNA labeling was identified as the more robust method for aCGH of such 
technically challenging specimens. 
 
TT27. Rapid Genotyping of HLA-B27 by Direct Real-Time Allele-Specific PCR 
and Melting Curve Analysis without DNA Preparation from Whole Blood 
G. Park, H. Kim 
Chosun University College of Medicine, Gwangju. 
Introduction: HLA-B27  genotyping is a common laboratory molecular test for several 
rheumatic diseases. Despite real-time melting curve analysis for HLA-B27 genotyping is 
introduced, this technique is required for purified DNA as template. We develop a rapid 
genotyping technique using direct real-time allele-specific PCR and melting curve 
analysis without DNA extraction from whole blood. Methods: Two hundred twenty 
samples of randomly selected K2EDTA-treated venous blood were used in the study. 
Because hemoglobin is a strong quencher, we treated 300 ȝL of whole blood by 600 ȝL 
of rapid RBC lysis solution at room temperature for 3 min. After centrifugation and 
discard of supernatant, cell pellet was diluted with 200 ȝL of phosphate-buffer saline. A 
leukocyte suspension was used directly in the direct real-time allele-specific PCR using 
sequence-specific primers. We performed direct real-time PCR and melting curve 
analysis by AnyDirect qPCR Hot master mix (BioQuest, Seoul, Korea), EvaGreen 
fluorescence dye (Biotium, Hayward, CA), and Rotor-Gene Q (Qiagen, Valencia, CA). 
For confirmation of results of direct real-time melting curve analysis, we also confirmed 
by a commercial HLA-B27 genotyping kit (BioWithus, Seoul, Korea) using purified DNA 
as template. Results: Melting temperatures of HLA-B27 positive melting peak and 
internal control melting peak were 87.4±0.3Υ and 89.5±0.4Υ, respectively. 
Concordance rate with direct real-time melting curve analysis and commercial kit was 
100%. Total running time and handling time of direct real-time melting curve analysis for 
15 samples was 1.8 hr and only 15 min, respectively. Conclusions: Direct real-time 
allele-specific PCR and melting curve analysis for HLA-B27 genotyping is a reliable, 
labor-saving and economic technique. 
 
TT28. Evaluation of the Maxwell Automated Nucleic Acid Extraction Instrument 
Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens 
A.D. Crouch, R.G. Rich, K.M. Andrews, D.S. Cohen, G.A. Hosler, K.M. Murphy 
ProPath, Dallas, TX. 
Introduction: Molecular Diagnostic Laboratories are often required to isolate nucleic 
acid from formalin-fixed, paraffin-embedded (FFPE) tissue sections for downstream 
molecular testing. Extraction of high quality/quantity DNA from these samples can be 
challenging and labor-intensive.  In general, automation in the clinical lab can lead to 
improved standardization and reduced hands-on and total testing time. In this study, the 
Maxwell Automated Nucleic Acid Extraction Instrument was evaluated and compared to 
a manual extraction method. Methods: DNA was isolated from 13 microdissected, 
unstained FFPE tissue specimens (2 skin, 11 colon) using a manual method (QIAamp 
DNA FFPE Tissue Kit, Qiagen) and an automated method (Maxwell 16 FFPE Plus LEV 
DNA Purification Kit, Promega) according to the manufacturer’s protocol. The 
concentration and purity of the extracted DNA specimens was determined by 
spectrophotometric readings at 260 and 280 nm. Total amplifiable DNA was determined 
using real-time PCR amplification on the Applied Biosystems 7500 Fast Dx Real-Time 
PCR Instrument. All specimens were analyzed for the BRAF V600E mutation using 
PCR and pyrosequencing on the PyroMark Q24 system. The colon specimens were 
analyzed for microsatellite instability (MSI) using the Promega MSI Analysis System 
v1.2 on the Applied Biosystems 3500 Genetic Analyzer. Results: In general, DNA yield, 
as determined by 260 nm spectrophotometric readings, was approximately 40% greater 
using the Maxwell automated extraction method versus the Qiagen manual extraction 
method. The total amount of amplifiable DNA, as determined by real-time PCR, was 
approximately 200% greater using the Maxwell method versus the Qiagen method. 
DNA from both isolation methods yielded interpretable data for the MSI and BRAF 
assays using a fixed amount of input DNA. In general, there was no significant 
difference in MSI peak heights or BRAF pyrosequencing signal intensities from the 
samples extracted by both methods. Conclusions: Samples isolated by the automated 
Maxwell method yielded higher total quantity, and amplifiable DNA compared to 
samples isolated by the manual Qiagen kit, indicating that DNA specimens isolated by 
the Maxwell method could generate more test results from the same amount of starting 
tissue. The Maxwell method had a higher cost for reagents, but a significant savings in 
labor expenditure compared to the Qiagen method. 
 
TT29. Implementation of Histology Sectioning in a Clinical Molecular 
Diagnostics Laboratory: A Process Improvement Project 
J.M. Bergendahl, J.K. Sanks, M. Weighman, K. Martin, C. Rigney, B.L. Betz, R. Rabah, 
E. Kojo 
University of Michigan Health System, Ann Arbor, MI. 
Introduction: Molecular testing of paraffin-embedded tissue specimens requires 
pathologist review and assessment of tumor cell content to determine specimen 
adequacy. Some cases may also require enrichment by slide-based microdissection 
techniques. These processes require histologic sectioning and staining of the 
specimen, techniques generally performed in a clinical histology laboratory. Our clinical 
Molecular Diagnostics laboratory is located off-site from the main anatomic pathology 
laboratory, requiring transport of specimens to and from the molecular laboratory via 
courier. Receipt of specimens that required sectioning and staining for tissue review 
meant return transport and routing of the specimen to the histology laboratory. Specific 
instructions on each specimen were issued based on the type of the molecular assay 
requested. This previous process required multiple hand-offs and led to misrouted or 
misplaced specimens and extended test turn-around times (TAT). A histology 
sectioning area within the Molecular Diagnostics lab was created to alleviate these 
issues. Methods: Root cause analysis and flow diagrams were created to determine 
areas of inefficiency. A plan to pilot histology processing of paraffin block specimens in 
the Molecular Diagnostics lab was developed. The goal of the pilot was to reduce the 
number of hand-offs/misrouted specimens and to improve test TAT. An area in the lab 
was identified for histology processing, all necessary equipment was obtained, and a 
senior histotechnologist from the hospital histology lab was recruited to train multiple 
molecular staff in sectioning and staining. Results: Measurement of the number of site 
changes (routing) and TAT was performed prior to and after implementation of the pilot. 
Routing of samples in the pre-pilot study required 6 site changes (hand-offs), while 
post-pilot routing required 2. Average pre-pilot and post-pilot test TAT was 7.47 and 
4.96 days, respectively. The incidence of paraffin block re-sectioning due to incorrect 
processing was significantly reduced since the molecular staff were more familiar with 
the test-specific sectioning requirements. Conclusions: Implementation of histology 
procedures and pathologist review within the testing laboratory led to significant 
improvements in test TAT, specimen handling, and ultimately improved patient care and 
customer service. 
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TT30. Pyromaker: A Virtual Pyrogram Generator with Clinical and Research 
Applications 
M. Olson, A. O'Neill, K. Beierl, J.R. Eshleman 
Johns Hopkins School of Medicine, Baltimore, MD. 
Introduction: Some pyrosequencing traces can be complex and extremely difficult to 
interpret. Methods: We report a freely accessible software program, Pyromaker, which 
generates simulated traces for pyrosequencing results based on user inputs. The user 
inputs wild-type and mutant sequences, whether the mutation is heterozygous or 
homozygous, and the % tumor cells. Using this information, Pyromaker first calculates 
the percent mutant alleles and the percent wild-type alleles. Using either a default or 
custom dispensation order, it then calculates and graphs a simulated pyrogram. 
Results: Simulated pyrograms can be used for a variety of applications, such as 
assisting in the analysis of complex sequencing results where various hypothesized 
mutations can be tested, and the resultant virtual pyrograms can be pattern-matched 
with the actual pyrogram. It also can be used to quantify the relative percentage of 
cancer and normal cells within a tumor, and can display at each peak position the 
relative contribution of mutant and wild-type alleles. Pyromaker also can be used to 
detect homozygous cases, and to test various dispensation orders and identify 
suboptimal ones. We validated Pyromaker virtual pyrograms against the actual 
pyrograms for 7 common KRAS codons 12 and 13 mutations and the V600E BRAF 
mutation. We used Pyromaker to demonstrate that all single base mutations within 
codons 12 and 13 of KRAS generate unique pyrosequencing traces. Pyromaker was 
also used to optimize sequencing primer design by illustrating the utility of defining 1x 
using codon 11, prior to sequencing codons 12 and 13 that contain mutations. 
Conclusions: Pyromaker is a valuable tool for many aspects of pyrosequencing, 
especially as an aid in decoding complex pyrosequencing results. Pyromaker may also 
be useful for other applications such as methylation and teaching the fundamentals of 
pyrosequencing. 
 
TT31. Preliminary Comparison of Sensitivity between Real-Time PCR and 
iCubate Cassette Versions of Two Molecular Assays 
J. Brunstein1, H. Liu1, R. Vereen2, T. Bumpus2, J. Han1,2 
1iCubate, Inc., Huntsville, AL; 2HudsonAlpha Institute for Biotechnology, Huntsville, AL. 
Introduction: The iCubate system uses cassettes preloaded with all the reagents 
necessary to perform sample extraction, nucleic acid amplification, and product 
detection for a sample. The closed design of the cassette safeguards against possible 
amplicon contamination while providing a turnkey molecular assay system for the user. 
We report on the evaluation of two, single target iCubate system assays in comparison 
with two simplex real-time PCR assays for the same bacterial genomic targets to 
evaluate the sensitivity and burden of assay optimization for the iCubate platform. 
Methods: Two S. aureus genomic targets were chosen to compare both platforms: 
aadD (aminoglycoside adenyltransferase) and nuc (thermonuclease). The amplicon for 
each target was selected and the same amplicon region used for both assay types. 
Real-time PCR was performed using a single round with SYBR Green I detection. 
iCubate assays were performed with a proprietary two stage ARM-PCR method, with 
detection by hybridization to the in-cassette array and readout on the system iC 
Reader. Sensitivity by either method was determined by limiting dilution assay with a 
95% LoD being determined on each system for each assay. Results: The iCubate 
system assays were determined to have better (lower) 95% LoD values than the 
comparable real-time PCR assays. Differential performance of the two assays on the 
two platforms was observed, with the iCubate and real-time systems showing generally 
similar performance levels for one target, and the iCubate assay being much better for 
the other target tested. In both cases, the complete iCubate assay gave LoD95 values 
below 500 cfu/assay. Conclusions: With equivalent levels of optimization performed, 
the iCubate system showed detection performance on par with, or better, than 
conventional real-time PCR for the same targets. In part this is likely due to the ARM-
PCR method. While the real-time PCR reactions could likely have been brought to 
similar performance as the iCubate assay with sufficient optimization, our results 
demonstrate the iCubate system and ARM-PCR combine to provide a robust, simple 
platform with a simple assay optimization requirements.  
 
TT32. Tracking and Controlling All Laboratory Processes with a Single Software 
Platform  
L. Nelson1, T. Tait1, R. Chettier1, D. Cook1, C. Hull2 
1Axial Biotech, Inc., Salt Lake City, UT; 2UNIConnect, Salt Lake City, UT. 
Introduction: Axial Biotech has developed a prognostic test for adolescent idiopathic 
scoliosis using 53 genetic markers and a logistic regression algorithm. Research and 
development of the prognostic test was completed in-house and our processes for 
developing a clinical assay were developed internally. Based on a large expected 
volume of tests, selection of a Laboratory Information Management System (LIMS) was 
critical to the development of the assay. Investigation into many LIMS options was 
frustrating as most were extremely costly and inflexible, limiting continued 
improvements to the assay. We report here the selection of an extremely flexible LIMS 
platform that we have expanded to encompass our entire process. Methods: We 
decided to select our LIMS system early in the assay development process to ensure 
integration of all components of the process. The UNIFlow™ platform was selected 
because of its extreme flexibility and adaptability and also because it was completely 
configurable by our personnel. The system provided the basic framework for developing 
a customized LIMS using a simple interface utilizing tags. Our IT specialist configured 
the system. Initially it was designed to manage the genotyping process. Subsequently, 
the system was extended to include DNA extraction and data review. As the processes 
evolved, we continued to use our own personnel to expand the LIMS to track samples 
from receipt, through a dynamic report generator and coordination with third party billing 
systems. Today the system includes account set up, accessioning, client interfacing, all 
laboratory processes, including direct interfacing with multiple instrument platforms, and 
report generation. Additionally, the system provides quality assurance oversight for 
director review. Results: Development of our comprehensive LIMS has been 
completed. We found that this platform could expand in multiple directions to meet all 
requirements. To date the LIMS system has been used to manage over 650 different 
institutions with 1100 plus physicians using the test. Expansion and improvements are 
made as needed, still using internal personnel. None of the internal personnel are 
computer programmers as the LIMS framework is easy to understand with minimal 
training. Installation of a complete flexible LIMS has enabled lower FTEs, thus reducing 
laboratory costs. Conclusions: The right LIMS can be configured and expanded to 
manage and control the entire testing process. This is made possible by selecting a 
LIMS platform that has the flexibility to adapt to any situation, both seen and 
unforeseen, and to have the power to do most of the configuration internally. 
 
TT33. Ambient Temperature Collection and Storage of Whole Blood for DNA 
and RNA Preservation 
O. Clement, R. Muller, S. Wilkinson, A. Stassinopoulus, J. Muller-Cohn, S. Whitney,  
L. Shireen 
Biomatrica, Inc., San Diego, CA. 
Introduction: The field of molecular medicine is progressing rapidly with new 
technologies utilizing patient DNA (genomic and mitochondrial) and RNA expression 
profiles to diagnose specific diseases, monitor disease progression and assess patient 
responses to medical treatment. However, RNA and DNA integrity in patient samples is 
highly labile post-collection when cell death removes genetically encoded mechanisms 
for repairing DNA and exposes cellular nucleic acids to numerous damaging enzymatic 
and non-enzymatic agents. Such damaging effects include nucleolytic attack, oxidative 
damage to nucleobases and the sugar-phosphate backbone and hydrolysis (in 
particular, base-catalyzed hydrolysis of RNA and depurination in DNA). The cumulative 
effect of the damage that accrues post-collection and during sample shipment and 
storage can severely disrupt genotyping and DNA sequencing efforts. In particular, 
transcription profiles are highly dynamic and can change rapidly during and after 
sample collection using current methods. Methods: Human blood was collected in K2-
EDTA VacutainersTM and in PAXgene Blood DNA tubes (PBD). Aliquots of blood from 
the K2-EDTA VacutainersTM were mixed with DNAgard Blood (DGB) stabilization 
formulation and stored at room temperature. Aliquots were also stored in the absence 
of stabilizer at room temperature (non-protected; NP) or frozen at -200C. Total RNA 
was extracted from unstabilized blood immediately after collection and from RNAgard 
Blood (RGB), NP and -800C samples at specified time points using the RiboPure Blood 
Kit (Ambion). RNA was extracted from PAXgene Blood RNA (PBR) samples using the 
PAXgene Blood RNA Kit. Results: Genomic DNA integrity in blood stored at room 
temperature in DNAgard Blood was equivalent to freezer storage in maintaining intact, 
high molecular weight gDNA for at least 8 months. Samples stored unprotected or in 
PAXgene Blood DNA resulted in partially degraded DNA. The gene expression profile 
of total RNA recovered from blood stored in RNAgard Blood (RGB) or -80ºC freezer for 
7 days are similar in terms of the number and magnitude of genes up- or down-
regulated. These results were much better than profiles from PAXgene Blood RNA-
stored samples. Conclusions: These results demonstrate that ambient temperature-
based preservation of DNA and RNA in whole blood provides a superior alternative to 
conventional (and problematic) methods of cold storage. 
 
TT34. Sequencing DNA Using Semiconductor Chips Instead of Light 
J. Rothberg 
Ion Torrent, South San Francisco, CA. 
Introduction: Ion Torrent has invented the first device, a new semiconductor chip, 
capable of directly translating chemical signals into digital information. The first 
application of this technology is sequencing DNA. The device leverages decades of 
semiconductor technology advances, and in just a few years has brought the entire 
design, fabrication and supply chain infrastructure of that industry, a trillion dollar 
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investment, to bear on the challenge of sequencing. The result is Ion semiconductor 
sequencing, the first commercial sequencing technology that does not use light, and as 
a result delivers unprecedented speed, scalability and low cost. Methods: Ion Torrent 
sequencing uses only natural (label-free) reagents and takes place in disposable 
semiconductor microchips that contain sensors that have been fabricated as individual 
electronic detectors, allowing one sequence read per sensor. Results: The system 
performance has been demonstrated by sequencing four bacterial genomes, ranging in 
genomes size and GC content from Vibrio fisheri (4.3Mb genome, 38% GC) to 
Escherichia coli K12 – (4.6Mb genome, 51%GC) and DH10b (4.7Mb genome, 51%GC) 
to Rhodopseudomonas palustris (5.5 Mb genome, 65%GC). Besides comprising the 
first genomes sequenced with post-light technology, the genomes are remarkable in the 
lack of data bias, which is as good, or better, than existing commercial platforms. 
Conclusions: Ion’s technological applicability to routine human sequencing has also 
been demonstrated by utilizing Ion chips to sequence a human genome. We will show 
how the technology has scaled in just a few months from 1.2 million sensors in the first-
generation Ion 314 chips to 6.1 and 11 million sensors in the second-generation Ion 316 
and 318 chips respectively, all while maintaining the same 1- to 2-hour runtime. 
Additionally, Ion has successfully accomplished design, manufacture and sequencing 
using chips possessing the smaller 1-micron diameter well, enabling further increases 
in well density and sequencing throughput in subsequent chip designs. Because the 
heart of the system is a novel, disposable sensor, built and assembled using standard 
semiconductor fabrication methodologies, able to sequence without the need for 
intermediate enzymes or the constraints of having to image using light, the cost of 
genome sequencing will continue to fall with each successive generation of denser 
chips according to Moore’s law.  
 
TT35. Evaluation of the Asuragen Signature LTx Leukemia Translocation Panel 
H.B. Steinmetz1, M. Hong1, S.F. Allen1, C.L. Lefferts1, K.A. Lebel2, D.L. Ornstein1,  
G.J. Tsongalis1, L.J. Tafe1 
1Dartmouth Hitchcock Medical Center, Lebanon, NH; 2Baystate Health System, 
Springfield, MA. 
Introduction: Chromosomal translocation results in the production of abnormally 
functioning fusion proteins, leading to diseases such as chronic myelogenous leukemia 
(CML), acute lymphoblastic leukemia (ALL), acute promyelocytic leukemia (APL), and 
acute myelocytic leukemia (AML). In this study, we evaluated the performance of the 
Asuragen Signature LTx Leukemia Translocation Panel for the detection of twelve 
different fusion transcripts found in the hematologic malignancies mentioned as a first 
line screen for diagnosis. Methods: Total RNA was extracted using two different 
methods, manual extraction with the Ambion RNAqueous 4PCR Kit and automated 
extraction with the Qiagen RNA Cell Mini Kit on the EZ1 BioRobot, from fresh in-house 
residual patient whole blood and bone marrow samples, and frozen cell pellets from a 
cytogenetic laboratory. Total RNA input ranging from 400ng - 1000ng was required in 
each reaction. RNA was first reversed transcribed then amplified using a multiplex RT-
PCR. Amplicons, including the GAPDH internal control, hybridized to target-specific 
capture probes bound to spectrally identified beads. Upon the addition of reporter 
molecules, fluorescence was detected and measured as median fluorescence intensity 
(MFI) by flow cytometry to determine the presence or absence of the specific fusion 
transcripts. Results: Of 73 samples tested, 38 passed the GAPDH MFI cutoff (>1000 
MFI) and were available for further analysis. For the automated extraction, 0 out of 18 
isolates from fresh in-house samples passed the GAPDH control, whereas 6 out of 8 
isolates from cell pellets passed. With the manual extraction, 23 out of 28 fresh and 9 
out of 19 cell pellet isolates also passed the internal control QC check. Twenty-two out 
of 38 results were concordant with either cytogenetic or GeneXpert analysis. Thirteen 
were false negatives and of these, six had a tumor ratio of less than 10%. The 
remaining seven false negative samples were isolates from cell pellets with higher 
tumor ratio. Conclusions: We determined that the Ambion RNAqueous-4PCR Kit 
method for RNA isolation is more suitable for use with the Signature LTx v2.0 Leukemia 
Translocation Panel. This assay is useful in the initial diagnosis of hematologic 
malignancies but is not suitable for monitoring of minimal residual disease. 
 
TT36. Compatibility of Cellulose-Based DNA Purification Chemistries with 
Affymetrix Arrays 
T.L. Schagat, D. Wieczorek, C.L. Helt, C. Cowan, D. Smith, D.H. White, E.B. Vincent 
Promega Corporation, Madison, WI. 
Introduction: The quality of nucleic acid preparations can affect the outcome of 
microarray studies. Poor absorbance purity ratios are often used as a predictor of array 
performance. Typically nucleic acids used for microarray studies are purified by 
traditional precipitation-based or more convenient, silica-based methods. However, the 
carryover of alcohols and salts can affect absorbance ratios and interfere with 
subsequent microarrays. The use of cellulose as a binding matrix for nucleic acid 
purification relies on different purification chemistries, is amenable to a variety of 
purification formats and sample types, and is an ideal option for microarray sample 
preparation. Methods: We examined the use of new cellulose-based purification 
chemistries from Promega Corporation for preparing nucleic acid for microarray 
analysis. DNA was isolated from whole blood in triplicate by each purification method. A 
range of cellulose-based purification formats were examined: columns and particles, 
manual and automated, small (<0.5ml) and large (3-10ml) sample volume. Three new 
reagent systems were tested: the ReliaPrep™ Blood gDNA Miniprep Isolation System, 
ReliaPrep™ Large Volume HT gDNA Isolation System, and Maxwell® 16 LEV Blood 
DNA Kit (Promega Corporation). For comparison, samples were also prepared by more 
traditional techniques: silica-based QIAamp DNA Blood Mini Kit (Qiagen) and 
precipitation-based Wizard® Genomic DNA Purification System (Promega). All DNA 
were analyzed by UV absorbance and then tested for compatibility with the Affymetrix 
Genome-wide Human SNP Array 6.0. Results: All nucleic acid purification kits tested 
yielded DNA of a concentration greater than the minimum needed for Affymetrix Array 
processing (50ng/µl). For small volume blood purification (200 to 300µl), Maxwell® 16 
LEV Blood DNA Kit and ReliaPrep™ Blood gDNA Miniprep Isolation System gave the 
highest concentrations (>100ng/µl). All kits tested yielded DNA with an A260/A280 
purity ratio of 1.8-1.9. The A260/A230 purity ratios were > 1.8 for the cellulose-based 
and precipitation-based kit but the silica-base QIAamp DNA Blood Mini Kit tended to be 
lower <1.7. All samples were subsequently analyzed by microarray and passed 
standard requirements for array processing (QC Call Rates >97%). Conclusions: All 
manual and automated formats tested yielded DNA of high purity and concentration, as 
evaluated by absorbance measurements, and were successfully analyzed by Affymetrix 
Genome-Wide Human SNP Array 6.0. This study indicates the new cellulose-based 
purification chemistries offered by Promega are compatible for with Affymetrix SNP 
Arrays.   
 
TT37. Paraffin Block Core Punching Is an Effective Method for Tumor 
Enrichment for Solid Tumor Mutational Studies 
J. Pillai, T.A. Boyle, P.C. Chesnut, N.J. Thomas, P. Lenhart, J.J. Bohn, M.J. Leonard, 
R. Aikens, W.A. Franklin, D.L. Aisner 
University of Colorado, Aurora, CO. 
Introduction: Tumor enrichment is a critical component of many solid tumor molecular 
assays and can be achieved by tissue core punch (TCP).  One potential disadvantage 
of TCP is that selection of tumor for enrichment is based upon examination of one H&E 
stained section. Thus, the tumor cellularity (TC) within the TCP may be different from 
what is seen on the evaluated section, resulting in potential reduction in TC and 
alteration in molecular findings. In this study we systematically evaluate changes in TC 
and mutational findings within TCPs. Methods: 47 paraffin-embedded solid tumor 
samples were subjected to TCP using a 1mm punching instrument. The core was re-
embedded at 90° to evaluate the TC along its length, independently performed by three 
pathologists. 31/47 samples were microdissected for top half (TH) and bottom half (BH); 
DNA extraction and mutational analysis of each half was performed based on parallel 
clinical testing and results compared. Results: Nine samples had a  30% change in 
the TC within the core. Of 31 specimens with molecular data, six discrepancies were 
observed between the clinical results and the BH.  In 2 cases, this finding corresponded 
to reduction in TC. In one case, additional testing demonstrated low-level mutational 
heterogeneity. Two cases demonstrated variation in detection of silent SNPs, and one 
case demonstrated EGFR T790M only in TH. One case demonstrated a discrepancy 
only when a low analytic sensitivity methodology was used. With the exception of the 
one case with low-level mutational heterogeneity, no mutations were identified in the 
TCP specimens that were not reported clinically. Five specimens demonstrated <30% 
tumor cellularity in the top half, indicating suboptimal placement of the sampling needle. 
Conclusions: Our data suggests that TCP is an effective methodology for enrichment 
of solid tumors however it does have limitations. TC was reduced in the lower half of 
approximately 30% of cores. The reduced cellularity did not reduce mutant signal 
strength sufficiently to diminish the overall mutational status and no false negatives 
were apparent in the clinical testing. Moreover, the clinical cases routinely combine 3 
TCPs in the DNA extraction, which suggests that multiple cores of a single specimen 
may mitigate against any potential false negative due to reduction in TC over the span 
of the TCPs. 
 
TT38. A High Throughput Automation System for the Cervista® HPV HR Test 
E. Coffman1, T. Myers2, M. Kaiser2, R. Lahr2, S. Friedle2, J. Hall2, T. Hutchins1,  
K. Melanson1, S. Hecht1, S. Scully1, P. MacLean1, R. Noe1, W. Iszczyszyn2,  
C. Fleming2, R. Grygiel2, S. Mayer1, L. Chehak2, P. Costa1 
1Hologic, Inc., Marlborough, MA; 2Hologic Molecular Diagnostics, Madison, WI. 
Introduction: The Cervista® HPV HR test is an in vitro diagnostic test for the 
qualitative detection of DNA from 14 high risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, 68) in cervical specimens. The current FDA approved method of 
performing the Cervista test includes manual processing of specimens to extract DNA 
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with the Genfind® DNA Extraction Kit and the set up of the Cervista reaction. This 
report describes a new Investigational Use Only automated platform for performing the 
test, the Cervista HPV HR High Throughput Automation (HTA). Methods: All system 
testing was in accordance with FDA guidance document “Assay Migration Studies for In 
Vitro Diagnostic Devices” (http://www.fda.gov/downloads/MedicalDevices/ 
DeviceRegulationandGuidance/GuidanceDocuments/ucm092752.pdf). Results: The 
Cervista HTA fully automates DNA extraction, reaction setup, and results processing on 
a single platform. The system has a compact footprint of 15.6 square feet and provides 
flexible processing capabilities to perform multiple sample batch sizes. A batch size of 
192 samples can be processed in an eight hour shift with fully automated results 
generated before the next day. For a 192 sample run, hands-on time was less than one 
hour including deck set up and daily maintenance. More than 90% of processing time 
was completely walk–away. To determine system reproducibility, a 9-member sample 
panel including high negatives, low positives, and moderate positives was tested across 
three different study sites. A comparative sample panel consisting of 288 residual 
clinical samples with various levels of HPV was tested at three external sites. The 
percent negative and positive agreement were both greater than 96% for the HTA 
versus the FDA–approved test. The potential for cross-contamination on the HTA 
system was also evaluated and no cross-contamination was observed. Conclusions: 
The Investigational Use Only HTA system, for use with the Cervista HPV HR test, is a 
fully automated, flexible system, designed to enable high throughput screening of 
cervical specimens for the presence of HPV DNA with limited hands-on time. 
 
TT39. Analysis of JAK2 V617F Mutational Burden in Myeloproliferative 
Neoplasia by Deep Sequencing 
Z. Wang, B. Evans, M. Weiss, J. Gong, S.C. Peiper 
Thomas Jefferson University, Philadelphia, PA. 
Introduction: The spectrum of Philadelphia chromosome negative myeloproliferative 
neoplasms (MPN) includes polycythemia vera (PV), essential thrombocythemia (ET), 
and acute myelofibrosis (MF). The G>T somatic mutation in codon 617 of the JAK2 
gene resulting in a substitution of phenylalanine for the naturally occurring valine 
residue (V617F) has emerged as a diagnostic criterion for PV, ET, and MF. Since the 
natural progression of MPN involves expansion of the clonal progenitor population 
containing the JAK2V617F mutation, analysis of the mutational burden can provide 
important clues to prognosis. Current methods for analysis of this mutation include 
qualitative and quantitative PCR with allele specific probes and pyrosequencing. We 
describe the use of next generation sequencing for quantification of mutation burden. 
Methods: With approval by the IRB for analysis of de-identified specimens, 23 genomic 
DNA samples were selected. All cases were previously analyzed using Ipsogen 
Mutascreen qualitative/semi-quantitative assay (assay sensitivity 2%).  Among them, 5 
were positive at various levels. 17 were borderline positives, and one was negative. 
These gDNA were amplified with primers flanking exon 14 of the JAK2 gene by PCR 
and subjected to NextGen sequencing using a 454 Junior and the percentage of 
fragments carrying the V617F mutation was determined. Up to 12 specimens were 
performed in the same sequencing run. Positive cases were analyzed in parallel by 
Sanger sequencing. Results: The 5 positive specimens had a V617F mutation burden 
from 2.3% to 78%. Of 17 cases with low level positivity with the Ipsogen test, only 1 
contained this mutation, which was quantified at 0.4% by deep sequencing. Average 
Junior read number per sample was 8697 combining forward and reverse reads. 
Positive cases were confirmed by Sanger Sequencing but mutation loads below 10% by 
deep sequencing were below the limits of detection. Conclusions: Deep sequencing of 
exon 14 of the JAK2 gene is a sensitive and specific approach for the quantification of 
the V617F mutation in patients with MPN.  The sensitivity of Sanger sequencing was 
insufficient for the detection of low levels of mutational load and the Ipsogen 
Mutascreen assay gave false positive values in the borderline positive range. Deep 
sequencing is superior in comparison to other widely used mutation detection assays 
when sensitivity and accuracy are required. Simplifying procedure for deep sequencing 
with automation is needed for future diagnostic applications of this technology. 
 
TT41. Automated Total Nucleic Acid Purification from FFPE Tissues Using 
Maxwell® 16 
D.J. Wieczorek, C. Cowan, N. Nassif, D.R. Storts, T.L. Schagat 
Promega, Madison, WI. 
Introduction: Traditional methods for the purification of nucleic acids from formalin-
fixed, paraffin-embedded (FFPE) tissue samples are often labor intensive and include 
the use of hazardous organic reagents. In addition, carryover of formalin throughout the 
purification process can inhibit amplification. Thus, a consistent method using 
appropriate extraction and purification techniques is essential for the success of purified 
nucleic acids from FFPE samples in downstream applications. Here, we describe an 
automated method for the purification of total nucleic acid from FFPE tissue sections 
using the Maxwell® 16 instrument that eliminates the need for toxic reagents and with 
minimal hands on time. Methods: Pre-processing of 10 micron mouse FFPE tissue 
sections involved a simplified protocol with no xylene or phenol extraction required. 
Following pre-processing, samples were placed directly into the Maxwell® 16 
cartridges, and purified total nucleic acid was ready in approximately 45 minutes. All 
samples were eluted in 50µl of nuclease-free water. Yield and purity of the purified total 
nucleic acid was analyzed by the NanoDrop 1000. RNA recovery was analyzed by 
quantitative RT-PCR using primers specific to mouse actin. Results: Total nucleic acid 
from a variety of mouse FFPE tissue sections was successfully purified, including liver, 
brain, heart, kidney, and spleen. Automated RNA purification with Maxwell®16 was 
compared to manual purification kits from Qiagen and Invitrogen. RNA recovery was 
equivalent to these commonly used manual methods as determined by quantitative RT-
PCR analysis. Conclusions: Total nucleic acid from FFPE tissue samples was 
successfully purified using the Maxwell® 16 instrument. Automated nucleic acid 
purification decreases hands on time spent manually extracting, provides more 
consistent results from difficult to purify sample types, and reduces the risk of RNase 
contamination. The low elution volume format provides for highly concentrated nucleic 
acid ready for downstream applications. The method does not require the use of 
hazardous organic solvents, providing a safer method of extraction and purification. 
 
TT42. Utility of Whole Genome Amplification for Assessing Copy Number 
Variation with High Density SNP Arrays from Formalin-Fixed, Paraffin-Embedded 
Tissue 
L.M. Voeghtly1, D.T. Croft1, B. Deyarmin1, M.N. Vernalis2, C.D. Shriver2, D.L. Ellsworth1 
1Windber Research Institute, Windber, PA; 2Walter Reed Army Medical Center, 
Washington, DC. 
Introduction: The ability to obtain sufficient high quality DNA from archival formalin-
fixed, paraffin-embedded (FFPE) tissue often limits genomic analysis for researchers 
and clinicians alike. Of numerous methods developed to optimize the quantity of DNA 
extracted from FFPE tissues, whole genome amplification (WGA) has become a robust 
and reliable technique for obtaining sufficient genomic material for a variety of 
molecular applications. Previous studies suggest that DNA obtained from FFPE 
samples may be used on high-density single nucleotide polymorphism (SNP) arrays to 
provide information on SNP genotypes, chromosome copy number (CN), and loss of 
heterozygosity, but spurious results occur with insufficient DNA template. Methods: We 
examined the feasibility of assessing chromosome CN variation using whole-genome 
amplification on DNA extracted from FFPE tissue, as well as fresh frozen (FF) tissue in 
OCT, and high-density Affymetrix GeneChip® 500K SNP Mapping Arrays. Genomic 
DNA was extracted from microdissected regions (approx 2.9 mm2) of human tissue 
preserved in paraffin using the GenomePlex® Tissue Whole Genome Amplification Kit 
(Sigma®) and from human FF tissue using QiaAmp® DNA Mini Kit (Qiagen®). Whole-
genome amplification was then performed on 1.5 ȝl of FF or FFPE DNA using the 
REPLI-g® whole-genome amplification kit (Qiagen®). Genotypes were determined 
using the Dynamic Model Mapping Algorithm in the Affymetrix GeneChip® Genotyping 
Analysis Software (GTYPE 4.0) package and CN variation was assessed with 
Genotyping Console™ (Affymetrix). Results: Acceptable genotyping call rates were 
obtained for all unamplified DNA samples (96.3 ± 1.5%) and wgaDNA samples (93.3 ± 
1.6%) from FF tissue. Call rates were significantly lower; however, for wgaDNA 
samples from FFPE (67.5 ± 5.1%) (p<0.001). Assessment of CN variation was highly 
consistent between unamplified and whole-genome amplified FF samples, but was 
clearly discordant between amplified FF and amplified FFPE samples. Conclusions: 
These results indicate that FF tissue, even if whole-genome amplified, is useful for 
genome-wide SNP genotyping and determining chromosome CN variation, but large 
discrepancies are likely to occur when using whole-genome amplification on DNA 
isolated from FFPE. CN variation may be affected by uneven amplification of the 
genome with small quantities of suboptimal DNA template extracted from FFPE 
samples.  
 
TT43. Workflow Comparison of Two FDA-Cleared Factor V Leiden Detection 
Systems 
A. Sanders, M. Doleshal, S. Day 
Hologic Molecular Diagnostics, Madison, WI. 
Introduction: To provide an operational review of the Roche Factor V Leiden Mutation 
Detection Kit for use on the LightCycler Instrument 1.2 and the Hologic Invader®  
Factor V using Invader® Plus Chemistry. Extraction methods, equipment, and total time 
requirements were evaluated for a similar number of samples. Both manufacturers also 
have Prothrombin (Factor II) Detection Kits that have equivalent workflows to the Factor 
V Leiden tests. Methods: Manufacturer’s package inserts and peer reviewed 
publications were used to gather information to compare the methods. Multiple factors 
outlining the workflow of the procedure and ease of use were evaluated. Comparison 
data was expressed as total run time post extraction to final result for a similar number 
of samples. Hands-on-time included all interaction with the samples and 
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instrumentation. Total walk-away time associated with each run time, including all wait 
time where the operator is available to perform other tasks and not be present at the 
instrumentation, was also captured. Equipment required for both methods was also 
compared including equipment needed for extraction. Results: For 92 reportable 
results the Hologic Invader® Factor V Leiden Test had 20 minutes hands on time, 90 
minutes cycle time, and 10 minutes for data analysis. This allowed for 90-minute 
operator walk-away time that was 75% of the total run time. For 90 samples the Roche 
Factor V Leiden Detection Kit for the LightCycler 1.2 had 45 minutes hands-on time, 
114 minutes cycle time, and 45 minutes for data analysis. This allowed for 114 minute 
operator walk-away time that was 59% of the total run time. Conclusions: Both 
systems provide opportunities for the operator to walk-away during the testing process 
with the Hologic Invader® Factor V test having the highest percentage versus total run 
time. The Hologic Invader® test also demonstrated the least total hands-on time and 
had the shortest run time to result for approximately 92 samples compared to Roche 
LightCycler 1.2 for 90 samples. Both systems have a similar amount of equipment 
required post extraction. The difference between the methods occurs with the 
extraction. The Roche method requires the MagNA Pure LC instrument be used for 
reproducible DNA preparation and PCR set-up. The Hologic method does not require a 
specific extraction method be followed, only that commercially available extraction kits 
or laboratory validated methods should provide sufficient concentration at sufficient 
purity per the Invader® Factor V package insert. 
 
TT44. Performance of Whole-Genome Amplified DNA Isolated from Serum and 
Plasma for Estimating Copy Number Variation with High Density Single 
Nucleotide Polymorphism Arrays 
D.T. Croft1, L.M. Voeghtly1, H.L. Patney1, C.D. Shriver2, M.N. Vernalis2, D.L. Ellsworth1 
1Windber Research Institute, Windber, PA; 2Walter Reed Army Medical Center, 
Washington, DC. 
Introduction: Defining genetic variation associated with complex human diseases 
requires high-quality DNA from well-characterized patients. With the development of 
robust technologies for whole-genome amplification, sample repositories such as serum 
banks now represent a potentially valuable source of DNA for genomic studies and 
clinical diagnostics. We assessed the performance of whole-genome amplified (wga) 
DNA derived from stored serum/plasma for estimating chromosome copy number (CN) 
variation on high-density single nucleotide polymorphism (SNP) arrays. Methods: 
Fresh serum and plasma samples were obtained from subjects who voluntarily agreed 
to participate in this study and gave written informed consent. DNA was extracted from 
200 µl of serum or plasma using the QIAamp® DNA Blood Mini Kit. Genomic (g) DNA 
was isolated from peripheral blood mononuclear cells with the Puregene® DNA 
Purification Kit according to the manufacturer’s protocol. Whole-genome amplification 
was then performed on 2.5 µl of serum/plasma DNA using the REPLI-g® whole-
genome amplification kit. Genotypes were determined using Affymetrix GeneChip® 
Genotyping Analysis Software and CN variation was assessed with Genotyping 
Console™. Results: Storage time and usage history did not affect DNA extraction or 
whole-genome amplification yields; however, samples that had been thawed and 
refrozen showed significantly lower call rates (73.9 + 7.8%) compared to samples that 
had never been thawed (92.0 + 3.3%) (P<0.001). Genotype call rates did not differ 
significantly (P=0.13) between wgaDNA from never-thawed serum/plasma (92.9 + 
2.6%) and gDNA (97.5 + 0.3%) isolated from whole blood. Approximately 400,000+ 
genotypes were consistent between wgaDNA and gDNA; however, patterns of CN 
variation were highly discordant between serum/plasma wgaDNA and gDNA from the 
same patients. The CNV in the wgaDNA samples showed spurious regions of 
amplifications and deletions compared to the unamplified gDNA. These regions showed 
much larger areas of amplification and deletions across all the chromosomes compared 
to the unamplified gDNA CNV. Conclusions: While use of stringent quality control 
requirements can facilitate the collection of quality SNP genotype data from wgaDNA, 
our data suggest that more advanced analyses, such as CN and loss of heterozygosity 
assessments, may be compromised due to spurious amplification during the whole-
genome amplification process.  
 
TT45. Rapid High Throughput TaqMan SNP Genotyping Assay for FVL, PT, and 
MTHFR 
E.I. Reader, H.B. Steinmetz, C.L. Lefferts, B. Wood, G.J. Tsongalis, L.J. Tafe 
Dartmouth Hitchcock Medical Center, Lebanon, NH. 
Introduction: Testing for Factor V Leiden (FVL) 1691G>A, Prothrombin (PT) 
20210G>A, and 5, 10- methylene tetrahydrofolate reductase (MTHFR) 677C>T 
polymorphisms is commonly performed in clinical molecular laboratories as part of a 
work up for thrombophilia. A variety of testing methods are commercially available that 
utilize different platforms and chemistries. In this study, we compare the performance of 
the Hologic Invader assay for these three polymorphisms with a TaqMan laboratory 
developed assay. Methods: We utilized DNA samples from 18 patients who had been 
previously tested for FVL, PT, and/or MTHFR polymorphisms by the Hologic Invader 
technology. DNA was isolated from whole blood using the EZ1 DNA Blood Kits 
(Qiagen, Valencia, CA). All cases were analyzed using custom TaqMan SNP 
Genotyping Assays for FVL (rs6025), PT (rs1799963) and MTHFR (rs1801133) 
polymorphisms (Life Technologies, Carlsbad, CA). Real-time PCR was performed on 
the AB 7500 instrument using AB 2x fast universal master mix, 10-20 ng of genomic 
DNA in a total reaction volume of 10 µl with the default fast cycling conditions. A post 
amplification plate read was used for allelic discrimination. Known wild-type and mutant 
samples were tested as controls in each assay run. Results: Of 18 patient samples, the 
results were as follows: FVL – 10 wild type (WT), 5 heterozygous and 3 homozygous; 
PT – 13 WT, 3 heterozygous and 1 homozygous; MTHFR – 6 WT, 7 heterozygous and 
5 homozygous. There was 100% concordance between the two assays. All control 
samples gave the expected results. Hands-on time for this assay was approximately 45 
minutes and the time to result was approximately 3 hours versus 5 hours for the Hologic 
Invader assay. Conclusions: Our study shows that the 7500 FAST TaqMan SNP 
Genotyping Assay is comparable to the Hologic Invader assay in detecting and 
characterizing FVL, PT, and MTHFR polymorphisms. In addition, the TaqMan assay is 
easy to perform, requires less technologist time, shorter incubation and an improved 
time to result as compared to the Hologic Invader assay. 
 
TT46. A Workflow Integrating High-Throughput Automated RNA and DNA 
Extraction from FFPE Samples and Second Generation Sequencing 
T. Guettouche, D. Hedges, J. Rantus, K. Slosek, I. Konidari, W. Hulme, A. Andersen,  
A. Diaz, R. Gentry, Y. Pasco, M. Pericak-Vance, J. Gilbert 
University of Miami, School of Medicine, Miami, FL. 
Introduction: Biorepositories around the world store vast numbers of formalin-fixed, 
paraffin-embedded (FFPE) samples. These samples contain a large collection of 
phenotypic, histological and pathological data. For genomics studies, such as 
biomarker discovery, targeted resequencing or gene expression profiling, this resource 
has been largely unutilized because sample extraction can be challenging and the 
quality of the extracted nucleic acids is often poor. Currently, RNA and DNA extractions 
from FFPE samples are commonly performed manually and involve laborious protocols 
that are not amenable to high throughput processing. In addition there are no standard 
quality control methods for downstream applications such as second generation 
sequencing. Methods: In this study, we present a fully automated RNA and DNA 
extraction method (Tissue Preparation System, Siemens Healthcare Diagnostics; 
Tarrytown,NY) for IVD and research use that allows simultaneous or separate 
extraction of DNA and RNA from up to 48 samples in 4h with minimum operator 
interaction. In contrast to most other FFPE extraction protocols this method uses an 
innovative deparaffinization step on the instrument that does not require incubation with 
Xylene or other solvents. We have successfully extracted DNA and RNA from breast 
and prostate cancer tissue (n=100) and the study is being extended to an additional 5 
different tumor tissues including breast, prostate, lung, pancreas, bladder and cervix 
(n=350). Qualitative and quantitative analysis was carried out by Bioanalyzer, real-time 
PCR and Qubit. RNA and DNA were sequenced on a Hiseq2000 second generation 
sequencing instrument. Results: Extraction of both DNA and RNA was successful in 
FFPE samples from breast and prostate cancer tissue. From adjacent 10µm paraffin 
sections the automated system, on average, extracts longer nucleic acid fragments as 
judged by Bioanalyzer traces and similar amounts of RNA and DNA measured by the 
Qubit method, compared to a standard commercially available manual protocol. 
Matched fresh frozen and FFPE samples are being analyzed by second generation 
sequencing on a HiSeq2000. Conclusions: We present an integrated FFPE analysis 
workflow that includes standardized and fully automated nucleic acid extraction and 
quality controls for high-quality, high-throughput preparation of FFPE samples (96 
samples/8 hr work day) for downstream analysis such as resequencing or 
transcriptome analysis by second generation sequencing. Our integrated workflow 
should significantly simplify utilization of FFPE samples for downstream genomic 
analyses such as second generation sequencing and as a consequence unlock a 
largely untapped source of information.  
 
TT47. RNA Is Isolated in High Yield and Purity from PAXgene® Stabilized Blood 
and from Buffy Coat Using the Maxwell® 16 SimplyRNA Method 
J. English, M. Mandrekar, A.K. Brekke, B.A. Hook, T.L. Shagat, T. Lubben 
Promega, Madison, WI. 
Introduction: The analysis of gene expression data in research has needed a critical 
evaluation of easy, reproducible methods for RNA extraction. The reliability of a novel 
chemistry on the Maxwell 16® instrument provided a middle-throughput automated 
procedure to isolate RNA from whole blood or its leukocyte compartment (buffy coat) to 
evaluate this. Methods: Evaluation included reproducibility, yield, and purity using the 
Nanodrop, Agilent Bioanalyzer and denaturing gels. A combination of quantitative RT-
PCR and quantitative PCR was used to evaluate DNA contamination of the RNA. Buffy 
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coat from up to 10ml blood or up to 3 PAXgene® tubes could be processed in one 
preparation. Following isolation of the buffy coat, or collection and washing of the 
PAXgene® pellet, further processing involved only addition of reagents and vortexing to 
mix and lyse cells.  All subsequent steps were fully automated. Up to 16 separate 
preparations were completed in approximately 1 hour on the Maxwell 16® instrument. 
The procedure uses no E-mercaptoethanol, so odors are minimal. Results: RNA 
concentration from one PAXgene® tube was approximately 80ng/µl or higher, in an 
elution volume of 50µl. RNA from the preparations reproducibly showed A260/A280 
ratios 2.0 or greater. 28S/18S RNA ratios, as analyzed by Agilent Bioanalyzer, were 
1.8-2.0. RIN values were 8.0-10.0. The RNA was free of significant contamination from 
purification reagents and DNA as determined by several measurements. Specifically, 
A260/A230 ratios were over 2.0; 5S bands were visible on denaturing gels and on the 
Bioanalyzer trace, but no contamination by DNA was visible by these methods; and 
DNA contamination as determined by qPCR was minimal. The mRNA could be readily 
measured by RT-PCR and RNA from these preparations was also suitable for analysis 
in microarrays. Conclusions: Thus, Maxwell 16® simplyRNA provides a simple and 
reliable way to purify high purity RNA from PAXgene® - preserved blood and from buffy 
coats in good yield, suitable for various downstream applications, in a medium-
throughput automated format. 
 
TT48. Validation of Genomic DNA Extraction and Amplification from Stored 
Samples in RNAlater 
C. Valencia, S. Askree, J. Rosado, C.E. Hill, K.P. Mann 
Emory University, Decatur, GA. 
Introduction: RNAlater® (RNAL) is a cell storage reagent that stabilizes and protects 
cellular RNA from fresh tissue and cell samples. Use of this reagent eliminates the need 
to immediately process samples when they are received for testing. Stability of human 
RNA in RNAL has been well established; however, DNA integrity has not been 
investigated. Here we report the validation of genomic DNA extractions and DNA quality 
from 1-week old and 10-month old RNAL-stored leukocytes for the application of reflex 
DNA diagnostic testing. Methods: Two experiments were performed: 1) DNA extraction 
and amplification from fresh leukocytes were compared to 1 week old RNAL-stored 
leukocytes (4oC); and, 2) DNA extraction and amplification from RNAL-stored 
leukocytes (-80ºC for 10 months) were compared to polyclonal control DNA 
(Invivoscribe Technologies). Three blood pools were made from 2 blood samples. Red 
cells were lysed followed by low speed centrifugation and PBS wash to collect 
leukocytes. Samples were subdivided into 4 fractions: A, B, C and D. DNA extractions 
were immediately performed on fractions A and B and one week later on C and D. DNA 
was also extracted from six 10-month-old RNAL samples. DNA was quantified 
(Nanodrop) and amplification was performed targeting a Specimen control size ladder 
(Invivoscribe Technologies, BIOMED-2). Amplification was evaluated by analyzing on a 
ABI3100XL. Results: DNA yield was 60% higher from the 1-week old RNAL samples 
as compared to our immediate DNA extraction. Likewise, DNA yield was obtained from 
all 10-month old RNAL samples. DNA amplification as judged by amplification of control 
DNA ladders showed no significant difference in amplification efficiency between DNA 
prepared at time = 0 (samples a, b), 1-week later (samples c, d) and the 10-month 
samples. Conclusions: RNAL storage allows easy archiving of cells for later RNA 
based molecular testing. DNA of comparable quality and yield can be obtained from 
cells that have been stored in RNAL solution for up to 10 months. These results 
suggest that DNA from appropriately RNAL stored samples can be used for reflex 
molecular diagnostic testing without the need to store samples separately for RNA and 
DNA based testing. 
 
TT50. Improvement in Quality Control Programs through the Addition of Peer 
Data Analysis with Equality Peer Review  
C. Long, M. Unger, P. Garrett, K. Huang, B. Anekella 
SeraCare Life Sciences, Attleboro, MA. 
Introduction: Accurate evaluation of test performance with run controls is vital for 
delivering reliable diagnostic results and making valid clinical decisions. According to 
CLIA and FDA regulations, clinical laboratories are responsible for monitoring the 
accuracy and precision of the testing process by using control procedures that will 
detect immediate errors and errors occurring over time.  Monitoring test performance 
with independent quality controls can help detect and reduce deficiencies in a 
laboratory’s internal testing process prior to the release of laboratory test results. 
Changes in control lots, kit lots, and personnel can lead to variation in test performance. 
Peer data for the performance of the same control lot with the same test kit lot gives a 
more robust picture of performance. In a peer review program, individual laboratories 
submit test results to a centralized database to compare results with other labs running 
the same control lot on the same kit, allowing faster identification of significant 
deviations without running additional controls. SeraCare’s eQuality Peer Review is a 
web based QC data comparison tool, providing an additional layer of control and quality 
assurance. Methods: To begin implementation of eQuality for HIV RNA, data for two 
users of ACCURUN® 315 HIV-1 RNA Positive Control with Roche’s TaqMan® HIV-1 
RNA kit were uploaded to SeraCare’s eQuality Peer Review program. Data from these 
users were compared utilizing eQuality’s reports to review differences in performance 
(shifts and trends) over time. Results: The eQuality reports mean, standard deviation, 
%CV and graphs with user-defined or default limits. Two users in the same laboratory 
had means (%CV)s of 3.5E+03 (44%) and 4.4E+03 (32%) while overall mean (%CV) 
was 4.8E+03 (30%). CVI could also be calculated from the data by dividing the users 
SD by the peer SD. One user had a CVI of 1.05 while the other user’s CVI was .95. 
Conclusions: The eQuality Peer Review web based QC system allows individual 
laboratories to create a more robust picture of test performance across time through 
comparative results. Combined with the use of independent quality controls, eQuality 
allows clinical laboratories to track test performance and to begin troubleshooting as 
soon as significant deviation is observed compared to peer values, instead of relying 
solely on the data generated within the laboratory, ensuring greater confidence and 
improved regulatory compliance. 
 
TT51. A Digital Cancer Karyogram for the 21st Century: Integral Graphical 
Representation of Cytogenetic, Genetic and Epigenetic Level Whole Cancer 
Genome Data 
G. Pihan1,2, A. Kazeroonian1 
1Beth Israell Deaconess Medical Center, Boston, MA; 2Harvard Medical School, Boston, 
MA. 
Introduction: Graphical correlative representation of the vast amount of information 
that can accrue from just a single human genome represents a formidable challenge, 
yet is pivotal to the realization of the full potential of personalized medicine. Cancer 
adds an additional layer of complexity in that cancer genomes are grossly abnormal 
and continuously evolving. A graphical, intuitive user interface that enables synthesis 
and visualization of information can effectively facilitate communication between those 
that curate genome-wide data into information, i.e., molecular pathologists, and those 
that use the curated medically actionable information, i.e., clinicians. Integrative 
approaches such as this can also facilitate the capture of important emerging 
correlative patterns defining critical determinants of cancer clinical behavior, which are 
not immediately apparent through the analysis of individual data sets. Methods: 
Emerging software tools were co-opted and enhanced to achieve this very specific yet 
vital aim, i.e., simple intuitive representation of the most important features of a cancer 
genome, as we know them to date. A core component of the digital cancer karyotype 
(DCK) is a coded graphical representation of cytogenetic abnormalities in cancer that 
was developed so as to maintain the human reference genome coordinates intact. In 
such a manner, gross chromosome abnormalities in cancer could be directly visually 
correlated with multiple other layers of genome-wide data sets without the interfering 
effects of omnipresent chromosome numerical and structural abnormalities in cancer. In 
addition representation of the karyotype in such a manner allows immediate visual 
correlation with RNA expression levels and copy number variation. Results: We 
demonstrate in this work co-representation of complex cytogenetic, genetic and 
epigenetic level genome changes in cancer. Such an approach permitted the 
superposition of multiple layers of genome-wide data such as genome sequence, 
transcriptome sequence, methylation patterns, CNV, chromatin code changes, etc., 
potentially permitting the display of important cancer features such as genes at 
translocation or inversion breakpoints, important LOH areas, regions of uniparental 
disomy, homozygously deleted areas, predictably functionally important point 
mutations, epigenetic silenced areas, etc., all in one highly correlated graphical 
representation. Conclusions: This proof of principle approach is encouraging and 
should catalyze further developments in this important area of genome-wide multi-
layered data/information representation and normalization in cancer. Rapid advances in 
whole genome sequence, makes this endeavor ever more important and pressing.  
 
TT52. Exon Capture and Targeted Nextgen Sequencing for the Detection of 
Mutations in Hematopoietic, Gastrointestinal, and Occular Malignancies 
Z. Wang1, B. Evans1, K. O'Rourke2, R. Bajaj2, A. Burkart2, J. Baliff2, J. Gong2,  
R.C. Eagle2, S.C. Peiper2 
1Thomas Jefferson University, Philadelphia, PA; 2Thomas Jefferson University Hospital, 
Philadelphia, PA. 
Introduction: The pathologic evaluation of malignant diseases increasingly requires 
the analysis of genetic mutations for the assignment of proper therapy. Currently, a 
cadre of somatic mutations provides critical information to guide the use of molecularly 
targeted therapies in colorectal and non-small cell lung carcinomas. Similarly, the 
presence of somatic mutations may predict prognosis of hematopoietic malignancies. 
To facilitate the application of next generation sequencing to the multi-parameter 
analysis of human malignancies, we developed an exon capture strategy for targeted 
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sequencing. Methods: With IRB approval for analysis of de-identified tissues, formalin-
fixed, paraffin-embedded (FFPE) and fresh specimens were selected from diagnostic 
archives and biorepositories of our institutions, respectively, based on diagnosis and 
known mutation status. Three cases of tumors associated with Lynch syndrome with 
known germline mutations (FFPE), 3 cases of acute myelogenous leukemia (AML) 
(fresh), 1 patient and 2 cell lines known to harbor the JAK2V617F mutation (fresh), and 
1 case of uveal melanoma (fresh) were selected for analysis. DNA was extracted and 
275 exons from 51 genes known to harbor mutations in these tumors were captured 
with NimbleGen SeqCap EZ custom beads. Captured DNA fragments were sequenced 
using a 454 Junior. Sequence analysis was performed using GS Mapper software. 
Results: Analysis of the 3 Lynch syndrome FFPE specimens revealed mutations in 
DNA mismatch repair genes identical to germline mutations detected in these patients. 
One AML case known to have MLL amplification and loss of heterozygosity of P53 
demonstrated increased copies of MLL, decreased copies of P53, and a P53 mutation 
in a naturally occurring hotspot. The other two cases of AML lacked mutations that 
recur in AML. The uveal melanoma had a mutation in codon 209 of GNAQ, but lacked 
mutations in GNA11, BAP1, and BRAF. There was >96% coverage of the targeted 
exons and >97% of captured sequences mapped to the human genome. Conclusions: 
Targeted next generation sequencing of captured exons represents an efficient and 
accurate approach for the characterization of human malignancies with complex 
mutational profiles. This strategy can be performed on one or two 10 Pm sections of 
FFPE tissues, indicating the utility of this approach in the normal workflow of diagnostic 
pathology. 
 
TT53. Validation of Results from High-Throughput Sequencing Systems Using 
Orthogonal Methods 
R. Fang, L. Degoricija, J. Liu, M.R. Furtado 
Life Technologies, Foster City, CA.  
Introduction: High-Throughput (HT) sequencing systems have the advantage of 
providing larger data sets that enable better interpretation and greater monitoring 
capability. In this presentation we will describe an HT sequencing system that uses 
DNA polymerase and measures protons released during deoxynucleotide triphosphate 
incorporation to obtain sequence information. Applications described will include the 
detection of multiple mutations in the KRAS and EGFR genes, and identification 
multiple bacterial and viral pathogens along with drug resistance markers. Methods: A 
panel DNA from ten cell lines containing mutations in CYP2D6, KRAS and EGFR were 
used for detection of mutations with HT system and the results were confirmed by 
Sanger sequencing or PCR-OLA based genotyping methods using a capillary 
electrophoresis instrument. Nucleic acid isolated from panels of viruses and bacteria 
were spiked into plasma and used for pathogen identification and drug resistant 
mutation detection. Real-time PCR based methods and sequencing were used to 
confirm results obtained by the HT sequencing system Results: Our results indicate 
that the HT sequencing system can detect multiple targets (20-40) and multiple 
mutations (10-20) in a single run. Comparison with traditional methods indicated 100% 
concordance for target identification and 99% concordance for mutation detection. 
Higher levels of multiplexing on the HT sequencing system are being studied. 
Conclusions: Based on our initial studies it is evident that HT Sequencing systems 
have the accuracy to serve the needs of a testing laboratory. The high levels of 
multiplexing capability will generate larger data sets with less effort and reagents 
 
TT54. Evaluation of Pyrosequencing for the Detection of MLH1 Promoter 
Hypermethylation in Colorectal and Endometrial Cancers 
L. Zhang1, R. Bacares1, D. Wong1, L.J. Tafe2, S. Dogan1, K. Nafa1 
1Memorial Sloan-Kettering Cancer Center, New York, NY; 2Dartmouth Hitchcock 
Medical Center, Lebanon, NH. 
Introduction: MLH1 hypermethylation and its consequent transcriptional silencing is 
the cause of the microsatellite instability phenotype in 10% to 15% of sporadic 
colorectal cancers and 20% to 30% of endometrial cancers. In both MSI+ colorectal and 
endometrial cancers, absence of MLH1 hypermethylation is associated with increased 
risk for HNPCC (Lynch Syndrome). Methods: DNA was extracted from 10 FFPE tissue 
sections from colorectal or endometrial tumors using the Qiagen DNeasy Tissue kit 
(Qiagen, 69504) from a total of 9 cases. Blood DNA or normal tissue DNA was 
extracted to rule out germline MLH1 hypermethylation. DNA was then bisulfite 
converted using the Zymo EZ DNA Methylation-Direct kit. Treated DNA was then run on 
the Qiagen PyroMark Q24 pyrosequencer using the Qiagen CpG MLH1 kit. All samples 
had previously been tested at a reference laboratory using methylation-specific PCR. 
To determine the sensitivity of this assay, we performed a dilution series experiment 
using 7 mixtures of methylated DNA and unmethylated genomic DNA (100%, 50%, 
25%, 12.5%, 6.25%, 3.125%, and 1.56%). Results: Upon evaluation of the 9 cases, we 
found MLH1 hypermethylation in 5 cases (3 in colorectal cancer and 2 in endometrial 
cancer). The other 4 cases (3 colon and 1 uterine) were negative for MLH1 
hypermethylation. Germline inactivation of MLH1 by promoter hypermethylation was not 
detected in the normal tissue from these cases. We did not have any failures indicating 
the smaller-sized PCR products are well amplified from fragmented FFPE DNA. We did 
not observe significant variation in the level of methylation across the 5 CpG sites, so 
we determined a cutoff of >10% methylation at all 5 CpG sites to be positive for 
hypermethylation. Using these criteria, all 9 cases had concordant results with 
methylation- specific PCR. For the sensitivity assay, we observed a high degree of 
correlation (r > 0.996) between predicted and observed results. The sensitivity of this 
assay is 6%. Conclusions: The PyroMark Q24 pyrosequencer assay had 100% 
concordance for both colorectal and endometrial cancers. This assay was approved by 
the New York State Department of Health as a laboratory specific assay and has now 
been put into clinical use. 
 
TT55. Microdissection of Cytology Diff-Quik Smears as a Source of Cellular 
Material for BRAF Mutational Analysis in Thyroid Fine Needle Aspirates 
J.J. Bohn, J. Haney, P.C. Chesnut, K.C. Councilman, N.J. Thomas, S. Said,  
J.P. Klopper, B.R. Haugen, W.A. Franklin, D.L. Aisner 
University of Colorado, Aurora, CO. 
Introduction: Analysis of BRAF V600E mutation status has been demonstrated to 
improve the diagnostic accuracy of thyroid fine needle aspirates (FNAs). Potential 
methods for specimen acquisition for such analysis includes extra FNA passes, 
utilization of needle rinse material, and harvesting cells from prepared slides. Previous 
studies have demonstrated that archival cytology material can be utilized to extract 
high-quality nucleic acids. Here we evaluate microdissection of lesional cells directly 
from Diff-Quik slide preparations for utilization in diagnostic molecular pathology 
assays. Methods: Thirty-seven archival Diff-Quik slides of thyroid FNAs were included 
in the study. Of the 37 cases evaluated, 9 were diagnosed as papillary thyroid 
carcinoma (PTC), 17 were indeterminate and 11 were benign. The smears were 
evaluated for lesional/epithelial cell content, and areas for microdissection including 
clusters and single lesional cells were identified followed by glass etching on the back 
of the slide. After de-coverslipping, the selected areas were microdissected with a 
manual dissecting microscope and a pneumatic cell aspiration device. DNA was 
isolated from the microdissected cells and utilized for direct sequencing of exon 15 of 
BRAF. Results: All specimens were microdissected with a range of 4 to 40 areas 
measuring ~2mm2 in diameter. The areas selected for microdissection were visually 
determined to consist of > 50% lesional cells. All specimens had DNA yields of >150ng 
after extraction, with a median yield of 258ng based on spectrophotometric analysis. All 
specimens were successfully evaluated by direct sequencing for BRAF V600E 
mutation. Of the 37 specimens evaluated, 5 were positive for BRAF V600E mutation, 
and all positive specimens were morphologically diagnosed as PTC for a mutation 
detection rate of 55.5% in PTC. None of the 17 indeterminate or benign cases 
demonstrated the presence of a mutation. Conclusions: These findings demonstrate 
that DNA can be successfully extracted from microdissected archival cytology material 
for use in clinical molecular pathology assays. De-coverslipping of cytologic smears is 
an acceptable method for accessing lesional cells present in archival material, and 
microdissection directly from Diff-Quik slides allows for enrichment of the lesional cells 
for subsequent molecular studies. The lack of detection of BRAF mutation in 
indeterminate specimens may be attributed to a low number of tested specimens in this 
study. 
 
TT56. Validation of High Resolution Melting Curve Analysis (HRMA) Using Light 
Cycler 480 for Screening of TP53 Mutations in Human Malignancies  
R. Kanagal-Shamanna, A. Paladugu, B. Barkoh, H. Rahimi, S.S. Chen, R.L. Sargent,  
L. Medeiros, R. Luthra, K.P. Patel  
The University of Texas M.D. Anderson Cancer Center, Houston, TX. 
Introduction: TP53 mutations have been implicated in the pathogenesis of many 
human malignancies. The presence of these mutations often provides prognostic 
information for risk stratification of disease. Most TP53 mutations are clustered in 
hotspot regions located in exons 5 through 9. Conventional Sanger sequencing for 
detection of these mutations is both time and labor intensive. High resolution melting 
analysis (HRMA) is a potentially efficient alternative to screen for mutations and select 
specific exons for further sequencing. We validated the HRMA assay for screening for 
TP53 mutations in hematological and solid tumors as a part of the routine diagnostic 
work-up in the clinical laboratory setting. Methods: The HRMA assay was established 
and optimized using cell lines H2122 (exon 5, p.C176[C,F]), H69-1-1 (exon 5, 
E171[E,*]), DLD1 (exon 7, S241[S,F]), H1437 (exon 8, R267[P,R]), SW480 (exon 8, 
R273H; exon 8, R273H; exon 9, P309S). The assay was further validated using bone 
marrow aspirate and peripheral blood samples from acute myeloid leukemia/ 
myelodysplastic syndrome cases and formalin-fixed, paraffin-embedded tissue (FFPET) 
from solid tumor cases. HRMA primers were tagged with M13 for use in subsequent 
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Sanger sequencing. The results of HRMA and Sanger sequencing were compared. 
Results: HRMA was successfully validated for exons 5, 7, 8 and 9 of TP53. Assay for 
exon 6 is still being optimized to exclude an unwanted intronic SNP included in the 
original primer design. Overall, 88.5% HRMA calls (both variant and wild type) were in 
concordance with Sanger sequencing (exon 5 (89.6%), exon 7 (93.3%), exon 8 (85.4%) 
and exon 9 (89.6%)). Of the discordant results, HRMA detected a variant in exon 5 
(5/48, 10.4%), exon 7 (2/30, 6.7%), exon 8 (7/48, 14.6%) and exon 9 (5/48, 10.4%), but 
no mutation was detected by Sanger sequencing. Importantly, no false negative results 
were detected by HRMA (i.e. HRMA- and Sanger+). Additionally, the HRMA assay 
performed well with DNA obtained from FFPE tissue of solid tumors. Conclusions: 
HRMA is a useful clinical tool to screen for TP53 mutation, providing a cost-effective 
and efficient platform with marked reduction in turnaround time. Optimal performance 
on FFPE tissue samples makes HRMA a particularly useful technique for solid tumors, 
where fresh tissue is often not available.  
 
TT57. Exonic Deletions in Known Disease Genes Detected by aCGH: 
Verification of Microarray Results by Standard PCR or Quantitative Real-Time 
PCR 
G. Scharer, G. Creadon-Swindell, Z. Prutch, E. Spector 
University of Colorado Denver/The Children's Hospital, Aurora, CO. 
Introduction: Array based genomic hybridization (aCGH) has quickly become the 
method of choice for the detection of genomic copy number variants (CNVs, 
microdeletions/duplications), and increasingly is also used to identify exonic deletions in 
known disease genes utilizing targeted oligonucleotide microarray. Still, there is 
consensus that these results should be verified by standard well-established molecular 
or cytogenetic assays (i.e. PCR or FISH). This is often effortless in cases of sizeable 
CNVs, but more challenging for small exonic deletions, for which FISH probes are not 
available or not feasible. We report our initial experience utilizing standard PCR and 
real-time PCR for verification of exonic intragenic deletions detected by a customized 
targeted 135k Nimblegen® oligonucleotide microarray. Methods: For small intragenic 
deletions (one or few exons) we decided to bridge the deletions by designing flanking 
PCR primers and sequence the resulting fragments to identify the deletion breakpoints 
(standard PCR method). For larger multi-exon deletions we chose a quantitative PCR 
method (Dual Taqman® probe Realtime PCR) utilizing 2 probes (one in the region of 
the deletion and one in a control region determined by the array). Samples were run in 
duplicate and 3 dilutions on an ABI® 7500 FAST RT-PCR system. Copy number was 
defined as 2íǻǻCT, where ǻCT is the difference in threshold cycles for the sample in 
question versus a control DNA. Results: The standard PCR method was successful in 
many instances (n=3) of single exon deletions, where the breakpoints did not fall into 
repetitive intronic sequences. The quantitative PCR method (Dual Taqman® probe 
Realtime PCR) was much more time and labor intensive, but did yield very reliable 
results and confirmed deletions in all selected cases (n=6). The simultaneous use of 2 
Taqman probes allowed for compensation of differences in PCR efficiency and DNA 
template concentrations. The quantitative PCR method was especially effective for 
larger multi-exon deletions. Conclusions: In summary, while quite reliable and easy to 
set-up, there are limits in applying standard PCR for the detection of intragenic exonic 
deletions. The quantitative PCR method (Dual Taqman® probe Realtime PCR) was 
much more time and labor intensive, but did yield very reliable results and confirmed 
deletions in all selected cases. Still, questions remain in regard to the inability of 
visualizing CNVs or chromosomal rearrangements with molecular assays or to clearly 
define nonlinear CNVs (complex rearrangements, including multiple deletions and 
duplications of genomic DNA).  
 
TT58. Excellent Correlation of Her-2/neu Status of Gastroesophageal 
Carcinomas Tested by Immunohistochemistry (IHC) and Fluorescence in Situ 
Hybridization (FISH) Using the Hofmann Guideline 
F. Zhou, K. Norton, R. Cordery, D. Suchie 
Peace Health Southwest Medical Center, Vancouver, WA. 
Introduction: Trastuzmab has been shown to improve survival of patients with 
advanced gastroesophageal carcinomas that are Her-2/neu positive. Literature has 
shown an excellent correlation of IHC results and FISH results using Dako’s 
HercepTest. Few data are available to address validity of using Ventana Pathway Her-
2/neu kit for testing gastroesophageal carcinomas. Methods: A total of twenty patients 
were obtained from SWMC Pathology Archive, and only 18 cases were possible for 
analysis (two cases had insufficient tumor cells for FISH analysis). Of the 18 samples, 9 
were esophageal adenocarcinomas and 9 were gastric adenocarcinomas. Her-2/neu 
IHC testing on these cases using Ventana Pathway Her-2/neu kit was carried out the 
same way as testing on breast cancers. Her-2 stain was scored based on the published 
recommendation on biopsy and resection specimens (Histopathology, 2008, 52:797). 
Her-2 FISH testing utilized the Vysis PathVysion® HER2 DNA probe kit and the tumors 
were scored for Her-2/neu overexpression the same way as for the breast cancers. The 
Her-2/CEP17 ratio is calculated for determination of amplification of Her-2/neu genes. 
Results: Three cases that were read as 3+ positive by IHC were all amplified by FISH 
tests. None of the thirteen cases that were IHC negative (five case with 0 score and 8 
with 1+ score) showed Her-2/neu gene amplification by FISH. Two cases that were 
read equivocal also failed to show significant Her-2/neu gene amplification. Our results 
showed an excellent correlation between Her-2/neu IHC testing and Her-2/neu FISH 
testing using the Hofmann’s scoring criteria. Conclusions: Her-2/neu status of 
gastroesophageal carcinomas could be tested immunohistochemically using Ventana 
Pathway system. The excellent correlation of IHC results and FISH results supports the 
CAP recommendation of a small validation study before implementation.  
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